PN 78001
RN 00782 
AN 78231664
AU Mei-Liu-H.
TI Reactive neuroaxonal dystrophy in children.  Clinical pathological
   correlation.
SO Acta-Neuropathol (Berl). 1978 Jun 30. 42(3). P 237-41.
MJ BRAIN-DISEASES: pa.
MN AUTOPSY.  BILE-DUCTS: ab.  BRAIN-DISEASES: ci, et.  BRAIN-STEM: pa.
   CHILD.  CYSTIC-FIBROSIS: co.  HEART-FAILURE-CONGESTIVE: co.  HUMAN.
   KIDNEY-FAILURE-CHRONIC: co.  NUTRITION-DISORDERS: co.
   SPINAL-CORD: pa.  TIME-FACTORS.  VINCRISTINE: ae.
AB The aim of the present study was to determine the frequency and
   etioloical factors of neuroaxonal dystrophy (N.D.) in brainstem and
   spinal cord of children with various non-neurological diseases.  The
   materials used in this study consisted of 266 consecutive autopsies
   from 1974-1976 and an additional 13 cases from previous years.  By
   far, the most common cause of N.D. in children was chemotherapeutic
   drugs, particularly vincristine, used for the treatment of malignant
   tumors.  Approximately 90% of these children developed N.D. and the
   changes ranged from mild to severe.  Approximately two-thirds of
   children with cystic fibrosis, congestive heart failure and chronic
   renal failure developed N.D. and the changes were mostly mild.  Only
   one-third of patients with congenital biliary atresia and
   malnutrition developed N.D. and the changes were always mild.  The
   frequency and severity of N.D. increased in patients who had
   prolonged clinical courses; no N.D. was seen in patients who died
   from acute cases such as trauma, acute infection, intoxication,
   acute renal failure or prematurity.  This type of N.D. may be
   considered as reactive to a wide variety of injurious factors such
   as drug toxicity, malnutrition, chronic hypoxia and chronic renal
   failure, either alone or in combination.  In contrast to previous
   reports of a low incidence of N.D. in children, there has been a
   sharp increase in recent years due to the advent of chemotherapy.
RF 001   BERARD-BADIER M       ACTA NEUROPATH (BERL)           28   261 974
   002   BORISY GG             J CELL BIOL                     34   525 967
   003   BRANNON W             ACTA NEUROPATH (BERL)            9     1 967
   004   CHOU SM               ACTA NEUROPATH (BERL)            3   428 964
   005   FUJISAWA K            ACTA NEUROPATH (BERL)            8   255 967
   006   JELLINGER K           GERMAN MEDICAL MONTHLY BD       13   341 968
   007$  LAMPERT P             J NEUROPATH EXP NEUROL          23    60 964
   008   LIU HM                ACTA NEUROPATH (BERL)           37   207 977
   009   LIU HM                NEUROLOGY (MINN)                24   547 974
   010   LUI HM                ACTA NEUROPATH (BERL)           27   201 974
   011   MARTIN JJ             EUR NEUROL                       8   239 972
   012   PENTSCHEW A           ACTA NEUROPATH (BERL)            1   313 962
   013   SEITELBERGER F        ACTA NEUROPATH (BERL) SUPPL      5    17 971
   014   SEITELBERGER F        PROC CONG NEUROPATH 1ST          3   323 952
   015   SUNG JH               J NEUROPATH EXP NEUROL          25   341 966
   016   SUNG JH               J NEUROPATH EXP NEUROL          25   341 966
   017   WISNIEWSKI H          J CELL BIOL                     38   224 968
CT   1   AICARDI J             BRAIN                          102   727 979
     2   GRAFE MR              J NEUROPATHOL EXP NEUROL        39   555 980
     3   SUNG JH               J NEUROPATHOL EXP NEUROL        39   584 980
     4   SUNG JH               J NEUROPATHOL EXP NEUROL        40    37 981
     5   TOMIWA K              J NEUROL                       229   267 983
     6   ROBAIN  O             J NEUROL NEUROSURG PSYCHIAT     47    65 984
     7   WISNIEWSKI KE         ACTA NEUROPATH (BERL)           66    68 985

PN 78002
RN 00783 
AN 78120444
AU Kraemer-R.  Rudeberg-A.  Hadorn-B.  Rossi-E.
TI Relative underweight in cystic fibrosis and its prognostic value.
SO Acta-Paediatr-Scand. 1978 Jan. 67(1). P 33-7.
MJ BODY-WEIGHT.  CYSTIC-FIBROSIS: mo.
MN CHILD.  HUMAN.  PROGNOSIS.
AB On the basis of observations in 117 children with cystic fibrosis,
   seen from January 1956 to June 1976, it is demonstrated that the
   relative underweight (weight loss corrected for height) is most
   pronounced in children with predominantly pulmonary sypmtoms. The
   degree of underweight closely correlates inversely with survival.
   Because of its prognostic value, it is recommended that this clinical
   parameter be included in the checkups which are periodically carried
   out on children suffering from cystic fibrosis.
RF 001   COOPERMAN EM          CAN MED ASSOC J                105   580 971
   002   CUTLER SJ             J CHRON DIS                      8   699 958
   003   DOERSHUK CF           J PEDIATR                       65   677 964
   004   FRIOLET B             THER UMSCH                      31   578 974
   005   GEORGE L              ARCH DIS CHILD                  46   139 971
   006   HADORN B              SCHWEIZ RUNDSCHAU MED           14   454 973
   007   HOGGER GP             HELV PAEDIATR ACTA              30   151 975
   008   HUANG NN              AM J DIS CHILD                 120   289 970
   009   KERREBIJN KF          PROC INT CF CONG 7TH                     976
   010   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107   271 977
   011   KRAEMER R             HELV PAEDIATR ACTA              32   107 977
   012   LAPEY A               J PEDIATR                       84   328 974
   013   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015   SHWACHMAN H           HOSP PRACT                       9   143 974
   016   SHWACHMAN H           PEDIATRICS                      46   335 970
   017   SPROUL A              J PEDIATR                       65   664 964
   018   TAUSSIG LM            J PEDIATR                       82   380 973
   019   TANNER JM             ARCH DIS CHILD                  41   454 966
   020   WARWICK WJ            J CHRON DIS                     28   609 975
CT   1   SANTAGNESE PAD        AM J MED                        66   121 979
     2   KRAEMER R             SCHWEIZ MED WOCHENSCHR         109    39 979
     3   KARP RJ               CLIN CHEST MED                   1   375 980
     4   COATES AL             ACTA PAEDIATR SCAND             69   353 980
     5   SHEPHERD R            J PEDIATR                       97   351 980
     6   GOW R                 LANCET                           2  1071 981
     7   BELL L                J CAN DIET ASSOC                42    62 981
     8   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
     9   MILLER M              AM J CLIN NUTR                  36   492 982
    10   PARSONS HG            J PEDIATR GASTROENTEROL NUTR     2    44 983
    11   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
    12   GIUNTA A              RIV ITAL PEDIATR                 9   171 983
    13   POSSELT HG            ATEMWEGS LUNGENKRANKH           10   345 984
    14   HOLT TL               IRCS MED SCI BIOCHEM            12   370 984
    15   WELLS AL              J FOOD NUTR                     41    65 984
    16   BERTRAND JM           J PEDIATR                      104    41 984
    17   MANSELL AL            J PEDIATR                      104   700 984
    18   CANCIANI M            J PEDIATR GASTROENTEROL NUTR     4   735 985
    19   DAVIS PB              SEM RESPIR MED                   6   261 985
    20   MISCHLER EH           SEM RESPIR MED                   6   271 985
    21   GRAHAM N              CLIN RADIOL                     36   199 985
    22   HOLT TL               AM J CLIN NUTR                  41  1061 985
    23   SCHRODER R            SCHWEIZ MED WOCHENSCHR         115   828 985
    24   WILSON DO             AM REV RESPIR DIS              132  1347 985
    25   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    26   HUGHES RL             ACTA PAEDIATR SCAND SUPPL 317 1985    42 985
    27   NEIJENS HJ            ACTA PAEDIATR SCAND SUPPL 317 1985    38 985
    28   ANON                  LANCET                           1   249 986
    29   LEVY L                J PEDIATR GASTROENTEROL NUTR     5    97 986
    30   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    31   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    32   OLOUGHLIN E           AM J CLIN NUTR                  43   732 986
    33   MOORE MC              AM J CLIN NUTR                  44    33 986
    34   MAHANEY MC            HUM BIOL                        58   445 986
    35   SCHAAD UB             ACTA PAEDIATR SCAND             75   128 986
    36   DODGE JA              J ROY SOC MED                   79    27 986
    37   MARCOTTE JE           CHEST                           90   375 986
    38   SHEPHERD RW           J PEDIATR                      109   788 986
    39   STEAD RJ              CLIN ENDOCRINOL                 26   187 987
    40   GUELPA G              SCHWEIZ MED WOCHENSCHR         117   168 987

PN 78003
RN 00784 
AN 78231746
AU Nielsen-H-E.  Lundh-S.  Jacobsen-S-V.  Hoiby-N.
TI Hypergammaglobulinemic purpura in cystic fibrosis.
SO Acta-Paediatr-Scand. 1978 Jul. 67(4). P 443-7.
MJ CYSTIC-FIBROSIS: co.  PURPURA-HYPERGLOBULINEMIC: co.
MN ADOLESCENCE.  ADULT.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: bl, im.
   FEMALE.  HAEMOPHILUS-INFECTIONS: co.  HAEMOPHILUS-INFLUENZAE.  HUMAN.
   LEG.  MALE.  PNEUMONIA: co.  PURPURA-HYPERGLOBULINEMIC: bl, im.
   SPUTUM: mi.
AB Four patients are presented aged 14 to 20 years with cystic fibrosis
   and recurrent purpura of the legs. They have polyclonal increase of
   Ig but no intermediate complexes demonstrable by ultracentrifugation.
   The 4 patients differ from other patients with cystic fibrosis by a
   rapid deterioration of the clinical condition after the establishment
   of permanent pulmonary infection, and also by their proneness to
   Haemophilus influenzae infections. The clinical and laboratory
   findings are compatible with the diagnosis of Waldenstrom's
   hypergammaglobulinemic purpura. The heterogeneity of this syndrome is
   discussed.
RF 001   ANON                  BR MED J                         1     7 973
   002   CAPRA JD              MEDICINE (BALTIMORE)            50   125 971
   003   CARR RD               ARCH DERMATOL                   94   536 966
   004   DANES BS              CLIN GENET                       8    85 975
   005   FARRELL C             SCAND J IMMUNOL                  4   673 975
   006   HOIGNE R              IN: DUKES NG                         551 975
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   008   HOIBY N               SCAND J RESPIR DIS              56    38 975
   009   HOIBY N               SCAND J RESPIR DIS              58    65 977
   010   JACOBS JC             J PEDIATR                       87    91 975
   011   JOHNSON KJ            J CLIN INVEST                   54   349 974
   012   KATTAMIS C            HELV PAEDIATR ACTA              25   421 970
   013   KYLE RA               MEDICINE (BALTIMORE)            50   113 971
   014   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   015   SCHWARTZ HJ           JAMA                           187   230 964
   016   STRAUSS WG            N ENGL J MED                   260   857 959
   017$  WALDENSTROM JG        NORD MED                        20  2288 943
   018   WALDENSTROM JG        ACTA MED SCAND SUPPL           142   931 952
   019   WALDENSTROM JG        MONOCLONAL AND POLYCLONAL HYP            968
   020   WIDMER U              MINERVA PEDIATR                 27   104 975
   021   ZAHARIA L             ACTA MED SCAND                 199   429 976
   022   ZAVALA DC             J ALLERGY CLIN IMMUNOL          56   450 975
CT   1   SOTER NA              J PEDIATR                       95   197 979
     2   CELADA A              HELV PAEDIATR ACTA              35   569 980
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     5   SCHIDLOW DV           ARCH DIS CHILD                  59   377 984
     6   CIRIELLO MM           HAEMATOLOGICA                   69   435 984
     7   PRESSLER T            ACTA PAEDIATR SCAND             73   541 984
     8   SUMMERS GD            BR J RHEUMATOL                  25   393 986
     9   HOIBY N               ANNU REV MICROBIOL              40    29 986
    10   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 78004
RN 00785 
AN 78120454
AU Roomans-G-M.  Afzelius-B-A.  Kollberg-H.  Forslind-B.
TI Electrolytes in nails analysed by X-ray microanalysis in electron
   microscopy.  Considerations on a new method for the diagnosis of
   cystic fibrosis.
SO Acta-Paediatr-Scand. 1978 Jan. 67(1). P 89-94.
MJ CYSTIC-FIBROSIS: di.  ELECTROLYTES: an.  NAILS: an.
MN CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: me.  EVALUATION-STUDIES.  HUMAN.
   METHODS.  MICROSCOPY-ELECTRON.  SODIUM: an.
   ELECTRON-PROBE-MICROANALYSIS.
AB Patients with cystic fibrosis (CF) have an increased concentration of
   sodium in their nails. Hitherto, only neutron activation analysis has
   been considered for the diagnosis of cystic fibrosis by analysis of
   electrolytes in nails. It has been thoroughly tested methodologically
   and clinically. However, the intrinsic advantages of X-ray
   microanalysis and the results obtained in this study suggest that
   this method, after further testing, may be a useful diagnostic acid
   for cystic fibrosis. In comparison with neutron activation analysis,
   X-ray microanalysis has the advantage of simultaneously giving the
   concentrations of several elements and may be accessible at any
   hospital with an electron microscope fitted with the necessary
   equipment. Nails of CF-patients are here shown to have increased
   concentrations of Na, K and Cl, which will make the diagnosis of
   cystic fibrosis more reliable. The possibility of using sulphur as a
   reference element may eliminate the weighing procedure necessary in
   neutron activation analysis.
RF 001   BERG T                NORTHERN PEDIATR CONG 15                 967
   002   CHANDLER JA           J MICROSC                      106   291 976
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   FITE LE               PROC INT CONF MOD TRENDS             147 968
   005   FORSLIND B            ACTA DERM VENEREOL (STOCKH)     50   161 970
   006   FORSLIND B            J INVEST DERMATOL               67   273 976
   007   GEORGE L              ARCH DIS CHILD                  46   139 971
   008   GIBSON LE             PEDIATRICS                      23   545 959
   009   HALL TA               MICROSCOPIC BIOL CELL           22   271 975
   010   HARRISON WW           CLIN CHIM ACTA                  36   483 972
   011   HEIN W                MIKROCHIM ACTA WIEN SUPPL        5     1 974
   012   HEINTZ PH             THESIS                                   967
   013   JOHNSON GF            PEDIATRICS                      47    88 971
   014   KANABROCKI E          J NUCL MED                       9   478 968
   015   KOLLBERG H            ACTA PAEDIATR SCAND             63   411 974
   016   KOLLBERG H            ACTA PAEDIATR SCAND             63   405 974
   017   KOPITO L              N ENGL J MED                   272   504 965
   018   MORGAN AJ             J MICROSC                      104   271 975
   019   SHWACHMAN H           PEDIATRICS                      46   335 970
CT   1   STEPHAN U             MONOGR PAEDIATR                 10    41 979
     2   GHADIALLY FN          PATHOLOGY                       11    95 979
     3   KUYPERS GAJ           HISTOCHEMISTRY                  69   145 980
     4   DAVID H               BIOL ZENTRALBL                 101   715 982
     5   FORSLIND B            SCANN ELECTRON MICROSC        1982  1715 982
     6   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
     7   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
     8   ROOMANS GM            ANN NY ACAD SCI                428   121 984
     9   FORSLIND B            SCANN ELECTRON MICROSC        1984   183 984
    10   CHAPMAN AL            EUR J RESPIR DIS                66   218 985
    11   BAKER D               SCANN ELECTRON MICROSC        1985   659 985
    12   DJALDETTI M           CLIN SCI                        72   669 987
    13   DJALDETTI M           DERMATOLOGICA                  174   114 987

PN 78005
RN 00786 
AN 79018054
AU Hosli-P.  Kollberg-H.  Vogt-E.
TI Reliable diagnosis of the major type of cystic fibrosis with
   fibroblast cultures.  A double blind study.
SO Acta-Paediatr-Scand. 1978 Sep. 67(5). P 617-20.
MJ CYSTIC-FIBROSIS: di.  FIBROBLASTS: en.  GLYCOPROTEINS: du.
MN ADOLESCENCE.  ADULT.  ALKALINE-PHOSPHATASE: me.  CELLS-CULTURED.
   CHILD.  CHILD-PRESCHOOL.  CLINICAL-TRIALS.  CYSTIC-FIBROSIS: en.
   DOUBLE-BLIND-METHOD.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   ISOPROTERENOL: du.  MALE.  MIDDLE-AGE.  SKIN: en.  THEOPHYLLINE: du.
AB A double blind study has been carried out to demonstrate that the
   most common type of cystic fibrosis (CF) can be reliably diagnosed
   with skin-derived fibroblast cultures. Alkaline phosphatase (AIP)
   activity has been measured in 6 normal controls, 12 CF-heterozygotes
   and 6 CF-homozygotes before and after stimulation with Tamm-Horsfall-
   glycoprotein (THP), isoproterenol and theophyline ("THP-induction
   test"). The mean AIP-activities after THP-induction were 8.8, 12.7
   and 34.6 for the three different genotypes respectively. There was no
   overlap between the values of CF-homozygotes on the one hand, and the
   values of CF-heterozygotes and normal controls on the other hand. All
   24 specimens were correctly diagnosed in the present double blind
   study, indicating the very high degree of reliability of the THP-
   induction test in the detection of the predominant type of cystic
   fibrosis with fibroblast cultures. Normal controls and CF-
   heterozygotes could not be discriminated on an individual basis, but
   as a group the CF-heterozygotes displayed higher AIP-values.
RF 001   BARTMAN J             J PEDIATR                       76   430 970
   002   DANES BS              J EXP MED                      129   775 969
   003   FARRELL PM            PROC SOC EXP BIOL MED          149   340 975
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   HICKMAN S             BIOCHEM BIOPHYS RES COMMUN      49   992 972
   006   HOSLI P               TISSUE CULTIVATION ON PLASTIC            972
   007   HOSLI P               IN: MOTULSKY AG                      226 974
   008   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   009   HOSLI P               ADV EXP MED BIOL                68     1 976
   010   HOSLI P               CLIN CHEM                       23  1476 977
   011   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   013   HOSLI P               HUM GENET                       41   169 978
   015   KOLLBERG H            ACTA PAEDIATR SCAND             63   411 974
   016   LIGHTBODY J           LANCET                           1   451 971
   017   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   018   PALLAVICINI JC        J PEDIATR                       77   280 970
   019   WARWICK WJ            PEDIATRICS                      34   621 964
CT   1   MAHONEY MJ            CLIN PERINATOL                   6   255 979
     2   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
     3   CAREY WF              AUST J EXP BIOL MED SCI         57   225 979
     4   DAVIS PB              PEDIATR RES                     14    83 980
     5   CHASE HP              METABOLISM                      29   365 980
     6   FASTH A               ACTA PAEDIATR SCAND             69   189 980
     7   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
     8   CEDER O               ULTRASTRUCTURAL PATHOL           4   305 983
     9   KHALID BAK            CLIN ENDOCRINOL                 18   407 983
    10   CEDER O               CLIN GENET                      23   298 983
    11   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    12   BUYS CHCM             CLIN CHIM ACTA                 136   229 984

PN 78006
RN 00787 
AN 79018052
AU Katznelson-D.
TI Increased intracranial pressure in cystic fibrosis.
SO Acta-Paediatr-Scand. 1978 Sep. 67(5). P 607-9.
MJ CYSTIC-FIBROSIS: co.  PSEUDOTUMOR-CEREBRI: et.
MN CASE-REPORT.  CYSTIC-FIBROSIS: pp.  FEMALE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  MALE.  RESPIRATORY-INSUFFICIENCY: co, et.
   VENOUS-PRESSURE.
AB Three cystic fibrosis infants with severe respiratory distress had
   increased intracranial pressure (with bulging fontanels) which
   cleared parri passu with improvement in the chest condition. It is
   proposed that the intracranial hypertension is a result of raised
   venous pressure, itself secondary to the intrathoracic obstruction to
   venous return, consequent on the bronchial obstructive disease.
RF 001   BRAY PF               AM J DIS CHILD                 126    78 973
   002   DEES SC               PEDIATRICS                      23  1143 959
   003   FIELDS JP             J PEDIATR                       58    74 961
   004   JOHNSTON I            BRAIN                           97   289 974
   005   JOHNSTON I            BRAIN                           97   301 974
   006   LOBECK CC             IN: STANBURY JB                     1605 972
   007   MARIE J               AM J DIS CHILD                  87   731 954
   008   SHWACHMAN H           IN: KENDIG EL JR                 1   524 972
   009   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   TAUSSIG LM            ACTA PAEDIATR SCAND             68   615 979
     2   MAGAZZU G             RIV ITAL PEDIATR                 7    73 981
     3   ROACH ES              PEDIATRICS                      68   300 981
     4   PALMER EA             J TOXICOL CUTAN OCUL TOXICOL     1   181 982

PN 78007
RN 00788 
AN 78141570
AU Matsuo-T.  Ikeda-T.  Mori-Y.  Nonaka-M.  Fujiwara-H.  Yun-K.
TI Cystic fibrosis of the pancreas in a human fetus.
SO Acta-Pathol-Jpn. 1978 Jan. 28(1). P 77-82.
MJ CYSTIC-FIBROSIS: em.
MN CYSTIC-FIBROSIS: pa.  FEMALE.  GESTATIONAL-AGE.  HUMAN.
   PANCREAS: pa.  PREGNANCY.
AB Postmortem examination of a 26 week old (postmenstrual) human fetus
   delivered by Cesarean section revealed meconium ileus and many
   swollen mucus-secreting cells in the gastro-intestinal mucosa. The
   pancreas showed extensive fibrosis, acinar destruction and dilatation
   of ducts containing eosinophilic casts. Mucous glands of the lungs
   also revealed mucous cells swollen and distended with their secretory
   products. The patient is believed to have cystic fibrosis of the
   pancreas, suggesting that the pathologic manifestations of the
   disease may begin early in fetal life.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BAUMANN T             HELV PAEDIATR ACTA SUPPL 8      13     1 958
   003   BOYER PH              PEDIATRICS                      16   778 955
   004   JOHANSEN PG           LANCET                           1   455 968
   005   KEENE MFL             LANCET                           1   767 929
   006   LOBECK CC             IN: STANBURY JB                     1605 972
   007   MARKS BL              LANCET                           1   365 960
   008   WARKANY J             CONGENITAL MALFORMATIONS NOTE        732 971

PN 78008
RN 00789 
AN 78141584
AU Rolla-G.  Melsen-B.  Sonju-T.
TI Is sulphated blood-group substance in pancreas a factor in cystic
   fibrosis?.
SO Acta-Pathol-Microbiol-Scand [A]. 1978 Jan. 86(1). P 83-6.
MJ BLOOD-GROUPS.  CYSTIC-FIBROSIS: bl.  GLYCOPROTEINS: bl.
MN ANIMAL.  AUTORADIOGRAPHY.  CALCIUM: bl.  CERCOPITHECUS.
   MACACA-FASCICULARIS.  ANTHROPOIDEA.  PANCREAS: me.  SULFATES: me.
AB The present study showed that the pancreas of two monkey species
   contained sulphated blood-group substance. Such strongly anionic
   molecules are known to bind calcium, and their solutions form gels in
   the presence of cations. It is suggested that such a mechanism may be
   involved in cystic fibrosis.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   HAUG A                ACTA CHEM SCAND                 24   843 970
   003   KOPITO LE             PEDIATR RES                     10   742 976
   004   LAMB D                BR J DIS CHEST                  66   239 972
   005   LUDWIG H              SCAND J IMMUNOL                  6   724 977
   006   ROLLA G               ARCH ORAL BIOL                  20   341 975
   007   SMIDSROD O            CHEM SOC FARADAY DISC           57   263 974
   008   SZULMAN AE            J EXP MED                      111   785 960
   009   SONJU T               ACTA PATH MICROBIOL SCAND       79    95 971
   010   SONJU T               ARCH ORAL BIOL                  19   897 974
   011   SONJU T               CARIES RES                       8   113 974
   012   SONJU T               ACTA PATH MICROBIOL SCAND       83   215 975
   013   WATKINS WM            IN: GOTTSCHALK A                     830 972
   014   WEISS A               KOLLOID ZEITSCHRIFT            158    22 958
   015   WOOD RE               AM REV RESPIR DIS              113   833 976
   016   YOSIZAWA Z            IN: GOTTSCHALK A                 5  1000 972
CT   1   MICHALSEN H           MONOGR PAEDIATR                 10   148 979

PN 78009
RN 00790 
AN 79038683
AU Schiotz-P-O.  Nielsen-H.  Hoiby-N.  Glikmann-G.  Svehag-S-E.
TI Immune complexes in the sputum of patients with cystic fibrosis
   suffering from chronic Pseudomonas aeruginosa lung infection.
SO Acta-Pathol-Microbiol-Scand [C]. 1978 Feb. 86(1). P 37-40.
MJ ANTIGEN-ANTIBODY-COMPLEX.  CYSTIC-FIBROSIS: co.  PNEUMONIA: co.
   PSEUDOMONAS-INFECTIONS: co.  SPUTUM: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHRONIC-DISEASE.
   COMPLEMENT-FIXATION-TESTS.  CYSTIC-FIBROSIS: im.  FEMALE.  HUMAN.
   IGG.  IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.  PNEUMONIA: im.
   PSEUDOMONAS-INFECTIONS: im.  RHEUMATOID-FACTOR.
AB 12 cystic fibrosis (CF) patients chronically infected with mucoid P.
   aeruginosa and presenting multiple precipitins in serum against this
   bacterium and 12 patients without P. aeruginosa infection were
   examined for occurrence of soluble immune complexes in their sputum
   sol phase by a complement consumption assay and a solid phase
   rheumatoid factor binding assay. The correlation between the results
   obtained in the two assays was significant (r = 0.625, p less than
   0.01). The patients chronically infected with P. aeruginosa showed a
   significantly (p less than 0.01) higher frequency of immune complex
   activity in their sputum sol phase, as compared to the patients
   without P. aeruginosa lung infection. These findings point to the
   possibility that chronic lung infection with mucoid P. aeruginosa in
   CF may be an immune complex disease.
RF 001   BROGAN TD             THORAX                          30    72 975
   002   COCHRANE CG           IN: ZWEIFACH BW                  3    85 974
   003   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   004   GALLIN JI             IN: KIRKPATRICK CH                   161 976
   005   GIBSON LE             PEDIATRICS                      23   545 959
   007   HIRSCHHORN R          IN: ZWEIFACH BW                  1   259 974
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   011   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   433 975
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   014   HOIBY N               SCAND J RESPIR DIS              56    38 975
   015   HOIBY N               SCAND J RESPIR DIS              58    65 977
   016   LEBER PD              IN: ZWEIFACH BW                  3   401 974
   017   NIELSEN H             ACTA PATH MICROBIOL SCAND (C)   84   261 976
   018   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   019   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   020   STALENHEIM G          IMMUNOCHEMISTRY                 10   501 973
   021   THORELL JI            BIOCHIM BIOPHYS ACTA           251   363 971
   022   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   023   TURK JL               BOLL IST SIEROTER MILAN SUPPL   53   208 974
CT   1   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
     2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     3   HOIBY N               ACTA PAEDIATR SCAND             68   495 979
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
     5   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
     6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   345 979
     7   BERDISCHEWSKY M       PEDIATR RES                     14   830 980
     8   HODSON ME             THORAX                          35   801 980
     9   SKOV PS               ALLERGY                         35    23 980
    10   MATTHEWS WJ           N ENGL J MED                   302   245 980
    11   SORENSEN RU           PEDIATR RES                     15    14 981
    12   CHURCH JA             CHEST                           80   405 981
    13   MOSS RB               J PEDIATR                       99   215 981
    14   DANIELE RP            AM REV RESPIR DIS              124   738 981
    15   PERMIN H              ALLERGY                         37    93 982
    16   MOSS RB               CLIN EXP IMMUNOL                47   301 982
    17   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   577 982
    18   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
    19   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    20   ANON                  LANCET                           2   257 983
    21   SCHILLER NL           PEDIATR RES                     17   747 983
    22   DORING G              INFECT IMMUN                    42   197 983
    23   SCHIOTZ PO            ACTA PAEDIATR SCAND             72   283 983
    24   SPEERT DP             PEDIATR RES                     18   431 984
    25   DORING G              ACTA PATH MICROB IMMU SCA (C)   92   307 984
    26   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    27   MISCHLER EH           SEM RESPIR MED                   6   271 985
    28   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    29   WOODS DE              J INFECT DIS                   151   581 985
    30   KHARAZMI A            EUR J CLIN INVEST               16   143 986
    31   HOIBY N               ANNU REV MICROBIOL              40    29 986
    32   PIEDRA P              J PEDIATR                      108   817 986
    33   MOSS RB               AM REV RESPIR DIS              133   648 986
    34   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987

PN 78010
RN 00791 
AN 79121553
AU Lebenthal-E.
TI Pancreatic function and disease in infancy and childhood.
SO Adv-Pediatr. 1978. 25. P 223-61. (REVIEW).
MJ CYSTIC-FIBROSIS: pp.  PANCREAS: ph.  PANCREATIC-DISEASES: pp.
   PANCREATITIS: et.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  DIGESTION.  HUMAN.
   INFANT.  INFANT-NEWBORN.  PANCREAS: ab, en.
   PANCREATIC-DISEASES: dt, en.  PANCREATIC-NEOPLASMS: pp.
   PANCREATITIS: th.  REVIEW.  STARCH.  SYNDROME.
EX Normal development of the pancreas is of great importance in the
   neonate and infant.  This review evaluates the development of
   exocrine pancreatic function, the hormonal control of this function,
   the interrelationship of pancreatic enzymes and pancreatic adaptation
   to food.  The functional changes that occur in different disease
   processes of the pancreas affecting the infant will also be
   discussed.  Since the treatment of pancreatic exocrine insufficiency
   with orally administered pancreatic enzymes in children is often more
   difficult than expected, the practical approach to enzyme treatment
   will be discussed.  The morphological development and congenital
   malformations of the pancreas, tumors of the pancreas, the normal
   function of the exocrine pancreas, the development of the exocrine
   pancreatic function, developmental aspects of amylase activity and
   starch digestion, dietary adaptation of the exocrine pancreas,
   pancreatic function tests, pancreatic insufficiency, cystic fibrosis,
   Shwachman syndrome, isolated pancreatic enzyme deficiencies, the
   treatment of exocrine pancreatic insufficiency, pancreatitis in
   childhood, and the treatment of acute pancreatitis are discussed.
RF 001   ABRUZZO JL            ANN SURG                       147   921 958
   002   ADAMS JT              SURGERY                         63   877 968
   003   AKERS DR              SURGERY                         71   817 972
   004   ALLAN BJ              ARCH BIOCHEM BIOPHYS           136   529 970
   005   ANTONOWICZ I          GASTROENTEROLOGY                72  1299 977
   006   ANDERSON TA           J LAB CLIN MED                  79    31 972
   007   APPEL MF              ARCH SURG                      108    63 974
   008   AREY LB               DEVELOPMENTAL ANATOMY 7TH ED             965
   009   AURICCHIO S           PEDIATRICS                      39   853 967
   010   AURICCHIO S           PEDIATRICS                      35   944 965
   011   BABKIN BP             SECRETORY MECHANISMS OF THE D         54 950
   012   BACHRACH WH           GASTROENTEROLOGY                63   890 972
   013   BALZER E              Z GASTROENTEROL                  5   239 967
   014   BANKS PA              GASTROENTEROLOGY                61   382 971
   015   BARBERO GJ            AM J DIS CHILD                 112   536 966
   016   BARBEZAT GO           PEDIATRICS                      42    77 968
   017   BARTHOLOMEW C         BR MED J                         1   666 970
   018   BECKER WF             ANN SURG                       163   892 966
   019   BEN ABDELJLIL A       BIOCHEM BIOPHYS RES COMMUN      10   112 963
   020   BENZONANA G           BIOCHIM BIOPHYS ACTA           105   121 965
   021   BERK JE               JAMA                           199    98 967
   022   BISHOP RP             AM J GASTROENTEROL              49   112 968
   023   BLAINEY JD            CLIN SCI                        32   377 967
   024   BLOCK MB              N ENGL J MED                   282   380 970
   025   BLUMENTHAL HT         ANN SURG                        27   533 961
   026   BODIAN M              ACTA PAEDIATR SCAND             53   282 964
   027   BONIN A               J PEDIATR                       83   594 973
   028   BORGSTROM B           BIOCHIM BIOPHYS ACTA           242   509 971
   029   BROOKS FP             N ENGL J MED                   286   300 972
   030   BUNNELL CE            J PEDIATR                       80   465 972
   031   CAREY MC              GUT                              9   700 968
   032   CASTLEMAN B           N ENGL J MED                   286  1353 972
   033   CHRISTOPHE J          GUT                              7   298 966
   034   CHRISTOPHE J          HORM METAB RES                   3   393 971
   035   COMFORT MW            GASTROENTEROLOGY                21    54 952
   036   CORNET E              J CHIR (PARIS)                  84   527 962
   037   COTTON PB             LANCET                           1    53 972
   038   DAGORN JC             GASTROENTEROLOGY                73    42 977
   039   DELACHAUME-SALEM E    BIOL GASTROENTEROL               2   135 970
   040   DESNUELLE P           CIBA FOUND SYMP                       90 962
   041   DEVIZIA B             J PEDIATR                       86    50 975
   042   DIMAGNO EP            N ENGL J MED                   296  1318 977
   043   DI SANTAGNESE PA      PEDIATRICS                      15   683 955
   044   DI SANTAGNESE PA      ACTA PAEDIATR SCAND             63   163 974
   045   DIVINCENTI FC         J TRAUMA                         8  1004 968
   046   DREILING DA           GASTROENTEROLOGY                30   382 956
   047   DOLAN RV              ARCH SURG                      109   762 974
   048   DONOWITZ M            J PEDIATR                       87   241 975
   049   DRUMMEY GD            N ENGL J MED                   264    85 961
   050   ANON                  LANCET                           1   205 975
   051   ELLIOTT GB            CAN J SURG                      11   357 968
   052   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   053   FARMER RG             AM J MED                        54   161 973
   054   FELDMAN M             JAMA                           148   893 952
   055   FOMON SJ              AM J CLIN NUTR                  28  1299 970
   056   FRABLE WJ             CANCER                          27   667 971
   057   FREDRICKSON DS        IN: STANBURY JB                      545 972
   058   FREDRICKSON DS        N ENGL J MED                   276    34 967
   059   FREY C                PEDIATRICS                      32    93 963
   060   FRINGLE EM            PROC R SOC MED                  61   776 968
   061   FRUCHT DA             AM J DIS CHILD                  92   182 956
   062   GEOKAS MC             CALIF MED                      117     1 972
   063   GIBBS GE              PEDIATRICS                       5   941 950
   064   GIEDION A             FORTSCHR GEB ROENTG NUKL       108    51 968
   065   YOUNGS G              GUT                             13   154 972
   066   GERATZ JD             AM J PHYSIOL                   219   705 970
   067   GO VLW                J CLIN INVEST                   49  1558 970
   068   GOULD BS              AM J DIS CHILD                  91   584 956
   069   GRACES L              PEDIATRICS                      41   789 968
   070   GRAHAM DY             N ENGL J MED                   296  1314 977
   071   GREENBERGER NJ        MEDICINE (BALTIMORE)            45   161 966
   072   GROSFELD J            ARCH SURG                      101   370 970
   073   GROSS JB              AM J MED                        33   358 962
   074   GROSS RE              SURGERY OF INFANCY AND CHILDH            953
   075   GRYBOSKI J            MAJ PROB CLIN PEDIATR           13   450 975
   076   GUNDERSEN AE          J PEDIATR SURG                   4   478 969
   077   HADORN B              IN: ANDERSON CM                      289 975
   078   HADORN B              CAN MED ASSOC J                 98   377 968
   079   HADORN B              LANCET                           1   812 969
   080   HADORN B              J PEDIATR                       73    39 968
   081   HAYS D                ANN SURG                       153   103 961
   082   HENDREN WH            ARCH DIS CHILD                  40   132 965
   083   HUDSON E              ARCH INTERN MED                125   314 970
   084   HONG SS               AM J PHYSIOL                   191    71 957
   085   HOWARD JM             ANN SURG                       165   293 967
   086   HOWARD F              BR J NUTR                       17   281 963
   087   JACKSON CE            AM J MED                        43   727 967
   088   JAMIESON JD           J CELL BIOL                     34   597 967
   089   JANOWITZ HD           ANN INTERN MED                  74   444 971
   090   JODL J                ACTA PAEDIATR SCAND             64   619 975
   091$  JOHNSON WC            ANN SURG                         9   562 970
   092   JORDAN SC             J PEDIATR                       91   211 977
   093   KARJOO M              ARCH DIS CHILD                  48   143 973
   094   KATTWINKEL J          PEDIATRICS                      51    55 973
   095   KAWANISHI H           N ENGL J MED                   289   357 973
   096   KEENE MFL             LANCET                           1   767 929
   097   KELLER PJ             J BIOL CHEM                    242   281 967
   098   KIESSWETTER WB        SURGERY                         36   146 954
   099   KILMAN JW             SURGERY                         55   455 964
   100   KLEIN B               CLIN CHEM                       16    32 970
   101   KLEITSCH WP           ARCH SURG                       71   795 955
   102   KONIJN AM             AM J PHYSIOL                   218  1113 970
   103   KLUMPP TG             AM J DIS CHILD                  40  1215 930
   104   KREJS GJ              AM J DIG DIS                    22   280 977
   105   KUNITZ M              J GEN PHYSIOL                   22   429 939
   106   LAGERLOF HO           ACTA MED SCAND SUPPL           128     1 942
   107   LEBENTHAL E           PEDIATRICS                      56   585 975
   108   LEBENTHAL E           GASTROENTEROLOGY                70   508 976
   109   LEBENTHAL E           BIOCHIM BIOPHYS ACTA           497   558 977
   110   LIEBERMAN J           GASTROENTEROLOGY                50   183 966
   111   LIECHTY RD            JAMA                           230  1538 974
   112   LILLIBRIDGE CB        J PEDIATR                       82   279 973
   113   LIESTYNA JA           AM J DIS CHILD                 107   644 964
   114   LIEBOW C              SCIENCE                        189   472 975
   115   LIFTON LJ             JAMA                           229    47 974
   116   LINDBERG T            ACTA PAEDIATR SCAND             63   805 974
   117   LONG WB               GASTROENTEROLOGY                71   589 976
   118   LOUVARD D             BIOCHIM BIOPHYS ACTA           309   127 973
   119   LOWE CU               AM J DIS CHILD                  82   459 951
   120   LUNDH G               GASTROENTEROLOGY                42   275 962
   121   LYMAN RL              J NUTR                          79    28 963
   122   MACGREGOR IL          GASTROENTEROLOGY                72   195 977
   123   MALAISSE-LAGAE F      SCIENCE                        190   795 975
   124   MALLARD RE            J PEDIATR                       91   445 977
   125   MALONE JI             J PEDIATR                       85   825 974
   126   MARCHIS-MOUREN G      ARCH BIOCHEM BIOPHYS            83   309 959
   127   MARDH PA              BR MED J                         2   240 973
   128   MARTIN DU PAN R       INT Z VITAMINFORSCH              1    67 971
   129   MARTINEZ W            ANN SURG                       147     1 958
   130   MATSUMOTO Y           SURGERY                         76   827 974
   131   MCELROY R             AM J MED                        52   228 972
   132   MOORE JG              AM J DIG DIS                    16    97 971
   133   MORENS DM             AM J DIS CHILD                 128   401 974
   134   MOYNAN RW             J PEDIATR                       65   711 964
   135   NAGEL W               PHYSIOL CHEM                   340     1 965
   136   NEELEY WA             ANN SURG                       173   657 971
   137   NORDSTROM C           BIOCHIM BIOPHYS ACTA           242   209 971
   138   NORMAN A              ACTA PAEDIATR SCAND             61   571 972
   139   NORTHRUP WF           SURGERY                         71    27 972
   140   OTHERSON HB           J TRAUMA                         8   535 968
   141   PALADE GE             IN: DE REUCK AVS                         962
   142   PALADE GE             SCIENCE                        189   347 975
   143   PATTEN BM             HUMAN EMBRYOLOGY                         968
   144   PAVLOV JP             ARBEIT DER VERDEUUNGSDRUS             48 898
   145   PERRIER CV            GASTROENTEROLOGY                44   493 963
   146   PETERSEN H            SCAND J GASTROENTEROL            5   555 970
   147   PRATT CB              J PEDIATR                       77   474 970
   148   REETSMA K             SURGERY                         42    22 957
   149   REGAN PT              GASTROENTEROLOGY                72   A95 977
   150   RICKHAM PP            ARCH DIS CHILD                  29    80 954
   151   RICOUR C              ACTA PAEDIATR SCAND             63   168 974
   152   RIEMENSCHNEIDER TA    PEDIATRICS                      41   428 968
   153   ROBINSON MJ           PEDIATRICS                      48   232 971
   154   ROSSI E               HELV PAEDIATR ACTA               8   530 953
   155   ROTHMAN SS            NATURE                         213   460 967
   156   ROTHMAN SS            AM J PHYSIOL                   217   504 969
   157   ROTHMAN SS            SCIENCE                        190   747 975
   158   SAID SI               N ENGL J MED                   293   155 975
   159   SALMAN AJ             PROC SOC EXP BIOL MED          126   694 967
   160   SAUNDERS JHB          BR MED J                         1   418 977
   161   SCHMIDT H             CLIN ORTHOP                     69   135 970
   162   SHANKLIN DR           N ENGL J MED                   266  1097 962
   163   SHELDON W             ARCH DIS CHILD                  39   268 964
   164   SHMERLING DH          HELV PAEDIATR ACTA              24   547 969
   165   SHWACHMAN H           J PEDIATR                       63   835 963
   166   SHWACHMAN H           J PEDIATR                       65   645 964
   167   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   168   SHWACHMAN H           IN: SLEISENGER MH                   1206 973
   169   SHWACHMAN H           BIRTH DEF ORIG ART SER           8    46 972
   170   SHWACHMAN H           PEDIATRICS                      55    86 975
   171   SHWACHMAN H           ADV PEDIATR                      7   249 955
   172   SIBERT JR             GUT                             16    81 975
   173   SIBERT JR             GUT                             16    81 975
   174   SIBERT JR             ARCH DIS CHILD                  50   443 975
   175   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
   176   SNOOK JT              J NUTR                          87   297 965
   177   SNOOK JT              AM J PHYSIOL                   221  1383 971
   178   SOLOMON AK            FED PROC                        11   722 952
   179   STOVER SL             J PEDIATR                       73   235 968
   180   SWAN DC               LANCET                           1    60 966
   181   TACHIBANA T           JAPAN J OBSTET GYNECOL          10    27 927
   182   TACHIBANA T           JAPAN J OBSTET GYNECOL          10    40 927
   183   TACHIBANA T           JAPAN J OBSTET GYNECOL          11    92 928
   184   TAUSSIG LM            PEDIATRICS                      54   229 974
   185   THEODORIDES T         J CHIR (PARIS)                  87   445 964
   186   UDALL JN              J PEDIATR                       88   819 976
   187   URSING B              BR MED J                         3   524 973
   188$  WALTERS RL            AM J SURG                        3   364 966
   189   WARSHAW AL            N ENGL J MED                   292   325 975
   190   WEIJERS HA            ACTA PAEDIATR SCAND             42    24 953
   191   WELCH KJ              TRAUMATIC LESIONS OF ABDOMEN     6       962
   192   WEITZMAN JJ           SURGERY                         57   309 965
   193   WERNER B              ACTA PAEDIATR SCAND SUPPL 6     35     1 948
   194   WHALEN J              AM J SURG                      121    16 971
   195   WHITE TT              AM J SURG                      129   132 970
   196   WITTE CL              JAMA                           203  1068 968
   197   WOLF RO               OBSTET GYNECOL                  41   337 973
   198   WOODLEY JF            GUT                             13   900 972
   199$  WORMSLEY KG           GASTROENTEROLOGY                 1    27 972
   200   WORMSLEY KG           GUT                             13   398 972
   201   WORNING H             SCAND J GASTROENTEROL            1   268 966
   202   WRIGHT E              SURGERY                         69   389 971
   203   ZOPPI G               ACTA PAEDIATR SCAND             59   692 970
   204   ZOPPI G               PEDIATR RES                      6   880 972
   205   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
CT   1   LEBENTHAL E           PEDIATR RES                     14  1356 980
     2   LEBENTHAL E           J PEDIATR                       97   389 980
     3   LEBENTHAL E           PEDIATR RES                     15  1240 981
     4   CARREL O              HELV PAEDIATR ACTA              36   405 981
     5   LEBENTHAL E           AM J GASTROENTEROL              75   436 981
     6   ANON                  J AM DIET ASSOC                 78   443 981
     7   ANDERSEN DW           PEDIATR RES                     16   304 982
     8   BOWLING SA            AM J MED TECHNOLOGY             48    25 982
     9   RANDOLPH VS           AM J MED TECHNOLOGY             48    15 982
    10   ADRIAENSSENS K        ARCH DIS CHILD                  57   553 982
    11   LONGNECKER DS         AM J PATHOL                    107   103 982
    12   SVENDSEN LS           ACTA VET SCAND SUPPL 78       1982     1 982
    13   LEBENTHAL E           J PEDIATR                      102     1 983
    14   ANDERSEN DW           J NUTR                         113   430 983
    15   COURTOIS P            ANN BIOL CLIN                   43   127 985
    16   STEGINK LD            METABOLISM                      35   519 986
    17   ANDERSEN DW           J NUTR                         117   274 987

PN 78011
RN 00792 
AN 79038961
AU Griscom-N-T.
TI Total body opacification.
SO AJR. 1978 Nov. 131(5). P 919-25. (REVIEW).
MJ IODIZED-OILS: du.  RADIOGRAPHY: mt.
MN ABSCESS: ra.  AGE-FACTORS.  ASCITES: ra.  CHILD-PRESCHOOL.
   COMMON-BILE-DUCT: ab.  CYSTIC-FIBROSIS: co.  CYSTS: ra.  FEMALE.
   HUMAN.  INFANT.  INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: ra.
   INTESTINAL-OBSTRUCTION: cn, ra.  IODIZED-OILS: ad, ae.
   LIVER-DISEASES: ra.  DIATRIZOATE-MEGLUMINE: du.  RADIOGRAPHY: ae.
   REVIEW.  TECHNOLOGY-RADIOLOGIC.  URETERAL-OBSTRUCTION: ra.
AB Total body opacification is the phenomenon whereby introduction of
   iodinated contrast material into the blood stream renders structures
   differentially radiopaque according to their blood supply.  The term
   implies the physiology: it is the whole body which is opacified, in
   proportion to the iodine in its plasma and extravascular
   extracellular fluid at the time of the radiograph.  To the density
   inherent in the tissue before injection is added the opacity of the
   iodine circulating through and transuding into it.  Just as tissues,
   even those of "water density," have minor intrinsic differences in
   x-ray absorption, so they may also have minor differences in blood
   flow and transudation into the extracellular fluid; the combination
   of these minor differences often makes the invisible visible.
RF 001   ALFIDI R              AM J ROENTG RAD THER NUCL MED  124   199 975
   002   NEW PFJ               RADIOLOGY                      110   109 974
   003   MATEGRANO VC          RADIOLOGY                      125   135 977
   004   BIRNHOLZ JC           RADIOLOGY                      105   303 972
   005   PHILLIPS JC           RADIOLOGY                      112    17 974
   006   IMRAY TJ              AM J ROENTG RAD THER NUCL MED  125    60 975
   007   WIRTANEN GW           RADIOLOGY                      108    51 973
   008   HEGEDUS V             INVEST RADIOL                    9    56 974
   009   KORMANO M             RADIOLOGY                      121   379 976
   010   GOODING CA            RADIOLOGY                      102    77 972
   011   MESSINA AV            RADIOLOGY                      120   345 976
   012   SHANSER JD            RADIOL SOC NORTH AM ANNU MTG             977
   013   LACHMAN RS            PEDIATR RADIOL                   3   117 975
   014   YOUNG LW              ANN RADIOL (PARIS)              17   391 974
   015   MONCADA R             AM J ROENTGENOL                129   583 977
   016   MARTIN DJ             BR J RADIOL                     45   185 972
   017   EFFMANN EL            RADIOL SOC NORTH AM ANNU MTG             975
   018   GRISCOM NT            AM J ROENTG RAD THER NUCL MED   93   447 965
   019   RABINOWITZ JG         J CAN ASSOC RADIOL              24   226 973
   020   FELLOWS KE            RADIOL CLIN NORTH AM            10   349 972
   021   ROSENFIELD N          RADIOLOGY                      114   113 975
   022   KURLANDER GJ          RADIOLOGY                       89  1075 967
   023   BERDON WE             AM J ROENTG RAD THER NUCL MED  118    18 973
   024   ROBINSON AE           RADIOLOGY                      122   749 977
   025   ANON                  N ENGL J MED                   295   608 976
   026   CROWE JE              AM J ROENTGENOL                130   167 978
   027   LEAPE LL              PEDIATRICS                      47   101 971
   028   MEYERS MA             RADIOLOGY                      117   539 975
   029   GENEREUX GP           J CAN ASSOC RADIOL              21   242 970
   030   MONCADA R             AM J ROENTGENOL                129   583 977
   031   MORIN ME              RADIOLOGY                      121   307 976
   032   BALIKIAN JP           AM J ROENTG RAD THER NUCL MED  122   692 974
   033   HATFIELD PM           AM J ROENTG RAD THER NUCL MED  119   687 973
   034   LOVE L                AM J ROENTG RAD THER NUCL MED  122   299 974
   035   LILIENFELD RM         J UROL                         115   123 976
   036   MITTY HA              AM J ROENTG RAD THER NUCL MED  115   630 972
   037   SMITH AM              AM J ROENTG RAD THER NUCL MED  104   389 968
   038   KURTI DJ              AM J ROENTG RAD THER NUCL MED  119   576 973
   039   RABUSHKA SE           RADIOLOGY                      109   549 973
   040   MORGAN H              RADIOLOGY                       97   301 970
   041   BRILL PW              AM J ROENTGENOL                127   289 976
   042   STANLEY P             PEDIATR RADIOL                   5    58 976
   043   BALSYS R              INVEST RADIOL ABSTR             12   393 977
   044   BARBARIC ZL           RADIOLOGY                      123   587 977
   045   BENTON C              RADIOLOGY                      104    61 972
   046   GRISCOM NT            J PEDIATR SURG                   1    76 966
   047   DUNBAR JS             RADIOL CLIN NORTH AM            10   367 972
   048   WITTEN DM             AM J ROENTG RAD THER NUCL MED  119   832 973
   049   MARTIN DJ             RADIOL CLIN NORTH AM            13   359 975
   050   TALNER LB             CONTRIB NEPHROL                  5     3 977
   051   STANDEN JR            AM J ROENTG RAD THER NUCL MED   93   473 965
   052   ANSELL G              BR J RADIOL                     43   395 970
   053   DOUST BD              RADIOLOGY                      104   557 972
   054   MOREAU JF             RADIOLOGY                      115   329 975
   055   ELKIN M               RADIOLOGY                      116   259 975
   056   DUNBAR JS             AM J ROENTG RAD THER NUCL MED  110   520 970
   057   GRISCOM NT            RADIOLOGY                      106   385 973
   058   OCONNOR JF            AM J ROENTG RAD THER NUCL MED   90    63 963
   059   HOLT JF               YEARBOOK OF RADIOLOGY                    965
   060   GOODING CA            AM J ROENTG RAD THER NUCL MED  123   802 975
   061   MCALISTER W           SOC PEDIATR RADIOL ANNU MTG              978
   062   BORRA S               N ENGL J MED                   284   592 971
   063   BERGMAN LA            N ENGL J MED                   279  1277 968
CT   1   CREMIN BJ             AM J ROENTGENOL                132   857 979
     2   MAHMUD F              AM J ROENTGENOL                133  1180 979
     3   DEAN PB               INVEST RADIOL                   15  S164 980
     4   AUSTIN RM             CLIN RADIOL                     31   697 980
     5   KATZBERG RW           RADIOLOGY                      134   297 980
     6   MORIN ME              CRC CRIT REV DIAGN IMAGING      15   237 981
     7   NEWHOUSE JH           AM J ROENTGENOL                136   463 981
     8   AXIOTIS CA            J CLIN GASTROENTEROL             5   541 983
     9   MINDELZUN RE          SEM ROENTGENOL                  19   259 984

PN 78012
RN 00793 
AN 78253890
AU Strauss-A.  Mendes-E.
TI Exocrine disorder in asthmatics: demonstration of high sweat
   chloride levels in chronic patients and their relatives.
SO Allergol-Immunopathol (Madr). 1978 Jan-Feb. 6(1). P 19-24.
MJ ASTHMA: pp.  CHLORIDES: an.  CYSTIC-FIBROSIS: pp.  SWEAT: an.
MN ADOLESCENCE.  ADULT.  ASTHMA: et, fg.  CHILD.  CHILD-PRESCHOOL.
   CHRONIC-DISEASE.  CYSTIC-FIBROSIS: co, di.  FEMALE.  HUMAN.  INFANT.
   MALE.  MIDDLE-AGE.  RESPIRATORY-HYPERSENSITIVITY: et.
AB In 87 patients with svere chronic asthma, the sweat chloride (Cl)
   level was determined, and increased concentrations were found in 12
   (13.7%).  In 76% of the relatives of these patients increased sweat
   Cl levels were also found.  The authors give data of their clinical
   and allergy study and conclude that 13.7% of the patients under
   investigation had clinical characteristics of asthma, allergy and a
   functional exocrine disorder.  The exocrinopathy may be an important
   factor in the pathophysiology of certain types of asthma.
RF 001   CAPLIN I              ANN ALLERGY                     31   320 973
   002   ANON                  IN: PORTER R                    38   174 971
   003   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   004   FIGUEIRA F            REV PAUL MED                    51    99 967
   005   KOPITO L              PEDIATRICS                      43   794 969
   006   MEARNS MB             LANCET                           1   538 967
   007   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   008   SPOCK A               PEDIATR RES                      1   173 967
   009   STRAUSS A             J PEDIATR RIO DE JANEIRO        35    12 970
   010   WARNER JO             LANCET                           1   990 976
   011   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 78013
RN 00794 
AN 78142110
AU Jacob-R-A.  Sandstead-H-H.  Solomons-N-W.  Rieger-C.  Rothberg-R.
TI Zinc status and vitamin A transport in cystic fibrosis.
SO Am-J-Clin-Nutr. 1978 Apr. 31(4). P 638-44.
MJ CYSTIC-FIBROSIS: me.  VITAMIN-A: me.  ZINC: me.
MN ADOLESCENCE.  CHILD.  HAIR: an.  HUMAN.
   RETINOL-BINDING-PROTEINS: bl.  SERUM-ALBUMIN: me.
AB Zinc status and the retinol transport system were examined in 18
   retinol supplemented cystic fibrosis (CF) patients and 40 age-matched
   controls. Plasma vitamin A was significantly lower in the CF group as
   compared to the controls and correlated positively with plasma
   retinol-binding protein (RBP) in both the CF and control groups.
   Plasma zinc of the CF group was not significantly lower than controls
   whereas hair zinc was. Plasma zinc was positively correlated with
   plasma RBP, vitamin A, and albumin in the CF group but not in the
   controls. Plasma concentrations of vitamin A, RBP, albumin, and zinc
   decreased with age in the CF group but not in the controls. The data
   support previous suggestions that low plasma vitamin A levels in CF
   are due to defects in the retinol transport system. The zinc status
   of the CF groups as a whole was judged to be low-normal however a
   subgroup of CF patients were in the marginal to deficient category.
   This subgroup also had lower levels of plasma vitamin A and RBP. The
   data suggest that zinc may be a contributing factor in the low plasma
   vitamin A/RBP levels of CF patients with marginal or deficient zinc
   status.
RF 001   ANDERSEN DH           J PEDIATR                       15   763 939
   002   KANAI MA              J CLIN INVEST                   47  2025 968
   003   SMITH FR              J CLIN INVEST                   49  1754 970
   004   UNDERWOOD BA          PEDIATR RES                      6    26 972
   005   SMITH FR              J LAB CLIN MED                  80   423 972
   006   SMITH JC JR           SCIENCE                        181   954 973
   007   SMITH JE              J LAB CLIN MED                  84   692 974
   008   HALSTED JA            LANCET                           1   322 970
   009   BROWN ED              J NUTR                         106   563 976
   010   SMITH JC JR           J NUTR                         106   569 976
   011   HUBER AM              J NUTR                         105  1486 975
   012   CARNEY SM             J NUTR                         106  1773 976
   013   SINHA SN              AM J CLIN PATHOL                54   570 970
   014   NEELD JB              J NUTR                          79   454 963
   015   KLEVAY LM             AM J CLIN NUTR                  23   284 970
   016   PALIN HD              PEDIATR RES ABST 343            10   358 976
   017   KNOEPFLE G            Z KINDERHEILK                  119   279 975
   018   HENKIN RI             AM J MED SCI                   264   401 972
   019   KIRCHGESSNER M        IN: PRASAD AS                    1   189 976
   020   MORRISON SA           AM J CLIN NUTR                  30   612 977
   021   BEISEL WR             ANN INTERN MED                  67   744 967
   022   PEKAREK RS            PROC SOC EXP BIOL MED          138   728 971
   023   SANDSTEAD HH          IN: PRASAD AS                         33 976
   024   BEISEL WR             IN: PRASAD AS                    1    87 976
   025   HALSTED JA            GASTROENTEROLOGY                67   193 974
   026   MUTO Y                J BIOL CHEM                    247  2542 972
   027   SMITH FR              AM J CLIN NUTR                  26   973 973
   028   SMITH FR              AM J CLIN NUTR                  26   982 973
   029   SMITH FR              J CLIN INVEST                   50  2426 971
   030   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   031   CRAIG JM              AM J DIS CHILD                  93   357 957
   032   STERLING K            J CLIN INVEST                   30  1238 951
   033   PITTMAN FE            AM J DIS CHILD                 108   360 964
   034   STROBER W             PEDIATRICS                      43   416 969
   035   GIROUX EL             BIOINORG CHEM                    5   211 976
CT   1   PALIN D               AM J CLIN NUTR                  32  1253 979
     2   PEKAREK RS            AM J CLIN NUTR                  32  1466 979
     3   SOLOMONS NW           AM J CLIN NUTR                  32   856 979
     4   ATUKORALA S           BR J CANCER                     40   927 979
     5   CHASE HP              J PEDIATR                       95   337 979
     6   CASPER RC             AM J CLIN NUTR                  33  1801 980
     7   SOLOMONS NW           AM J CLIN NUTR                  33  2031 980
     8   MAGAZZU G             RIV ITAL PEDIATR                 7    73 981
     9   ANDREWS WS            J PEDIATR SURG                  16   284 981
    10   HOOPER PL             AM J CLIN NUTR                  34   970 981
    11   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
    12   GORDON EF             J PEDIATR                       99   341 981
    13   HANSEN MA             ANNU REV NUTRITION               2   151 982
    14   MIKHAIL MM            EUR J CLIN INVEST               12   345 982
    15   SOLOMONS NW           AM J CLIN NUTR                  35  1048 982
    16   SOLOMONS NW           J AM DIET ASSOC                 80   115 982
    17   DELUCA F              EUR J PEDIATR                  138   327 982
    18   VANDERHOOF JA         DIG DIS SCI                     28   300 983
    19   HANSEN RC             ARCH DERMATOL                  119    51 983
    20   BALY DL               AM J CLIN NUTR                  40   199 984
    21   HUBBARD VS            SEM RESPIR MED                   6   308 985
    22   DELVES HT             CLIN ENDOCRINOL METAB           14   725 985
    23   VANWOUWE JP           SCI TOTAL ENVIRON               42   149 985
    24   RASMUSSEN M           J PEDIATR GASTROENTEROL NUTR     5   397 986

PN 78014
RN 00795 
AN 78208255
AU Finley-P-R.  Dye-J-A.  Lichti-D-A.  Byers-J-M-3d.  Williams-R-J.
TI A modified ion-selective electrode method for measurement of
   chloride in sweat.
SO Am-J-Clin-Pathol. 1978 Jun. 69(6). P 615-8.
MJ CHLORIDES: an.  CYSTIC-FIBROSIS: di.  SWEAT: an.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  ELECTRODES: is.
   HUMAN.  INFANT.
AB A modified method of analysis of sweat chloride concentration with an
   ion-selective electrode is presented. The original method of sweat
   chloride analysis proposed by the Orion Research Corporation
   (Cambridge, Massachusetts 02139) is inadequate because it produces
   erratic and misleading results. The modified method was compared with
   the reference quantitative method of Gibson and Cooke. In the
   modified method, individual electrode pads are cut and placed in the
   electrodes rather than using the pads supplied by the company;
   pilocarpine nitrate (2,000 mg/l) is used in place of pilocarpine HCl
   (640 mg/l); sodium bicarbonate as the weak electrolyte is used
   instead of K2SO4. A 10-minute period for sweat accumulation is
   employed rather than a zero-time collection as in the original Orion
   method. The modification has been studied for reproducibility in
   individuals, reproducibility between right and left arm in
   individuals; it has been compared extensively with the quantitative
   method of Gibson and Cooke, both in normal individuals and in
   patients with cystic fibrosis. There is excellent agreement between
   the modified method and the quantitative reference method. There
   appears to be a slight bias toward higher concentrations of chloride
   from the right arm compared with the left arm, but this difference is
   not medically significant.
RF 001   BOWMAN BH             N ENGL J MED                   294   937 976
   002   BRIMBLECOMBE FSW      LANCET                           2  1428 973
   003   DI SANTAGNESE PA      AM J MED                        15   777 953
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   IBBOTT FA             STANDARD METH CLIN CHEM          5   101 965
   006   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   007   ANON                  J PEDIATR                       88   711 976
   008   ROSENLUND ML          CRC CRIT REV CLIN LAB SCI        3   257 972
   009   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   010   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   011   SZABO L               CLIN CHEM                       19   727 973
   012   WARWICK WJ            CF CLUB ABST                    16    58 975

PN 78015
RN 00796 
AN 78121163
AU Rosenstein-B-J.
TI Cystic fibrosis presenting with the meconium plug syndrome.
SO Am-J-Dis-Child. 1978 Feb. 132(2). P 167-9.
MJ CYSTIC-FIBROSIS: di.  INFANT-NEWBORN-DISEASES: di.
   INTESTINAL-OBSTRUCTION: di.  MECONIUM.
MN CASE-REPORT.  CYSTIC-FIBROSIS: co, ra.  DIAGNOSIS-DIFFERENTIAL.
   FEMALE.  HUMAN.  INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: et, ra.
   INTESTINAL-OBSTRUCTION: et, ra.  MALE.  MEGACOLON: co, di.  SYNDROME.
AB The meconium plug syndrome (MPS) is a common cause of low intestinal
   obstruction in newborn infants. Usually, it is benign and not
   associated with other intestinal dysfunction. We describe the cases
   of three infants in whom there was intestinal obstruction consistent
   with the MPS and in which cystic fibrosis (CF) was later documented.
   We suggest that there is an association between the MPS and CF, and
   that the condition of all infants with the MPS be evaluated for the
   possibility of both Hirschsprung's disease and CF.
RF 001   CLATWORTHY HW         SURGERY                         39   131 956
   002   ELLIS DG              J PEDIATR SURG                   1    54 966
   003   SWISCHUK LE           AM J ROENTG RAD THER NUCL MED  103   339 968
   004   MIKITY VG             RADIOLOGY                       88   740 967
   005   GILLIS DA             CAN MED ASSOC J                 92   225 965
   006   GROSSMAN H            AM J ROENTG RAD THER NUCL MED   97   227 966
   007   EMERY JL              ARCH DIS CHILD                  32    17 957
   008   CHING NPH             ARCH SURG                       90    65 965
   009   SOKAL MM              N ENGL J MED                   286   823 972
   010   BRUNS WT              AM J DIS CHILD                 131    71 977
   011   POOLE CA              J PEDIATR SURG                  11  1011 976
   012   GREEN MN              PEDIATRICS                      41   989 968
   013   DOLAN TF JR           J PEDIATR SURG                   9   821 974
   014   STEPHAN U             PEDIATRICS                      55    35 975
CT   1   HEN J                 PEDIATRICS                      66   466 980
     2   ROSENSTEIN BJ         AM J DIS CHILD                 134    72 980
     3   STARSHAK RJ           GASTROINTEST RADIOL              6    75 981
     4   PARK RW               GASTROENTEROLOGY                81  1143 981
     5   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     6   MULLER F              PRENAT DIAGN                     5   109 985
     7   ABRAMSON SJ           SEM ROENTGENOL                  22    97 987
     8   HALL SL               CLIN PEDIATR                    26   191 987

PN 78016
RN 00797 
AN 78121196
AU Gunn-T.  Belmonte-M-M.  Colle-E.  Dupont-C.
TI Edema as the presenting symptom of cystic fibrosis: difficulties in
   diagnosis.
SO Am-J-Dis-Child. 1978 Mar. 132(3). P 317-8.
MJ CYSTIC-FIBROSIS: co.  EDEMA: et.
MN CHLORIDES: an.  CYSTIC-FIBROSIS: di.  FEMALE.  HUMAN.
   HYPOPROTEINEMIA: et.  INFANT.  MALE.  SWEAT: an.
EX Hypoproteinemia and edema may develop in infants with cystic fibrosis
   whatever their diet although prior ingestion of soy bean formula
   appears to be a predisposing factor, and a negative sweat chloride
   test may be present in a CF child during the hypoproteinemic phase of
   the illness.  The diagnosis cannot be excluded until a negative test
   with adequate secretion of sweat is obtained after edema and
   hypoproteinemia have resolved.
RF 001   FLEISHER DS           J PEDIATR                       64   341 964
   002   MULNE A               PEDIATR RES ABST 342            10   358 976
   003   BILLE BSV             ACTA PAEDIATR SCAND             44   435 955
   004   GOLDMAN AS            J PEDIATR                       59   301 961
   005   ANDERSON C            MED J AUST                       2   195 966
   006   MASI M                INT ANESTHESIOL CLIN            53    55 971
   007   MACLEAN WC JR         J PEDIATR                       83    86 973
   008   LEE PA                JAMA                           228   585 974
   009   VLACHOS P             J PEDIATR                       84   926 974
   010   DOLAN TF JR           CLIN PEDIATR                     9   295 970
   011   LOCK J                J PEDIATR                       84   912 974
   012   PAXSON CL JR          JAMA                           230  1257 974
   013   BASS HN               PEDIATRICS                      59   126 977
   014   SHAHIDI NT            J PEDIATR                       59   533 961
   015   ROGER R               J PEDIATR                       86   264 975
CT   1   NIELSEN OH            J PEDIATR GASTROENTEROL NUTR     1   355 982
     2   TURKEL SB             CLIN PERINATOL                   9   613 982
     3   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     4   CHRISTOFFEL KS        J PEDIATR                      107   231 985

PN 78017
RN 00798 
AN 79059455
AU Townes-P-L.  Kopelman-A-E.
TI Meconium plug syndrome, cystic fibrosis, and exocrine pancreatic
   deficiency [letter].
SO Am-J-Dis-Child. 1978 Oct. 132(10). P 1043-4.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: et.  MECONIUM.
   PANCREATIC-DISEASES: co.
MN CASE-REPORT.  HUMAN.  INFANT-NEWBORN.  SYNDROME.
EX We have observed severe meconium plug syndrome (MPS) in a newborn
   infant who was found during the neonatal period to have extensive
   exocrine pancreatic deficiency.  Cystic fibrosis was excluded by
   several sweat chloride tests.  Our observation of MPS in a patient
   with exocrine pancreatic deficiency suggests that the MPS observed in
   the CF patients reported by Rosenstein is probably caused by
   pancreatic deficiency.  The frequent occurrence of meconium ileus
   (MI) in CF and the rarity of MPS in CF is curious, since they may be
   different manifestations of the same pathologic process.
   Conceivably, MPS may occur with total absence of pancreatic enzymes
   (as in our patient and in a few patients with CF).  Low levels of
   enzymes in CF may limit expression to meconium ileus.  We wish to
   suggest the evaluation of exocrine pancreatic function in these
   patients even if CF has been excluded by sweat tests. - There is
   conflicting, albeit fragmentary, data suggesting that exocrine
   pancreatic deficiency may not be the sole cause of meconium
   obstruction in CF.  Several investigators have suggested that MI may
   be the result of abnormal protein and mucoprotein secretions by the
   intestinal goblet cells and not from lack of pancreatic enzymes
   alone.  While these observations suggest that exocrine pancreatic
   deficiency may not play a major role in all instance of meconium
   obstruction, it is important to note that there may be little
   correlation between the histologic appearance of the pancreas and
   exocrine function.
RF 001   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   001   ROSENSTEIN BJ         AM J DIS CHILD                 132   167 978
   002   THOMAIDIS TS          J PEDIATR                       63   444 963
   002   GROSSMAN H            AM J ROENTG RAD THER NUCL MED   97   227 966
   003   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
CT   1   ROSENSTEIN BJ         AM J DIS CHILD                 134    72 980

PN 78018
RN 00799 
AN 78208347
AU Spiro-R-K.  Landman-M-E.
TI Meconium ileus equivalent.
SO Am-J-Gastroenterol. 1978 Mar. 69(3 Pt 1). P 302-6.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: et.
MN ACETYLCYSTEINE: tu.  ADOLESCENCE.  ADULT.  AGE-FACTORS.  CASE-REPORT.
   CHILD.  CHILD-PRESCHOOL.  FECES-IMPACTED: co.  HUMAN.  ILEUM: pa, ra.
   INFANT.  INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: pa.  MALE.
   MECONIUM.  RESPIRATION-ARTIFICIAL.
AB A case of meconium ileus equivalent in a 30-year old man is
   presented. The pathology and therapy for the condition are discussed.
RF 001   HUNTON DB             GASTROENTEROLOGY                50    99 966
   002   DAVIDSON M            HOSP PRACT                       2    47 976
   003   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   004   DI SANTAGNESE PA      ANN INTERN MED                  50  1321 959
   005   QUINLAN MF            AUSTRALAS ANN MED               16    84 967
   006   SIGLER RM             MAYO CLIN PROC                  40   477 965
   007   ROWE MI               AM J SURG                      125   185 973
   008   SCHILLER M            AM J SURG                      122    22 971
   009   BROWN PM              N ENGL J MED                   263   544 960
   010   NANKIN P              AM J SURG                      123   609 972
   011   LILLIBRIDGE CB        J PEDIATR                       71   887 967
CT   1   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     2   ROSENBERG E           KLIN PAEDIATR                  195   323 983
     3   RUBINSTEIN S          PEDIATRICS                      78   473 986

PN 78019
RN 00800 
AN 78184587
AU Parry-M-F.  Neu-H-C.
TI A comparative study of ticarcillin plus tobramycin versus
   carbenicillin plus gentamicin for the treatment of serious
   infections due to gram-negative bacilli.
SO Am-J-Med. 1978 Jun. 64(6). P 961-6.
MJ ANTIBIOTICS: tu.  CARBENICILLIN: tu.  GENTAMICINS: tu.
   GRAM-NEGATIVE-AEROBIC-BACTERIA: de.  PENICILLINS: tu.
   PSEUDOMONAS-INFECTIONS: dt.  TICARCILLIN: tu.  TOBRAMYCIN: tu.
MN COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: dt.  DRUG-RESISTANCE-MICROBIAL.
   DRUG-THERAPY-COMBINATION.  HUMAN.  KIDNEY-FUNCTION-TESTS.
   KIDNEY: de.  PNEUMONIA: dt.  SEPTICEMIA: dt.
AB The combination of ticarcillin plus tobramycin (TT) or carbenicillin
   plus gentamicin (CG) was used to treat 82 patients with severe
   systemic gram-negative infection in a prospective, randomized study.
   Pseudomonas aeruginosa was the primary pathogen in 7 (93 per cent) of
   these patients. Patients treated with TT responded more frequently
   (92 per cent or 37 of 40) than patients treated with CG (71 per cent
   or 30 of 42) (p is less than 0.05). This difference was primarily due
   to a greater response to TT in patients with pulmonary infections (93
   per cent versus 68 per cent) and infections due to Pseudomonas (92
   per cent versus 70 per cent). Severity of underlying disease was also
   an important determinant of response. Except for a greater incidence
   of hepatotoxicity with CG (23 per cent versus 3 per cent; p is less
   than 0.02), there was no difference in toxicity, colonization with
   drug-resistant microorganisms or superinfection between the two
   treatment groups. The combination of TT appears to be superior to CG
   for the treatment of pulmonary infections due to Pseudomonas
   aeruginosa.
RF 001   ANDRIOLE VT           J INFECT DIS                   129   124 974
   002   LUMISH RM             J INFECT DIS                   133   538 976
   003   SCOTT RE              ANTIMICROB AGENTS CHEMOTHER     10   646 976
   004   MYEROWITZ RL          J INFECT DIS                   124   239 971
   005   MCCABE WR             BULL NY ACAD MED                51  1084 975
   006   KLASTERSKY J          J INFECT DIS                   129   187 974
   007   KLASTERSKY J          ANTIMICROB AGENTS CHEMOTHER      7   640 975
   008   PARRY MF              J PEDIATR                       90   144 977
   009   FELD R                J INFECT DIS                   135    61 977
   010   SMITH CR              N ENGL J MED                   296   349 977
   011   NEU HC                ANTIMICROB AGENTS CHEMOTHER     10   385 970
   012   NEU HC                J INFECT DIS SUPPL             134     3 976
   013   NEU HC                ANTIMICROB AGENTS CHEMOTHER      8   457 975
   014   PARRY MF              J INFECT DIS                   133    46 976
   015   MCHENRY MC            ANN INTERN MED                  74   192 971
   016   BAUER AW              AM J CLIN PATHOL                45   493 966
   017   NEU HC                APPL MICROBIOL                  21    66 971
   018   FU KP                 ANTIMICROB AGENTS CHEMOTHER     10   511 976
   019   PARRY MF              ANTIMICROB AGENTS CHEMOTHER      9   625 976
   020   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   021   PARRY MF              J INFECT DIS SUPPL             134   194 976
   022   HEWITT WL             POSTGRAD MED J SUPPL 7          50    55 974
   023   LIPNER HI             J LAB CLIN MED                  86   183 975
   024   BROWN CH 3RD          N ENGL J MED                   291   265 974
   025   PARRY MF              J INFECT DIS                   134   476 976
   026   LAU WK                AM J MED                        62   959 977
CT   1   STEWART C             DRUG INTEL CLIN PHARM           13   692 979
     2   MEYER M               CAN J MICROBIOL                 25  1232 979
     3   HOPEFL AW             AM J HOSP PHARM                 36   178 979
     4   CHOW M                CONN MED                        43    25 979
     5   PANCOAST SJ           AM J MED                        67   747 979
     6   ANDRIOLE VT           J LAB CLIN MED                  94   196 979
     7   PENNINGTON JE         J INFECT DIS                   140   881 979
     8   NEU HC                INFECTION                        8  S 62 980
     9   KOHLER RB             J CLIN MICROBIOL                12    39 980
    10   BROGDEN RN            DRUGS                           20   325 980
    11   SORKNESS R            AM J HOSP PHARM                 37   555 980
    12   YOUNG LS              J ANTIMICROB CHEMOTHER           8   121 981
    13   BELL WE               ANN NEUROL                       9   313 981
    14   HOPEFL AW             DRUG INTEL CLIN PHARM           15   697 981
    15   ELLIS PP              CAN J OPHTHALMOL                16    79 981
    16   MOZZANA R             HAEMATOLOGICA                   66   634 981
    17   BRINKER KR            J LAB CLIN MED                  98   292 981
    18   HYATT AC              J PEDIATR                       99   307 981
    19   ELIOPOULOS GM         REV INFECT DIS                   4   282 982
    20   BELL WE               SEM PERINATOL                    6     1 982
    21   PARRY MF              J ANTIMICROB CHEMOTHER           9   273 982
    22   PENNINGTON JE         ANTIMICROB AGENTS CHEMOTHER     22   406 982
    23   ABRAMOWITZ PW         AM J HOSP PHARM                 39  1176 982
    24   TENENBAUM MJ          MED CLIN NORTH AM               66    17 982
    25   GRAFT DF              J PEDIATR                      100   497 982
    26   KOHLER RB             ARCH INTERN MED                142  1335 982
    27   BODEY GP              REV INFECT DIS                   5   279 983
    28   SAVOIA D              DRUGS UNDER EXP CLIN RES         9   143 983
    29   CHIN NX               J ANTIMICROB CHEMOTHER          11    33 983
    30   SRINIVASAN S          INFECTION                       11   291 983
    31   BINT AJ               J ANTIMICROB CHEMOTHER          12   115 983
    32   GASPARETTO A          J ANTIMICROB CHEMOTHER          12   171 983
    33   SHLAES DM             PEDIATR CLIN NORTH AM           30   121 983
    34   KAHLMETER G           J ANTIMICROB CHEMOTHER          13     9 984
    35   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    36   ENG RHK               INT J DERMATOL                  23   153 984
    37   YOUNG LS              AM J MED                        76    61 984
    38   MOORE RD              AM J MED                        77   657 984
    39   SCULLY BE             ARCH INTERN MED                144    57 984
    40   ACAR JF               REV INFECT DIS                   7  S513 985
    41   LEVISON ME            REV INFECT DIS                   7  S656 985
    42   SCULLY BE             REV INFECT DIS                   7  S669 985
    43   CONE LA               ANTIMICROB AGENTS CHEMOTHER     28    33 985
    44   BALTCH AL             AM J MED                        79     8 985
    45   WILSON CB             J PEDIATR                      106  1049 985
    46   HANNO P               UROL CLIN NORTH AM              13   577 986
    47   ARPI M                CHEMOTHERAPY                    32    68 986
    48   EVANS DA              AM J MED                        80    39 986

PN 78020
RN 00801 
AN 78254310
AU Knox-G-E.  Palmer-M-D.  Huddleston-J-F.
TI Fetal cystic fibrosis presenting as dystocia due to midgut volvulus
   with lethal perforation.
SO Am-J-Obstet-Gynecol. 1978 Jul 15. 131(6). P 698-9.
MJ CYSTIC-FIBROSIS: di.  DYSTOCIA: di.  FETAL-DISEASES: di.
MN ADULT.  DIAGNOSIS-DIFFERENTIAL.  DYSTOCIA: et.  FEMALE.  HUMAN.
   INTESTINAL-OBSTRUCTION: co.  PERITONITIS: co, et.  PREGNANCY.
   RUPTURE-SPONTANEOUS.
EX Fetal or neonatal volvulus is a rare event and is usually associated
   with an anatomic defect.  Massive abdominal distension secondary to a
   ruptured or unruptured volvulus has never been reported as a cause of
   obstructed labor.  The present report documents such a case,
   secondary to chemical peritonitis resulting from a ruptured midgut
   volvulus.  This case demonstrates an unusual presentation of presumed
   cystic fibrosis with meconium ileus and volvulus which led to
   ischemic infarction and perforation of the small bowel.  This case
   likewise emphasizes the need to consider the presence of other fetal
   anomalies, such as omphalocele or gastroschisis, when the usual
   maneuvers fail to relieve shoulder dystocia.
RF 001   KRASNA IH             J PEDIATR SURG                   8   615 973
   002   SROUJI MN             J PEDIATR SURG                   9   779 974
CT   1   SHALEV J              J MED GENET                     20   229 983

PN 78021
RN 00802 
AN 78078929
AU Davis-S-D.  Bruns-W-T.
TI Effects of sputum from patients with cystic fibrosis on the activity
   in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa.
SO Am-Rev-Respir-Dis. 1978 Jan. 117(1). P 176-8.
MJ ANTIBIOTICS: pd.  CYSTIC-FIBROSIS.  PSEUDOMONAS-AERUGINOSA: de.
   SPUTUM.
MN CARBENICILLIN: pd.  GENTAMICINS: pd.  HUMAN.
   MICROBIAL-SENSITIVITY-TESTS.  NEOMYCIN: pd.  POLYMYXIN-B: pd.
   TOBRAMYCIN: pd.  SUPPORT-U-S-GOVT-P-H-S.
AB By in vitro tests on 12 strains of Pseudomonas aeruginosa, sputum
   from patients with cystic fibrosis sharply increased the minimal
   bactericidal concentrations of polymyxin B and neomycin. Sputum had a
   lesser effect on tests with gentamicin and tobramycin and essentially
   none on tests with carbenicillin.
RF 001   NEWTON BA             NATURE                         172   160 953
   002   NEWTON BA             J GEN MICROBIOL                 10   491 954
   003   POTTER JL             ANN NY ACAD SCI                106   692 963
   004   POTTER JL             PEDIATRICS                      36   714 965
   005   GARROD LP             J CLIN PATHOL                   22   534 969
   006   SAGGERS BA            J CLIN PATHOL                   23   266 970
   007   KUNIN CM              J INFECT DIS                   121    55 970
   008   DAVIS SD              J INFECT DIS                   123   392 971
   009   DAVIS SD              J INFECT DIS                   124   610 971
   010   CHEN CH               ANTIMICROB AGENTS CHEMOTHER      2   331 972
   011   DAVIS SD              APPL MICROBIOL                  23   775 972
   012   DAVIS SD              ANTIMICROB AGENTS CHEMOTHER      1   466 972
   013   DAVIS SD              CHEMOTHERAPY                    19   243 973
   014   DIENSTAG J            ANTIMICROB AGENTS CHEMOTHER      1    41 972
   015   ZIMELIS VM            J INFECT DIS                   127   663 973
   016   BRYANT RE             ANTIMICROB AGENTS CHEMOTHER      6   702 974
   017   D AMATO RF            ANTIMICROB AGENTS CHEMOTHER      7   596 975
   018   LENNETTE EH           MANUAL OF CLINICAL MICROBIOLO            974
   019   RELLER LD             J INFECT DIS                   130   454 974
   020   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            974
CT   1   ALEXANDER MR          CHEST                           75   675 979
     2   VAUDAUX P             J ANTIMICROB CHEMOTHER           8    17 981
     3   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     4   MAXWELL D             J ANTIMICROB CHEMOTHER          11   203 983
     5   STACK BHR             THORAX                          40   358 985
     6   MENDELMAN PM          AM REV RESPIR DIS              132   761 985
     7   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985

PN 78022
RN 00803 
AN 78164287
AU Lemen-R-J.  Gates-A-J.  Mathe-A-A.  Waring-W-W.  Hyman-A-L.
   Kadowitz-P-D.
TI Relationships among digital clubbing, disease severity, and serum
   prostaglandins F2alpha and E concentrations in cystic fibrosis
   patients.
SO Am-Rev-Respir-Dis. 1978 Apr. 117(4). P 639-46.
MJ CYSTIC-FIBROSIS: di.  OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: et.
   PROSTAGLANDINS-E: bl.  PROSTAGLANDINS-F: bl.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: bl, co.  FEMALE.  HUMAN.  MALE.
   OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: bl.  SUPPORT-U-S-GOVT-P-H-S.
   VITAL-CAPACITY.
AB Nine patients with cystic fibrosis but without digital clubbing
   (Group A) were matched, prospectively, by sex and approximate age to
   9 cystic fibrosis patients with digital clubbing (Group B) and to 9
   normal persons (control subjects). Patients in Group B had
   significantly (P less than 0.05) lower clinical scores and forced
   vital capacity than did those in Group A, indicating more severe
   pulmonary disease in the former; however, other spirometer tests of
   pulmonary function revealed no differences between Groups A and B.
   The degree of digital clubbing had significant (P less than 0.05)
   linear relationships to forced vital capacity (r = -0.73) and
   clinical scores (r = 0.853) for Groups A and B. Plasma concentrations
   of prostaglandins F2alpha and E were significantly increased (P less
   than 0.05) in both Group A (X +/- SE, 0.48 +/- 0.03 and 0.87 +/- 0.10
   ng per ml, respectively) and Group B (X +/- SE, 0.68 +/- 0.04 and
   1.81 +/- 0.16 ng per ml, respectively) compared to the control group
   (X +/- SE, 0.14 +/- 0.01 and 0.39 +/- 0.02 ng per ml, respectively).
   Group B had significantly larger concentrations than did Group A;
   however, plasma concentrations of prostaglandin 15-keto-13, 14-
   dihydro metabolite were not different in Groups A and B, and were
   significantly smaller than in the control group. These studies
   suggest that the degree of digital clubbing in cystic fibrosis is
   related to the severity of the pulmonary involvement and that the
   prostaglandin system may play an important role in this disease.
RF 001   BIGLER FC             AM J PATHOL                     34   237 958
   002   LOVELL RRH            CLIN SCI                         9   299 950
   003   DEGOWIN EL            BEDSIDE DIAGNOSTIC EXAMINATIO        546 965
   004   MELLINS RB            CIRCULATION                     33   143 966
   005   WIERMAN WH            JAMA                           155  1459 954
   006   WARING WW             AM REV RESPIR DIS              104   166 971
   007   MAUER EF              AM HEART J                      34   852 947
   008   TURNER-WARWICK M      THORAX                          18   238 963
   009   MCLAUGHLIN GE         ANN INTERN MED                  67   579 967
   010   BASHOUR FA            J LAB CLIN MED                  58   613 961
   011   GREEN K               LANCET                           2  1419 974
   012   MATHE AA              IN: RAMSWELL PW                  3   169 977
   013   WOOD RE               AM REV RESPIR DIS              113   833 976
   014   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   015   LEMEN RG              IN: KENDIG EL JR                     166 977
   016   LEVINE L              ADV BIOL SCI                     9    71 973
   017   MATHE AA              ACTA PHYSIOL SCAND SUPPL 98    441   155 976
   018   MATHE AA              BIOCHEM PHARMACOL               26   181 977
   019   SNEDECOR GW           STATISTICAL METHODS                      967
   020   REID L                MOD PROBL PEDIATR               10   195 967
   021   ZUELZER WW            PEDIATRICS                       4    53 949
   022   BEIER FR              AM REV RESPIR DIS               94   430 966
   023   COOK CD               PEDIATRICS                      24   181 959
   024$  SIEGLER RL            J PEDIATR                       81   734 977
   025   FERREIRA SH           NATURE                         216   868 967
   026   BOWDEN DH             AM J MED                        38   226 965
   027   ROSENTHAL A           PEDIATRICS                      59   588 977
   028   LIEBERMAN J           ANN INTERN MED                  82   806 975
   029   HALL GH               J APPL PHYSIOL                  21   923 966
   030$  SAMUELSSON B          ANNU REV BIOCHEM               898   669 975
   031   NAKANO J              PROC SOC EXP BIOL MED          144   506 973
   032   HABBOUSHE C           PEDIATRICS                      48   973 971
   033   SAID SI               FED PROC                        32  1972 973
   034   KUO PT                J PEDIATR                       60   394 962
   035   ROSENLUND ML          PEDIATRICS                      59   428 977
   036   ELLIOTT RB            PEDIATRICS                      57   474 976
   037   ELLIOTT RB            PEDIATR RES                      7   427 973
   038   CAMPBELL IM           PEDIATRICS                      57   480 976
   039   BAKHLE YS             PHYSIOL REV                     54  1007 974
   040   LIEBERMAN J           AM REV RESPIR DIS              109   743 974
CT   1   DODGE JA              LANCET                           2   475 978
     2   SCHRIJEN F            CLIN SCI MOL MED                55   485 978
     3   LLOYDSTILL JD         PEDIATRICS                      64    50 979
     4   GIRI SN               J PHARMACOL METHODS              4   335 980
     5   GIRI SN               ENVIRON RES                     21   467 980
     6   CHANDLER DB           PROSTAGLANDINS MED               7   571 981
     7   METZ SA               METABOLISM                      30   299 981
     8   GODARD P              RESPIRATION                     42    43 981
     9   SHNEERSON JM          BR J DIS CHEST                  75    75 981
    10   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
    11   MARTINEZLAVIN M       ARTHRITIS RHEUM                 25  1186 982
    12   LAVI Y                J THORAC CARDIOVASC SURG        84   373 982
    13   CHANDLER DB           PROSTAGLANDINS LEUKOTR MED      11    11 983
    14   MOON MA               PROSTAGLANDINS                  25   615 983
    15   HANSEN RC             ARCH DERMATOL                  119    51 983
    16   CHANDLER DB           AM REV RESPIR DIS              128    71 983
    17   ANDERSON CM           J PEDIATR GASTROENTEROL NUTR     3    15 984
    18   DAVIS PB              J LAB CLIN MED                 104   203 984
    19   RUSSI EW              BR MED J                       288  1160 984
    20   SPRINCE  NL           N ENGL J MED                   310   375 984
    21   GIRI SN               EXP LUNG RES                     9   119 985
    22   CHANDLER DB           PROSTAGLANDINS LEUKOTR MED      19   139 985
    23   LEUNG FW              WEST J MED                     142   345 985
    24   MATUCCICERINIC M      J RHEUMATOL                     13   834 986
    25   MISCHLER EH           PEDIATR RES                     20    36 986
    26   PITTSTUCKER TJ        ARCH DIS CHILD                  61   576 986
    27   BENDVOLD E            J REPROD FERTIL                 78   311 986
    28   OZAKI T               J APPL PHYSIOL                  62   219 987

PN 78023
RN 00804 
AN 78185256
AU Stern-R-C.  Wood-R-E.  Boat-T-F.  Matthews-L-W.  Tucker-A-S.
   Doershuk-C-F.
TI Treatment and prognosis of massive hemoptysis in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1978 May. 117(5). P 825-8.
MJ CYSTIC-FIBROSIS: co.  HEMOPTYSIS: th.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: tu.  BLOOD-TRANSFUSION.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: th.  DRAINAGE.  FEMALE.
   HEMOPTYSIS: et, mo.  HUMAN.  MALE.  OHIO.  PHYSICAL-THERAPY.
   PROGNOSIS.  RECURRENCE.  SUPPORT-U-S-GOVT-P-H-S.  VITAMIN-K: tu.
AB Massive hemoptysis (volume of expectorated blood > 300 ml in 24
   hours) occurred in 38 (5 per cent) of 728 patients with cystic
   fibrosis.  Twenty-two of the patients were in the midst of a
   relatively long-lasting flare-up of pulmonary infection.  There was
   no other consistent precipitating event.  All but 7 of the patients
   were admitted after the initial episode and were treated with
   parenteral antimicrobial drugs.  Postural drainage was resumed as
   rapidly as possible after cessation of acute bleeding.  Vitamin K
   was administered to all patients.  Volumes of expectorated blood
   were as large as 2,500 ml with the initial episode.  Blood pressure
   changes occurred in 4 patients.  Five patients received blood
   transfusions.  Bleeding stopped without surgical intervention in all
   patients, usually within 4 days.  The 38 patients had a total of 85
   episodes of bleeding.  No surgical treatment was undertaken at this
   center.  One patient underwent a lobectomoy at another hospital but
   continued to bleed postoperatively.  Ten patients died (mean
   survival after hemoptysis, 2.5 years; range, 3 months to 6 years).
   This survival rate is comparable to that of another group of
   patients with equally severe lung disease who had never bled
   profusely.  The other 28 patients remain alive from 7 months to 20
   years after their initial episode.  Our dat suggest that massive
   hemoptysis complicating cystic fibrosis may not be as ominous an
   event as has been believed in the past.  Because of the tendency of
   most patients to stop bleeding without aggressive surgical
   intervention, future studies of new therapeutic measures for massive
   hemoptysis must have appropriate untreated control patients who
   receive only medical management.
RF 001   HOLSCLAW DS           J PEDIATR                       76   829 970
   002   LEVITSKY S            JAMA                           213   125 970
   003   FELLOWS KE            RADIOLOGY                      114   551 975
   004   ORES CN               AM REV RESPIR DIS               99   790 969
   005   KHAW K-T              CF CLUB ABST                             977
   006   REMY J                RADIOLOGY                      122    33 977
   007   DOERSHUK CF           J PEDIATR                       65   677 964
   008   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   009   WOOD RE               AM REV RESPIR DIS              113   833 976
   010   MACK JF               BR J RADIOL                     38   422 965
   011   SAW EC                CHEST                           70   589 976
   012$  SAHEBJAMI H           CHEST                           69   131 977
CT   1   REMY J                NOUV PRESSE MED                  7  4306 978
     2   FINK RJ               CHEST                           74   643 978
     3   WOOD RE               SOUTH MED J                     72   189 979
     4   MARACHE P             ANN RADIOL (PARIS)              23   337 980
     5   FAIRFAX AJ            BR J DIS CHEST                  74   345 980
     6   TOM LWC               ANN OTOL RHINOL LARYNGOL        89   419 980
     7   FRIEDMAN PJ           AM J ROENTGENOL                136  1131 981
     8   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     9   MAGEE G               LUNG                           160   165 982
    10   MARMON L              J PEDIATR SURG                  18   811 983
    11   PORTER DK             J THORAC CARDIOVASC SURG        86   409 983
    12   BOBROWITZ ID          ARCH INTERN MED                143  1343 983
    13   PORTER DK             ARCH INTERN MED                143   287 983
    14   DAVIS PB              CHEST                           85   802 984
    15   LESTER LA             SEM RESPIR MED                   6   285 985
    16   BERKIN KE             EUR J RESPIR DIS                67   103 985
    17   TAFRESHI M            NY STATE J MED                  85    38 985

PN 78024
RN 00805 
AN 78122210
AU Lopez-Vidriero-M-T.  Reid-L.
TI Chemical markers of mucous and serum glycoproteins and their
   relation to viscosity in mucoid and purulent sputum from various
   hypersecretory diseases.
SO Am-Rev-Respir-Dis. 1978 Mar. 117(3). P 465-77.
MJ BRONCHIAL-DISEASES: me.  CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: an.
   MUCUS: an.  SPUTUM: an.
MN ASTHMA: me.  BRONCHIECTASIS: me.  BRONCHITIS: me.  CHRONIC-DISEASE.
   FEMALE.  FUCOSE: an.  HUMAN.  MALE.  SIALOGLYCOPROTEINS: an.
   VISCOSITY.
AB Mucus and serum are always present in sputum. The concentrations of
   their markers were measured in mucoid and purulent sputum from
   patients with chronic bronchitis, asthma, cystic fibrosis, or
   bronchiectasis. Differences in the concentrations of both mucous and
   serum glycoproteins were greater among different macroscopic types of
   sputum than among diseases for the same macroscopic type. Comparison
   between diseases showed that sputum from patients with asthma had the
   widest variation in concentrations of markers of mucous glycoprotein
   and dry macromolecular weight. When the astham group was further
   analyzed, it became apparent that patients with extrinsic asthma
   without chronic bronchitis represented a homogeneous group, whereas
   those with intrinsic asthma, with or without chronic bronchitis, were
   responsible for the wide variation. The concentrations of markers of
   mucous and serum glycoproteins in a sputum sample were correlated
   with the apparent viscosity of the sputum to establish the relative
   contribution of the glycoproteins to the viscosity of sputum. In
   mucoid sputum, the mucous glycoprotein was most important in
   determining the viscosity, whereas when in infected sputum, both
   mucous and serum components contributed to the viscosity.
RF 001   DEGAND P              BULL PHYSIOPATH RESPIR NANCY     9   199 973
   002   BOAT TF               IN: DULFANO MJ                       243 973
   003   ROBERTS GP            EUR J BIOCHEM                   50   265 974
   004   CREETH JM             BIOCHEM J                      167   557 977
   005   BROGAN TD             THORAX                          26   418 971
   006   BROGAN TD             THORAX                          30    72 975
   007   SPIRO SG              J CLIN PATHOL                   28    60 975
   008   KEAL EE               POSTGRAD MED J                  47   171 971
   009   LOPEZ-VIDRIERO MT     THORAX                          28   401 973
   010   PUCHELLE E            BULL PHYSIOPATH RESPIR NANCY     9   237 973
   011   ROBERTS GP            ARCH BIOCHEM BIOPHYS           173   528 976
   012   LITT M                BIORHEOLOGY                     11   111 974
   013   MARRIOTT C            BIORHEOLOGY                     11   119 974
   014   MARRIOTT C            BIORHEOLOGY                     11   129 974
   015   LITT M                BIORHEOLOGY                     13    37 976
   016   CHEN TM               BIORHEOLOGY                     13   211 976
   017   FORBES J              LANCET                           2   767 957
   018   MUNIES R              J PHARM SCI                     57   824 968
   019   LIEBERMAN J           AM REV RESPIR DIS               97   654 968
   020   DAVIS SS              BULL PHYSIOPATH RESPIR NANCY     9    47 973
   021   ANON                  LANCET                           2   775 965
   022   PORTER R              CIBA FOUND STUDY GROUP 38                971
   023   ANDERSON CM           MED J AUST                       1   419 958
   024   CHARMAN J             BIORHEOLOGY                      9   185 972
   025   WARREN L              J BIOL CHEM                    234  1971 959
   026   GIBBONS MN            ANALYST                         80   268 955
   027   ANTONOPOULOS CA       ACTA CHEM SCAND                 16  1521 962
   028   DAS I                 FED EUR BIOCHEM SOC 9TH MTG          438 974
   029   PALMER KNV            BR J DIS CHEST                  64   185 970
   031   LAMB D                HISTOCHEM J                      4    91 972
   032   JONES R               HISTOCHEM J                      5    19 973
   033   LAMB D                THESIS                                   969
   034   KEAL EE               THESIS                                   970
   035   LAMB D                J PATHOL                        98   213 969
   036   LAMB D                BR J DIS CHEST                  66   239 972
   037   JONES R               J PATHOL                       116     1 975
   038   JONES R               PROC INT SYMP ON MUCUS I             397 976
   039   MCCARTHY C            Q J EXP PHYSIOL                 49    85 964
   040   LAMB D                J PATHOL BACTERIOL              96    87 968
   041   JONES R               BR MED J                         2   142 972
   042   JONES R               BR J EXP PATHOL                 54   229 973
   043   MATTHEWS LW           AM REV RESPIR DIS               88   199 963
   044   DENNIS EG             J ALLERGY                       35   464 964
   045   SCHULTZE HE           MOLECULAR BIOL OF HUMAN PROTE    1       966
   046   HOUSTON JC            THORAX                           8   207 953
   047   KEAL EE               IN: STEIN M                          223 975
   048   EARLE BV              THORAX                           8   195 953
   049   GLYNN AA              THORAX                          15   142 960
   050   GORDON WI             PROC SYMP NATURE OF ASTHMA            25 964
   051   VIDAL J               COLLOQ INT PATHOL THORAC LILL         69 968
   052   DUNNILL MS            IN: STEIN M                          213 975
   053   TURIAF J              J FRANC MED CHIR THORAC         12   290 958
   054   GIBBONS RA            BIOCHEM J                       73   209 959
   055   GIBBONS RA            BIOCHEM J                       73   209 959
   056   PUCHELLE E            BIORHEOLOGY                     12   219 975
   057   MEYER FA              BIORHEOLOGY                     13    49 976
   058   KEAL EE               THORAX                          27   643 972
CT   1   LOPEZVIDRIERO MT      THORAX                          34   512 979
     2   WANNER A              AM J MED                        67   477 979
     3   LOPEZVIDRIERO MT      SCAND J RESPIR DIS            1979    33 979
     4   SHIMURA S             BIORHEOLOGY                     17   363 980
     5   BATTISTA SP           ARCH ENVIRON HEALTH             35   239 980
     6   REID LM               ENVIRON HEALTH PERSPECT         35   113 980
     7   KING M                FED PROC                        39  3080 980
     8   KING M                EUR J RESPIR DIS                61    39 980
     9   LOPEZVIDRIERO MT      EUR J RESPIR DIS                61    21 980
    10   LOPEZVIDRIERO MT      J COMP PATHOL                   90   415 980
    11   KING M                PEDIATR RES                     15   120 981
    12   PUCHELLE E            BIORHEOLOGY                     18   659 981
    13   BAUER E               RES COMMUN CHEM PATH PHARM      34   547 981
    14   MIRRAKHIMOV MM        TER ARKH                        53   110 981
    15   SNYDER CE             CARBOHYD RES                   105    87 982
    16   MORRIS JB             ANAL BIOCHEM                   121   129 982
    17   REID L                ADV EXP MED BIOL               144   369 982
    18   REID L                EXP LUNG RES                     4   157 983
    19   HARBITZ O             EUR J RESPIR DIS                65   512 984
    20   MORETTI M             EUR J RESPIR DIS                65   365 984
    21   STELANDER M           EUR J RESPIR DIS                65     5 984
    22   GREENSTONE M          BR J DIS CHEST                  79     9 985
    23   BROWN DT              ANN OTOL RHINOL LARYNGOL        94     3 985
    24   BROFELDT S            AM REV RESPIR DIS              133  1138 986
    25   MORETTI M             THORAX                          42   229 987
    26   ROGERS DF             CLIN SCI                        72   629 987

PN 78025
RN 00806 
AN 79101945
AU Stern-R-C.  Boat-T-F.  Orenstein-D-M.  Wood-R-E.  Matthews-L-W.
   Doershuk-C-F.
TI Treatment and prognosis of lobar and segmental atelectasis in cystic
   fibrosis.
SO Am-Rev-Respir-Dis. 1978 Nov. 118(5). P 821-6.
MJ ATELECTASIS: et.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  ATELECTASIS: di, th.  BRONCHOSCOPY.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HUMAN.  INFANT.  MALE.  PROGNOSIS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Lobar atelectasis occurred in 30 (4.1 per cent) and segmental
   atelectasis occurred in 6 (0.8 per cent) of 728 patients with cystic
   fibrosis. The right lung was involved in all 11 patients less than 5
   years of age and in 18 of 26 episodes in 19 older patients. Five of
   the younger patients died within 5 years of the initial episode.
   Bronchoscopy (with or without local lavage) performed in addition to
   intensified medical therapy did not appear to improve the outcome.
   Future studies of therapeutic measures (including bronchoscopy) for
   treatment of atelectasis complicating cystic fibrosis must include
   appropriate control patients who receive only medical therapy.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   178 953
   002   LLOYD-STILL JD        PEDIATRICS                      53   678 974
   003   WOOD RE               AM REV RESPIR DIS              113   833 976
   004   WARING WW             ADV PEDIATR                     23   401 976
   005   SHWACHMAN H           PEDIATRICS                      46   335 970
   006   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            963
   007   JAY SJ                N ENGL J MED                   293   798 975
   008   FOX HM                AM REV RESPIR DIS              108   469 973
   009   ABDULMAJID OA         THORAX                          31   635 976
   010   WELLONS HA            AM J DIS CHILD                 130   301 976
   011   DEES SC               JAMA                           197     8 966
   012   LIU PV                HOSP PRACT                      11   139 976
   013   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   014   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   015   HOLSCLAW DS           CLIN PEDIATR                     9   346 970
CT   1   REDDING GJ            PEDIATR CLIN NORTH AM           31   891 984
     2   HODSON ME             POSTGRAD MED J                  60   225 984
     3   LESTER LA             SEM RESPIR MED                   6   285 985
     4   REDDING GJ            PEDIATR RES                     19   552 985
     5   NUSSBAUM E            CLIN PEDIATR                    24   379 985
     6   ABMAN SH              J PEDIATR                      107   933 985
     7   SHERMAN JM            PEDIATR PULMONOL                 2   244 986
     8   TOMASHEFSKI JF        AM REV RESPIR DIS              133   535 986

PN 78026
RN 00807 
AN 79081157
AU Brackenridge-C-J.
TI The seasonal variation of births of offspring from couples
   heterozygous for cystic fibrosis.
SO Ann-Hum-Genet. 1978 Oct. 42(2). P 197-201.
MJ CYSTIC-FIBROSIS: fg.  SEASONS.
MN AUSTRALIA.  BIRTH-RATE.  FEMALE.  FERTILITY.  GENES.  HETEROZYGOTE.
   HUMAN.  INFANT-NEWBORN.  MALE.  STATISTICS.  TEMPERATURE.
AB To test whether the month of birth of patients with cystic fibrosis
   (CF) is seasonally distributed as reported in a Dutch survey,
   published Australian data were examined and no difference in the
   monthly variation was found between births of CF patients and their
   unaffected sibs. When the two groups were combined and analysed by
   periodic regression using successively higher Fourier terms, a
   significant fit to the observed frequencies was obtained with a
   bimodal curve. Possession of a single CF gene seems therefore
   sufficient for expression of the cyclic variation. In substantial
   agreement with the Dutch series, maximum frequencies were found to
   occur in March or April and in September. It is suggested that one or
   both parents may be subject to variable fertility mediated by a
   temperature-dependent mechanism. The relevance of a periodic
   fertility pattern in preserving the CF gene in the population by
   selective heterozygote advantage is discussed.
RF 001   BLISS CI              STATISTICS IN BIOLOGY            2   219 970
   002   DANKS DM              ANN HUM GENET                   28   323 965
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   EDWARDS JH            ANN HUM GENET                   25    89 961
   005   FROGGATT P            BR J PREV SOC MED               25   119 971
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   GUMBEL EJ             J AM STATIST ASSOC              49   267 954
   008   KESSLER WR            PEDIATRICS                       8   648 951
   009   LOWE CU               AM J DIS CHILD                  78   349 949
   010   MIETTINEN OS          BR HEART J                      32   103 970
   011   PIKE MC               BR MED J                         2   395 967
   012   SHWACHMAN H           N ENGL J MED                   255   999 956
   013   TEN KATE LP           INT J EPIDEMIOL                  6    23 977
CT   1   BRACKENRIDGE CJ       AM J MED GENET                   5   303 980
     2   BRACKENRIDGE CJ       AM J MED GENET                   5   295 980
     3   ROMEO G               RIV ITAL PEDIATR                 7   201 981
     4   DAVID TJ              J MED GENET                     18   299 981
     5   PASSARGE E            EUR J PEDIATR                  143    54 984
     6   MITCHELL RJ           HUM BIOL                        57   213 985

PN 78027
RN 00808 
AN 78078968
AU Andrews-C.  Mango-M.  Venuto-R-C.
TI Cystic fibrosis in adults [letter].
SO Ann-Intern-Med. 1978 Jan. 88(1). P 128-9.
MJ CYSTIC-FIBROSIS: di.
MN ADULT.  CASE-REPORT.  CYSTIC-FIBROSIS: co.  HEAT-EXHAUSTION: et.
   HUMAN.  HYPONATREMIA: et.  MALE.
EX An adult male was recently discovered to have cystic fibrosis after a
   unique clinical presentation not mentioned in the review article.
   This patient with recurrent episodes of heat exhaustion and
   hyponatremia had no extraordinary source of Na+ loss other than his
   sweat.  This case represents an important new presentation of cystic
   fibrosis.  Most internists view this disease as one seen only in
   chronically ill children.
RF 001   STERN RC              ANN INTERN MED                  87   188 977
   002   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   003   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 78028
RN 00809 
AN 79061093
AU Schaad-U.  Kraemer-R.  Gaze-H.  Hadorn-B.
TI One-hour blood-xylose in cystic fibrosis.
SO Arch-Dis-Child. 1978 Sep. 53(9). P 756-7.
MJ CYSTIC-FIBROSIS: bl.  XYLOSE: bl.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.  INFANT.
   MALE.  TIME-FACTORS.
AB One-hour blood-xylose concentrations after an oral xylose load were
   measured in children with cystic fibrosis (CF) and healthy controls.
   The mean of the 1-hour blood-xylose values was significantly
   increased in the group with CF. The finding confirms an earlier
   observation by Rolles et al. (1973). Its significance is not at
   present understood but it suggests that small intestinal function
   should be further investigated in CF.
RF 001   COLOMBO JP            IN: RICHTERICH R                     462 978
   002   GIBBONS ISE           ARCH DIS CHILD                  44    63 969
   003   ROE JH                J BIOL CHEM                    173   507 948
   004   ROLLES CJ             LANCET                           2  1043 973
   005   SCHAAD U              ARCH DIS CHILD                  53   420 978
   006   SCHAAD U              HELV PAEDIATR ACTA              30   331 975
CT   1   FRASE LL              GASTROENTEROLOGY                88   478 985
     2   PENNY DJ              ARCH DIS CHILD                  61  1127 986
     3   LECLERCQFOUCART J     J PEDIATR GASTROENTEROL NUTR     6    66 987

PN 78029
RN 00810 
AN 79061100
AU Ahuja-A-S.  Mann-N-M.
TI Cimetidine in cystic fibrosis [letter].
SO Arch-Dis-Child. 1978 Sep. 53(9). P 766.
MJ CIMETIDINE: tu.  CYSTIC-FIBROSIS: dt.  GUANIDINES: tu.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  FATS: an.  FECES: an.
   FEMALE.  HUMAN.  MALE.
EX A pilot study has examined the effect of cimetidine on steatorrhea in
   children with pancreatic insufficiency due to CF who were receiving
   pancreatic supplements.  Administration of cimetidine with pancreatic
   supplements reduced the faecal fat excretion in 4 out of 5 children,
   in 3 cases by more than 50%.  In Case 4 steatorrhea increased on
   cimetidine but without any symptoms and we have no explanation for
   it.  None of the children had any side effects from the drug.
   Further studies are needed to determine the indications of cimetidine
   in the dietary management of CF.
RF 001   HEIZER WD             BULL JOHNS HOPKINS HOSP        116   261 965
   002   KATTWINKEL J          PEDIATRICS                      50   133 972
   003   REGAN PT              GASTROENTEROLOGY                72   A95 977
CT   1   SCHONI M              HELV PAEDIATR ACTA              36   359 981
     2   BELL L                J CAN DIET ASSOC                42    62 981

PN 78030
RN 00811 
AN 78164870
AU Smalley-C-A.  Addy-D-P.  Anderson-C-M.
TI Limitations of the sweat test [letter].
SO Arch-Dis-Child. 1978 Apr. 53(4). P 351-2.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHILD.  CHLORIDES: an.  HUMAN.  PANCREAS: pp.  SODIUM: an.
EX We are in agreement with Schwarz et al. when they state that the
   sweat test has some limitations in the diagnosis of cystic fibrosis
   (CF) and that the diagnosis is not justified on the basis of an
   abnormal sweat test unless there is other supporting evidence of the
   disease.  In our experience a much greater problem of sweat test
   accuracy occurs in hospitals where the test is carried out on a very
   much smaller number of patients and where the laboratory has a much
   lesser degree of experience than that of the authors.  We have had a
   significant number of patients referred to our regional children's
   hospital who have had abnormal sweat electrolyte measurements
   elsewhere, but unequivocally normal measurements when repeated by a
   laboratory carrying out a large number of tests.  We have not needed
   to go to the extent of serial collections of sweat and of giving
   spironolactone as have the authors.  If we obtain a test within the
   'grey area' on repeated occasions, we carefully seek other evidence
   of the disease, particularly evidence of pancreatic disease. - We do
   not advocate the general use of spironolactone: the merit of this
   drug in our experiments on certain patients was merely to support our
   suspicion of temporary hyperaldosteronism, a condition which might
   have led to erroneous conclusions in the absence of K or Cl
   determinations.
RF 001   SCHWARZ V             ARCH DIS CHILD                  52   870 977
   002   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   003   HADORN B              CAN MED ASSOC J                 98   377 968

PN 78031
RN 00812 
AN 79040865
AU Turner-M-W.  Warner-J-O.  Stokes-C-R.
TI Immunological studies in cystic fibrosis.
SO Arch-Dis-Child. 1978 Aug. 53(8). P 631-8.
MJ CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  HUMAN.
   HLA-ANTIGENS: an.  IGE: an.  IMMUNOGLOBULINS: an.  INFANT.
   RESPIRATORY-HYPERSENSITIVITY: co, im.
AB Evidence is presented to support the concept that much of the
   allergy in cystic fibrosis (CF) is IgE mediated.  Total IgE levels
   were higher in allergic than in nonallergic CF patients.  Levels
   were also higher in those patients who had had the greatest number
   of chest infections in the preceding 12 months.  IgE antibody levels
   to Dermatophagoides pteronyssinus, Timothy grass pollen, and
   Aspergillus fumigatus were higher in those with positive results
   from skin tests to these allergens.  The serum IgG, IgM, and IgA
   levels of allergic and nonallergic CF patients did not differ but
   the overall mean values for IgG and iGM were higher than those
   reported for healthy British children.  The highest levels tended to
   be present in patients with the greatest number of recent major
   chest infections and the difference was significant for IgG.  16
   patients had IgA levels >2 SD below the reported means for
   age-matched controls and 11 of these were nonallergic.  IgA levels
   were also higher in patients who had recently experienced major
   chest infections.  45 of the patients were tissue types for HLA A
   and B antigens but no significant clinical associations with single
   antigens were observed.  The antigen phenotype A1 + B8 was more
   common in patients with multiple allergic symptoms than in those
   with a single allergy or merely a positive result from a skin test.
   Nonsignificant increases of W19 in patients with frequent infections
   and of A2 in patients presenting with meconium ileus were also
   noted.  The data presented do not permit a choice to be made between
   the alternative concepts of allergy as a primary abnormality in CF,
   and allergy arising secondary to infection.
RF 001   ALLAN JD              CLIN ALLERGY                     5   255 975
   002   COOMBS RRA            IN: GELL PGH                         761 975
   003   FAHEY JL              J IMMUNOL                       94    84 965
   004   GEBHARD RL            LANCET                           2   760 973
   005   HOBBS JR              ASSOC CLIN PATHOLOGISTS BROAD          1 970
   006   KAISER GI             HLA AND DISEASE                      252 976
   007   ANON                  LANCET                           2  1291 975
   008   MACKAY IR             LANCET                           2   793 972
   009   MCNEISH AS            LANCET                           1   668 973
   010   MEARNS MB             LANCET                           1   538 967
   011   MICKEY MR             TISSUE ANTIGENS                  1    57 971
   012   MITTAL KK             TRANSPLANTATION                  6   913 968
   013   NELSON SD             TISSUE ANTIGENS                  4   361 974
   014   NYE L                 CLIN ALLERGY                     5    13 975
   015   PARISH WE             LANCET                           2   591 970
   016   PIRSKANEN R           ANN CLIN RES                     4   304 972
   017   POLYMENIDIS Z         LANCET                           2  1452 973
   018   SHAKIB F              CLIN ALLERGY                     6   237 976
   019   SOOTHILL JF           CLIN ALLERGY                     6   305 976
   020   STANWORTH DR          CLIN ALLERGY                     3    37 973
   021   SVEJGAARD A           TRANSPLANT REV                  22     3 975
   022   TAYLOR B              LANCET                           2   111 973
   023   TURNER MW             CLIN EXP IMMUNOL                27    43 977
   024   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   025   WARNER JO             LANCET                           1   990 976
   026   WARNER JO             ARCH DIS CHILD                  51   507 976
   027   WARREN CPW            CLIN ALLERGY                     5     1 975
   028   WEEKE B               DAN MED BULL                    23   155 976
   029   WIDE L                LANCET                           2  1105 967
CT   1   VANASPEREN PP         AUST PAEDIATR J                 16    53 980
     2   ORMEROD LP            THORAX                          35   768 980
     3   BRUETON MJ            ARCH DIS CHILD                  55   348 980
     4   HARPER TB             LUNG                           157   219 980
     5   DINWIDDIE R           PRACTITIONER                   224   291 980
     6   MATTHEWS WJ           N ENGL J MED                   302   245 980
     7   REEN DJ               CLIN ALLERGY                    11   571 981
     8   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   577 982
     9   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    10   GUIDOTTI TL           AM J MED SCI                   283   157 982
    11   ANON                  LANCET                           2   257 983
    12   AUERBACH HS           LANCET                           2   686 985
    13   MOSS RB               MONOGR ALLERGY                  19   202 986
    14   FERGUSON A            HUM NUTR CLIN NUTR             40C   255 986
    15   CANNY GJ              THORAX                          41   221 986
    16   FICK RB               AM REV RESPIR DIS              133   418 986
    17   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987
    18   MOSS RB               CHEST                           91   522 987

PN 78032
RN 00813 
AN 79081404
AU Yassa-J-G.  Prosser-R.  Dodge-J-A.
TI Effects of an artificial diet on growth of patients with cystic
   fibrosis.
SO Arch-Dis-Child. 1978 Oct. 53(10). P 777-83.
MJ CYSTIC-FIBROSIS: dh.  FOOD-FORMULATED.
MN ADOLESCENCE.  AGE-DETERMINATION-BY-SKELETON.  BODY-HEIGHT.
   BODY-WEIGHT.  CEPHALOMETRY.  CHILD.  CHILD-PRESCHOOL.
   CLINICAL-TRIALS.  FEMALE.  HUMAN.  MALE.  SKINFOLD-THICKNESS.
AB The effects of an artificial diet on growth were examined in a
   controlled trial on 43 patients with cystic fibrosis. 28 patients
   received the diet for 12 months. Comparison was made between their
   growth before, during, and after dietary treatment. Growth changes
   were also assessed in 15 other patients who received a conventional
   diet. Artificial dietary treatment led to some improvement in height,
   weight, subscapular skinfold thickness, and a disproportionate
   advance of bone age for the group as a whole. Only 10 (36%) patients
   had a 'clinically' significant improvement in height, weight, or both-
   -i.e. more than 0.5 standard deviation score. Greatest improvements
   were in young and mildly affected patients. It is proposed that the
   future use of such an unpleasant and expensive diet should be
   restricted to a few selected cases, rather than given as routine
   treatment.
RF 001   ALLAN JD              AM J DIS CHILD                 126    22 973
   002   BERRY HK              AM J DIS CHILD                 129   165 975
   003   CLARKE CW             Q J MED                         17   358 924
   004   DOERSHUK CF           J PEDIATR                       65   677 964
   005   HARPER MH             MED J AUST                       2   663 930
   006   LOBER CW              AM J DIS CHILD                 129  1239 975
   007   PASSINI F             DTSCH MED WSCHR                 45   851 919
   008   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   009   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   010   SPROUL A              J PEDIATR                       65   664 964
   011   TANNER JM             IN: FORFAR JO                        270 973
   012   TANNER JM             ARCH DIS CHILD                  50   142 975
   013   TANNER JM             ASSESSMENT OF SKELETAL MATURI            975
   014   TANNER JM             ARCH DIS CHILD                  41   454 966
CT   1   CHASE HP              J PEDIATR                       95   337 979
     2   KASPER H              LEBER MAGEN DARM                10   269 980
     3   KORETZ RL             GASTROENTEROLOGY                78   393 980
     4   SHEPHERD R            J PEDIATR                       97   351 980
     5   MILLER M              AM J CLIN NUTR                  36   492 982
     6   PENCHARZ PB           J PEDIATR GASTROENTEROL NUTR     2   400 983
     7   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
     8   BERTRAND JM           J PEDIATR                      104    41 984
     9   MANSELL AL            J PEDIATR                      104   700 984
    10   CANCIANI M            J PEDIATR GASTROENTEROL NUTR     4   735 985
    11   HEINE W               Z KLIN MED                      40   181 985
    12   HOLT TL               AM J CLIN NUTR                  41  1061 985
    13   RUSSELL RI            PROC NUTR SOC                   44    87 985
    14   MEARNS MB             ARCH DIS CHILD                  60   272 985
    15   CHALMERS DM           ACTA PAEDIATR SCAND             74   114 985
    16   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    17   NEIJENS HJ            ACTA PAEDIATR SCAND SUPPL 317 1985    38 985
    18   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    19   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    20   FERGUSON A            HUM NUTR CLIN NUTR             40C   255 986
    21   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    22   OLOUGHLIN E           AM J CLIN NUTR                  43   732 986
    23   MOORE MC              AM J CLIN NUTR                  44    33 986
    24   GOODCHILD MC          J ROY SOC MED                   79    32 986

PN 78033
RN 00814 
AN 78122876
AU Godfrey-S.  Mearns-M.  Howlett-G.
TI Serial lung function studies in cystic fibrosis in the first 5 years
   of life.
SO Arch-Dis-Child. 1978 Jan. 53(1). P 83-5.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN CHILD-PRESCHOOL.  FEMALE.  HUMAN.  INFANT.  MALE.
   RESPIRATORY-FUNCTION-TESTS.
AB Lung mechanics were studied in 8 infants with cystic fibrosis at 6
   months of life and radiosotopic lung function was measured in 5 of
   them at 5 years of age. The children who were initially asymptomatic
   had normal lung mechanics in infancy but the 2 restudied later had
   abnormal radioisotopic lung function. The symptomatic children showed
   abnormalities in infancy and more marked changes later. It is
   concluded that the lungs in cystic fibrosis are probably normal
   initially and that damage occurs later even in the absence of
   symptoms.
RF 001   DUBOIS AB             J CLIN INVEST                   35   322 956
   002   HOWLETT G             ARCH DIS CHILD                  47   707 972
   003   LAMARRE A             PEDIATRICS                      50   291 972
   004   PHELAN PD             ARCH DIS CHILD                  44   393 969
   005   RONCHETTI R           ARCH DIS CHILD                  50   595 975
CT   1   KRAEMER R             HELV PAEDIATR ACTA              34   417 979
     2   PEDERZINI F           RIV ITAL PEDIATR                 9   445 983
     3   GODFREY S             PEDIATRICS                      72   517 983
     4   TEPPER RS             AM REV RESPIR DIS              135  1075 987

PN 78034
RN 00815 
AN 79040866
AU Sacher-M.  Kobsa-A.  Shmerling-D-H.
TI PABA screening test for exocrine pancreatic function in infants and
   children.
SO Arch-Dis-Child. 1978 Aug. 53(8). P 639-41.
MJ P-AMINOBENZOIC-ACID: du.  AMINOBENZOIC-ACIDS: du.  INFANT-NEWBORN.
   PANCREAS: ph.  PANCREATIC-DISEASES: di.
MN P-AMINOBENZOIC-ACID: ur.  ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.
   CHYMOTRYPSIN: me.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.  INFANT.
   MALE.  PANCREAS: pp.  PANCREATIC-DISEASES: et, ur.
AB P-Amino-benzoic acid (PABA) is split specifically by pancreatic
   chymotrypsin from the synthetic tripeptide N-benzoyl-L-tyrosyl-PABA.
   The urinary excretion of absorbed PABA serves as an index for
   exocrine pancreatic function. The peptide (0.015 g/kg) was
   administered orally to 20 controls (aged between 5 months and 16
   years), 6 patients with exocrine pancreatic insufficiency caused by
   cystic fibrosis (CF), and 9 newborn infants. In the controls the mean
   6-hour PABA recovery was 58.5% (+/- 11.2 SD). Recovery in patients
   with CF was lower (P less than 0.001) with no overlap. In newborn
   infants the mean 6-hour PABA recovery was 23.4 (+/- 17.7 SD);
   overlapping in 3 instances with the results in CF patients. This
   simple, noninvasive test thus appears promising and merits further
   investigation in younger infants, especially newborns.
RF 001   ARVANITAKIS C         LANCET                           1   663 976
   002   GYR K                 GUT                             17    27 976
   003   GYR K                 GASTROENTEROLOGY                68   488 975
   004   HADORN B              J PEDIATR                       73    39 968
   005   HAVERBACK BJ          GASTROENTEROLOGY                44   588 963
   006   IMONDI AR             GUT                             13   726 972
   007   SMITH HW              J CLIN INVEST                   24   388 945
CT   1   IMONDI AR             BIOCHEM MED                     22   198 979
     2   SACHER M              J PEDIATR                       94   159 979
     3   WALLER SL             AUST NZ J MED                   10   351 980
     4   LANKISCH PG           DTSCH MED WSCHR                105  1418 980
     5   LANG C                SCHWEIZ MED WOCHENSCHR         110   522 980
     6   DOCKTER G             MONATSSCHR KINDERHEILKD        128   732 980
     7   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   746 980
     8   OSSWALD P             MONATSSCHR KINDERHEILKD        128   340 980
     9   HOEK FJ               GUT                             22     8 981
    10   LANKISCH PG           HEPATOGASTROENTEROLOGY          28   333 981
    11   LANG C                BR J SURG                       68   771 981
    12   PARK RW               GASTROENTEROLOGY                81  1143 981
    13   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    14   LIBEER JC             CLIN CHIM ACTA                 115   119 981
    15   DOCKTER G             EUR J PEDIATR                  135   277 981
    16   KAI H                 J PEDIATR GASTROENTEROL NUTR     1   445 982
    17   LANKISCH PG           GUT                             23   777 982
    18   LENTZE MJ             J PEDIATR GASTROENTEROL NUTR     2  S252 983
    19   RYAN ME               CLIN GASTROENTEROL              12   533 983
    20   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             2   249 984
    21   SATO M                J PEDIATR GASTROENTEROL NUTR     3   415 984
    22   TOSKES PP             PHARMACOTHERAPY                  4    74 984
    23   LANKISCH PG           CLIN GASTROENTEROL              13   717 984
    24   SCHONI M              PEDIATR RES                     18    66 984
    25   HUBBARD VS            DIG DIS SCI                     29   881 984
    26   HODSON ME             POSTGRAD MED J                  60   225 984
    27   GILLARD BK            AM J DIS CHILD                 138   577 984
    28   BELLENTANI S          EUR J PEDIATR                  143   145 984
    29   SCOTTA MS             CLIN BIOCHEM                    18   233 985
    30   MEE AS                GUT                             26  1257 985
    31   RIEU D                ANN PEDIATR (PARIS)             32   205 985
    32   NIEDERAU C            GASTROENTEROLOGY                88  1973 985
    33   HEYMAN MB             GASTROENTEROLOGY                89   685 985
    34   WEIZMAN Z             GASTROENTEROLOGY                89   596 985
    35   GHARBO SA             ANAL BIOCHEM                   148   228 985
    36   SCHARPE S             CLIN CHEM                       33     5 987
    37   SARLES J              ARCH FR PEDIATR                 44   311 987

PN 78035
RN 00816 
AN 78255586
AU Smalley-C-A.  Brown-G-A.  Parkes-M-E.  Tease-H.  Brookes-V.
   Anderson-C-M.
TI Reduction of bile acid loss in cystic fibrosis by dietary means.
SO Arch-Dis-Child. 1978 Jun. 53(6). P 477-82.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: dh.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co, me.  FECES: an.
   HUMAN.  PANCREATIN: tu.  CELIAC-DISEASE: dh, et.  TRIGLYCERIDES: tu.
AB On a 'normal' diet increased faecal bile acid excretion was found in
   14 of 16 children with cystic fibrosis who had steatorrhoea, but
   excretion was normal in 2 such children without steatorrhoea. The 16
   children with steatorrhoea took 3 regimens of diet and therapy: a
   'normal' diet with pancreatic enzyme supplements, a diet of reduced
   long-chain triglycerides with added medium-chain triglycerides, and
   the same diet with added pancreatic enzyme supplements. On each of
   these three regimens steatorrhoea and faecal bile acid loss were
   significantly less than on no treatment, with the lowest excretions
   occurring on the diet of reduced long-chain triglycerides with added
   medium-chain triglycerides and pancreatic enzyme supplements.
   Although a reduction in steatorrhoea was nearly always accompanied by
   a decrease in bile acid excretion, the initial bile acid loss was
   very variable and could not be predicted for any given degree of
   steatorrhoea. This suggests that at least one other factor, possibly
   liver disease or bile acid pool size, influences bile acid loss in
   the faeces.
RF 001   ANDERSON CM           MOD PROBL PEDIATR               10   326 967
   002   ANDERSON CM           LANCET                           1   836 952
   003   ANSANELLI V           FRACASTORO (VERONA)             63   637 970
   004   BAGHERI SA            GASTROENTEROLOGY                66   878 974
   005   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   006   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   007   FOSBROOKE AS          CLIN CHIM ACTA                  20   517 968
   008   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   009   GRACEY M              ARCH DIS CHILD                  45   445 970
   010   HADORN B              CAN MED ASSOC J                 98   377 968
   011   HOFMANN AF            IN: SENIOR JR                          9 968
   012   IWATA T               J BIOCHEM (TOKYO)               56   424 964
   013   LEYLAND FC            ARCH DIS CHILD                  44   170 969
   014   MURPHY GM             IN: ANDERSON CM                      667 975
   015   REDINGER RN           GASTROENTEROLOGY                64   610 973
   016   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   017   SHERR HP              AM J CLIN NUTR                  27  1369 974
   018   SHWACHMAN H           PEDIATRICS                      36   689 965
   019   TYSON KRT             J PEDIATR SURG                   3   271 968
   020   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   021   WATKINS JB            GASTROENTEROLOGY                67   835 974
   022   WEBER AM              CLIN CHIM ACTA                  39   524 972
   023   WEBER AM              N ENGL J MED                   289  1001 973
   024   WEBER AM              GASTROENTEROLOGY                68  1066 975
   025   WEBER AM              GUT                             17   295 976
   026   WEBSTER R             ARCH DIS CHILD                  28   343 953
CT   1   STARKEY BJ            MONOGR PAEDIATR                 10    12 979
     2   JONAS A               J PEDIATR                       95   366 979
     3   BALISTRERI WF         J PEDIATR                       96   582 980
     4   COLOMBO C             RIV ITAL PEDIATR                 8    77 982
     5   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
     6   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
     7   COLOMBO C             DIG DIS SCI                     28   306 983
     8   COLOMBO C             J PEDIATR GASTROENTEROL NUTR     3   556 984
     9   SETCHELL KDR          CLIN CHIM ACTA                 151   101 985
    10   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
    11   LEROY C               DIG DIS SCI                     31   911 986

PN 78036
RN 00817 
AN 78255587
AU Bray-P-T.  Clark-G-C.  Moody-G-J.  Thomas-G.  Thomas-J-D.
TI Sweat testing for cystic fibrosis.  Diagnostic screening with a
   combination chloride ion-selective electrode.
SO Arch-Dis-Child. 1978 Jun. 53(6). P 483-6.
MJ CHLORIDES: an.  CYSTIC-FIBROSIS: di.  INFANT-NEWBORN-DISEASES: di.
   SWEAT: an.
MN AGE-FACTORS.  ELECTRODES.  FEMALE.  HUMAN.  INFANT-NEWBORN.  MALE.
   METHODS.
AB Screening of sweat chloride in newborn infants with the Orion Skin
   Chloride Measuring System and incorporating some procedural
   innovations is described. The results indicate that while diagnostic
   screening for cystic fibrosis can be readily undertaken, the test
   with the chloride ion-selective electrode is best left at least to
   the second day of life or later because of insufficient sweating in
   very young babies. Measurements on 2 babies with cystic fibrosis are
   also discussed.
RF 001   ARMSTRONG D           ORION RES INC NEWSLETTER         3    28 971
   002   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   003   BRAY PT               CLIN CHIM ACTA                  77    69 977
   004   BRAY PT               CLIN CHIM ACTA                  80   333 977
   005   CHERIAN AG            CLIN CHEM                       17   652 971
   006   GIBSON LE             GAP CONF REP PROB SWEAT TESTI            975
   007   GIBSON LE             PEDIATRICS                      23   545 959
   008   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   009   KOPITO L              PEDIATRICS                      43   794 969
CT   1   BRAY PT               ARCH DIS CHILD                  53   918 978
     2   LITTLEWOOD JM         ARCH DIS CHILD                  61  1041 986
     3   BECK R                ACTA PAEDIATR SCAND             75   639 986

PN 78037
RN 00818 
AN 79081443
AU Griffiths-A-D.  Bull-F-E.
TI Sweat testing for cystic fibrosis [letter].
SO Arch-Dis-Child. 1978 Nov. 53(11). P 918.
MJ CHLORIDES: an.  CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CYSTIC-FIBROSIS: oc.  FALSE-NEGATIVE-REACTIONS.  HUMAN.
   INFANT-NEWBORN.  MASS-SCREENING.
EX Bray et al. conclude that the mass screening of newborn babies with
   chloride ion-selective electrodes is a feasible method for the
   diagnosis of cystic fibrosis; they also suggest that this procedure
   might be used in conjunction with meconium analysis to reduce the
   incidence of false positive results.  In 1972 we reported the details
   of a child with proved cystic fibrosis in whom raised sweat sodium
   but normal sweat chloride levels were obtained during treatment with
   cloxacillin.  Attention was drawn to the implication of the finding
   with regard to screening procedures, and the suggestion was made
   that, in at least some children with cystic fibrosis, the cloxacillin
   radical might replace the chloride ion in the sweat.  When mass
   screening for cystic fibrosis is to be undertaken using methods based
   on the estimation of sweat chloride levels, it is therefore prudent
   to inquire whether the infant is receiving medication from any source
   and, if so, to interpret the results with caution. - These are
   instances of false-negative sweat chloride readings, but there is no
   evidence yet from our 1205 tests of any negative cystic fibrosis
   sweat chloride; the statistical chance of this is in any case small.
   These several cases suggest a need for a systematic investigation of
   the effect of medication on sweat ion levels in general as well as in
   cystic fibrosis cases.
RF 001   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   002   BRAY PT               ARCH DIS CHILD                  53   483 978
   003   DI SANTAGNESE PA      GAP CONF REP PROB SWEAT TESTI          9 975
   004   GRIFFITHS AD          ARCH DIS CHILD                  47   132 972

PN 78038
RN 00819 
AN 79081430
AU Silverman-M.  Hobbs-F-D.  Gordon-I-R.  Carswell-F.
TI Cystic fibrosis, atopy, and airways lability.
SO Arch-Dis-Child. 1978 Nov. 53(11). P 873-7.
MJ AIRWAY-OBSTRUCTION: co.  CYSTIC-FIBROSIS: co.
   HYPERSENSITIVITY-IMMEDIATE: co.
MN ADULT.  ALLERGENS.  ASPERGILLUS-FUMIGATUS: im.  CHILD.
   CYSTIC-FIBROSIS: pp.  EXERTION.  FEMALE.  HUMAN.  MALE.
   PEAK-EXPIRATORY-FLOW-RATE.  PROSPECTIVE-STUDIES.
AB In a survey of cystic fibrosis (CF) in the Avon area, 48 children
   with CF from 40 families together with 71 of their parents were
   studied by spirometry, exercise tests, and pinch tests. A control
   group of 42 young adults was similarly tested; control data for
   children were taken from previously published work. The prevalence of
   atopy (any positive prick test) in children with CF was 48%.
   Sensitivity to grass pollens and house dust mite was no more common
   in these children (29%) than in a normal population (34%).
   Hypersensitivity to Aspergillus fumigatus was found in 35% of
   children with CF and was associated with severe lung disease. The
   parents had a normal pattern and prevalence of atopy. Exercise-
   induced airways obstruction was present in only 22% of children with
   CF; its association with severe lung disease rendered interpretation
   difficult. The parents had a normal response to exercise. Both
   hypersensitivity to A. fumigatus and exercise-induced airways
   lability had the features of acquired characteristics. There was
   nothing in the present study to support the hypothesis that the
   possession of a CF gene predisposed to atopy.
RF 001   ABBOTT V              CAN MED ASSOC J                 64   419 951
   002   ALLAN JD              CLIN ALLERGY                     5   255 975
   003   ANDERSON SD           THESIS                                   972
   004   ANDERSON SD           THORAX                          26   396 971
   005   ASTRAND PO            TEXTBOOK OF WORK PHYSIOLOGY              970
   006   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   007   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   008   COTES JE              LUNG FUNCTION                            975
   009   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   010   DAY G                 ARCH DIS CHILD                  48   355 973
   011   FEATHERBY EA          CAN MED ASSOC J                102   835 970
   012   GODFREY RC            CLIN ALLERGY                     6    79 976
   013   GODFREY S             BR J DIS CHEST                  64    15 970
   014   JONES RS              ARCH DIS CHILD                  50   909 975
   015   KULCZYCKI LL          JAMA                           175   358 961
   016   LANDAU LI             J PEDIATR                       82   863 973
   017   MCFARLANE H           LANCET                           1  1241 976
   018   PEPYS J               BR J HOSP MED                   14   412 975
   019   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   020   SILVERMAN M           THESIS                                   973
   021   SILVERMAN M           ARCH DIS CHILD                  47   882 972
   022   SWINSCOW TDV          STATISTICS AT SQUARE ONE                 977
   023   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
   024   WARNER JO             ARCH DIS CHILD                  51   507 976
   025   WARREN CPW            CLIN ALLERGY                     5     1 975
   026   ZAPLETAL A            PEDIATRICS                      48    64 971
CT   1   PRICE JF              CLIN ALLERGY                     9   563 979
     2   VANASPEREN PP         AUST PAEDIATR J                 16    53 980
     3   ORMEROD LP            THORAX                          35   768 980
     4   BRUETON MJ            ARCH DIS CHILD                  55   348 980
     5   MOSS RB               AM REV RESPIR DIS              121    23 980
     6   VANASPEREN P          AM J DIS CHILD                 135   815 981
     7   HENRY RL              AUST PAEDIATR J                 18   110 982
     8   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   582 982
     9   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    10   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    11   WILSON N              J INT BIOMED INFOR DATA          5    37 984
    12   WONNE R               CLIN ALLERGY                    15   455 985
    13   LAUFER P              CUTIS                           36   245 985
    14   SCHONHEYDER H         ACTA PATH MICROB IMMU SCA (B)   93   105 985
    15   WILMOTT RW            AM J DIS CHILD                 139   669 985
    16   DARGA LL              PEDIATR PULMONOL                 2    82 986
    17   LAROCHE D             J PEDIATR GASTROENTEROL NUTR     5   404 986

PN 78039
RN 00820 
AN 79164993
AU Rudnik-J.  Kurzawa-R.  Gawel-J.  Majewska-Zalewska-H.  Zebrak-J.
TI Activity of serum inhibitory proteases in bronchial secretions from
   children with various chronic non-specific respiratory diseases.
SO Arch-Immunol-Ther-Exp (Warsz). 1978. 26(1-6). P 717-22.
MJ ALPHA-1-ANTITRYPSIN: me.  BRONCHI: en.  BRONCHIAL-DISEASES: en.
   PROTEASE-INHIBITORS: me.
MN BRONCHI: se.  BRONCHIECTASIS: en.  BRONCHITIS: en.
   CYSTIC-FIBROSIS: en.  HUMAN.  RESPIRATORY-TRACT-INFECTIONS: en, pa.
AB In a group of 223 children with various chronic, non-specific
   respiratory diseases, the levels of serum inhibitory proteolytic
   enzymes in bronchial secretions was measured. Activity of inhibitory
   proteolytic enzymes was analyzed according to the nature of bronchial
   lesions observed at bronchoscopy and character and cellular
   composition of bronchial secretion. Statistically significant
   increase of the mean inhibitory value in comparison to values in the
   control group, was found in children with recurrent bronchitis (a-1-
   AT), cystic fibrosis (a-1-AT and a-1-X), chronic bronchitis (a-1-X),
   bronchiectases (a-1-X) and in children with obstructive bronchitis (a-
   2-M).
RF 001   BERGMANN K            Z ERKR ATMUNGSORGANE           136     3 973
   002   BROGAN TD             THORAX                          26   418 971
   003   BROGAN TD             THORAX                          30    72 975
   004   COHEN AB              J CLIN INVEST                   52  2793 973
   005   ERIKSSON S            ACTA MED SCAND                 175   197 964
   006   FEIGELSON J           ANN PEDIATR (PARIS)             18   704 971
   008   HOCHSTRASSER K        BAYER SYMPOSIUM V PROTEINASE         111 974
   009   HOCHSTRASSER K        RESPIRATION                     31   343 974
   010   HOCHSTRASSER K        HOPPE SEYLERS Z PHYSIOL CHEM   353   221 972
   011   GUNTHER W             HUSTEN AND AUSWURF                       972
   012   HUTCHISON DCS         BR J DIS CHEST                  67   171 973
   013   KIKINDJANIN V         ALLERGIE IMMUNOL                22    17 976
   014   KLEIBAUER JP          REV FR MAL RESP                  1   923 973
   015   KOSMIDER ST           PNEUM POL                       44   937 976
   016   KURZAWA R             GRUZLICA                       743   189 975
   017   LAINE A               CLIN CHIM ACTA                  67   159 976
   018   LINDH E               ACTA UNIV UPSALM                     232 975
   019   LOWRY OH              J BIOL CHEM                    193   265 951
   020   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   021   MICHEL FB             NOUV PRESSE MED                  3  2245 974
   022   MITTMAN C             AM REV RESPIR DIS              105   430 972
   023   MOSHER DF             J CLIN INVEST                   60  1036 977
   024   NEIMANN N             PEDIATRIE                       49   351 974
   025   RASCHE B              KLIN WOCHENSCHR                 55   795 977
   026   RASCHE B              PNEUMONOLOGIE                  149   157 973
   027   RASCHE B              PNEUMONOLOGIE                  144    10 971
   028   RYLEY HC              J CLIN PATHOL                   26   852 973
   029   RUDNIK J              J PEDIATR POL                   51  1279 976
   030   STEINBUCH M           BAYER SYMPOSIUM V PROTEINASE          78 974
   031   TALAMO RC             ANN NY ACAD SCI                221   234 974
   032   TOMASI TB JR          J IMMUNOL                      112  2274 974

PN 78040
RN 00821 
AN 79061368
AU Ranga-V.  Kleinerman-J.
TI Structure and function of small airways in health and disease.
SO Arch-Pathol-Lab-Med. 1978 Dec. 102(12). P 609-17. (REVIEW).
MJ BRONCHI.
MN AGING.  AIRWAY-RESISTANCE.  ANIMAL.  BRONCHI: pa, ph, pp.
   BRONCHIAL-DISEASES: di.  BRONCHITIS: pa.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: pa.  DOGS.  GRAVITATION.  HUMAN.  INFANT.
   LUNG-COMPLIANCE.  LUNG-VOLUME-MEASUREMENTS.
   MAXIMAL-EXPIRATORY-FLOW-RATE.  PULMONARY-EMPHYSEMA: pa.
   RESPIRATORY-TRACT-DISEASES: pa.  REVIEW.  SMOKING.
AB During the last two decades, great strides have been made in our
   understanding of the functional aspects of airflow in the periphery
   of the lung. It seems that the small airways are the important site
   of obstruction in a variety of chronic respiratory disorders
   associated with airflow obstruction. This review deals with the
   anatomic and functional aspects of small airways in normal and
   diseased lungs. In particular, the basis of obstruction or narrowing
   that is not dependent on intrinsic airway lesion is reviewed. The
   variety of pathologic changes in small airways observed in these
   diseases are outlined along with physiologic tests that are currently
   used to detect dysfunction at a stage long before they produce
   symptoms or alter standard tests of lung function.
RF 001   GOUGH J               PROC R SOC MED                  45   576 952
   002   MATSUBA K             AM REV RESPIR DIS              104   516 971
   003   WEST JB               J APPL PHYSIOL                  14   753 959
   004   PEDLEY TJ             RESPIR PHYSIOL                   9   387 970
   005   AMBERSON JB           TRANS ASSOC AM PHYSICIANS       60    92 947
   006   SPAIN DM              AM REV TUBERC                   68    24 953
   007   WEIBEL ER             MORPHOMETRY OF THE HUMAN LUNG            963
   008   HORSEFIELD K          J APPL PHYSIOL                  24   373 968
   009   SMITH P               THORAX                          29   147 974
   010   KUHN C                IN: BOUHUYS A                         91 976
   011   BREEZE RG             AM REV RESPIR DIS              116   705 977
   012   BASSET F              Z ZELLFORSCH MIKROSK ANAT      116    45 971
   013   EL-BERMANI AL-W       AM J ANAT                      137    12 973
   014   HUNG K-S              J ULTRASTRUCT RES               43   426 973
   015   HUGHES JMB            J APPL PHYSIOL                  32    25 972
   016   BRISCOE WA            J CLIN INVEST                   37  1279 958
   017   MILIC-EMILI J         J APPL PHYSIOL                  21   749 966
   018   GLAZIER JB            J APPL PHYSIOL                  23   694 967
   019   WEST JB               J APPL PHYSIOL                  32   332 972
   020   TURNER JM             J APPL PHYSIOL                  25   664 968
   021   NIEWOEHNER DE         J APPL PHYSIOL                  36   412 974
   022   MACKLEM PT            RESPIR PHYSIOL                   8   191 970
   023   MACKLEM PT            J APPL PHYSIOL                  22   395 967
   024   HOGG JC               N ENGL J MED                   278  1355 968
   025   WOOLCOCK AJ           J CLIN INVEST                   48  1097 969
   026   OLSON DE              J APPL PHYSIOL                  28   482 970
   027   HOGG JC               N ENGL J MED                   282  1283 970
   028   HIGH RH               PEDIATR CLIN NORTH AM            4   183 957
   029   KILBURN KH            LAB INVEST                      28    55 973
   030   MAHVI D               AM J PATHOL                     86   559 977
   031   LULLMANN-RAUCH R      VIRCHOWS ARCH CELL PATHOL       11   167 972
   032   SNIDER GL             AM REV RESPIR DIS               85   666 962
   033   BIGNON J              AM REV RESPIR DIS               99   669 969
   034   BIGNON J              THORAX                          25   556 970
   035   MATSUBA K             AM J PATHOL                     67   265 972
   036   DEPIERRE A            CHEST                           62   699 972
   037   MATSUBA K             AM REV RESPIR DIS              107   552 973
   038   ZUELZER WW            PEDIATRICS                       4    53 949
   039   WHITWELL F            THORAX                           7   213 952
   040   ANON                  HEALTH CONSEQUENCES OF SM                972
   041   ANDERSON AE JR        ARCH ENVIRON HEALTH             12   569 966
   042   SEELY JE              SCIENCE                        172   741 971
   043   NIEWOEHNER DE         N ENGL J MED                   291   755 974
   044   BODE FR               AM J MED                        59    43 975
   045   INGRAM RH             BULL PHYSIOPATH RESPIR NANCY     7   195 971
   046   DAYMAN H              J CLIN INVEST                   30  1175 951
   047   FRY DL                AM J MED                        29   672 960
   048   MEAD J                J APPL PHYSIOL                  22    95 967
   049   MACKLEM PT            J APPL PHYSIOL                  20   653 965
   050   MARTIN RR             AM REV RESPIR DIS              111   119 975
   051   SCHILDER DP           J CLIN INVEST                   42  1705 963
   052   HUTCHEON M            AM REV RESPIR DIS              110   458 974
   053   MACKLEM PT            J CLIN INVEST                   44   897 965
   054   DESPAS PJ             J CLIN INVEST                   51  3235 972
   055   MCCARTHY DS           AM J MED                        52   747 972
   056   ANTHONISEN NR         RESPIR PHYSIOL                   8    58 969
   057$  OTIS AB               J APPL PHYSIOL                  22   395 967
   058   HOWELL JBL            IN: STRETTON TB                      157 976
CT   1   BASKERVILLE A         NZ VET J                        29   235 981
     2   EBERT RV              BR J DIS CHEST                  75   277 981
     3   LINHARTOVA A          ARCH PATHOL LAB MED            106   499 982
     4   MARIN ML              LUNG                           160   257 982
     5   KILBURN KH            ARCH ENVIRON HEALTH             38   277 983

PN 78041
RN 00822 
AN 78186162
AU Beckerman-R-C.  Taussig-L-M.
TI The spectrum of cystic fibrosis in children and adults.
SO Ariz-Med. 1978 Apr. 35(4). P 246-9.
MJ CYSTIC-FIBROSIS.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di.  FEMALE.  HUMAN.  INFANT.  INFANT-NEWBORN.
   MALE.
EX Cystic fibrosis, an autosomal recessive disorder, remains the most
   common lethal genetic disease of Caucasian people.  The diagnosis of
   CF is usually made based upon the clinical presentation of chronic
   respiratory and/or gastrointestinal symptoms, a positive sweat
   electrolyte test and, often, a family history of the disorder.  The
   manifestations of chronic cough, recurrent pneumonias, bronchiectasis
   with clubbing, pneumothorax, hemoptysis, and malabsorption secondary
   to pancreatic insufficiency are so well associated with cystic
   fibrosis that the diagnosis is usually not delayed.  However, it is
   often not appreciated by physicians that CF may be associated with a
   broad spectrum of less common manifestations as well as extreme
   variability in severity of illness.  Lack of familiarity with these
   manifestations may delay diagnosis until adolescence or adulthood.
   First, there seems to be mild clinical expression of the disorder in
   some patients (genetic variability).  Second, the subtle
   manifestations of CF are not widely appreciated by physicians in
   practice.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   004   NADLER HL             IN: STANBURY JB                     1683 978
   005   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   006   TAUSSIG LM            PRACTICE OF PEDIATRICS                   976
   007   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 78042
RN 00823 
AN 78256546
AU Davidson-G-P.  Phelan-P-D.  Townley-R-R.
TI A controlled trial using intravenous infusion of soya oil emulsion
   in the treatment of children with cystic fibrosis.
SO Aust-Paediatr-J. 1978 Jun. 14(2). P 80-2.
MJ CYSTIC-FIBROSIS: dt.  OILS: ad.
MN CLINICAL-TRIALS.  EMULSIONS.  FEMALE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INFUSIONS-PARENTERAL.  MALE.  OILS: tu.  SOY-BEANS.
AB Five children with cystic fibrosis were given repeated intravenous
   infusions of soya oil emulsion (Intralipid) for 12 to 18 months and
   the effects on growth, health, sweat chloride and pancreatic enzyme
   activity compared with a control group.  No beneficial effect was
   demonstrated and it is recommended that this form of therapy has no
   place in the routine treatment of children with cystic fibrosis.  It
   is possible that treatment may have modified the degree of weight
   loss noted after 12 months of age.  The lack of other beneficial
   effects and the problems involved in long-term Intralipid infusion
   should preclude the use of this form of therapy in the routine
   treatment of children with cystic fibrosis.
RF 001   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   002   ELLIOTT RB            PEDIATRICS                      57   474 976
   003   FAJANS SS             HANDBOOK OF PHYSIOLOGY SECT 7    1   473 972
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   WATSON EH             GROWTH AND DEVELOPMENT OF CHI         96 967
   006   WILLIAMS HE           RESPIRATORY ILLNESS IN CHILDR            975
CT   1   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
     2   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983
     3   ROGIERS V             EUR J PEDIATR                  141    39 983
     4   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986

PN 78043
RN 00824 
AN 78256539
AU Phelan-P-D.
TI Management of cystic fibrosis [editorial].
SO Aust-Paediatr-J. 1978 Jun. 14(2). P 61-2.
MJ CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  CHILD.  HUMAN.  PATIENT-CARE-TEAM.
EX Controversy still surrounds the most appropriate method of management
   of children with cystic fibrosis.  The reason for much of the
   uncertainty about management of cystic fibrosis is that many
   therapeutic approaches have been proposed without properly conducted
   controlled trials.  With the current approaches to therapy, at least
   80% of children with cystic fibrosis can expect to reach adult life,
   most with minimal or no lung damage.  However, this dramatic
   improvement in survival does not indicate that cystic fibrosis is now
   an easy condition to manage and that it no longer requires
   specialised care.
RF 001   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   002   ELLIOTT RB            PEDIATRICS                      57   474 976
CT   1   NOLAN G               J PEDIATR                      101   626 982

PN 78044
RN 00825 
AN 78256545
AU Barnes-G-L.  McNaught-S.
TI False negative sweat tests with apparently adequate sweat
   collections.
SO Aust-Paediatr-J. 1978 Jun. 14(2). P 78-9.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHILD.  CHLORIDES: an.  FALSE-NEGATIVE-REACTIONS.  HUMAN.  SODIUM: an.
AB Sweat tests collected on two or more occasions from normal children
   and children with cystic fibrosis have been analysed according to
   the weight of sweat collected.  In five cases collections of 50-99
   mg of sweat gave false negative results.  Although 50-100 mg of
   sweat is considered adequate by some authorities our results do not
   support this.  The study confirms the view that at least 100 mg of
   sweat must be collected to give reliable results.
RF 001   BRAY PT               CLIN CHIM ACTA                  80   333 977
   002   ANON                  J PEDIATR                       88   711 976
   003   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   004   GIBSON LE             PROC FOR QUANTITATIVE ION                975
   005   SCHWARZ V             ARCH DIS CHILD                  52   870 977
CT   1   COLLINS JE            ACTA PAEDIATR SCAND             74   423 985
     2   CHRISTOFFEL KS        J PEDIATR                      107   231 985

PN 78045
RN 00826 
AN 78256549
AU Field-P.
TI Cystic fibrosis: a review of clinic patients.
SO Aust-Paediatr-J. 1978 Jun. 14(2). P 91-4.
MJ CYSTIC-FIBROSIS: th.  RESPIRATORY-TRACT-INFECTIONS: pc.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.
AB The response of 72 patients to an intensive antimicrobial
   prophylactic programme is presented in this review.  Treatment was
   first commenced in 1968 and was evaluated during the last 4 months
   of 1975.  The assessment confirmed a favourable clinical impression.
RF 001   SHWACHMAN H           AM J DIS CHILD                  96     6 958
CT   1   NOLAN G               J PEDIATR                      101   626 982

PN 78046
RN 00827 
AN 79021079
AU Conover-J-H.  Conod-E-J.
TI The influence of cystic fibrosis serum and calcium on secretion in
   the rabbit tracheal mucociliary apparatus.
SO Biochem-Biophys-Res-Commun. 1978 Aug 29. 83(4). P 1595-601.
MJ CALCIUM: pd.  CYSTIC-FIBROSIS: bl.  IGG: ph.  MUCUS: se.  TRACHEA: se.
MN A-23187: pd.  ANIMAL.  CYSTIC-FIBROSIS: fg, pp.  EPITHELIUM: se.
   HETEROZYGOTE.  RABBITS.  TISSUE-CULTURE.  TRACHEA: de.
AB Cystic Fibrosis serum or its isolated component IgG fraction and
   calcium ionophore A23187 all produced a quantitatively greater
   increase of mucus glycoprotein secretion in the rabbit tracheal
   epithelium than did control serum or its isolated component IgG
   fraction.  These values were determined by dry weight secretion per
   gram of tissue and on subsequent sialic acid content of secretions.
   This demonstrable increase in mucus production represents a
   measurable difference in the functioning of the cultured mucociliary
   apparatus due to the influence of cystic fibrosis serum.
RF 001   BOGART BI             PEDIATR RES                     11   131 977
   002   WILSON GB             PEDIATR RES                     11   143 977
   003   SPOCK A               PEDIATR RES                      1   173 967
   004   CONOVER JH            PEDIATR RES                      7   220 973
   005   CONOVER JH            LANCET                           2  1362 976
   006   BOGART BI             PEDIATR RES                     12    15 978
   007   WARREN L              J BIOL CHEM                    234  1971 959
   008   SCHNEIDER WC          METHODS ENZYMOL                  3   680 957
   009   CONOD EJ              PEDIATR RES                     11    45 977
   010   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   011   LOWRY OH              J BIOL CHEM                    193   265 951
CT   1   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
     2   DAVIS PB              IRCS MED SCI BIOCHEM             8   413 980
     3   DAVIS PB              PEDIATR RES                     14    83 980
     4   KENNEDY JR            PEDIATR RES                     14  1173 980
     5   PHIPPS RJ             EUR J RESPIR DIS                61    33 980
     6   WILSON GB             J CLIN INVEST                   66  1010 980
     7   HALLINAN F            MED HYPOTHESES                   7   793 981
     8   ADLER KB              LAB INVEST                      45   372 981
     9   BOAT TF               PEDIATR RES                     16   792 982
    10   BOGART BI             PEDIATR RES                     16   223 982
    11   QUISSELL DO           PEDIATR RES                     17   899 983
    12   MCPHERSON MA          CLIN CHIM ACTA                 135   181 983
    13   KATZ S                CELL CALC                        5   421 984
    14   BARBIERI EJ           BR J PHARMACOL                  82   199 984
    15   RUSSI EW              CHEST                           86   475 984
    16   WOOTEN MW             J CELL PHYSIOL                 121   490 984
    17   NEAL JL               EVOLUTIONARY THEORY              7   153 985

PN 78047
RN 00828 
AN 79020917
AU Choy-H.  Applegarth-D-A.  Davidson-A-G.  Wong-L-T.
TI Anti-plasmin (alpha2-macroglobulin) activity of plasma from cystic
   fibrosis patients.
SO Biochem-Biophys-Res-Commun. 1978 Jun 29. 82(4). P 1325-8.
MJ ALPHA-MACROGLOBULINS: me.  CYSTIC-FIBROSIS: bl.
MN CASEINS.  FIBRINOLYSIN: ai.  HUMAN.
AB We have studied the plasim-alpha2-macroglobulin interaction using
   plasma from cystic fibrosis patients.  In this system
   alpha2-macroglobulin from cystic fibrosis plasma does not differ
   from controls in its ability to bind with and inhibit plasmin.
RF 001   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   002   SHAPIRA E             CLIN CHIM ACTA                  78   359 977
   003   CRAWFORD GPM          CLIN SCI MOL MED                51   215 976
   004   SGOURIS JT            VOX SANG                         5   357 960
   005   ALKAERSIG N           J BIOL CHEM                    234    32 959
   006   NORMAN PS             J EXP MED                      106   423 957
   007   NORMAN PS             J EXP MED                      108   639 958
   008   HARPEL PC             PROC 5TH CONG INT SOC THROM H            975
   009   BARRETT AJ            BIOCHEM J                      133   709 973
CT   1   DAVIS PB              PEDIATR RES                     14    83 980
     2   ROMEO G               J LAB CLIN MED                  95   116 980
     3   PARSONS M             CLIN CHIM ACTA                 100   215 980
     4   RICHMAN JBY           CAN J BIOCHEM                   59   519 981
     5   BURY AF               IRCS MED SCI BIOCHEM            10   255 982
     6   ROBERTS RC            PEDIATR RES                     16   416 982
     7   BACK SA               BIOCHEM MED                     30    34 983
     8   SHAPIRA E             ANN NY ACAD SCI                421   352 983
     9   BRUCE MC              AM REV RESPIR DIS              132   529 985

PN 78048
RN 00829 
AN 79082306
AU Banschbach-M-W.  Karam-A-G.  Love-P-K.  Hilman-B-C.
TI Cystic fibrosis serum promotes [45Ca] uptake by normal human
   leukocytes.
SO Biochem-Biophys-Res-Commun. 1978 Oct 30. 84(4). P 922-7.
MJ CALCIUM: bl.  CYSTIC-FIBROSIS: pp.  LEUKOCYTES: me.
MN BIOLOGICAL-TRANSPORT-ACTIVE.  HUMAN.
AB A two-fold increase in [45Ca] labeling was observed when normal
   human leukocytes were incubated in the presence of serum obtained
   from patients with cystic fibrosis.  The degree of [45Ca] labeling
   of leukocytes isolated from patients with cystic fibrosis was also
   significantly greater than that observed for leukocytes that had
   been isolated from normal individuals.
RF 001   BOGART BI             PEDIATR RES                     11   131 977
   002   BOGART BI             PEDIATR RES                     12    15 978
   003   OCHSMAN JL            GAP CONF REP CALC ION CELL SE            976
   004   DAVIS PB              PEDIATR RES                     12   703 978
   005   RASMUSSEN H           ADV CYCLIC NUCLEO RES            5   375 975
   006   ANDERSON LE           ANAL BIOCHEM                    51   173 973
   007   SCHREURS VVAM         BIOCHIM BIOPHYS ACTA           419   320 976
   008   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   009   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   010   WILKOWSKE CJ          MAYO CLIN PROC                  52   616 977
   011   NEU HC                BULL NY ACAD MED                54   141 978
   012   MAREN TH              ANNU REV PHARMACOL TOXICOL      16   309 976
   013   WILSON GB             NATURE                         266   463 977
CT   1   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
     2   DAVIS PB              IRCS MED SCI BIOCHEM             8   413 980
     3   DAVIS PB              PEDIATR RES                     14    83 980
     4   DAVIS PB              J LAB CLIN MED                  96    75 980
     5   BOGART BI             PEDIATR RES                     16   223 982
     6   FEIGAL RJ             LIFE SCI                        30    93 982
     7   SHAPIRO BL            SCIENCE                        216   417 982
     8   KATZ S                CELL CALC                        5   421 984
     9   BOUCHER RC            PEDIATR RES                     18  1336 984
    10   VONRUECKER AA         PEDIATR RES                     18   594 984
    11   HART DA               IRCS MED SCI BIOCHEM            14   213 986
    12   KEMP T                PEDIATR RES                     20   520 986
    13   FEIGAL RJ             ANN NY ACAD SCI                488    82 986
    14   ZAKRZEWSKI JT         BR J CLIN PHARMACOL             23    19 987

PN 78049
RN 00830 
AN 78186681
AU Gahl-W-A.  Chesney-J.  Pitot-H-C.
TI Serum ribonuclease levels in patients with cystic fibrosis.
SO Biochem-Med. 1978 Apr. 19(2). P 294-7.
MJ CYSTIC-FIBROSIS: en.  RIBONUCLEASES: bl.
MN CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  HOMOZYGOTE.  PANCREAS: en.
   SUPPORT-U-S-GOVT-P-H-S.
EX Cystic fibrosis is an autosomal recessive disease, usually fatal
   before the third decade, characterized by chronic obstructive lung
   disease, elevated sweat electrolyte concentrations, and pancreatic
   insufficiency.  The present investigation was carried out to
   determine if P-type serum RNase activity was reduced in CF patients 3
   to 24 years of age.  No difference in serum RNase activity was found
   among the groups of 17 normals, 21 CF patients, and 5 CF
   heterozygotes.  It appears that observations of decreased RNase
   activity in the serum of young children with pancreatic insufficiency
   cannot be extended to older children, at least without withholding
   pancreatic supplements.
RF 001   LEVY CC               LIFE SCI                        17   311 975
   002   BARDON A              CLIN CHIM ACTA                  67   231 976
   003   REDDI KK              BIOCHEM BIOPHYS RES COMMUN      67   110 975
   004   ALPERS DH             J BIOL CHEM                    242  5617 967
   005   SCHMUKLER M           J BIOL CHEM                    250  2206 975
   006   ZAN-KOWALCZEWSKA M    BIOCHIM BIOPHYS ACTA           341   138 974
   007   BARDON A              BIOCHIM BIOPHYS ACTA           438   461 976
   008   ZIMMERMAN SB          ANAL BIOCHEM                    10   444 965
CT   1   WARSHAW AL            SURGERY                         86   227 979
     2   ISAACS P              DIGESTION                       22   101 981
     3   THOMAS JM             CLIN CHIM ACTA                 111   199 981
     4   WEICKMANN JL          J BIOL CHEM                    257  8705 982
     5   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983

PN 78050
RN 00831 
AN 79104083
AU Antonowicz-I.  Ishida-S.  Shwachman-H.
TI Studies in meconium in cystic fibrosis: the activities of
   alpha-D-mannosidase, beta-glucuronidase, beta-D-fucosidase, acid and
   alkaline phosphatase.
SO Biol-Neonate. 1978. 34(5-6). P 225-30.
MJ CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: me.  MECONIUM: en.
   PHOSPHATASES: me.
MN ACID-PHOSPHATASE: me.  ALKALINE-PHOSPHATASE: me.  FUCOSIDASE: me.
   GLUCURONIDASE: me.  HUMAN.  INFANT-NEWBORN.  MANNOSIDASES: me.
AB The specific activities of alpha-D-mannosidase, beta-glucuronidase,
   beta-D-fucosidase, acid and alkaline phosphatase were studied in
   meconium from infants with cystic fibrosis (CF) and control subjects.
   The study revealed significant variations in the specific activity of
   the enzymes except for acid phosphatase. The variations were not
   uniform. The activities of alpha-D-mannosidase, beta-glucuronidase
   and alkaline phosphatase were markedly decreased (p less than 0.001,
   p less than 0.002, p less than 0.001, respectively), while the
   activity of beta-D-fucosidase was significantly increased (p less
   than 0.001) in meconium from the infants with CF. It is suggested
   that the decreased activity of alpha-D-mannosidase and beta-
   glucuronidase might contribute to the accumulation of the abnormal
   substances in CF meconium. The highly increased activity of beta-D-
   fucosidase raises the possibility of an additional or alternative
   method for screening newborns for CF using meconium as the test
   material.
RF 001   ANDERSEN H            ACTA PATH MICROBIOL SCAND       61   377 964
   002   ANDERSEN DH           AM J DIS CHILD                  72    62 946
   003   ANTONOWICZ I          GASTROENTEROLOGY                67    51 974
   004   ANTONOWICZ I          PEDIATRICS                      56   782 975
   005   ANTONOWICZ I          PEDIATR RES                      6   803 972
   006   BARRETT AJ            IN: DINGLE JT                        116 973
   007   BIERRING F            ACTA PATH MICROBIOL SCAND       61   365 964
   008   BUCHANAN DJ           PEDIATRICS                       9   304 952
   009   CAIN ARR              ARCH DIS CHILD                  47   131 972
   010   CHERNICK WS           ANN NY ACAD SCI                106   698 963
   011   CROW JF               IN: NEEL JV                           23 965
   012   DANKS DM              ANN HUM GENET                   28   323 965
   013   DISCHE Z              AM J DIS CHILD                 102   733 961
   014   DISCHE Z              PEDIATRICS                      24    74 959
   015   EGGSTEIN M            KLIN WOCHENSCHR                 33   879 955
   016   FRASER D              CLIN CHIM ACTA                  59   301 975
   017   GREEN MN              PEDIATRICS                      21   635 958
   018   GREEN MN              PEDIATRICS                      41   989 968
   019   JOHANSEN PG           ANN NY ACAD SCI                106   755 963
   020   KNAUFF RE             PROC SOC EXP BIOL MED          127   801 968
   021   KOPITO L              J PEDIATR                       68   313 966
   022   LEV R                 HISTOCHEMIE                     29   103 972
   023   LEVVY GA              BIOCHEM J                       80   433 961
   024   LINHARDT K            IN: BERGMEYER HU                     783 965
   025   LOWRY OH              J BIOL CHEM                    193   265 951
   026   PALLAVICINI JC        ANN NY ACAD SCI                106   330 963
   027   ROELFS RE             AM J DIS CHILD                 113   419 967
   028   ROMEO D               BIOCHIM BIOPHYS ACTA           159   194 968
   029   RULE AH               PEDIATRICS                      45   847 970
   030   RULE AH               PEDIATRICS                      48   601 971
   031   RYLEY HC              ARCH DIS CHILD                  49   901 974
   032   SCHACHTER H           CAN J BIOCHEM                   43   381 965
   033   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   034   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   035   SIEGAL S              NONPARAMETRIC STATISTICS                 956
   036   STEINBERG AG          AM J HUM GENET                  12   416 960
   037   STEPHAN U             PEDIATRICS                      55    35 975
   038   TAPPEL AL             J BIOL CHEM                    242  2463 967
   039   VAN HOOF F            IN: HERS HG                              973
   040   WATZKA M              VERH ANAT GES                   66       971
CT   1   HSIEH MC              CLIN CHEM                       27   388 981
     2   LAMBOTTE C            J GENET HUM                     29    85 981
     3   CABEZAS JA            INT J BIOCHEM                   15   243 983
     4   RYLEY HC              CLIN CHIM ACTA                 135    49 983

PN 78051
RN 00832 
AN 79083227
AU Summitt-R-L.
TI Wolffian duct anomalies [editorial].
SO Birth-Defects. 1978. 14(6C). P 54-5.
MJ CYSTIC-FIBROSIS: fg.  VAS-DEFERENS: ab.  WOLFFIAN-DUCT.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  HUMAN.  INFANT.
   INFANT-NEWBORN.  MALE.  MIDDLE-AGE.  PHENOTYPE.  INFERTILITY-MALE.
EX The fact that a serum factor in cystic fibrosis patients inhibits
   ciliary movement of cells of isolated tracheae, and the observation
   that ciliary movement is associated with pinocytotic activity led
   Ohno et al. to suggest that this defect is responsible for aplasia or
   hypoplasia of the wolffian duct structures in males with cystic
   fibrosis.  While Ohno's hypothesis lacks definitive proof, the
   hypoplasia or aplasia of the vas in males with cystic fibrosis is
   extremely common, producing sterility in affected males.
RF 001   KAPLAN E              N ENGL J MED                   279    65 968
   002   VALMAN HB             LANCET                           2   566 969
   003   OHNO S                HEREDITAS                       69   107 971

PN 78052
RN 00833 
AN 78103772
AU Mathieu-J-P.  Stack-B-H.  Dick-W-C.  Buchanan-W-W.
TI Pulmonary infection and rheumatoid arthritis.
SO Br-J-Dis-Chest. 1978 Jan. 72(1). P 57-61.
MJ ARTHRITIS-RHEUMATOID: co.  BRONCHIECTASIS: co.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  ARTHRITIS-RHEUMATOID: im.  FEMALE.  HUMAN.
   MALE.  RESPIRATORY-FUNCTION-TESTS.  RHEUMATOID-FACTOR: an.
AB Five of eleven patients with bronchiectasis and/or cystic fibrosis
   developed a polyarthritis with positive tests for rheumatoid factor.
   Possible mechanisms of this complication are discussed.
RF 001   ALARCON-SEGOVIA D     MEDICINE (BALTIMORE)            46     1 967
   002   ARONOFF A             BR MED J                         2   228 955
   003   BERKSON J             PROC STAFF MTG MAYO CLIN        30   319 955
   004   BRINKMAN GH           AM REV TUBERC PULM DIS          80   732 959
   005   GROSSMAN H            AM J DIS CHILD                 107     1 964
   006   HARRIS J              ARTHRITIS RHEUM                  4    47 961
   007   ISAACS AJ             TUBERCLE                        55   135 974
   008   KELLGREN JH           PRACTITIONER                   193   257 964
   009   KUNKEL HG             ARTHRITIS RHEUM                  1   289 958
   010   LEE SL                ARCH INTERN MED                117   620 966
   011   MAINLAND D            AM HEART J                      45   644 953
   012   MURRAY HW             AM J MED                        58   229 975
   013   PONCET A              POLYARTHRITE TUBERCULEU                  897
   014   SINGER JM             ARTHRITIS RHEUM                  4   124 961
   015   VIRSHUP AM            ARTHRITIS RHEUM                 16   388 973
   016   VOGL A                AM J MED                        18    51 955
   017   WALKER WC             Q J MED                         36   239 967
   018   WEINSTEIN MP          AM J DIS CHILD                 127   125 974
   019   WHITE C               BR MED J                         2  1284 953
CT   1   HOWIE AD              SCOTT MED J                     24   193 979
     2   SAGRANSKY DM          AM J DIS CHILD                 134   319 980
     3   SUTTON PP             ANN RHEUM DIS                   41    47 982
     4   DELUMLEY L            ARCH FR PEDIATR                 40   723 983
     5   HILTON AM             THORAX                          39   185 984
     6   SCHIDLOW DV           ARCH DIS CHILD                  59   377 984
     7   BAMJI A               SCAND J RHEUMATOL               14    15 985
     8   BERKIN KE             EUR J RESPIR DIS                67   103 985
     9   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    10   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 78053
RN 00834 
AN 78145446
AU Benghial-A.
TI Meconium ileus equivalent an adult: a case report.
SO Br-J-Surg. 1978 Mar. 65(3). P 215.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: co.
   INTESTINE-SMALL.
MN ACETYLCYSTEINE: tu.  ADULT.  CASE-REPORT.  HUMAN.
   INTESTINAL-OBSTRUCTION: dt.  MALE.
AB A case is described of meconium ileus equivalent presenting as a
   small bowel obstruction in an adult patient with cystic fibrosis. The
   importance of conservative management with acetylcysteine and
   intravenous fluids is emphasized.
RF 001   FISHER OD             ARCH DIS CHILD                  29   262 954
   002   GRACEY M              ARCH DIS CHILD                  44   404 969
   003   HODSON ME             BR MED J                         2   790 976
   004   HUNTON DB             GASTROENTEROLOGY                50    99 966
   005   LILLIBRIDGE CB        J PEDIATR                       71   887 967

PN 78054
RN 00835 
AN 78104639
AU Harries-J-T.
TI Meconium in health and disease.
SO Br-Med-Bull. 1978 Jan. 34(1). P 75-8. (REVIEW).
MJ CYSTIC-FIBROSIS: me.  MECONIUM: an.
MN BILE-ACIDS-AND-SALTS: an.  BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: co.
   GLYCOPROTEINS: an.  HEMOGLOBINS: an.  HUMAN.  INFANT-NEWBORN.
   INTESTINAL-OBSTRUCTION: et, me.  MECONIUM: en.  REVIEW.  STEROIDS: an.
EX Meconium can be defined as the first stools passed by a newborn
   infant, the first stool being passed within 24 hours of birth by more
   than 90% of newborns.  This paper will review current knowledge on
   the sources of meconium, and its composition in health and disease
   states.  The precise origin of the components of meconium has not
   been defined.  The qualitative and quantitative patterns of the
   individual constituents of meconium in health are considered: water
   and inorganic elements, enzymes, plasma proteins, glycoproteins,
   lipids, haemoglobin metabolites, steroids and bile acids, and
   sterols.  Meconium from infants with cystic fibrosis has been more
   extensively studied than in any other disease and the paper
   concentrates on this entity.  The composition of meconium in cystic
   fibrosis, screening tests for cystic fibrosis, the diagnosis of
   cystic fibrosis, and meconium ileus are discussed.
RF 001   ANTONOWICZ I          PEDIATRICS                      56   782 975
   002   BUCHANAN DJ           J BIOL CHEM                    192   251 951
   003   BUCHANAN DJ           PEDIATRICS                       9   304 952
   004   COTE RH               IN: WOLLHEIM E                   1   489 962
   005   COTE RH               IN: AMINOFF D                        249 970
   006   COTE RH               BIOCHEM J                      153    63 976
   007   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   008   EGGERMONT E           BIOL NEONATE                    10   266 966
   009   FARBER S              J PEDIATR                       24   387 944
   010   FRASER D              CLIN CHIM ACTA                  59   301 975
   011   FRENCH J              BIOCHEM J                      120   393 970
   012   GIBSON LE             PEDIATRICS                      23   545 959
   013   GREEN MN              PEDIATRICS                      41   989 968
   014   GUSTAFSSON JA         EUR J BIOCHEM                   22   246 971
   015   HALL IC               AM J DIS CHILD                  47  1270 934
   016   HURWITT ES            AM J DIS CHILD                  64   443 942
   017   KARLSON P             INTRODUCTION TO MODERN BIOCHE        314 968
   018   KINSELLA RA JR        J CLIN ENDOCRINOL METAB         32   801 971
   019   KNAUFF RE             PROC SOC EXP BIOL MED          127   801 968
   020   KOPITO L              J PEDIATR                       68   313 966
   021   LIEBERMAN J           GASTROENTEROLOGY                50   183 966
   022   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   023   PRITCHARD JA          OBSTET GYNECOL                  28   606 966
   024   PROSSER R             ARCH DIS CHILD                  49   597 974
   025   RULE AH               PEDIATRICS                      45   847 970
   026   RULE AH               PEDIATRICS                      48   601 971
   027   RYLEY HC              ARCH DIS CHILD                  49   901 974
   028   SCHACHTER H           CAN J BIOCHEM                   43   381 965
   029   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   030   SCHWARZ E             ANN PAEDIATR                   181   306 953
   031   ACHWIDT W             VERH ANAT GES                   66    55 971
   032   SHARP HL              PEDIATR RES                      5   274 971
   033   SMITH CA              PHYSIOLOGY OF THE NEWBORN            235 959
   034   SPRINGER GF           BIOCHEMISTRY                     5  3254 966
   035   YOUNG DM              PROC SOC EXP BIOL MED           99   673 958
CT   1   KARLSSON KA           J BIOL CHEM                    256  3512 981
     2   KATZ S                DIGESTION                       24    98 982
     3   FRANCOUAL J           ANN BIOL CLIN                   40   227 982
     4   STPYREK J             J STEROID BIOCHEM               18   341 983
     5   FRANCOUAL J           CLIN CHEM                       29  2054 983
     6   SLOMIANY A            J BIOL CHEM                    258  8535 983
     7   HANLY JG              BR MED J                       286  1411 983
     8   DEHNER LP             HUM PATHOL                      17   807 986
     9   MELLANDER L           CLIN EXP IMMUNOL                63   555 986
    10   CLARK DA              J PEDIATR                      110   765 987

PN 78055
RN 00836 
AN 78104725
AU Dodge-J-A.  Yassa-J-G.
TI Zinc deficiency syndrome in a British youth with cystic fibrosis.
SO Br-Med-J. 1978 Feb 18. 1(6110). P 411.
MJ CYSTIC-FIBROSIS: co.  ZINC: df.
MN ADULT.  CASE-REPORT.  GENITALIA-MALE.  GROWTH-DISORDERS: et.  HUMAN.
   MALE.  SEX-MATURATION.  SYNDROME.
EX A syndrome of dwarfism and retarded sexual development among Iranian
   and Egyptian teenage boys has been shown to be due to zinc
   deficiency.  A British patient with cystic fibrosis and nephrotic
   syndrome showed growth retardation and hypogonadism, associated with
   low plasma zinc concentrations.  The combination of cystic fibrosis
   and nephrotic syndrome appears to be fortuitous, and undoubtedly
   adverse effects on zinc homoeostasis were cumulative.  Nevertheless,
   zinc deficiency should be considered when somatic and sexual growth
   failure occur in patients with cystic fibrosis.
RF 001   PRASAD AS             ARCH INTERN MED                111   407 963
   002   HALSTED JA            LANCET                           1   322 970
   003   EVANS GW              IN: PRASAD AS                            976
   004   SANDSTEAD HH          IN: PRASAD AS                        137 976
   005   STEELE TH             J LAB CLIN MED                  78  1019 971
CT   1   ATKINSON RL           ANN INTERN MED                  89   491 978
     2   AGGETT PJ             MONOGR PAEDIATR                 10     8 979
     3   WALRAVENS PA          WEST J MED                     130   133 979
     4   SHAW JCL              AM J DIS CHILD                 133  1260 979
     5   KYNAST G              J PERINATAL MED                  8   171 980
     6   SOLOMONS NW           AM J CLIN NUTR                  33  2031 980
     7   PARSONS HG            PEDIATRICS                      66   812 980
     8   MITCHELL EA           NZ MED J                        92     6 980
     9   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
    10   BEDDOES V             PRACTITIONER                   225   557 981
    11   HANSEN MA             ANNU REV NUTRITION               2   151 982
    12   SOLOMONS NW           AM J CLIN NUTR                  35  1048 982
    13   SOLOMONS NW           J AM DIET ASSOC                 80   115 982
    14   PATRICK J             CRC CRIT REV CLIN LAB SCI       20    95 984
    15   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    16   DODGE JA              J ROY SOC MED                   79    27 986

PN 78056
RN 00837 
AN 78145601
AU Hodson-M-E.
TI Diseases of the respiratory system: Bronchiectasis and cystic
   fibrosis.
SO Br-Med-J. 1978 Apr 15. 1(6118). P 971-3.
MJ CYSTIC-FIBROSIS.
MN BRONCHIECTASIS: co, et, th.  CYSTIC-FIBROSIS: co, di, th.
   GENETIC-COUNSELING.  HUMAN.
EX Bronchiectasis is characterised by dilatation of the bronchi.  This
   dilation may be generalised or confined to a single segment or lobe
   of the lung, and it may be tubular, fusiform (spindle shaped), or
   saccular (cystic).  The aetiology, symptoms, diagnosis, treatment,
   complications, and prevention of bronchiectasis are considered.
   Cystic fibrosis affects many exocrine glands throughout the body.
   Presentation and diagnosis, treatment, complications and their
   treatment, management of associated social problems, and death due to
   cystic fibrosis are discussed.
RF 001   HODSON ME             BR MED J                         2   790 976
CT   1   TODD JW               BR MED J                         1  1281 978
     2   FLOWER KA             BR MED J                         2   630 979
     3   FLOWER KA             MONOGR PAEDIATR                 10    54 979
     4   REDDING GJ            AM REV RESPIR DIS              126    31 982
     5   ANON                  LANCET                           2   257 983
     6   HODSON ME             BR J DIS CHEST                  77    71 983

PN 78057
RN 00838 
AN 78145788
AU Norman-A-P.
TI Bronchiectasis and cystic fibrosis [letter].
SO Br-Med-J. 1978 May 6. 1(6121). P 1217.
MJ BRONCHIECTASIS: th.  CYSTIC-FIBROSIS: th.
MN CHILD.  HUMAN.  PROGNOSIS.
EX The otherwise excellent article on bronchiectasis and cystic fibrosis
   by Dr Margaret Hodson is seriously marred by the failure to emphasise
   that the advice on management and drug dosage is directed throughout
   to the adult and adolescent, and not to the child.  Firstly,
   tetracycline should not be prescribed for young children for obvious
   reasons; secondly, the dosage of all antibiotics recommended is high
   for infants and small children.  The final paragraph gives a
   pessimistic impression of an undoubtedly distressing condition by
   stressing the early mortality of the past and of many of the older
   patients of today, without noting the effect that early diagnosis -
   perhaps as a result of neonatal screening - together with more
   effective treatment may have in the future on the quality of life and
   length of life.
RF 001   HODSON ME             BR MED J                         1   971 978

PN 78058
RN 00839 
AN 79043563
AU Walker-L.
TI My fight for life.
SO Can-Nurse. 1978 Nov. 74(10). P 28-9.
MJ ATTITUDE-TO-DEATH.  CYSTIC-FIBROSIS: px.
MN ADULT.  CASE-REPORT.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.
   PNEUMONIA: co.  PULMONARY-EMPHYSEMA: et, px.
EX A patient with cystic fibrosis discusses her experiences with the
   disease.

PN 78059
RN 00840 
AN 78188959
AU Breslow-J-L.  Epstein-J.  Fontaine-J-H.
TI Dexamethasone-resistant cystic fibrosis fibroblasts show
   cross-resistance to sex steroids.
SO Cell. 1978 Apr. 13(4). P 663-9.
MJ CYSTIC-FIBROSIS.  DEXAMETHASONE: pd.  ESTRADIOL: pd.
   PROGESTERONE: pd.  STANOLONE: pd.
MN CELL-SURVIVAL: de.  CELLS-CULTURED.  DEXAMETHASONE: me.
   DRUG-RESISTANCE.  FEMALE.  FIBROBLASTS: de, me.  HUMAN.  MALE.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB Diploid skin fibroblasts derived from individuals with the autosomal
   recessive disease, cystic fibrosis (CF), were shown previously to be
   significantly  more resistant to the cytotoxicity of dexamethasone, a
   glucocorticoid hormone, than were normal human fibroblasts. Here
   cystic fibrosis fibroblasts are also shown to be more resistant than
   normal human fibroblasts to the cytotoxic effects of the sex
   hormones, 17 beta-estradiol, dihydrotestosterone and progesterone.
   Since cells are believed to contain different receptors for each of
   the steroid hormones, it is not probable than the resistance of CF
   cells to these hormones results from a receptor deficiency. This was
   shown by the fact that CF cells were found to exhibit the same
   receptor activity as normal cells for 3-H-dexamethasone. Furthermore,
   neither normal human nor CF fibroblasts could be demonstrated to
   contain detectable receptor activity for 3H-17 beta-estradiol. In
   addition, the studies of fibroblast killing by hormones led to the
   further interesting observation that normal human diploid
   fibroblasts, regardless of the sex of the tissue donor, are sensitive
   to killing by each of the sex hormones. These findings suggest that
   the cytotoxic effects of the steroid hormones may be observed
   independently of the specific hormone receptors. The studies reported
   here thus suggest that the resistance of CF cells to the different
   steroid hormones is probably the result of a defect in a pathway in
   cellular steroid hormone metabolism other than that involving
   receptors.
RF 001   BAXTER JD             SCIENCE                        171   189 971
   002   BOURGEOIS S           CELL                            11   423 977
   003   BRESLOW JL            EXP CELL RES                   110   399 977
   004   CHAN L                N ENGL J MED                   294  1322 976
   005   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   006   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   007   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   008   FREUND JE             MODERN ELEMENTARY STATISTICS             967
   009   GORSKI J              ANNU REV PHYSIOL                38   425 976
   010   GRIFFIN JE            J CLIN INVEST                   57  1342 976
   011   HORWITZ KB            STEROID                         26   785 975
   012   KAUFMAN M             J CLIN INVEST                   58   345 976
   013   KEENAN BS             J CLIN ENDOCRINOL METAB         38  1143 974
   014   LEUNG K               ANNU REV PHYSIOL                37   245 975
   015   LOWRY OH              J BIOL CHEM                    193   265 951
   016   MEYER WJ III          PROC NAT ACAD SCI USA           72  1469 975
   017   MIDDLEBROOK JL        ENDOCRINOLOGY                  100   271 977
   018   NEIFELD JP            J BIOL CHEM                    252  2972 977
   019   ROUSSEAU GG           J STEROID BIOCHEM                6    75 975
   020   SCATCHARD G           ANN NY ACAD SCI                 51   660 949
   021   SIBLEY CH             CELL                             2   221 974
   022   YAMAMOTO KR           PROC NAT ACAD SCI USA           71  3901 974
   023   YAMAMOTO KR           IN: GREEP RO                    32     3 976
CT   1   EPSTEIN J             SOMATIC CELL GENET               4   451 978
     2   BRESLOW JL            SCIENCE                        201   180 978
     3   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     4   BRESLOW JL            J CELL PHYSIOL                  99   343 979
     5   KURZ JB               SCIENCE                        206  1317 979
     6   THOMPSON EB           J STEROID BIOCHEM               12   193 980
     7   DAVIS PB              PEDIATR RES                     14    83 980
     8   CHASE HP              METABOLISM                      29   365 980
     9   KOEFFLER HP           CANCER RES                      40   563 980
    10   DEMEYTS P             CIRC RES                        46  I  3 980
    11   BRESLOW JL            SCIENCE                        207  1007 980
    12   PEDERSEN PS           ACTA PAEDIATR SCAND             70   507 981
    13   KELLER GH             ARCH BIOCHEM BIOPHYS           211   321 981
    14   BRESLOW JL            N ENGL J MED                   304     1 981
    15   SEALE TW              ANN CLIN LAB SCI                12   415 982
    16   MINGUELL JJ           ARCH BIOL MED EXP               15   457 982
    17   JUNEJA HS             EXP HEMATOL                     12   221 984
    18   LANGHOFF E            PEDIATR RES                     18   488 984
    19   GROSS NJ              AM REV RESPIR DIS              129   805 984
    20   PINSKY L              ADV HUM GENET                   16   299 987

PN 78060
RN 00841 
AN 79126049
AU Treton-J.  Boucays-A.  Dersakissian-H.  Boue-A.  Courtois-Y.
TI The repair of DNA single strand breaks in human cells with genetical
   disorders.
SO Cell-Biol-Int-Rep. 1978 Jul. 2(4). P 403-10.
MJ DNA-REPAIR.  DNA: re.  DNA-SINGLE-STRANDED: bi.
MN ADULT.  CELL-LINE.  CHILD-PRESCHOOL.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS.  FIBROBLASTS.  HUMAN.  LESCH-NYHAN-SYNDROME.
   RETINOBLASTOMA.  TRISOMY.  X-RAYS.
AB The aim of this work was to make a preliminary examination of some
   hereditary diseases, related to precocious aging in order to
   determine whether the defects involved resulted from an impairment of
   the DNA repair capacity. To test for an impairment in DNA single
   strand capacity, in cells from patients with different diseases, we
   have followed the rate of the DNA after X-irradiation by
   sedimentation on alkaline sucrose gradients. It was found that all
   cells observed from Lesh Nyhan, cystic fibrosis, trisomy 15 et 21,
   retinoblastoma, were able to repair the single strand breaks in their
   DNA to the same extent and at the same initial rate.
RF 001   BOUE A                IN VITRO                        11   409 975
   002   BRADLEY MO            MUTATION RES                    37   279 976
   003   CLEAVER JE            PROC NAT ACAD SCI USA           63   428 969
   004   COUNIS MF             DEVELOP BIOL                    57    47 977
   005   CURE S                MOLEC CELLUL MECH AGING         27    47 973
   006   EPSTEIN JL            PROC NAT ACAD SCI USA           70   977 973
   007   EPSTEIN J             BIOCHEM BIOPHYS RES COMMUN      59   850 974
   008   GIANNELLI F           NATURE                         265   446 977
   009   HART RN               IN: CUTLER RG                    9   134 976
   010   HIGURASHI M           PEDIATR RES                      6   514 972
   011   KATO H                NATURE                         260   447 976
   012   LAMBERT B             ACTA MED SCAND                 200   433 976
   013   LINN S                PROC NAT ACAD SCI USA           73  2818 976
   014   LITTLE JB             GERONTOLOGY                     22    28 976
   015   PATERSON MC           NATURE                         260   444 976
   016   STRAUSS BS            LIFE SCI                        15  1685 974
   017   TAYLOR AMR            NATURE                         258   427 975
   018   TAYLOR AMR            NATURE                         260   441 976
   019   TICE RR               IN: CUTLER RG                    9    60 976
   020   TRETON JA             EXP CELL RES                   102   410 976
   021   TRETON JA             IN: COURTOIS Y                  60   193 976
   022   TROSKO JE             IN: CUTLER RG                    9   168 976
   023   WEICHSELBAUM RR       NATURE                         266   726 977
CT   1   LEONARD JC            MUTATION RES                   105   417 982

PN 78061
RN 00842 
AN 79106567
AU Fink-R-J.  Doershuk-C-F.  Tucker-A-S.  Stern-R-C.  Boat-T-F.
   Matthews-L-W.
TI Pulmonary function and morbidity in 40 adult patients with cystic
   fibrosis.
SO Chest. 1978 Dec. 74(6). P 643-7.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN ADOLESCENCE.  ADULT.  CYSTIC-FIBROSIS: mi.  FEMALE.
   HAEMOPHILUS-INFLUENZAE: ip.  HUMAN.  LUNG-VOLUME-MEASUREMENTS.  MALE.
   PSEUDOMONAS-AERUGINOSA: ip.  RESIDUAL-VOLUME.
   RESPIRATORY-FUNCTION-TESTS.  SEX-FACTORS.  STAPHYLOCOCCUS-AUREUS: ip.
AB Pulmonary function and cardiopulmonary complications were studied in
   a group of 40 patients with cystic fibrosis who reached the age of 25
   years. Mean values for vital capacity (VC), functional residual
   capacity, residual volume (RV), the ratio of RV over total lung
   capacity (RV/TLC), conductance, and the ratio of the forced
   expiratory volume in one second over VC were abnormal. There was a
   variable pattern of progression from patient to patient. The men
   differed from the women only in that they had a significantly larger
   TLC and inspiratory capacity than the women. The resultant
   preservation of VC may have an advantage for survival in those
   patients in whom it is observed. Pseudomonas aeruginosa was
   encountered with increasing frequency with age. Massive hemoptysis
   did not result in early death. The occurrence of rightsided heart
   failure secondary to cor pulmonale, with or without respiratory
   failure, was a poor prognostic sign.
RF 001   ANON                  CF FND 1976 REP SURVI STUD PA            978
   002   STERN RC              ANN INTERN MED                  87   188 977
   003   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   004   MATTHEWS LW           J PEDIATR                       65   558 964
   005   COMROE JH JR          LUNG CLINICAL PHYSIOLOGY AND             962
   006   DUBOIS AB             J CLIN INVEST                   35   322 956
   007   HELLIESEN PJ          PEDIATRICS                      22    80 958
   008   DOERSHUK CF           J PEDIATR                       65   677 964
   009   SHWACHMAN H           AM J DIS CHILD                  96   615 958
   010   STOWE SM              AM REV RESPIR DIS              111   611 975
   011   STERN RC              AM REV RESPIR DIS              117   825 978
   012   HOLSCLAW DS           J PEDIATR                       76   829 970
   013   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
CT   1   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     2   MATTHAY RA            BR HEART J                      43   474 980
     3   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
     4   FICK RB               CLIN CHEST MED                   2    91 981
     5   MATTHAY RA            MED CLIN NORTH AM               65   489 981
     6   GUIDOTTI TL           RESPIRATION                     44   351 983
     7   HODGES P              J AM DIET ASSOC                 84   664 984
     8   DAVIS PB              SEM RESPIR MED                   6   261 985
     9   WIESEMANN HG          MONATSSCHR KINDERHEILKD        133   726 985
    10   KRUHLAK RT            WEST J MED                     145   196 986

PN 78062
RN 00843 
AN 78147498
AU Ewing-C-W.
TI Role of the fiberoptic bronchoscope in lung lavage of patients with
   cystic fibrosis.
SO Chest. 1978 May. 73(5 Suppl). P 750-4.
MJ BRONCHOSCOPY.  CYSTIC-FIBROSIS: co.  IRRIGATION.  LUNG.
   RESPIRATORY-INSUFFICIENCY: th.
MN ADOLESCENCE.  ADULT.  CHILD.  FEMALE.  IN-VITRO.  MALE.
   RESPIRATORY-INSUFFICIENCY: et.
EX This study compared the use of the fiberoptic bronchoscope with
   other lavage techniques under general anesthesia, and of techniques
   using the rigid bronchoscope.  Seventy-seven procedures were
   performed on 39 patients with cystic fibrosis.  Their vital
   capacities were improved in 46 of the 75 valid measurements.
   Arterial blood gas levels showed improvements in 14 of the 33 values
   obtained.  A prospective study is needed which incorporates the
   values of pre- and postoperative MMEV, RV/TLC, flow volume curves
   and arterial blood gas values.  An evaluation of the complications
   and ease of operation may be of greater value.
RF 001   DOERSHUK CF           PEDIATRICS                      36   675 965
   002   KLINE BS              J EXP MED                       21   311 915
   003   WINTERNITZ MC         IN: CONTRIB MED BIOL RES            1255 919
   004   VICENTE G             REV PROGR DE LA CLINICA                  928
   005   THOMPSON HT           LANCET                           2     8 964
   006   LEFEMINE AA           ANN THORAC SURG                  4   308 967
   007   HACKETT RR            ANESTHESIOLOGY                  26   248 965
   008   RAMIREZ RJ            ANN INTERN MED                  63   819 965
   009   RAMIREZ RJ            DIS CHEST                       50   581 966
   010   CEZEAUX G JR          JAMA                           199    15 967
   011   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   012   ALTMAN RP             J PEDIATR SURG                   8   809 973
   013   MILLIS RM             CHEST                           71   508 977
   014   SACKNER MA            AM REV RESPIR DIS              111    62 975
   015   SACKNER MA            CHEST                           62   705 972
   016$  DAHM LA               CHEST                           12   593 977
   017   HOLSCLAW DS           J PEDIATR                       76   829 970
   018   ALBERTINI RE          JAMA                           230  1666 974
   019   BARRETT CR JR         AM REV RESPIR DIS              109   429 974
   020   KARETZKY MS           NY STATE J MED                  74    62 974
   021   LOBER CW              CHEST                           68   382 975
   022   BRAUNSTEIN MS         CHEST                           66    96 974
   023   BEIER FR              AM REV RESPIR DIS               94   430 966
CT   1   EMSLANDER HP          INTERNIST                       21    11 980
     2   BURNS DM              AM REV RESPIR DIS              127   695 983
     3   SHERMAN JM            PEDIATR PULMONOL                 2   244 986

PN 78063
RN 00844 
AN 78147499
AU Quick-C-A.  Warwick-W.
TI Bronchoscopy and lavage in management of pulmonary complications of
   cystic fibrosis.
SO Chest. 1978 May. 73(5 Suppl). P 755-8.
MJ BRONCHOSCOPY.  CYSTIC-FIBROSIS: co.  IRRIGATION.  LUNG-DISEASES: th.
   LUNG.
MN ADOLESCENCE.  CASE-REPORT.  FEMALE.  HUMAN.  LUNG-DISEASES: et.
EX This article presents our experience with bronchoscopy as a
   therapeutic and diagnostic tool in the management of patients with
   cystic fibrosis.  The results from therapeutic bronchoscopy and
   bronchial irrigation in cystic fibrosis patients have been quite
   impressive.  Levels of blood gas after the procedure have generally
   shown improvement.  The vital capacity and FEF1 in general have shown
   small but consistent improvements.  The most dramatic effect has been
   the patient's own assessment of the operation.  These patients state
   that their breathing is less labored in that it is less rapid and
   much deeper.  Bronchoscopy offers an effective therapeutic tool in
   the management of pulmonary complications of cystic fibrosis.
   Unfortunately, the benefit is short-lived and repeated bronchoscopic
   procedures are often necessary.  It must be accepted that there is a
   point in time when the cardiopulmonary state of a patient's cystic
   fibrosis may have progressed beyond salvageable limits.  It is our
   conviction that earlier bronchoscopy and thorough bronchial
   irrigation may prevent the critical pulmonary event which is followed
   inevitably by progressive deterioration of the pulmonary status of
   patients with cystic fibrosis.
CT   1   EMSLANDER HP          INTERNIST                       21    11 980
     2   ROTHMANN BF           ANN OTOL RHINOL LARYNGOL        91   641 982
     3   FITZPATRICK SB        AM J DIS CHILD                 137   595 983
     4   MOAZAM F              J PEDIATR SURG                  20   398 985
     5   SHERMAN JM            PEDIATR PULMONOL                 2   244 986

PN 78064
RN 00845 
AN 79002962
AU Mikkelsen-C.  Waechter-E.  Crittenden-M.
TI Cystic fibrosis: a family challenge.
SO Child-Today. 1978 Jul-Aug. 7(4). P 22-6.
MJ CYSTIC-FIBROSIS: px.  FAMILY.
MN CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.  MALE.
EX To learn how families cope with cystic fibrosis, we interviewed 18
   families who gave us vivid descriptions of the day-to-day process of
   living with this devastating disease.  The families and the disease
   are described.  Pre-diagnosis and diagnosis, home management and
   treatment, family communication about CF, the reactions of siblings,
   relationships with peers, hospitalization, and sources of support are
   discussed.
RF 002   WAECHTER E            IN: GODIN A                              972
   003   WOOD RE               AM REV RESPIR DIS              113   833 976
   005   MCCOLLUM AT           J PEDIATR                       77   571 970
CT   1   DEWET B               S AFR MED J                     65   526 984
     2   DEWET B               S AFR MED J                     67   292 985

PN 78065
RN 00846 
AN 79044102
AU Warwick-W-J.  Hansen-L.
TI Measurement of chloride in sweat with the chloride-selective
   electrode.
SO Clin-Chem. 1978 Nov. 24(11). P 2050-3.
MJ CHLORIDES: an.  SWEAT: an.
MN CYSTIC-FIBROSIS: di.  ELECTRODES.  HUMAN.  INFANT-NEWBORN.  METHODS.
   PILOCARPINE: du.
EX We describe here an improved method for the sweat test with the
   chloride-selective electrode, after sweat production is stimulated
   with pilocarpine, which gives results comparable to the more tedious
   procedure of Gibson and Cooke.  Cystic fibrosis should never be
   diagnosed solely on the results of any kind of sweat test; the
   diagnosis must be consistent with the results of the physical
   examination, history, and other studies, including a repeat of the
   two sweat tests at another time.  Only by clinical examination and
   repeated sweat tests can a physician confirm or rule out this
   diagnosis.
RF 001   SHWACHMAN H           PEDIATRICS                      30   167 962
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   GIBSON LE             CLIN PEDIATR                    12   450 973
   004   HANSEN L              MINN MED                        50  1191 967
   005   WARWICK WJ            CF CLUB ABST                           5 975
   006   WARWICK WJ            PEDIATRICS                      36   261 965
   007   HANSEN L              AM J CLIN PATHOL                49   834 968
   008   KOPITO L              PEDIATRICS                      43   794 969
   009   SZABO L               CLIN CHEM                       19   727 973
   010   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   011   STEINRUD J            DAN MED BULL                    21   251 974
   012   WARWICK WJ            JAMA                           198    59 966
   013   CHERIAN AG            CLIN CHEM                       17   652 971
   014   BRAY PT               CLIN CHIM ACTA                  77    69 977
   015   WARWICK WJ            CLIN CHEM                       24   381 978
   016   BRAY PT               CLIN CHIM ACTA                  80   333 977
   017   ANON                  J PEDIATR                       88   711 976
   018   TOCCI PM              CLIN CHEM                       22  1841 976
   019   MACLEAN WC JR         J PEDIATR                       83    86 973
   020   VLACHOS P             J PEDIATR                       84   926 974
   021$  WARWICK WJ            CF CLUB ABST                    12    21 974
CT   1   WEBSTER HL            CLIN CHEM                       27   385 981
     2   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983
     3   COURY AJ              CLIN CHEM                       29  1593 983
     4   MILLER ME             CLIN CHEM                       31  1715 985

PN 78066
RN 00847 
AN 78213515
AU Guy-G-J.  Butterworth-J.
TI Carboxypeptidase A activity of cultured skin fibroblasts and
   relationship to cystic fibrosis.
SO Clin-Chim-Acta. 1978 Jul 1. 87(1). P 63-9.
MJ CARBOXYPEPTIDASES: me.  CYSTIC-FIBROSIS: en.  SKIN: en.
MN CARBOXYPEPTIDASES: ai.  CELLS-CULTURED.  ENZYME-ACTIVATION: de.
   FIBROBLASTS: en.  HUMAN.  KINETICS.  LYSOSOMES: en.
AB Properties of carboxypeptidase A of cultured skin fibroblasts from
   control and cystic fibrosis patients were studied using alpha-N-
   carbobenzoxy-L-glutamyl-L-tyrosine as substrate. Carboxypeptidase A
   was inhibited by thiomersal, cyanide, iodoacetate and N-
   ethylmaleimide in a similar manner for control and cystic fibrosis
   fibroblasts. Both trypsin and dithiothreitol treatment activated the
   enzyme, but 1,10-phenanthroline inhibited only in the presence of
   dithiothreitol. Both Zn2+ and Co2+ reversed this inhibition. Trypsin
   treatment of carboxypeptidase A produced a form of the enzyme having
   a higher KM value for both control and cystic fibrosis fibroblasts.
   Dithiothreitol treatment of control fibroblasts resulted in a form
   with similar properties to the trypsin activated form, but cystic
   fibrosis fibroblasts yielded a variant form with even higher KM and
   Vmax values. Since other properties were similar, it seems likely
   that this difference reflected binding of a molecule to the enzyme
   rather than of a defect in the enzyme.
RF 001   BUTTERWORTH J         CLIN CHIM ACTA                  44   295 973
   002   BUTTERWORTH J         CLIN GENET                       9   505 976
   003   BUTTERWORTH J         CLIN GENET                      12   297 977
   004   LOWRY OH              J BIOL CHEM                    193   265 951
   005   TAYLOR SL             BIOCHIM BIOPHYS ACTA           341    99 974
   006   ROTH M                ANAL CHEM                       43   880 971
   007   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   008   RAO GJS               PEDIATR RES                      9   739 975
   009   ERLANGER BF           ARCH BIOCHEM BIOPHYS            95   271 961
   010   RAO GJS               J PEDIATR                       80   573 972
   011   BERGSTROM K           SCIENCE TOOLS                   24     8 977
   012   BARRETT AJ            BIOCHEM J                      133   709 973
   013   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
CT   1   BUTTERWORTH J         CLIN CHIM ACTA                  97    39 979
     2   BUTTERWORTH J         ANAL BIOCHEM                   106   156 980
     3   BUTTERWORTH J         CLIN CHIM ACTA                 108   143 980
     4   BUTTERWORTH J         J INHERIT METAB DIS              5     9 982
     5   BUTTERWORTH J         CLIN CHIM ACTA                 122    51 982

PN 78067
RN 00848 
AN 78189501
AU Davis-P-B.
TI Urinary cyclic nucleotides in adult male cystic fibrosis patients.
SO Clin-Chim-Acta. 1978 Jul 15. 87(2). P 285-8.
MJ ADENOSINE-CYCLIC-MONOPHOSPHATE: ur.  CYSTIC-FIBROSIS: ur.
   GUANOSINE-CYCLIC-MONOPHOSPHATE: ur.
MN ADULT.  BODY-SURFACE-AREA.  CREATININE: ur.  HUMAN.  MALE.
   MIDDLE-AGE.  REFERENCE-VALUES.
AB Urinary adenosine 3':5' (cyclic) monophosphate and guanosine 3':5'
   (cyclic)-monophosphate excretion are significantly elevated in adult
   male cystic fibrosis patients compared to normal men when values are
   expressed in ways which consider the smaller size of the cystic
   fibrosis subjects of the same age. Cystic fibrosis patients excreted
   3.22 +/- 1.16 nmol adenosine 3':5' (cyclic)monophosphate/g creatinine
   per 24 h vs. 1.97 +/- 0.43 for normal men (p less than 0.02); and
   cystic fibrosis patients excreted 0.50 +/- 0.16 nmol guanosine 3':k'
   (cyclic)monophosphate/g creatinine per 24 h vs. 0.30 +/- 0.07 for
   normal men (p less than 0.05). Subjects were all adults who had
   completed linear growth and sexual development, thus eliminating any
   possible effects of slower maturation of cystic fibrosis patients,
   and all subjects were male, thus avoiding the fluctuation of urinary
   cyclic nucleotides with the menstrual cycle, problems which had
   complicated interpretation of previous studies.
RF 001   SIMOPOULOS AP         PROC AM PEDIATR SOC ANNU MTG         201 971
   002   MURAD F               J CLIN ENDOCRINOL METAB         40   552 975
   003   TAYLOR AL             J CLIN ENDOCRINOL METAB         30   316 970
   004   HAMADAH K             BIOCHEM SOC TRANS                2   461 974
   005   TAUSSIG LM            J PEDIATR                       82   380 973
   006   BROWN BL              BIOCHEM J                      121   561 971
   007$  STEINER AL            ADV CYCLIC NUCLEO RES            3    89 972
   008   MURAD F               ADV CYCLIC NUCLEO RES            3   355 973
   009   MURAD F               N ENGL J MED                   286  1382 972
   010   STAHL M               J PEDIATR                       84   821 974
CT   1   AURBACH GD            ADV CYCLIC NUCLEO RES           12     1 980
     2   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     3   HUNT NH               CLIN SCI                        58   463 980
     4   EBSTEIN RP            ISR J MED SCI                   21   302 985

PN 78068
RN 00849 
AN 78082699
AU Schuttringer-G.  Zinterhofer-L.
TI Automated immunoprecipitation of meconium albumin for cystic
   fibrosis screening in the newborn.
SO Clin-Chim-Acta. 1978 Feb 1. 83(1-2). P 109-16.
MJ ALBUMINS: an.  CYSTIC-FIBROSIS: di.  MECONIUM: an.
MN CYSTIC-FIBROSIS: pc.  FALSE-POSITIVE-REACTIONS.  HUMAN.
   INFANT-NEWBORN.  MASS-SCREENING.  PRECIPITIN-TESTS: is, mt.
AB Cystic fibrosis is the most frequent substantially lethal inherited
   disease in the United States. Newborn screening for cystic fibrosis
   has been suggested because early diagnosis permits genetic
   counselling of parents and improved treatment and prognosis for
   cystic fibrosis patients. The fact that cystic fibrosis newborns have
   abnormally high meconium albumin seems to offer the best screening
   approach. Because we have had equivocal and false positive results
   with meconium albumin test strips, we have developed a nephelometric
   automated immunoprecipitation method for the quantitative and
   specific analysis of meconium albumin. On a total of 3895 meconiums
   so far examined, eleven albumin elevations of undetermined origin
   have been detected. Nine of these were associated with prematurity.
   There have been, so far, no detected true positives and no known
   false negatives. The normal range for meconium albumin is in
   agreement with previously published ranges determined using manual
   immunochemical methods. This method is rapid and economic. The
   question of sensitivity, specificity and predictive value of this and
   other detection methods is discussed.
RF 001   DI SANTAGNESE PA      IN: DOWNEY JA                         25 974
   002   THOMPSON JS           GENETICS IN MEDICINE                  58 973
   003   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   004   GEORGE L              ARCH DIS CHILD                  46   139 971
   005   SHWACHMAN H           PEDIATRICS                      46   335 970
   006   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   007   BUCHANAN DJ           PEDIATRICS                       9   304 952
   008   GREEN MN              PEDIATRICS                      21   635 958
   009   WISER WC              PEDIATRICS                      33   115 964
   010   GREEN MN              PEDIATRICS                      41   989 968
   011   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   012   CAIN ARR              ARCH DIS CHILD                  47   131 972
   013   PROSSER R             ARCH DIS CHILD                  49   597 974
   014   STEPHAN U             PEDIATRICS                      55    35 975
   015   BULL FE               ARCH DIS CHILD                  49   602 974
   016   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   017   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   018   ANON                  MEDICAL LETTER ON DRU           18    35 967
   019   HARDY JD              ARCH DIS CHILD                  48   316 973
   020   GALEN RS              BEYOND NORMALITY THE PREDICTI            975
   021   KINGSBURY FB          J LAB CLIN MED                  11   981 926
CT   1   RYLEY HC              ARCH DIS CHILD                  54    92 979
     2   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
     3   FORREST DC            ARCH DIS CHILD                  56   151 981
     4   DODGE JA              ARCH DIS CHILD                  57   774 982
     5   NAYLOR EW             SEM PERINATOL                    9   232 985

PN 78069
RN 00850 
AN 78063089
AU Shapiro-B-L.  Feigal-R-J.  Laible-N-J.  Biros-M-H.  Warwick-W-J.
TI Doubling time alpha-aminoisobutyrate transport and calcium exchange
   in cultured fibroblasts from cystic fibrosis and control subjects.
SO Clin-Chim-Acta. 1978 Jan 2. 82(1-2). P 125-31.
MJ AMINOISOBUTYRIC-ACIDS: me.  CALCIUM: me.  CYSTIC-FIBROSIS: me.
MN BIOLOGICAL-TRANSPORT.  BIOLOGICAL-TRANSPORT-ACTIVE.  CELL-DIVISION.
   FEMALE.  FIBROBLASTS: me.  HUMAN.  KINETICS.  MALE.
   SUPPORT-U-S-GOVT-P-H-S.
AB Population doubling time, kinetics of transport of alpha-
   aminoisobutyrate (AIB) and calcium (Ca) exchange were studied in skin
   fibroblast monolayers obtained from 5 subjects with cystic fibrosis
   (CF) and 5 age- and sex-matched controls. Population doubling time as
   estimated from cell count, protein and DNA was no different in the
   two groups. KM, Vmax, maximal uptake and time of half maximal uptake
   of AIB were no different in the two groups. Intracellular Ca pool
   size based on exchange of 45Ca with unlabelled Ca was significantly
   greater in monolayers from CF subjects.
RF 001   OYAMA VI              PROC SOC EXP BIOL MED           91   305 956
   002   SWITZER BR            CLIN CHIM ACTA                  32   203 971
   003   HOUCK JC              PROC SOC EXP BIOL MED          147   167 974
   004   FARRELL PM            PROC SOC EXP BIOL MED          149   340 975
   005   BOLTON WE             AM J HUM GENET                  27   394 975
   006   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   007   BAUR PS               TEX REP BIOL MED                34   113 976
   008   MANGOS JA             PEDIATR RES ABST                10   357 976
CT   1   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
     2   FEIGAL RJ             PEDIATR RES                     13   764 979
     3   LAM LFH               LIFE SCI                        24  2483 979
     4   SHAPIRO BL            PROC NAT ACAD SCI USA           76  2979 979
     5   SWENEY LR             J MICROSC                      115   151 979
     6   SHAPIRO BL            SCIENCE                        203  1251 979
     7   FEIGAL RJ             NATURE                         278   276 979
     8   OWEN K                CANCER RES                      40  3167 980
     9   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
    10   GNEGY ME              BIOCHEM MED                     26   294 981
    11   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    12   SORSCHER EJ           LANCET                           1   368 982
    13   FEIGAL RJ             LIFE SCI                        30    93 982
    14   SHAPIRO BL            AM J HUM GENET                  34   846 982
    15   SHAPIRO BL            SCIENCE                        216   417 982
    16   FONDACARO JD          LIFE SCI                        32  1449 983
    17   HARRIS A              CLIN CHIM ACTA                 128    41 983
    18   WALLER RL             LIFE SCI                        35   775 984
    19   WALLER RL             CELL CALC                        6   245 985
    20   RUPP GM               MED HYPOTHESES                  20   245 986
    21   MORRISSEY SM          DIGESTION                       34    28 986
    22   FEIGAL RJ             ANN NY ACAD SCI                488    82 986

PN 78070
RN 00851 
AN 78063085
AU Brock-D-J.  Barron-L.  Manson-J.  McCrae-W-M.
TI Serum alphafetoprotein in cystic fibrosis of the pancreas.
SO Clin-Chim-Acta. 1978 Jan 2. 82(1-2). P 101-3.
MJ ALPHA-FETOPROTEINS: me.  CYSTIC-FIBROSIS: bl.
MN HETEROZYGOTE.  HUMAN.  RADIOIMMUNOASSAY.
AB Serum alphafetoprotein concentrations were measured by three
   different types of radioimmunoassay in 30 patients with cystic
   fibrosis of the pancreas and in 55 controls. The highest value
   obtained in cystic patient was 10.2 ng/ml and in a control 10.8
   ng/ml. These are within published normal limits. Previously reported
   large increases in serum AFP in patients with cystic fibrosis and in
   heterozygote carriers have not been confirmed.
RF 001   CHANDRA RK            BR MED J                         1   714 975
   002   BROCK DJH             BR MED J                         2   392 975
   003   WALLWORK JC           BR MED J                         2   392 975
   004   FITZSIMMONS JS        BR MED J                         3   544 975
   005   BELANGER L            BR MED J                         4   759 975
   006   BROCK DJH             CLIN CHIM ACTA                  57   315 974
   007   BROCK DJH             LANCET                           1   745 975
   008   VINCE JD              BR J OBSTET GYNAECOL            82   718 975
   009   FORRESTER PI          CLIN CHIM ACTA                  64   317 975
   010   HUNTER WM             IN: WEIR DM                              973
CT   1   GOSDEN C              BR MED J                         2  1186 978
     2   GOSDEN C              J MED GENET                     15   262 978
     3   BROCK DJH             BR J OBSTET GYNAECOL            85   575 978
     4   RODECK CH             LANCET                           1   949 980
     5   BROCK DJH             BR J OBSTET GYNAECOL            87   582 980
     6   BROCK DJH             BR J OBSTET GYNAECOL            89   348 982

PN 78071
RN 00852 
AN 79044172
AU Kenny-D.  Cooke-A.  Tempany-E.  McGeeney-K-F.
TI Activity of serum alpha-amylases in cystic fibrosis.
SO Clin-Chim-Acta. 1978 Nov 1. 89(3). P 429-33.
MJ ALPHA-AMYLASE: bl.  AMYLASES: bl.  CYSTIC-FIBROSIS: en.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  HUMAN.  MATHEMATICS.
   PANCREAS: en.  SALIVA: en.
AB A new method which uses a differential inhibitor to measure
   pancreatic and salivary type alpha-amylases (EC 3.2.1.1) was applied
   to serum samples from 46 cystic fibrosis (CF) patients (age range 4-
   14 years) and 50 controls of the same age group. The levels of
   pancreatic type amylase were lower in the CF patients (median 26.5
   I.U./1) than the controls (median 81.5) (P less than 0.001). The
   results for salivary-type enzyme, however, did not support the
   previously reported finding of higher than usual levels in CF
   patients. This discrepancy is probably due to differences in
   analytical methods. It is felt that this procedure will be of value
   in the investigation of patients for cystic fibrosis and other
   pancreatic disorders.
RF 001   BURTON P              GUT                              1   111 960
   002   LUNDH G               GASTROENTEROLOGY                42   275 962
   003   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   004   OTSUKI M              CLIN CHIM ACTA                  79     1 977
   005   TAKEUCHI T            CLIN CHIM ACTA                  60   207 975
   006   BERK JE               AM J GASTROENTEROL              63   457 975
   007   ODONNELL MD           BIOCHIM BIOPHYS ACTA           422   159 976
   008   ODONNELL MD           CLIN CHEM                       23   560 977
   009   CONOVER WG            PRACTICAL NONPARAMETRIC STATI            971
   010   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
CT   1   ODONNELL MD           CLIN CHIM ACTA                 104   265 980
     2   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   746 980
     3   TOBIN MJ              IR J MED SCI                   150   325 981
     4   BROWN RC              J CLIN PATHOL                   35   547 982
     5   MORGENSTERN T         MONATSSCHR KINDERHEILKD        132   661 984
     6   GILLARD BK            AM J DIS CHILD                 138   577 984
     7   MOLLERPETERSEN J      CLIN CHIM ACTA                 157   151 986

PN 78072
RN 00853 
AN 79044177
AU Alhadeff-J-A.
TI Lysosomal hydrolases in cystic fibrosis livers.
SO Clin-Chim-Acta. 1978 Nov 1. 89(3). P 469-73.
MJ CYSTIC-FIBROSIS: en.  HYDROLASES: me.  LIVER: en.  LYSOSOMES: en.
MN ACETYLGLUCOSAMINIDASE: me.  HUMAN.  IN-VITRO.  MANNOSIDASES: me.
   NEURAMINIDASE: me.  SUPPORT-U-S-GOVT-P-H-S.
AB The specific activity of several lysosomal hydrolases in normal and
   cystic fibrosis (CF) livers has been investigated. Neuraminidase
   activity with respect to two natural substrates (fetuin and bovine
   submaxillary mucin) is normal in CF livers. No significant
   differences were found between CF and normal livers in 4-
   methylumbelliferyl-alpha-D-mannosidase specific activities determined
   at three different pH values (4.3, 5.65 and 6.5) corresponding to
   lysosomal, golgi and cytosolic components of the enzyme,
   respectively. The specific activities of p-nitrophenyl-beta-D-
   mannosidase and 4-methylumbelliferyl-beta-N-acetylglucosaminidase
   were also both similar in CF and normal livers.
RF 001   NADLER HL             IN: STANBURY JB                     1683 978
   002   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   003   WRIGHT SW             AM J HUM GENET                  20   157 968
   004   ALHADEFF JA           CLIN GENET                      13   417 978
   005   OPHEIM DJ             J BIOL CHEM                    253  1017 978
   006   PHILLIPS NC           CLIN CHIM ACTA                  55    11 974
   007   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   008   WILSON RG             CLIN CHIM ACTA                  36   113 972
   009   CALLAHAN JW           PEDIATR RES                     11  1166 977
   010   LOWRY OH              J BIOL CHEM                    193   265 951
   011   WARREN L              J BIOL CHEM                    234  1971 959
   012   PHILLIPS N            BIOCHEM J                      151   469 975
   013   OKADA S               AM J HUM GENET                  23    55 971
   014   TULSIANI DRP          J BIOL CHEM                    245  1821 970
   015   ALHADEFF JA           CLIN GENET                      10    63 976
   016   ALHADEFF JA           MOL CELL BIOCHEM                18    33 977
   017   SPIRO RG              ADV PROT CHEM                   27   349 973
   018   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   019   ANTONOWICZ I          PEDIATR RES                      6   803 972
CT   1   MINAMI R              CLIN CHIM ACTA                  96   107 979
     2   MEYER DM              BIOCHEM BIOPHYS RES COMMUN     103  1302 981
     3   ALHADEFF JA           BIOCHEM J                      201    95 982
     4   DENTANDT WR           BIOCHEM MED                     31   287 984
     5   HULTCRANTZ R          HEPATOLOGY                       6   881 986
     6   PORTER WH             CLIN CHEM                       32   652 986

PN 78073
RN 00854 
AN 78105815
AU Alhadeff-J-A.  Cimino-G.
TI Cystic fibrosis liver sialyltransferase.
SO Clin-Genet. 1978 Feb. 13(2). P 207-12.
MJ CYSTIC-FIBROSIS: en.  LIVER: en.  SIALYLTRANSFERASES: me.
   TRANSFERASES: me.
MN HUMAN.  HYDROGEN-ION-CONCENTRATION.  ISOELECTRIC-FOCUSING.
   LIVER-DISEASES: en.  TEMPERATURE.
AB The activity of sialytransferase with regard to the glycoprotein
   substrates asialofetuin and asialo-ovine submaxillary mucin was
   determined in normal, pathological control, and cystic fibrosis liver
   homogenates. Cystic fibrosis and pathological livers have about 40%
   of the average normal specific activity for sialytransferase. Several
   properties of cystic fibrosis sialytransferase were investigated and
   compared to those of the normal liver enzyme (Alhadeff et al. 1977).
   The pH optima curves were similar, but cystic fibrosis
   sialyltransferase appears to be more thermolabile than the normal
   liver enzyme. Isoelectric focusing studies revealed that the three
   most basic forms of sialyltransferase which are found in normal
   livers are deficient or absent in most cystic fibrosis liver. The
   data suggest that altered glycoprotein-sialyltransferases may be
   present in cystic fibrosis livers, probably a secondary effect due to
   general liver pathology.
RF 001   ALHADEFF JA           BIOCHIM BIOPHYS ACTA           484   307 977
   002   ALHADEFF JA           CLIN CHIM ACTA                  57   307 974
   003   ALHADEFF JA           DEVELOP BIOL                    47   319 975
   004   ALHADEFF JA           CLIN GENET                      10    63 976
   005   GOLDSTONE AP          FEBS LETTERS                    13    68 971
   006   KATTWINKEL J          J PEDIATR                       82   234 973
   007   LOBECK CC             IN: STANBURY JB                     1605 972
   008   LOWRY OH              J BIOL CHEM                    193   265 951
   009   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   010   MOOKERJEA S           CAN J BIOCHEM                   50   738 972
   011   MURPHY WH             BIOCHIM BIOPHYS ACTA            52   349 961
   012   SCHACHTER H           IN: FISHMAN WH                   3     2 973
   013   SPIRO RG              J BIOL CHEM                    235  2860 960
   014   SPIRO RG              ADV PROT CHEM                   27   349 973
   015   TETTAMANTI G          ARCH BIOCHEM BIOPHYS           124    41 968
   016   THORPE R              FEBS LETTERS                    54    89 975
   017   WARREN L              J BIOL CHEM                    234  1971 959
CT   1   ALHADEFF JA           CLIN GENET                      13   417 978
     2   ALHADEFF JA           CLIN GENET                      14   189 978
     3   LAPINA EB             BIOORGAN KHIM                    5  1720 979
     4   ANFIMOVA ML           BIOORGAN KHIM                    7  1209 981
     5   HULTBERG B            CLIN CHIM ACTA                 112   167 981
     6   MARGOLIES R           PEDIATR RES                     17   931 983
     7   PASCALI VL            EUR J PEDIATR                  143   133 984

PN 78074
RN 00855 
AN 79002464
AU Bois-E.  Feingold-J.  Demenais-F.  Runavot-Y.  Jehanne-M.  Toudic-L.
TI Cluster of cystic fibrosis cases in a limited area of Brittany
   (France).
SO Clin-Genet. 1978 Aug. 14(2). P 73-76.
MJ CYSTIC-FIBROSIS: fg.
MN CYSTIC-FIBROSIS: oc.  FEMALE.  FRANCE.  GENE-FREQUENCY.  HUMAN.
   MALE.  PEDIGREE.
AB Cystic fibrosis in the northern sector of the French "departement"
   of Finistere is 1:1787 live births. Within this sector a
   concentration of the disease was found in a small area. The minimal
   frequency in this area, from 1946 to 1972, was calculated as 1 per
   377 live births, the gene frequency being 0.0515. Genealogic
   analysis, going back to the beginning of the 18th century, showed a
   relationship between 8 of the 10 families to which the patients
   belonged. The origin of the deleterious genes may be explained by a
   least five primary ancestral couples living in the 18th century.
   Random drift is the most probable explanation for the concentration
   of cystic fibrosis in this region.
RF 001   ANDERSON CM           MOD PROBL PEDIATR               10   381 967
   002   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   FEINGOLD J            ANN GENET (PARIS)               17   257 974
   005   GOURVIL F             NOMS DE FAMILLE BRETONS D-               970
   006   HIRSCHHORN K          IN: MANGOS JA                        275 976
   007   KNUDSON AG JR         AM J HUM GENET                  19   388 967
   008   RAO DC                AM J HUM GENET                  25   594 973
   009   RUNAVOT Y             THESIS                                   975
   010   TEN KATE LP           INT J EPIDEMIOL                  6    23 977
   011   WAGENER DK            AM J HUM GENET                  27   348 975
CT   1   COX DW                PEDIATR CLIN NORTH AM           26   467 979
     2   DEMENAIS F            REV EPIDEMIOL SANTE PUBLIQUE    27     5 979
     3   KLINGER KW            HUM GENET                       65    94 983
     4   PASCALETGUIDON MJ     CLIN GENET                      26    39 984
     5   KLINGER KW            SEM RESPIR MED                   6   243 985
     6   LIVINGSTONE FB        HUM BIOL                        59    59 987

PN 78075
RN 00856 
AN 79023672
AU Alhadeff-J-A.
TI Glycoproteins and cystic fibrosis: a review.
SO Clin-Genet. 1978 Oct. 14(4). P 189-201. (REVIEW).
MJ CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: me.
MN CHILD.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: en.  FUCOSE: me.
   FUCOSIDASE: me.  GLYCOPROTEINS: ip.  HUMAN.  REVIEW.
   SUPPORT-U-S-GOVT-P-H-S.
EX This article is a review of the major research of the last 20 years
   on abnormal glycoproteins and abnormal glycoprotein metabolism in
   cystic fibrosis.  Its purpose is to focus attention on an area
   considered by the author to be of great importance for elucidating
   the primary biochemical defect in CF.  The majority of the studies on
   glycoproteins in CF have been done on crude mixtures of glycoproteins
   from tissues or tissue fluids, secretions or excretions.  Very few
   studies have compared the properties and composition of purified
   glycoproteins from CF patients and controls.  Comparative studies on
   the enzymes involved in the degradation and biosynthesis of the
   carbohydrate portions of glycoproteins in CF patients and normal
   controls are discussed.  Several studies have suggested abnormalities
   in CF alpha-L-fucosidase and CF L-fucose metabolism.  There are
   several studies which indirectly suggest that abnormalities in
   glycoproteins or their metabolism may be involved in the pathogenesis
   of cystic fibrosis.  Fruitful areas for future investigation are
   comparison of the properties and composition of specific
   glycoproteins purified to homogeneity from CF and control tissues,
   particularly with regard to carbohydrate composition; comparison of
   the activities and properties of the enzymes involved in both the
   degradation and biosynthesis of glycoproteins in CF and control
   tissues; and studies of the effects of increased electrolyte
   concentration on the physical-chemical properties of glycoproteins.
RF 001   ALHADEFF JA           CLIN GENET                      13   207 978
   002   ALHADEFF JA           BIOCHIM BIOPHYS ACTA           484   307 977
   003   ALHADEFF JA           MOL CELL BIOCHEM                18    33 977
   004   ALHADEFF JA           J BIOL CHEM                    250  7106 975
   005   ALHADEFF JA           CLIN GENET                      10    63 976
   006   ALHADEFF JA           DEVELOP BIOL                    47   319 975
   007   ALHADEFF JA           CLIN GENET                      13   417 978
   008   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   009   ANTONOWICZ I          PEDIATR RES                      6   803 972
   010   ASHWELL G             ADV ENZYM MOLEC BIOL            41    99 974
   011   BAKER AP              FED PROC                        33  1300 974
   012   BAKER AP              ARCH BIOCHEM BIOPHYS           165   597 974
   013   BAUER U               ANN PAEDIATR                   194   236 960
   014   BESLEY GTN            J MED GENET                      6   278 969
   015   BISWAS S              CLIN CHIM ACTA                  69   541 976
   016   BLACKFAN KD           J PEDIATR                       13   627 938
   017   BOAT TF               ARCH BIOCHEM BIOPHYS           177    95 976
   018   BOAT TF               AM REV RESPIR DIS              110   428 974
   019   BOAT TF               PEDIATR RES                      8   531 974
   020   BOWMAN BH             SCIENCE                        164   325 969
   021   BROCK DJH             BR MED J                         2   392 975
   022   BUTTERWORTH J         CLIN CHIM ACTA                  56   159 974
   023   BUTTERWORTH J         CLIN CHIM ACTA                  41   367 972
   024   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   025   CHANDRA RK            BR MED J                         1   714 975
   026   COHEN LF              BLOOD                           48   469 976
   027   CROSBY P              HISTOCHEM J                      3   223 971
   028   DAVIS PB              CF CLUB ABST                           7 976
   029   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   030   DISCHE Z              PEDIATRICS                      24    74 959
   031   DISCHE Z              ANN NY ACAD SCI                 93   526 962
   032   DISCHE Z              AM J DIS CHILD                 102   733 961
   033   FILLIAT M             PATHOL BIOL (PARIS)             21    13 973
   034   FITZSIMMONS JS        BR MED J                         3   544 975
   035   FORSTNER JF           PEDIATR RES                     10   609 976
   036   FORSTNER JF           CF CLUB ABST                          10 976
   037   FRIEDMANN T           J LAB CLIN MED                  70   404 967
   038   GIBSON LE             PEDIATRICS                      23   545 959
   039   GIBSON LE             PEDIATRICS                      48   695 971
   040   GOLDSTONE AP          LIFE SCI                         9  1341 970
   041   GRIFFIN GD            PROC SOC EXP BIOL MED          137   438 971
   042   GUGLER EC             J PEDIATR                       71   585 967
   043   GUHA AK               CLIN BIOCHEM                    10   153 977
   044   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   045   KIM YS                J CLIN INVEST                   51  2033 972
   046   KNAUFF RE             CLIN CHIM ACTA                  19   245 968
   047   KNOPFLE G             BR MED J                         4   459 975
   048   KOLLBERG H            ACTA PAEDIATR SCAND             62   279 973
   049   KOPITO L              NATURE                         202   501 964
   050   KRAUS I               PEDIATRICS                      47  1010 971
   051   KUTTY KM              CF CLUB ABST                          45 976
   052   LOBECK CC             IN: STANBURY JB                     1605 972
   053   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   054   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   055   MANDEL ID             AM J DIS CHILD                 113   431 967
   056   MANDEL ID             AM J DIS CHILD                 110   646 965
   057   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   058   MAXFIELD M            J CLIN INVEST                   41   455 962
   059   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   060   MCEVOY FA             PEDIATR RES                      9   721 975
   061   MCNEELY MC            AM J HUM GENET                  29   73A 977
   062   MOOKERJEA S           CAN J BIOCHEM                   50   738 972
   063   NADLER HL             IN: STANBURY JB                     1683 978
   064   NEUTRA MR             LAB INVEST                      36   535 977
   065   NOVAK RA              TEX REP BIOL MED                34   199 976
   066   PALLAVICINI JC        ANN NY ACAD SCI                106   330 963
   067   PAPP Z                CLIN GENET                      11   431 977
   068   PEARSON RD            PEDIATR RES                     11   462 977
   069   POTTER JL             ANN NY ACAD SCI                106   692 963
   070   RAO GJS               CLIN RES                        24  436A 976
   071   ROELFS RE             AM J DIS CHILD                 113   419 967
   072   RUSSELL SB            J MED GENET                      8   441 971
   073   SCANLIN TF JR         PEDIATR RES ABST 549            11   463 977
   074   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   075   SCHACHTER H           BIOCHEM SOC SYMP                40    57 974
   076   SCHACHTER H           IN: FISHMAN WH                   3     2 973
   077   SCHULTZE HE           MOLECULAR BIOL OF HUMAN PROTE    1       966
   078   SCHWARTZ RH           J LAB CLIN MED                  70   725 967
   079   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   080   SHAPIRA E             J BIOL CHEM                    252  7923 977
   081   SHAPIRA E             PEDIATR RES                     10   812 976
   082   SHARON N              COMPLEX CARBOHYDRATES THEIR C            975
   083   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   084   SINGER L              CLIN BIOCHEM                     7   146 974
   085   SMITH JA              BR MED J                         2   392 975
   086   SPIRO RG              ADV PROT CHEM                   27   349 973
   087   SPOCK A               PEDIATR RES                      1   173 967
   088   STEVENSON FK          CLIN CHIM ACTA                  23   441 969
   089   TALAMO RC             J PEDIATR                       65   480 964
   090   TOUSTER O             MOL CELL BIOCHEM                 2   169 973
   091   WALLWORK JC           BR MED J                         2   392 975
   092   WELCH DW              PEDIATR RES                      9   698 975
   093   WILSON GB             SCAND J IMMUNOL                  5   829 976
   094   WILSON GB             PEDIATR RES                     10    87 976
   095   WILSON RG             CLIN CHIM ACTA                  36   113 972
   096   WRIGHT SW             AM J HUM GENET                  20   157 968
   097   WU JT                 PEDIATR RES                     10   235 976
CT   1   SHIER WT              MED HYPOTHESES                   5   661 979
     2   BENYOSEPH Y           CLIN CHIM ACTA                  99    31 979
     3   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     4   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     5   MALER T               FEBS LETTERS                   121   153 980
     6   HALLINAN F            MED HYPOTHESES                   7   793 981
     7   BENYOSEPH Y           PEDIATR RES                     15   839 981
     8   BUTTERWORTH J         CLIN CHIM ACTA                 110   319 981
     9   OWENSWILLIAMS L       J PEDIATR GASTROENTEROL NUTR     1   567 982
    10   BLITZER MG            PEDIATR RES                     16   203 982
    11   BLITZER MG            PEDIATR RES                     16   938 982
    12   MCNEELY MC            PEDIATR RES                     16    21 982
    13   LITIN BS              BIOL NEONATE                    42   228 982
    14   SNYDER CE             CARBOHYD RES                   105    87 982
    15   LONGNECKER DS         AM J PATHOL                    107   103 982
    16   BENYOSEPH Y           BIOCHIM BIOPHYS ACTA           718   172 982
    17   FRATES RC             PEDIATR RES                     17    30 983
    18   SLOMIANY A            J BIOL CHEM                    258  8535 983
    19   KARLSSON S            J MED GENET                     21   441 984
    20   HART DA               THROMB HAEMOST                  51   212 984
    21   GUEANT JL             CLIN CHIM ACTA                 143   217 984
    22   PASCALI VL            EUR J PEDIATR                  143   133 984
    23   PORTER WH             CLIN CHEM                       32   652 986

PN 78076
RN 00857 
AN 78189549
AU Alhadeff-J-A.  Watkins-P.  Freeze-H.
TI Purification and characterization of altered cystic fibrosis liver
   alpha-L-fucosidase.
SO Clin-Genet. 1978 May. 13(5). P 417-24.
MJ CYSTIC-FIBROSIS: en.  FUCOSIDASE: ip.  LIVER: en.
MN CARBOHYDRATES: an.  ELECTROPHORESIS-POLYACRYLAMIDE-GEL.
   FUCOSIDASE: an, me.  HUMAN.  ISOELECTRIC-FOCUSING.
   SUPPORT-U-S-GOVT-P-H-S.
AB alpha-L-Fucosidase (E.C.3.2.4.51) from two cystic fibrosis livers has
   been purified and characterized. Purification was accomplished by an
   affinity chromatographic procedure previously used for normal liver
   alpha-L-fucosidase. Characterization of the two cystic fibrosis alpha-
   L-fucosidases indicated that they were very similar to normal liver
   alpha-L-fucosidase with regard to pH optima profiles, Michaelis
   constants (Km's), subunit structure and antigenicity. However, gas
   liquid chromatographic analysis revealed altered carbohydrate
   compositions for both the cystic fibrosis alpha-L-fucosidases. The
   three major sugars found in normal purified liver alpha-L-fucosidase
   (mannose, N-acetylglucosamine and sialic acid) were reduced in the
   cystic fibrosis alpha-L-fucosidases, on average, to 51%, 44% and 32%,
   respectively, of their normal amounts.
RF 001   ALHADEFF JA           CLIN GENET                      13   207 978
   002   ALHADEFF JA           MOL CELL BIOCHEM                18    33 977
   003   ALHADEFF JA           J BIOL CHEM                    250  7106 975
   004   ALHADEFF JA           CLIN CHIM ACTA                  57   307 974
   005   ALHADEFF JA           CLIN GENET                      10    63 976
   006   ALHADEFF JA           DEVELOP BIOL                    47   319 975
   007   CLAMP JR              METHODS BIOCHEM ANAL            19   229 971
   008   DISCHE Z              PEDIATRICS                      24    74 959
   009   DISCHE Z              ANN NY ACAD SCI                 93   526 962
   010   DISCHE Z              AM J DIS CHILD                 102   733 961
   011   ETCHISON JR           VIROLOGY                        60   217 974
   012   GUHA AK               CLIN BIOCHEM                    10   153 977
   013   KNAUFF RE             CLIN CHIM ACTA                  19   245 968
   014   LAEMMLI UK            NATURE                         227   680 970
   015   LINEWEAVER H          J AM CHEM SOC                   56   658 934
   016   LOBECK CC             IN: STANBURY JB                     1605 972
   017   LOWRY OH              J BIOL CHEM                    193   265 951
   018   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   019   ROELFS RE             AM J DIS CHILD                 113   419 967
   020   SCANLIN TF JR         PEDIATR RES ABST 549            11   463 977
   021   SPIRO RG              ADV PROT CHEM                   27   349 973
   022   THORPE R              FEBS LETTERS                    54    89 975
   023   TURNER BM             AM J HUM GENET                  27   651 975
   024   WARREN L              J BIOL CHEM                    234  1971 959
CT   1   ALHADEFF JA           CLIN GENET                      14   189 978
     2   ALHADEFF JA           CLIN CHIM ACTA                  89   469 978
     3   ALHADEFF JA           BIOCHEM BIOPHYS RES COMMUN      86   787 979
     4   BENYOSEPH Y           CLIN CHIM ACTA                  99    31 979
     5   FREEZE H              BIOCHEM J                      177   749 979
     6   SCANLIN TF            CLIN CHEST MED                   1   424 980
     7   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     8   BENYOSEPH Y           PEDIATR RES                     15   839 981
     9   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    10   HARRIS A              CLIN CHIM ACTA                 116   171 981
    11   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
    12   MALER T               J BIOL CHEM                    256  1420 981
    13   BLITZER MG            PEDIATR RES                     16   203 982
    14   SCANLIN TF            BIOCHEMISTRY                    21   491 982
    15   MARGOLIES R           PEDIATR RES                     17   931 983
    16   RUDICK VL             J CELL PHYSIOL                 115   143 983
    17   BOURASSA C            CLIN CHIM ACTA                 129   263 983
    18   ALHADEFF JA           CLIN CHIM ACTA                 134     1 983
    19   SCANLIN TF            PEDIATR RES                     19   368 985
    20   HERMELIN B            CELL MOL BIOL                   33    83 987

PN 78077
RN 00858 
AN 78189535
AU Danes-B-S.  Beck-B.  Flensborg-E-W.
TI Cystic fibrosis: cell culture classes in a Danish population.
SO Clin-Genet. 1978 Apr. 13(4). P 327-34.
MJ CYSTIC-FIBROSIS: fg.
MN AGE-FACTORS.  CELLS-CULTURED.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di.  DENMARK.  HUMAN.  INFANT.
AB The cystic fibrosis (CF) culture phenotype of dermal fibroblasts
   (metachromasia, metabolic cooperation) of a group of 131 Danish CF
   patients and their families were studied to determine the
   distribution of the two CF culture classes and their prognostic
   significance. Of these, 62.6% (82) were Class I, 31.3% (41) Class II
   and 61.1% (8) were proposed to be genetic compounds. The occurrence
   of Class II was twice that found in a group of patients from New York
   (13%) and Minnesota (18%). The prognosis for Class II CF patients was
   considered to be poorer as: (1) The initial diagnosis was made
   earlier in Class II than in Class I or the compounds (63% of Class II
   were diagnosed in the first year of life, as compared to 35% in Class
   I and 13% of the compounds). (2) Only 5% of the Class II patients
   survived over the age of 15 years, both being deceased at the end of
   the study in 1976, whereas 24% of Class I and 63% of the compounds
   were over 15 years at the end of the study. This research added
   further evidence for genetic heterogeneity within the clinical
   syndrome, cystic fibrosis.
RF 001   BERATIS NG            PEDIATR RES                      7   958 973
   002   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   003   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   004   DANES BS              LANCET                           2   765 973
   005   DANES BS              CLIN GENET                       7   128 975
   006   DANES BS              TEX REP BIOL MED                34   135 976
   007   DANES BS              AM J HUM GENET                  23   297 971
   008   DANES BS              CLIN GENET                       9   527 976
   009   DANES BS              CLIN GENET                      11    83 977
   011   LYKKEGAARD E          DAN MED BULL                    22   177 975
   012   LYKKEGAARD E          DAN MED BULL                    22   169 975
   013   LYKKEGAARD E          DAN MED BULL                    22   175 975
   014   WOOD RE               LANCET                           2  1452 973
CT   1   WINGE P               DAN MED BULL                    29   358 982
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 78078
RN 00859 
AN 78189631
AU Erkkila-J-C.  Warwick-W-J.  Bradford-D-S.
TI Spine deformities and cystic fibrosis.
SO Clin-Orthop. 1978 Mar-Apr. (131). P 146-50.
MJ CYSTIC-FIBROSIS: co.  SPINAL-DISEASES: co.  SPINE: ab.
MN ADOLESCENCE.  ADULT.  AGE-DETERMINATION-BY-SKELETON.  AGE-FACTORS.
   BLOOD-PROTEINS.  BODY-WEIGHT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.
   GROWTH-DISORDERS: et.  HUMAN.  KYPHOSIS: cn.  MALE.  SCOLIOSIS: cn.
AB Patients with cystic fibrosis have an increased risk for developing
   kyphosis and scoliosis. The risk for both kyphosis and scoliosis
   increases with age. The severity of kyphosis did not appear greater
   in the older age groups. Patients with retarded bone age may be more
   likely to have a significant spinal deformity. The presence of spine
   deformity does not correlate with the severity of pulmonary
   involvement, height, weight, serum protein and albumin in patients
   with cystic fibrosis.
RF 002   BRADFORD DS           J BONE JOINT SURG              56A   740 974
   003   BROOKS HL             ORTHOP REV                       1    17 972
   004   BRUSZEWSKI J          CHIR NARZAD RUCHU ORTOP POL     22   115 972
   005   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   006   DI SANTAGNESE PA      ANN INTERN MED                  50  1321 959
   007   GREULICH WW           RADIOGRAPHIC ATLAS OF SKELETA            959
   008   KANE WJ               CLIN ORTHOP                     69   216 970
   009   KEMP FH               BR J RADIOL                     21   449 948
   010   KEMP FH               BR J SOC MED                     2    66 948
   011   MATTHEWS LW           IN: MANGOS JA                        303 973
   012   SCHEUERMANN HW        UGESKR LAEGER                   82   385 920
   013   SHANDS AR JR          J BONE JOINT SURG              37A  1243 955
   014   SORENSEN KH           SCHEUERMANN'S JUVENILE KYPHOS            964
   015   WARWICK WJ            MOD PROBL PEDIATR               10   353 967
   016   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   017   WYNNE-DAVIES R        J BONE JOINT SURG              50B    24 968
CT   1   PALING MR             SKELETAL RADIOL                  8    63 982
     2   LOGVINOFF MM          CLIN PEDIATR                    23   389 984
     3   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986

PN 78079
RN 00860 
AN 78168093
AU McFarlene-H.  Allan-J-D.  Malhotra-A.  Hozel-A.  Wallwork-J-C.
TI The precipitins and hypersensitivity reactions in cystic fibrosis.
SO Compr-Ther. 1978 Apr. 4(4). P 61-7.
MJ CYSTIC-FIBROSIS: im.  HYPERSENSITIVITY: im.  PRECIPITINS.
MN COMPLEMENT-3.  ELECTROPHORESIS-AGAR-GEL.
   FLUORESCENT-ANTIBODY-TECHNIC.  HUMAN.  IGA-SECRETORY.  IGE.
   OVALBUMIN: im.  SALIVA: im.  SERUM-ALBUMIN-BOVINE: im.  SPUTUM: im.
EX The large number and wide variety of precipitins detected in the
   sputum of cystic fibrosis patients suggest that the precipitins may
   be nonprotective and even harmful to the patients.  These sputum
   precipitins were directed principally against food, fungi, bacteria,
   and human body tissue.  On the other hand, precipitins to
   Staphylococcus alpha-hemolysin was the main type of immunoprecipitin
   detected in CF serum and was found in 60% of the serum specimens
   examined.  It seems likely that the precipitins in patients with CF
   may be involved in the formation of immune complexes which, in
   conjunction with complement, may be responsible for the respiratory
   and gastrointestinal lesions that are common in patients with CF.
   The immune complexes may be the result of excess food and bacterial
   antigens escaping across the gut and lungs as a result of some
   abnormality of the SIgA system.  Over 80% of the sputum specimens
   tested gave positive precipitins in agar gel against human seminal
   fluid and colostrum, suggesting that some of the antibodies formed in
   CF patients could be directed against host tissue, and may account
   for an autoimmune-type reaction in CF.  Crossreaction between the
   high-titer antibody to Staphylococcus and basement membrane of lungs
   and pancreas, with complement activation, may occur in CF and
   required further study.  The high number of B-cells, as detected by
   antibody, coated complement, activated sheep erythrocytes, and EAC
   rosettes, may be partly responsible for the synthesis of the variety
   of antibodies detected in CF patients.
RF 001   DOGGETT RG            J PEDIATR                       68   215 966
   002   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   003   SCHWARTZ RH           CF CLUB ABST                           9 965
   004   BURNS MW              LANCET                           1   270 968
   005   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   006   PEPYS J               LANCET                           2   134 968
   007   URIEL J               BULL SOC CHIM BIOL              48   969 966
   008   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   009   MCFARLANE H           BR MED J                         1   423 975
   010   MELLSTEDT H           CLIN EXP IMMUNOL                15   309 973
   011   JOHANSSEN SGO         IMMUNOLOGY                      10   265 968

PN 78080
RN 00861 
AN 78149018
AU Forstner-J-F.
TI Intestinal mucins in health and disease.
SO Digestion. 1978. 17(3). P 234-63. (REVIEW).
MJ INTESTINAL-MUCOSA.  MUCINS.
MN CARCINOMA: me.  CHEMISTRY.  CYSTIC-FIBROSIS: me.
   GASTROINTESTINAL-DISEASES: me.  HORMONES: ph.  HUMAN.
   INTESTINAL-MUCOSA: cy, me, ph.  MUCINS: bi, me, ph, se.
   NEUROREGULATORS: ph.  REVIEW.
AB Intestinal mucins are complex glycoproteins which are secreted from
   goblet cells, and form a gel-like covering over the mucosal surface.
   They are assumed to provide lubrication and protection of the
   underlying epithelium against potentially injurious chemicals,
   enzymes, bacteria and dietary constituents. Recent advances in our
   understanding of mucin structure, secretion and functional properties
   are reviewed in this paper. Implications for diseases such as cystic
   fibrosis, peptic ulcer, malignancy and inflammatory bowel disease are
   briefly discussed.
RF 001$  ABT AB                ARCH PATHOL                    100   301 976
   002   ALLEN A               BIOCHEM J                      106   306 968
   003   ALLEN A               FARADAY CHEM SOC                57   210 974
   004   ALLEN A               GUT                             13   666 972
   005   ALLEN A               BIOCHIM BIOPHYS ACTA           338   364 974
   006   ALLEN A               BIOCHEM SOC TRANS                2   630 974
   007   ALPERS DH             GASTROENTEROLOGY                64   471 973
   008   ANDERSON CG           BR J EXP PATHOL                 20    25 939
   009   ANDRE F               ACTA GASTROENTEROL BELG         37   469 974
   010   ARONSON NN            IN: GOTTSCHALK A                    1211 972
   011   BAUR PS               TEX REP BIOL MED                34   155 976
   012   BELLA A JR            ARCH BIOCHEM BIOPHYS           150   679 972
   013   BENNETT G             J CELL BIOL                     60   258 974
   014   BHASKAR KR            BIOCHEM J                      143   669 974
   015   BLOCH KJ              FED PROC FED AM SOC EXP BIOL    36  1054 977
   016   BOAT TF               ARCH BIOCHEM BIOPHYS           177    95 976
   017   BOAT TF               AM REV RESPIR DIS              110   428 974
   018   BOGART BI             J ULTRASTRUCT RES               52   139 975
   019   BOTTIN C              BIOL GASTROENTEROL               6   307 973
   020   BRAIN MC              BR J HAEMATOL                   18   183 970
   021   CALVER GA             CAN J MICROBIOL                 22   832 976
   022   CAMARRI E             ARZNEIMITTEL FORSCH             22   768 972
   023   CARLSON DM            J BIOL CHEM                    241  2984 966
   024   CARLSON DM            J BIOL CHEM                    243   616 968
   025   CHANG WWL             AM J ANAT                      144    39 975
   026   CLAUSER H             IN: GOTTSCHALK A                    1151 972
   027   CLAUSER H             IN: AMINOFF D                        479 970
   028   CRAWFORD BJ           CAN J ZOOL                      52  1427 974
   029   CREETH JM             MOD PROBL PEDIATR               19    34 977
   030   CREETH JM             BIOCHEM J                      143   159 974
   031   CULLING CFA           J CLIN PATHOL                   28   656 975
   032   CZEGLEDY-NAGY E       LAB INVEST                      35   588 976
   033   DEKANSKI JB           BR J PHARMACOL                  52   464 974
   034   DEKANSKI JB           BR J PHARMACOL                  55   387 975
   035   DI GIROLAMO R         APPL ENVIRON MICROBIOL          33    19 977
   036   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   037   DUNSTONE JR           BIOCHIM BIOPHYS ACTA           101   300 965
   038   EASTWOOD GL           GASTROENTEROLOGY                64   383 973
   039   ELLIS DB              BIOCHIM BIOPHYS ACTA           276   105 972
   040   FAILLARD H            IN: GOTTSCHALK A                    1246 972
   041   FILIPE MI             BR J CANCER                     32    60 975
   042   FLOREY H              PROC R SOC LOND BIOL           143   144 955
   043   FLOREY HW             GASTROENTEROLOGY                43   326 962
   044   FORD A                J BIOL STANDARDS                 4   353 976
   045   FORSTNER GG           CAN J PHYSIOL PHARMACOL         51   122 973
   046   FORSTNER JF           PEDIATR RES                     10   609 976
   047   FORSTNER JF           MOD PROBL PEDIATR               19    54 977
   048   FORSTNER JF           CAN J BIOCHEM                   51  1154 973
   050   FREEMAN JA            ANAT REC                       154   121 966
   051   FUKUDA M              BIOCHEM BIOPHYS RES COMMUN      64   465 975
   052   GALLAGHER JT          PROC R SOC LOND BIOL           192    49 975
   053   GELMAN RA             BIOCHIM BIOPHYS ACTA           427   627 976
   054   GIBBONS RA            BIOCHEM J                       73   209 959
   055   GIBBONS RA            NATURE                         200   665 963
   056   GIBBONS RA            IN: AMINOFF D                        307 970
   057   GIBBONS RJ            ADV EXP MED BIOL                45   315 974
   058   GIBSON LE             PEDIATRICS                      48   695 971
   059   GINSBURG V            ANNU REV BIOCHEM                38   371 969
   060   GORALSKI A            CELL TISSUE RES                160   551 975
   061   GORDON HA             EXPERIENTIA                     30   214 974
   062   GOTTSCHALK A          IN: GOTTSCHALK A                    1082 972
   063   GOTTSCHALK A          IN: GOTTSCHALK A                     529 972
   064   HARTIALA K            J BIOL CHEM                    195   251 952
   065   HEATLEY NG            GASTROENTEROLOGY                37   313 959
   066   HERNANDEZ FJ          DIS COLON RECTUM                19    63 976
   067   HOLLANDER F           ARCH INTERN MED                 93   107 954
   068   HOROWITZ MI           IN: CODE CF                         1063 967
   069   HOROWITZ MI           ANN NY ACAD SCI                140   784 967
   070   HOSKINS LC            GASTROENTEROLOGY                54   218 968
   071   HOSKINS LC            J CLIN INVEST                   57    63 976
   072   HOSKINS LC            J CLIN INVEST                   57    63 976
   073   HOSKINS LC            GASTROENTEROLOGY                54   210 968
   074   JABBAL I              CAN J BIOCHEM                   54   707 976
   075   JENNINGS MA           Q J EXP PHYSIOL                 41   131 956
   076   KASHKET S             J BACTERIOL                    112  1127 972
   077   KEEFER CS             J CLIN INVEST                   17    23 938
   078   KELLAWAY IW           J PHARM PHARMACOL               27   281 975
   079   KENT PW               BIOCHEM J                      106   645 968
   080   KIM SK                J ULTRASTRUCT RES               38   371 972
   081   KLAAS J               J PARASIT                       60   907 974
   082   KLEINMAN HK           BIOCHIM BIOPHYS ACTA           354    17 974
   083   KOGA A                Z ZELLFORSCH MIKROSK ANAT      139   463 973
   084   KOKAS E               COMPAR BIOCHEM PHYSIOL          22    81 967
   085   KORNFELD R            ANNU REV BIOCHEM                45   217 976
   086   KRAMER MF             HISTOCHEM J                      7   511 975
   087   KUPCHELLA CE          TRANS NY ACAD SCI               34   351 972
   088   LAMBLIN G             BIOCHIM BIOPHYS ACTA           322   372 973
   089   LAMBLIN G             BULL EUR PHYSIOPATH RESP        13   175 977
   090   LAMBERT R             DIGESTION                        5   116 972
   091   LAMONT JT             GASTROENTEROLOGY                72    82 977
   092   LAWFORD GR            CAN J BIOCHEM                   45   507 967
   093   LENT CM               SCIENCE                        179   693 973
   094   LEWIS RW              LIPIDS                           5   947 970
   095   LEWIS RW              LIPIDS                           8   321 973
   096   LHERMITTE M           BIOCHIMIE                       58   367 976
   097   LIAU YH               DIGESTION                       14   372 976
   098   LINDSTEDT G           J EXP MED                      121   201 965
   099   LLOYD KO              PROC NAT ACAD SCI USA           61  1470 968
   100   LUKIE BE              BIOCHIM BIOPHYS ACTA           261   353 972
   101   LUKIE BE              BIOCHIM BIOPHYS ACTA           261   353 972
   102   LUKIE BE              BIOCHIM BIOPHYS ACTA           273   390 972
   103   LUKIE BE              BIOCHIM BIOPHYS ACTA           338   345 974
   104   MACDERMOTT RP         J CLIN INVEST                   54   545 974
   105   MACHIN J              SCIENCE                        183   759 974
   106   MACPHERSON B          DIGESTION                       14   424 976
   107   MARTIN F              DIGESTION                        1   165 968
   108   MARTINEZ JR           PEDIATR RES                      9   463 975
   109   MCGUIRE EJ            IN: AMINOFF D                        461 970
   110   MEDLINE A             HUM PATHOL                       7   693 976
   111   MENGUY R              ANN NY ACAD SCI                140   797 967
   112   MERZEL J              AM J ANAT                      124   281 969
   113   MOON HW               LAB INVEST                      25   133 971
   114   OATES MDG             CARBOHYD RES                    34   115 974
   115   ODOHERTY PJA          INT J BIOCHEM                    6   435 975
   116   OEMRAWSINGH I         ARCH ORAL BIOL                  19   753 974
   117   OEMRAWSINGH I         ARCH ORAL BIOL                  21   755 976
   118   NEGUS V               PROC R SOC MED                  60    75 967
   119   NEMOTO T              BIOCHIM BIOPHYS ACTA           192    37 969
   120   NEUTRA M              SCI AM                         220   100 969
   121   NEUTRA M              J CELL BIOL                     30   119 966
   122   NEUTRA M              J CELL BIOL                     30   137 966
   123   NUNGESTER WJ          J INFECT DIS                    59    11 936
   124   PALAY SL              IN: PALAY SL                         305 958
   125   PIGMAN W              ANN ANAT PATHOL                 17   227 972
   126   PIGMAN W              EUR J BIOCHEM                   32   148 973
   127   PIGMAN W              IN: BLANAU                           143 973
   128   PINEO GF              ANN NY ACAD SCI                230   262 974
   129   PINEO GF              J LAB CLIN MED                  82   255 973
   130   POTTER JL             ANN NY ACAD SCI                106   692 963
   131   RAINSFORD KD          EXPERIENTIA                     15  1172 976
   132   REES DA               BIOCHEM J                      126   257 972
   133   ROBERTS GP            EUR J BIOCHEM                   50   265 974
   134   ROBERTS GP            ARCH BIOCHEM BIOPHYS           173   528 976
   135   ROBINSON DS           BIOCHEM J                      147    55 975
   136   RODRIGUES MM          ARCH OPHTHALMOL                 89   493 973
   137   ROSEMAN S             MOD PROBL PEDIATR               10   244 967
   138   ROSSIGNOL B           FEBS LETTERS                    43   241 974
   139   ROSSIGNOL B           FEBS LETTERS                    21   189 972
   140   ROUSSEL P             J BIOL CHEM                    250  2114 975
   141   SCHACHTER H           BIOCHEM SOC SYMP                40    57 974
   142   SCHRAGER J            GUT                             12   559 971
   143   SCHRAGER J            ARCH ORAL BIOL                  19  1215 974
   144   SHACKLEFORD JM        IN: AMINOFF D                        223 970
   145   SHARON N              REV BIOCHEM                     35   485 966
   146   SHERR H               GASTROENTEROLOGY                72  1130 977
   147   SHILLINGFORD JS       BIOCHEM SOC TRANS                2  1104 973
   148   SHORA W               GASTROENTEROLOGY                68   480 975
   149   SLAGLE GW             DIS COLON RECTUM                19   253 976
   150   SOERGEL KH            GASTROENTEROLOGY                47   610 964
   151   SPIRO RG              N ENGL J MED                   281   991 969
   152   SPIRO RG              REV BIOCHEM                     39   559 970
   153   STAHL GH              BIOCHEM J                      136   845 973
   154   STARKEY BJ            BIOCHEM J                      141   633 974
   155   STEINBERG SE          GASTROENTEROLOGY                68   309 975
   156   STROMBECK DR          INFECT IMMUN                    10  1266 974
   157   STURGESS JM           CLIN SCI                        43   533 972
   158   SZULMAN AE            ANNU REV MED                    17   307 966
   159   TAYLOR M              LARYNGOSCOPE                    84   612 974
   160   TRIER JS              IN: CODE CF                      3  1125 968
   161   TUPPY H               IN: GOTTSCHALK A                     403 972
   162   WAECHTER CJ           REV BIOCHEM                     45    95 976
   163   WALDRON-EDWARD D      PATHOL BIOL (PARIS)             24   521 976
   164   WALDRON-EDWARD D      GASTROENTEROLOGY                59   671 970
   165   WATKINS WM            IN: SMELLIE RMS                      125 974
   166   WILLIAMS RC           INFECT IMMUN                    11   711 975
   167$  WINDMUELLER HG        J BIOL CHEM                    249  5070 975
   168   WINET H               J EXP BIOL                      64   283 976
   169   WINSNES R             ACTA PATH MICROBIOL SCAND (C)   84    77 976
   170   WOLD JK               ACTA CHEM SCAND (B)             29   703 975
   171   WONG YC               EXP MOL PATH                    23   132 975
   173   YOSIZAWA Z            IN: GOTTSCHALK A                 5  1000 972
CT   1   GAD A                 SCAND J GASTROENTEROL           14    94 979
     2   ZHEREV S              AGRESSOLOGIE                    20   107 979
     3   QURESHI R             J CLIN INVEST                   64  1149 979
     4   SPECIAN RD            J CELL BIOL                     85   626 980
     5   NIMMERFALL F          BIOCHEM BIOPHYS RES COMMUN      94   960 980
     6   BONERANDI JJ          ANN DERMATOL VENEREOL          107    51 980
     7   BALAZS M              VIRCHOWS ARCH PATHOL ANAT HIS  387   193 980
     8   PRIZONT R             J CLIN INVEST                   67   336 981
     9   SPECIAN RD            AM J ANAT                      160   461 981
    10   TABAK LA              J ORAL PATHOL                   11     1 982
    11   SPICER SS             HUM PATHOL                      13   343 982
    12   ECKNAUER R            Z GASTROENTEROL                 20   150 982
    13   SLOMIANY BL           ARCH ORAL BIOL                  27   803 982
    14   GIBBONS RJ            AM J CLIN NUTR                  36   276 982
    15   HOUNSELL EF           MED BIOL                        60   227 982
    16   SLOMIANY BL           J DENT RES                      61  1163 982
    17   NEUTRA MR             CHEST                           81  S 14 982
    18   FERACCI H             GASTROENTEROLOGY                82   317 982
    19   BEYER EC              J CELL BIOL                     92    28 982
    20   SCHACHTER H           ADV EXP MED BIOL               144     3 982
    21   TRAYNOR OJ            ADV EXP MED BIOL               144   225 982
    22   NEUTRA MR             AM J PHYSIOL                   242  G380 982
    23   SPECIAN RD            AM J PHYSIOL                   242  G370 982
    24   CASTRO GA             AM J PHYSIOL                   243  G321 982
    25   SLOMIANY BL           J BIOL CHEM                    257  9561 982
    26   PETERS MW             BIOCHIM BIOPHYS ACTA           693   417 982
    27   KURIHARA H            BIOMED RES                       4   549 983
    28   ALLEN A               TRENDS BIOCHEM SCI               8   169 983
    29   DONALDSON JD          EUR SURG RES                    15    11 983
    30   MA J                  PATHOLOGY                       15   385 983
    31   SLOMIANY BL           ARCH ORAL BIOL                  28   711 983
    32   SCHULTE BA            J HISTOCHEM CYTOCHEM            31   391 983
    33   TRAYNOR OJ            CANCER                          51  1847 983
    34   POON H                CAN J BIOCHEM CELL BIOL         61   868 983
    35   LAMONT JT             GASTROENTEROLOGY                84   306 983
    36   STEPHEN AM            GASTROENTEROLOGY                85   589 983
    37   MOUWEN JMVM           DTSCH TIERARZ WSCHR             90   477 983
    38   SAROSIEK J            BIOCHEM BIOPHYS RES COMMUN     115  1053 983
    39   WESLEY AW             CARBOHYD RES                   115   151 983
    40   WITAS H               CARBOHYD RES                   120    67 983
    41   ZENTLERMUNRO PL       BR MED J                       287   501 983
    42   SHIMANO T             ANN NY ACAD SCI                417    97 983
    43   SLOMIANY A            BIOCHIM BIOPHYS ACTA           750   253 983
    44   YAMAMOTO A            J PHARMACOBIO DYN                7   728 984
    45   LINDAHL M             VET MICROBIOL                    9   249 984
    46   REID PE               HISTOCHEM J                     16   235 984
    47   ALLEN A               SCAND J GASTROENTEROL           19   101 984
    48   SAROSIEK J            SCAND J GASTROENTEROL           19   150 984
    49   BORSCH G              KLIN WSCHR                      62   699 984
    50   OHARA S               COMP BIOCHEM PHYSIOL (B)        79   325 984
    51   FORSTNER J            CIBA FOUND SYMP                109    61 984
    52   NEUTRA MR             CIBA FOUND SYMP                109    20 984
    53   MURTY VLN             BIOCHEM BIOPHYS RES COMMUN     121   521 984
    54   SALMONOWITZ E         AM J ROENTGENOL                142   721 984
    55   KITADA M              CLIN CHIM ACTA                 144   173 984
    56   STITH BJ              J COMP PHYSIOL (B)             155    89 984
    57   SLOMIANY A            J BIOL CHEM                    259  4743 984
    58   SAROSIEK J            ANN NY ACAD SCI                435   575 984
    59   BASBAUM C             GASTROENTEROL CLIN BIOL          9    45 985
    60   GOLDERMAN L           ISR J MED SCI                   21   410 985
    61   SEGAWA K              JAP J MED                       24   244 985
    62   GONZALEZ EA           FEMS MICROBIOL LETTERS          29   115 985
    63   ALLEN A               DIG DIS SCI                     30  S 55 985
    64   LASZEWICZ W           DIGESTION                       31    47 985
    65   COHEN PS              INFECT IMMUN                    48   139 985
    66   NEVOLA JJ             INFECT IMMUN                    50   152 985
    67   CHNG HS               J PHARM SCI                     74   399 985
    68   BELL AE               GASTROENTEROLOGY                88   269 985
    69   LOURENS JM            TIJDSCHR DIERGENEESKD          110   755 985
    70   SLOMIANY A            BIOCHEM BIOPHYS RES COMMUN     132   299 985
    71   ENE MD                CLIN CHIM ACTA                 153   165 985
    72   BRADY RC              AM J PHYSIOL                   248  G 54 985
    73   CARLSTEDTDUKE B       EUR J CLIN MICROBIOL             5   634 986
    74   SAITOH H              J PHARMACOBIO DYN                9  1008 986
    75   SALOMONOWITZ E        GASTROINTEST RADIOL             11    93 986
    76   TOOFANIAN F           LAB ANIM SCI                    36   157 986
    77   HALAMA AK             TIERARZ UMSCH                   41   340 986
    78   LAUX DC               INFECT IMMUN                    52    18 986
    79   CARLSTEDTDUKE B       ACTA PATH MICROB IMMU SCA (B)   94   293 986
    80   SMITH PL              AM J PHYSIOL                   250  G432 986
    81   MOURICOUT MA          INFECT IMMUN                    55  1216 987
    82   SNYDER JD             INT ARCH ALLERGY APPL IMMUNOL   82   351 987
    83   SHERMAN P             AM J PATHOL                    126   527 987

PN 78081
RN 00862 
AN 79045223
AU Rao-G-J.  Platt-M-W.  Nadler-H-L.
TI Reaction of 4-methylumbelliferylguanidinobenzoate with proteases in
   plasma of patients with cystic fibrosis.
SO Enzyme. 1978. 23(5). P 314-9.
MJ CYSTIC-FIBROSIS: en.  HYMECROMONE: du.  PEPTIDE-HYDROLASES: df.
   UMBELLIFERONES: du.
MN ADOLESCENCE.  ARGININE: aa, du.  BINDING-SITES.  CHILD.
   CHILD-PRESCHOOL.  GUANIDINES: du.  HUMAN.  HYMECROMONE: aa.
   IN-VITRO.  ISOELECTRIC-FOCUSING.  MOLECULAR-WEIGHT.
   PEPTIDE-HYDROLASES: bl.  SUPPORT-U-S-GOVT-P-H-S.
AB Protease activity, assayed using 4-
   methylumbelliferylguanidinobenzoate, an active site titrant of
   certain proteases, is significantly deficient in plasma of patients
   with cystic fibrosis. The deficiency can be demonstrated with both
   chloroform-ellagic acid activated plasma in which the proteases can
   hydrolyze esters of arginine and unactivated plasma in which the
   proteases have negligible activity towards these esters. The
   deficiency can also be demonstrated by separation of the proteases by
   isoelectric focusing on polyacrylamide gels or by chromatography on
   agarose columsn. Since protease deficiency can be demonstrated with
   unactivated plasma, the deficiency in cystic fibrosis is probably due
   to a reduced number of protease molecules rather than their decreased
   catalytic efficiency.
RF 001   BENDER ML             J AM CHEM SOC                   88  5890 966
   002   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   003   CHASE T JR            BIOCHEMISTRY                     8  2212 969
   004   COBURN MD             AM REV RESPIR DIS              110   368 974
   005   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   006   JAMESON GW            BIOCHEM J                      131   107 973
   007   KERR MA               BIOCHEMISTRY                    14  5088 975
   008   OUCHTERLONY O         ACTA PATH MICROBIOL SCAND       25   186 948
   009   RAO GJS               J PEDIATR                       80   573 972
   010   RAO GJS               PEDIATR RES                      8   684 974
   011   RAO GJS               PEDIATR RES                      9   739 975
   012   RAO GJS               SCIENCE                        177   610 972
   013   SCHONI M              EUR J CLIN INVEST                5   153 975
   014   SEALE TW              PEDIATR RES ABST 552            11   463 977
   015   SHAPIRA E             CLIN CHIM ACTA                  78   359 977
   016   SHAPIRA E             PEDIATR RES                     10   812 976
   017   BARRETT AJ            BIOCHEM J                      133   709 973
   018   WILSON GB             PEDIATR RES                     10    87 976
CT   1   BROCK DJH             LANCET                           1  1245 979
     2   WALSH MM              LANCET                           1   622 979
     3   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     4   RAO GJS               ENZYME                          24   280 979
     5   WALSHPLATT M          ENZYME                          24   224 979
     6   NADLER HL             LANCET                           2    96 980
     7   WALSH MMJ             PEDIATR RES                     14   353 980
     8   NADLER HL             PEDIATRICS                      66   690 980
     9   PARSONS M             CLIN CHIM ACTA                 100   215 980
    10   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
    11   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    12   LLOYDSTILL JD         J PEDIATR                       99   580 981
    13   NADLER HL             AM J OBSTET GYNECOL            141   885 981
    14   BROCK DJH             RIC CLIN LAB                    12   231 982
    15   SCHWARTZ M            CLIN CHIM ACTA                 124   213 982
    16   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    17   GREEN JR              EUR J PEDIATR                  139    35 982
    18   BRANCHINI BR          PEDIATR RES                     17   850 983
    19   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    20   HODSON ME             POSTGRAD MED J                  60   225 984
    21   BUYS CHCM             CLIN CHIM ACTA                 136   229 984
    22   MARYNEN P             BIOCHIM BIOPHYS ACTA           799   187 984
    23   PERINI JM             BULL EUR PHYSIOPATH RESP        21   569 985
    24   QURESHI AR            J PEDIATR                      106   913 985

PN 78082
RN 00863 
AN 78238710
AU Endres-W.  Wuttge-B.
TI Occurrence of secondary cystathioninuria in children with inherited
   metabolic disorders, liver diseases, neoplasms, cystic fibrosis and
   celiac disease.
SO Eur-J-Pediatr. 1978 Aug 17. 129(1). P 29-35.
MJ CELIAC-DISEASE: ur.  CYSTATHIONINE: ur.  CYSTIC-FIBROSIS: ur.
   LIVER-DISEASES: ur.  METABOLISM-INBORN-ERRORS: ur.  NEOPLASMS: ur.
MN ADOLESCENCE.  AGE-FACTORS.  BILE-DUCTS: ab.  CHILD.  CHILD-PRESCHOOL.
   CYTOMEGALIC-INCLUSION-DISEASE: ur.  HUMAN.  INFANT.
AB Secondary cystathioninuria was found in two of 46 children suffering
   from tumors, leukemia, liver disease, inherited metabolic disorders,
   cystic fibrosis and celiac disease. Of these two patients, one had
   congenital biliary atresia and the other cytomegalovirus infection.
   Seven further children had only moderately elevated excretion of
   cystathionine. It is suggested that secondary cystathioninuria is
   uncommon in the disease investigated.
RF 001   ENDRES W              Z KINDERHEILK                  110    46 971
   003   FOURMAN P             ARCH DIS CHILD                  41   273 966
   004   GEISER CF             CANCER                          22   856 968
   005   GJESSING LR           LANCET                           2  1281 963
   006   GJESSING LR           SCAND J CLIN LAB INVEST         17   513 965
   007   GJESSING LR           RECENT RESULTS CANCER RES        2    26 966
   008   LIEBERMAN E           PEDIATRICS                      40   828 967
   009   SCRIVER CR            PEDIATRICS                      31   240 963
   010   SHAW KNF              AM J DIS CHILD                 113   119 967
   011   STUDNITZ W            ACTA PAEDIATR SCAND             58   173 969
   012   STUDNITZ W            ACTA PAEDIATR SCAND             59    80 970
   013   VOUTE PA JR           CLIN CHIM ACTA                  22   373 968
CT   1   SHIN YS               CLIN CHIM ACTA                 127    77 983

PN 78083
RN 00864 
AN 78214700
AU Schroder-C-P.  Emrich-H-M.
TI Ultramicro-electrophoresis of protein in sweat from patients with
   cystic fibrosis of the pancreas and controls.
SO Eur-J-Pediatr. 1978 May 22. 128(1). P 49-56.
MJ CYSTIC-FIBROSIS: me.  PROTEINS: an.  SWEAT: an.
MN ADOLESCENCE.  BINDING-SITES.  CELL-MEMBRANE.  CHILD.
   CHILD-PRESCHOOL.  ELECTROPHORESIS: mt.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  SALIVA.  VISCOSITY.
AB 46 sweat-samples from 32 children with cystic fibrosis of the
   pancreas (C.F.) and 35 samples from 23 control-children were
   collected with glass micro-capillaries. Protein was determined by
   ultramicro-electrophoresis. Results: 1. Protein was detected in 48%
   of the samples (C.F. and controls). 2. At pH 2.3, C.F.-sweat showed
   at least one more band than control-sweat. 3. At pH 8.9, C.F.-sweat
   occasionally showed one more band than the control-group. 4. At pH
   2.3, more protein was found at the electrophoresis start point using
   C.F.-sweat, whereas at pH 8.9 the opposite was found. 5. At pH 2.3,
   protein was found in fewer samples than at pH 8.9. The "C.F.-factor"
   is postulated to represent a basic polyelectrolyte which induces the
   following pathogenic mechanisms: a) Aggregation of proteins giving
   rise to a high viscosity of secretions, such as saliva. b) Binding to
   the cell-membrane of the glandular epithelium, thus inducing a
   disturbance of active NaCl-reabsorption (e.g. by reduction of luminal
   passive Na+-influx).
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   BARNETT DR            TEX REP BIOL MED                31   709 973
   003   BOWMAN BH             AM J HUM GENET                  25   16A 973
   004   DOGGETT RG            NATURE NEW BIOL                243   250 973
   005   EMRICH HM             PFLUEGERS ARCH                 290   298 966
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007$  GROSSBACH U           IN: GLICK D                      3       975
   008   HEICK HMC             CLIN RES                        21  1037 973
   009   JIRKA M               NATURE                         199   283 963
   010   KAISER D              PEDIATR RES                      5   167 971
   011   LOBECK CC             IN: STANBURY JB                     1605 972
   012   MCEVOY FA             PEDIATR RES                      9   721 975
   013   MANGOS JA             SCIENCE                        158   135 967
   014   MANGOS JA             PEDIATR RES                      1   436 967
   015   MANGOS JA             PEDIATR RES                      2   378 968
   016   MANGOS JA             TEX REP BIOL MED                31   651 973
   017   NIKOLAJEK WP          EUR J PEDIATR                  122   289 976
   018   TAYLOR A              PEDIATR RES                      8   861 974

PN 78084
RN 00865 
AN 78106794
AU Gotz-M.  Lubec-G.
TI Complement in cystic fibrosis.
SO Eur-J-Pediatr. 1978 Jan 17. 127(2). P 133-9.
MJ COMPLEMENT: an.  CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  COMPLEMENT-3: an.
   COMPLEMENT-4: an.  FEMALE.  HUMAN.  INFANT.  MALE.
   PSEUDOMONAS-AERUGINOSA.  SEX-FACTORS.  SPUTUM: mi.
AB Complement components C3, C4, and C3A were estimated in 30 patients
   with cystic fibrosis aged 1 to 21 years (M:F = 16:14) and were
   compared with results in 40 healthy, age-matched subjects. The
   influences of the clinical score, sputum microbiology, and the
   patients' sex were also investigated. In contrast to most previous
   communications, this paper shows that, compared to the control group,
   a significant decrease of C3 (P less than 0.001) and C4 (P less than
   0.02) was observed whereas C3A levels were not altered. There were no
   increases in complement. Shwachman-scores above or below 70 did not
   influence the complement levels, nor did exacerbations of the disease
   change the levels. No influence of the patients' sex could be shown.
   Pseudomonas aer. in the sputum was clearly associated with complement
   defects (14/18). Alternative-pathway involvement of complement
   activation could be demonstrated in 32%. The results make complement
   activation due to pulmonary infection most likely. The defects
   observed probably represent secondary changes.
RF 001   ALPER CA              N ENGL J MED                   288   601 973
   002   ALPER CA              IN: NETER E                              975
   003   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   004   CHARLESWORTH JA       J CLIN INVEST                   53  1578 974
   005   CONOVER JH            LANCET                           2  1501 973
   006   CONOVER JH            LANCET                           1    47 975
   007   CONOVER JH            LIFE SCI                        14   253 974
   008   DANES BS              J EXP MED                      129   775 969
   009   ESTERLY JR            IN: MANGOS JA                        115 976
   010   FEARON DT             N ENGL J MED                   292   937 975
   011   FUST G                CLIN IMMUNOL IMMUNOPATHOL        5   293 976
   012   GIBBONS A             BR MED J                         1   120 976
   013   GIBSON LE             PEDIATRICS                      23   545 959
   014   GOETZ M               PROC EWGCF 6TH ANNU MTG                  975
   015   HANN S                LANCET                           2   520 974
   016   HANSSON LO            LANCET                           2   874 975
   017   HARPER BL             CF CLUB ABST                    17    20 976
   018   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   019   HOLZHAUER RJ          CF CLUB ABST                    17    22 976
   020   JOHNSTON RB           J PEDIATR                       90   169 977
   021   KAY AB                LANCET                           2   916 974
   022   LEDERBERG S           AM J HUM GENET                  28   597 976
   023   LEDERBERG S           AM J HUM GENET                  28   597 976
   024   MCFARLANE H           BR MED J                         1   423 975
   025   OSOFSKY SG            J PEDIATR                       90   180 977
   026   PALMER DG             AUST NZ J MED                    6   349 976
   027   POLMAR SH             IN: KIRKPATRICK CH                   191 976
   028   ROSSMAN CM            J PEDIATR                       90   579 977
   028A  ROY CC                PEDIATR CLIN GASTROENTEROL               975
   029   SCANLIN TF JR         LANCET                           1  1382 974
   030   STEPHAN U             PEDIATRICS                      55    35 975
   031   TAUSSIG LM            CF CLUB ABST                    17    21 976
   032   WEEKE B               DAN MED BULL                    23   155 976
   033   WOOD RE               AM REV RESPIR DIS              111   733 975
   034   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   SCHIOTZ PO            MONOGR PAEDIATR                 10   131 979
     2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     3   HODSON ME             THORAX                          35   801 980
     4   MOSS RB               AM REV RESPIR DIS              121    23 980
     5   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     6   FICK RB               J CLIN INVEST                   68   899 981
     7   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     8   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985
     9   FICK RB               PEDIATR RES                     20  1258 986

PN 78085
RN 00866 
AN 78107013
AU Watts-R-W.
TI Progress in screening for inborn errors of metabolism.
SO Experientia. 1978 Feb 15. 34(2). P 143-52.
MJ GENETIC-SCREENING.  MASS-SCREENING.  METABOLISM-INBORN-ERRORS: di.
MN ADULT.  LIPOIDOSIS: di.  ANEMIA-SICKLE-CELL: di.
   CARBOXYLIC-ACIDS: ur.  CYSTIC-FIBROSIS: di.  ENZYME-TESTS.  FEMALE.
   GALACTOSEMIA: di.  GLYCOSIDES: bl.  HUMAN.  HYPOTHYROIDISM: cn, di.
   INFANT.  INFANT-NEWBORN.  JEWS.  LYMPHOCYTES: me.  MALE.
   OLIGOSACCHARIDES: ur.  PHENYLKETONURIA: di.  PREGNANCY.
   THALASSEMIA: di.
AB The inborn errors of matabolism are a series of individually rare
   biochemical anomalies some of which cause serious clinical
   manifestations.  They are of great interest to biochemists and
   geneticists, as well as to paediatricians and internist for whom
   they often present special diagnostic and therapeutic problems.  The
   study of the inborn errors of metabolism also has implications in
   the fields of epidemiology and social medicine.  The number of known
   inborn errors of metabolism has increased rapidly in recent years,
   and others, as yet unidentified, presumably await recognition.  Only
   a few of these conditions can be treated now, but the realisation
   that early diagnosis is essential in order to achieve good results
   has stimulated interest in the possibility of examining either whole
   populations or selected predisposed groups of individuals for
   biochemical differences which characterise particular inherited
   metabolic diseases.  This article reviews some recent developments
   with particular reference to the indications for such screening
   programmes and progress in the identification of previously unknown
   inborn errors of metabolism in otherwise homogeneous population
   groups.  The inborn errors of metabolism are due to single gene
   mutations.  Recognition of the asymptomatic individuals who are
   heterozygous for the abnormal gene causing the disease may be
   important clinically and the identification has to be considered as
   one aspect of metabolic screening for the inborn errors of
   metabolism.
RF 001   WATTS RWE             LANCET                           1   368 975
   002   PURKISS P             PROC INT SYMP GLYCOCON 3RD            19 975
   005   BROWN E               METABOLISM                      26  1047 977
   006   CHALMERS RA           ANALYST                         97   224 972
   007   CHALMERS RA           ANALYST                         97   951 972
   008   CHALMERS RA           ANALYST                         97   958 972
   009   HEALY MJR             J CHROMATOGR                    87   365 973
   010   LAWSON AM             ADV MASS SPECTROMET              6   235 974
   011   LAWSON AM             BIOMED MASS SPECTROMET           1   199 974
   012   CHALMERS RA           CHEM BRIT                       11   290 975
   013   LEVY HL               N ENGL J MED                   291  1214 974
   014   CLAYTON BE            IN: RAINE DN                     1     1 974
   015   KOMROWER GM           PEDIATRICS                      53   182 974
   016   SEEGMILLER JE         IN: NATELSON S                       291 974
   017   SCRIVER CR            LANCET                           2   230 964
   018   SMITH DW              PEDIATRICS                      19  1011 957
   019   MAN EB                J PEDIATR                       63   926 963
   020   DUTAU G               ANN PEDIATR (PARIS)             22   315 975
   021   RAITI S               ARCH DIS CHILD                  46   692 971
   022   KLEIN AH              J PEDIATR                       81   912 972
   023   FISHER DA             J PEDIATR                       89   692 976
   024   CHOPRA IJ             N ENGL J MED                   293   740 975
   025   LAWSON D              ARCH DIS CHILD                  44   715 969
   026   BRAY PT               PERSPECTIVE OF SODIUM AND CHL            975
   027   BRAY PT               CLIN CHIM ACTA                  77    69 977
   028   STEPHAN U             PEDIATRICS                      55    35 975
   029   RYLEY HC              ARCH DIS CHILD                  49   901 974
   030   GIBSON LE             PEDIATRICS                      23   545 959
   031   SPOCK A               PEDIATR RES                      1   173 967
   032   BOWMAN BH             TEX REP BIOL MED                31   611 973
   033   GLUECK CJ             J LAB CLIN MED                  82   467 973
   034   KWITEROVICH PO JR     LANCET                           1   118 973
   035   ADRIAENSSENS K        PROTIDES BIOL FLUIDS            19   265 971
   036   DARMADY J             PROTIDES BIOL FLUIDS            19   26A 971
   037   DARMADY JM            BR MED J                         2   685 972
   038   OSE L                 LANCET                           2   625 975
   039   SAIFER A              IN: NATELSON S                       353 974
   040   KABACK MM             PROG MED GENET                  10   103 974
   041   CHILDS B              AM J HUM GENET                  28   537 976
   042   CHILDS B              AM J HUM GENET                  28   550 976
   043   KABACK MM             HUM HERED                       27   186 977
   044   PADEH B               HUM HERED                       27   200 977
   045   EVANS PR              IN: RAINE DN                          93 977
   046   KAN YW                LANCET                           1   269 977
   047   NATHAN DG             BR J HAEMATOL SUPPL             31   143 975
   048   CHALMERS RA           ANN CLIN BIOCHEM                14   149 977
   049   LAWSON AM             CLIN CHEM                       22  1283 976
   050   CHALMERS RA           CLIN CHEM                       22  1288 976
   051   CHALMERS RA           CLIN CHEM                       22  1292 976
   052   ROBERTS GE            BIOCHEM SOC SPEC PUBL            1     7 973
   053   LA DU BN              J BIOL CHEM                    230   251 958
   054   KAUFMAN S             N ENGL J MED                   293   785 975
   055   BARTHOLOME K          PEDIATR RES                      9   899 975
   056   WATTS RWE             NATURE                         201   396 963
   057   POLLACK VE            J LAB CLIN MED                  66   564 965
   058   LA DU BN              BIOCHEM BIOPHYS RES COMMUN       7   398 962
   059   RYMAN BE              IN: WILKINSON JH                         976
   060   SCRIVER CR            AMINO ACID METABOL DISORDERS             973
   061   GIBBS DA              ANN CLIN BIOCHEM                14   157 977
   063   LYON MF               AM J HUM GENET                  14   135 962
   064   WITKOP CJ JR          AM J HUM GENET                  22    55 970
   065   GARTLER SM            ANN HUM GENET                   33   171 969
   066   GARTLER SM            SCIENCE                        172   572 971
   067   WATTS RWE             IN: HOLTON J                             975
   068   SPENCE MW             J MED GENET                     14    91 977
   070   RAINE DN              J CLIN PATHOL SUPPL             27     8 974
CT   1   PURKISS P             CLIN CHEM                       24   669 978
     2   LEHNERT W             MONATSSCHR KINDERHEILKD        127   665 979
     3   FARRIAUX JP           ARCH FR PEDIATR                 37   367 980
     4   ISSAQ HJ              J LIQUID CHROMATOGR              4  2233 981
     5   BECKER K              MONATSSCHR KINDERHEILKD        129   556 981
     6   DHARESHWAR SS         INDIAN J MED RES                76   716 982

PN 78086
RN 00867 
AN 79046205
AU Neutra-M-R.  Trier-J-S.
TI Rectal mucosa in cystic fibrosis.  Morphological features before and
   after short term organ culture.
SO Gastroenterology. 1978 Oct. 75(4). P 701-10.
MJ CYSTIC-FIBROSIS: pa.  INTESTINAL-MUCOSA: pa.  RECTUM: pa.
MN ADOLESCENCE.  ADULT.  AUTORADIOGRAPHY.  BIOPSY.  CHILD.
   EPITHELIUM: pa.  HUMAN.  IN-VITRO.  MUCUS: an.  ORGAN-CULTURE.
   SUPPORT-U-S-GOVT-P-H-S.
AB Histological changes observed in the large intestinal mucosa of
   cystic fibrosis (CF) patients, including crypt enlargement as well as
   intracellular and extracellular accumulation of mucus, have been
   considered by some to be useful diagnostic signs of this disease. The
   extent of these changes, however, has not been evaluated
   quantitatively. In this study, quantitative stereological methods
   were applied to biopsies of rectal mucosa from 5 CF patients, 5
   sibling controls, and 2 normal adults, to measure goblet cell
   numbers, crypt luminal volume, and volume of intracellular mucus. It
   was found that CF crypt lumina were variably dilated, but that the
   average relative volume of intracellular mucus and the numbers of
   goblet cells in CF mucosae were comparable to those of sibling and
   adult controls. In CF biopsies, however, surface columnar absorptive
   cells consistently contained putative lipid droplets and rapidly
   accumulated additional large lipid droplets during short term organ
   culture. Lipid droplets were not observed in the same cell types of
   control biopsies before or after short term organ culture.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   004   NEUTRA MR             LAB INVEST                      36   535 977
   005   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   006   DONNISON AB           PEDIATRICS                      37   833 966
   007   EIDELMAN S            CF CLUB ABST                     5       964
   008   JABRO IH              J LANCET                        86   385 966
   009   PARKINS RA            LANCET                           2   851 963
   010   SHWACHMAN H           N ENGL J MED                   286  1300 972
   011   HAGE E                ACTA PATH MICROBIOL SCAND (A)   80   345 972
   012   DALTON AJ             ANAT REC                       121   281 955
   013   SHANTZ A              STAIN TECHNOL                   40   279 965
   014   WEIBEL ER             IN: HAYAT MA                     3   239 973
   015   BROWNING TH           J CLIN INVEST                   48  1423 969
   016   EASTWOOD GL           GASTROENTEROLOGY                64   375 973
   017   JODL J                ACTA PAEDIATR SCAND             60   367 971
   018   GEAR EV JR            GASTROENTEROLOGY                55   522 968
   019   THOMAIDIS TS          J PEDIATR                       63   444 963
   020   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   021   FORSTNER JF           PEDIATR RES                     10   609 976
   022   JOHANSEN PG           LANCET                           1   455 968
   023   BENNETT G             J CELL BIOL                     46   409 970
   024   FORSTNER GG           J BIOL CHEM                    245  3584 970
   025   DOBBINS WO            AM J CLIN NUTR                  22   257 969
   026   CARDELL RR            J CELL BIOL                     34   123 967
   027   PALAY SL              PROC INT SYMP LIPID TRANSPOR          33 964
   028   SABESIN SM            LIPIDS                          10   840 975
   029   BINDER HJ             PROC SOC EXP BIOL MED          131  1119 969
   030   MELNICK CS            GASTROENTEROLOGY                52   985 967
   031   HOUCK JC              PROC SOC EXP BIOL MED          147   167 974
   032   KESSLER JI            GASTROENTEROLOGY                68  1068 975
   033   CLARK SB              J LIPID RES                     14   581 973
   034   SNIPES R              LAB INVEST                      18   179 968
   035   ODOHERTY PJA          LIPIDS                           8   249 973
   036   GLICKMAN RM           GASTROENTEROLOGY                70   347 978
   037   JACOP JS              J CELL BIOL                     70  158A 976
   038   ELLIOTT RB            PEDIATRICS                      57   474 976
   039   CAMPBELL IM           PEDIATRICS                      57   480 976
   040   BUTCHER FR            IN: MANGOS JA                        243 976
CT   1   PARK RW               GASTROENTEROLOGY                81  1143 981
     2   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     3   GOLDMAN H             HUM PATHOL                      13   981 982
     4   HOWDLE PD             CLIN SCI                        65   105 983
     5   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
     6   BRADY RC              EXP CELL RES                   150   141 984

PN 78087
RN 00868 
AN 78150401
AU Pearson-R-D.  Lubin-A-H.
TI A simple method for estimating a 'heparin binding capacity' of human
   serum.
SO Health-Lab-Sci. 1978 Jan. 15(1). P 32-7.
MJ BLOOD-PROTEINS: me.  HEPARIN: me.  PROTEIN-BINDING.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: bl.  FEMALE.
   HEPARIN:  an, bl.  HUMAN.  MALE.  METHODS.  MIDDLE-AGE.
AB A method for estimating a 'heparin binding capacity' of human serum
   is described. When human serum is diluted with a low ionic strength,
   heparin-containing buffer at pH 5.5, protein-heparin electrostatic
   complexes form in solution with subsequent formation of insoluble
   aggregates which can be collected by centrifugation. Quantitative
   determination of the relative amounts by weight of protein and
   heparin in the insoluble heparin-protein aggregates permits
   estimation of a combining ratio at which serum proteins bind with
   heparin to precipitate from solution. This weight combining ratio of
   protein and heparin is a quantitative measure of the total affinity
   for heparin of all proteins in serum which bind heparin at pH 5.57 to
   form an insoluble complex. An unusually high affinity for heparin by
   an abnormal serum protein or an increase in amount of a normally-
   occuring, high heparin-affinity, serum protein would alter the
   average protein: heparin combining ratio and increase the 'heparin-
   binding capacity' of human serum. The converse would be true for
   serum proteins having a low affinity for heparin, lowering the
   'heparin-binding capacity' of human serum. The described method was
   used to evaluate the 'heparin-binding capacity' of serum proteins in
   normal individuals and in persons with cystic fibrosis.
RF 001   BITTER T              ANAL BIOCHEM                     4   330 962
   002   DI SANTAGNESE PA      LANCET                           2   765 967
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   DISCHE Z              J BIOL CHEM                    167   189 947
   005   DISCHE Z              J BIOL CHEM                    175   595 948
   006   EHRLICH J             J PHARM SCI                     62   517 973
   007   GOODMAN LS            PHARMACOLOGIC BASIS OF THE TH       1446 970
   008   HOMAN JDH             BIOCHIM BIOPHYS ACTA             2   333 948
   009   JAKOVCIC S            J PEDIATR                       62    25 963
   010   LASKER SE             ARCH BIOCHEM BIOPHYS           115   360 966
   011   LINDAHL U             IN: BALAZS EA                    2   943 970
   012   LOWRY OH              J BIOL CHEM                    193   265 951
   013   MARCINIAK E           J LAB CLIN MED                  84   344 974
   014   PEARSON RD            CF CLUB ABST                    17       976
   015   SLACK J               J LAB CLIN MED                  59   302 962
CT   1   PEARSON RD            PEDIATR RES                     13   834 979
     2   DUPOUY JP             J PHYSIOL (PARIS)               76   631 980
     3   VERPOORTE JA          INT J BIOCHEM                   13  1151 981
     4   MARGOLIES R           PEDIATR RES                     16   181 982
     5   MARGOLIES R           PEDIATR RES                     17   931 983
     6   DUPOUY JP             ANN ENDOCRINOL PARIS            47   429 986

PN 78088
RN 00869 
AN 79109072
AU Marchi-A-G.  Marchi-M-A.  Cigui-I.  Uxa-F.  Perticarari-S.  Nordio-S.
TI Further studies on lymphocyte beta-glucuronidase abnormality in
   cystic fibrosis.  Possible relations to carboxypeptidase B-like
   activity.
SO Helv-Paediatr-Acta. 1978 Dec. 33(6). P 517-25.
MJ CARBOXYPEPTIDASES: bl.  CYSTIC-FIBROSIS: en.  GLUCURONIDASE: bl.
   LYMPHOCYTES: en.
MN CHILD.  CYSTIC-FIBROSIS: di, fg.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.  LYMPHOCYTE-TRANSFORMATION.  MALE.  PHYTOHEMAGGLUTININS: pd.
AB The presence in the serum of both cystic fibrosis (CF) homozygotes
   and heterozygotes of a factor inhibiting the response of lymphocyte
   lysosome beta-glucuronidase activity to in vitro phytohaemagglutinin
   (PHA) stimulation is confirmed. Studying lymphocyte beta-
   glucuronidase activity on PHA stimulation represents a way to confirm
   CF diagnosis and to screen CF heterozygotes. For technical
   complexity, however, the method cannot be used for mass screening,
   but it can be useful for confirming the diagnosis in suspected cases.
   Relationships between serum factor inhibiting the effect of PHA on
   beta-glucuronidase, ciliary dyskinesia factor and carboxypeptidase B-
   like activity are discussed.
RF 001   CONOVER JH            LANCET                           2  1501 973
   002   CONOVER JH            PEDIATR RES                      7   220 973
   003   CONOVER JH            PEDIATR RES                      7   224 973
   004   CONOVER JH            LIFE SCI                        14   253 974
   005   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   006   ERDOS EG              BIOCHEM PHARMACOL               13   893 964
   007   FOLK JE               J BIOL CHEM                    235  2272 960
   008   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   009   LIEBERMAN J           AM REV RESPIR DIS              116  1047 977
   010   MANGIAROTTI-MARCHI MA MINERVA PEDIATR                 23  1847 971
   011   MARCHI AG             MINERVA PEDIATR                 23  1842 971
   012   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   013   MARCHI AG             ACTA PAEDIATR BELG              29    67 976
   014   NORDIO S              ACTA PAEDIATR SCAND             63   664 974
CT   1   JAKEL HP              BIOL ZENTRALBL                 100   273 981

PN 78089
RN 00870 
AN 79047858
AU Schwarz-H-P.  Kraemer-R.  Thurnheer-U.  Rossi-E.
TI Liver involvement in cystic fibrosis.  A report of 9 cases.
SO Helv-Paediatr-Acta. 1978 Nov. 33(4-5). P 351-64.
MJ CYSTIC-FIBROSIS: co.  LIVER-DISEASES.
MN ADOLESCENCE.  CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.
   INFANT.  LIVER-CIRRHOSIS: pa.  LIVER-CIRRHOSIS-BILIARY: pa.
   LIVER-DISEASES: pa.  LIVER: pa.  MALE.
AB 9 out of 204 unselected cystic fibrosis (CF) patients seen at the
   Department of Pediatrics, University of Berne, Switzerland, over the
   last 20 years had clinically overt liver disease. In 7 patients liver
   cirrhosis was demonstrated (3.4%). Focal biliary cirrhosis was the
   pertinent finding in 3 cases, whereas another 3 showed unspecific
   nodular cirrhosis. One infant presented with prolonged obstructive
   jaundice due to partial extrahepatic atresia and delayed passing of
   meconium. Two other patients had steatosis. A review of the
   literature dealing with clinical and laboratory findings in CF
   patients with liver disease is given.
RF 001   ALHADEFF JA           CLIN GENET                      10    63 976
   002   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   003   BERNSTEIN JG          AM J DIS CHILD                  99   804 960
   004   BOAT TF               CLIN PEDIATR                    13   505 974
   005   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   006   COOPER HS             JOHNS HOPKINS MED J            135   268 974
   007   CRAIG JM              AM J DIS CHILD                  93   357 957
   008   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   009   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   010   DONATH A              HELV PAEDIATR ACTA              25   634 970
   011   DUBOIS RS             GASTROENTEROLOGY                72  1052 977
   012$  EKLUND A              IN: PAUMGARTNER G                    241 977
   013   EXSS R                DTSCH MED WSCHR                 97   425 972
   014   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   015   FEIGELSON J           ACTA PAEDIATR SCAND             61   337 972
   016   FEIGELSON J           NOUV PRESSE MED                  1  1899 972
   017   FEIGELSON J           ACTA PAEDIATR SCAND             61   337 972
   018   GATZIMOS CD           AM J DIS CHILD                  89   182 955
   019   GIEGLER I             ANN ANAT PATHOL                  5   115 960
   020   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   021   GOODCHILD MC          ARCH DIS CHILD                  50   813 975
   022   ISENBERG JN           GASTROENTEROLOGY                66   887 974
   023   JEAN R                ARCH FR PEDIATR                 27   849 970
   024   KATTWINKEL J          J PEDIATR                       82   234 973
   025   KRAEMER R             SCHWEIZ MED WOCHENSCHR         107   271 977
   026   KRAEMER R             HELV PAEDIATR ACTA              32   107 977
   027   LITT IF               PEDIATR CLIN NORTH AM           20   945 973
   028   OPPENHEIMER EH        LANCET                           2  1031 973
   029   OPPENHEIMER EH        J PEDIATR                       86   683 975
   030   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   031   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   032   ROSENSTEIN BJ         J PEDIATR                       91  1022 977
   033   ROY CC                N ENGL J MED                   297  1301 977
   034   SCHWARZ HP            CLIN CHIM ACTA                  50   197 974
   035   SHIER KJ              CAN MED ASSOC J                 89   645 963
   036   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   037   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   038   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   039   SOLOWAY RD            AM J DIG DIS                    16  1082 971
   040   STERN RC              GASTROENTEROLOGY                70   645 976
   041   STERN RC              J PEDIATR                       89   406 976
   042   STERN RC              ANN INTERN MED                  87   188 977
   043   TALAMO RC             AM J DIS CHILD                 115    74 968
   044   TANNER JM             ARCH DIS CHILD                  41   454 966
   045   TAYLOR WF             AM J DIS CHILD                 123   161 972
   046   VALMAN HB             ARCH DIS CHILD                  46   805 971
   047   WARWICK WJ            JAMA                           238  2159 977
   048   WATKINS JB            GASTROENTEROLOGY                73  1023 977
   049   WEBER AM              N ENGL J MED                   289  1001 973
   050   WEBER AM              GUT                             17   295 976
   051   WILROY RS JR          J PEDIATR                       68    67 966
CT   1   CUNNINGHAM DG         J COMPUT ASSIST TOMOGR           4   151 980
     2   BALISTRERI WF         J PEDIATR                       97   689 980
     3   MAGAZZU G             RIV ITAL PEDIATR                 7    73 981
     4   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     5   MCCLURE HM            ADV VET SCI COMP MED            28   267 984
     6   BERNARD O             CLIN GASTROENTEROL              14    33 985
     7   FEIGELSON J           ANN PEDIATR (PARIS)             32   218 985
     8   SCHRODER R            SCHWEIZ MED WOCHENSCHR         115   828 985

PN 78090
RN 00871 
AN 78193578
AU Warwick-W-J.
TI The incidence of cystic fibrosis in Caucasian populations.
SO Helv-Paediatr-Acta. 1978 Jun. 33(2). P 117-25.
MJ CAUCASOID-RACE.  CYSTIC-FIBROSIS: oc.
MN HUMAN.
AB Estimates of the newborn frequency of cystic fibrosis in different
   Caucasian groups range from 4 times more to 40 times less common than
   the generally accepted figure of 1:2000. Current meconium screening
   trials which may be effective in populations with the incidence equal
   to or greater than 1:2000, may be useful for populations with an
   incidence as low as 1:7000 only after maximum improvement of the
   methods. Once the true incidence or the variable incidence is proven
   for Caucasian populations, screening trails in Negro, Oriental and
   Indian populations will be required.
RF 001   ANTONELLI M           FRACASTORO (VERONA)             63   207 970
   002   BECROFT DMO           NZ MED J                        68   113 968
   003   BOCHKOVA DN           PEDIATRIIA                      12    24 974
   004   BOZKOWA K             PEDIATR POLSKA                  46   677 971
   005   BOZKOWA K             PROC EWGCF 1ST ANNU MTG                  970
   006   BRUNECKY Z            J MED GENET                      9    33 972
   007   BRUNECKY Z            KINDERAERZTL PRAX               38   514 970
   008   BRUNECKY Z            CESK PEDIATR                    25    74 970
   009   CAIN ARR              ARCH DIS CHILD                  47   131 972
   010   CARTER CO             PHYSIOTHERAPY                   61   240 975
   011   CARTER CO             MOD PROBL PEDIATR               10   372 967
   012   CONNEALLY PM          AMER SOC HUM GENET PROGRAM            42 966
   013   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   014   DANKS DM              ANN HUM GENET                   28   323 965
   015   DIETZSCH HS           PROC EWGCF 6TH ANNU MTG                  975
   016   FEINGOLD J            CF Q ANNOTATED REFERENCES       13    15 974
   017   FEINGOLD J            ANN GENET (PARIS)               17   257 974
   018   GALEN RS              BEYOND NORMALITY THE PREDICTI            975
   019   GILLY R               ANN PEDIATR (PARIS)             20     5 973
   020   GILLY R               ARCH FR PEDIATR                 28    49 971
   021   GOTTSCHALK B          PROC INT CF CONG 7TH                  38 976
   022   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   023   HALL BD               J MED GENET                      5   262 968
   024   HALL BD               IN: LAWSON D PROC 5TH INT CF          82 969
   025   HANNA BL              IN: US PUB HEAL SERV PUB1163           7 963
   026   HONEYMAN MS           AM J HUM GENET                  17   461 965
   027   HONEYMAN MS           CONN HLTH BULL                  75   275 961
   028   HOUSTEK J             REV MED LIEGE                   22   421 967
   029   HOUSTEK J             CESK PEDIATR                    17   445 962
   030   HOUSTEK J             CAS LEK CES                    104   201 965
   031   KAISER D              PROC INT CF CONG 7TH                  33 976
   032   KOLLBERG H            PROC EWGCF 1ST ANNU MTG                  970
   033   KOLLBERG H            PROC INT CF CONG 7TH                  32 976
   034   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   035   KULCZYCKI LL          AM J DIS CHILD                 100   174 960
   036   LEVIN S               IN: GOLDSCHMIDT E                    294 963
   037   MERRITT AD            J LAB CLIN MED                  60   998 962
   038   MIGLIORI V            MINERVA MED                     64  4906 973
   039   NEVANLINNA HR         HEREDITAS                       71   195 972
   040   NIELSEN EL            UGESKR LAEGER                  133  1017 971
   041   NIELSEN EL            ACTA PAEDIATR SCAND             61   377 972
   042   OREILLY D             INT J EPIDEMIOL                  3   247 974
   043   PROSSER R             ARCH DIS CHILD                  49   597 974
   044   PUGH RJ               ARCH DIS CHILD                  42   544 967
   045   RACHINSKU SU          PEDIATRIIA                       3    60 973
   046   REIDERMAN MI          GENETIKA (SOV GENETICS)          7   148 971
   047   RIGHETTI ABB          PROC INT CF CONG 7TH                  36 976
   048   ROBERTS GBS           ANN HUM GENET                   24   127 960
   049   ROBINSON PG           PROC INT CF CONG 7TH                  40 976
   050   ROJO M                PROC INT CF CONG 7TH                  36 976
   051   SELANDER P            ACTA PAEDIATR SCAND             51    65 962
   052   SIMANKOVA N           ANN GENET (PARIS)                7    84 964
   053   STEINBERG AG          IN: GOLDSCHMIDT E                    133 963
   054   STEINBERG AG          AM J HUM GENET                  12   416 960
   055   SULTZ HA              AM J PUBLIC HEALTH              56  1461 966
   056   SULTZ HA              AM J PUBLIC HEALTH              58   491 968
   057   SUPER M               S AFR MED J                     49   818 975
   058   TEN KATE LP           THESIS                                   975
   059   TEN KATE LP           INT J EPIDEMIOL                  6    23 977
   061   TODD RM               MOD PROBL PEDIATR               10   387 967
   062   TRIMBLE BK            ANN HUM GENET                   38   199 974
   063   WRIGHT SW             AM J HUM GENET                  20   157 968
   064   WRIGHT SW             HAWAII MED J                    27   229 968
   065   ZYCHOWICZ C           PEDIATR POLSKA                  40   289 965
CT   1   ALLAN JL              AUST PAEDIATR J                 16   270 980
     2   JONES MB              J CHRON DIS                     33   697 980
     3   ROMEO G               RIV ITAL PEDIATR                 7   201 981
     4   WARWICK WJ            MINN MED                        64   553 981
     5   KLINGER KW            HUM GENET                       65    94 983
     6   MCCLURE HM            ADV VET SCI COMP MED            28   267 984
     7   KARJOO M              J TROP PEDIATR                  30   195 984
     8   ALLAN JL              ACTA PAEDIATR SCAND             74   286 985
     9   KNOPFLE G             KLIN PAEDIATR                  197   481 985
    10   KNOPFLE G             KLIN PAEDIATR                  197    13 985
    11   GEDSCHOLD J           HUM GENET                       75   277 987

PN 78091
RN 00872 
AN 78149805
AU Seaman-W-B.
TI The case of the abnormal duodenum.
SO Hosp-Pract. 1978 Mar. 13(3). P 80-1.
MJ CYSTIC-FIBROSIS: co.  DUODENAL-DISEASES: ra.
MN ADULT.  CHILD.  DUODENAL-DISEASES: et.  HUMAN.  MALE.
EX Intermittent epigastric pain, partially relieved by food, was the
   reason for examining the upper gastrointestinal tract in a
   30-year-old man.  The second portion of the duodenum was strikingly
   abnormal.  The patient had a history of daily, multiple loose stools
   since birth.  At age 12 a diagnosis of small bowel malabsorption due
   to fibrocystic disease of the pancreas was established.  In view of
   this history, the duodenal changes were considered to be a
   manifestation of fibrocystic disease of the pancreas.  At the present
   time the cause of these duodenal abnormalities is unknown.
RF 001   TAUSSIG LM            RADIOLOGY                      106   369 973
   002   BERK RN               RADIOLOGY                      106   377 973
CT   1   MABOGUNJE OA          SURGERY                         90   114 981

PN 78092
RN 00873 
AN 78149840
AU Hosli-P.  Vogt-E.
TI Reliable detection of cystic fibrosis in skin-derived fibroblast
   cultures.
SO Hum-Genet. 1978 Mar 17. 41(2). P 169-73.
MJ ALKALINE-PHOSPHATASE: bi.  CYSTIC-FIBROSIS: di.  FIBROBLASTS: en.
MN CELLS-CULTURED.  ENZYME-INDUCTION.  GLYCOPROTEINS.  HETEROZYGOTE.
   HUMAN.  ISOPROTERENOL.  PREGNANCY.  PRENATAL-DIAGNOSIS.  SKIN: cy.
   THEOPHYLLINE.
AB The specific induction of alkaline phosphatase with Tamm-Horsfall
   glycoprotein, isoproterenol, and theophylline in skin-derived
   fibroblast cultures from patients with cystic fibrosis permits one to
   reliably discriminate between cystic fibrosis patients on the one
   hand, and heterozygotes and normals on the other. It was found the
   fibroblast-like and intermediary types of amniotic fluid-derived
   cells behave essentially like skin-derived fibroblasts. These
   findings imply that if different amniotic fluid cell types can be
   reliably separated, prenatal diagnosis of cystic fibrosis should
   become feasable in the near future.
RF 001   BOXER LA              N ENGL J MED                   295  1041 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   HOSLI P               TISSUE CULTIVATION ON PLASTIC            972
   004   HOSLI P               IN: MOTULSKY AG                      226 974
   005   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   006   HOSLI P               ADV EXP MED BIOL                68     1 976
   007   HOSLI P               CLIN CHEM                       23  1476 977
   008   HOSLI P               HUM HERED                       27   185 977
CT   1   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
     2   HOSLI P               MONOGR PAEDIATR                 10    90 979
     3   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     4   CAREY WF              AUST J EXP BIOL MED SCI         57   225 979
     5   JAKEL HP              BIOL ZENTRALBL                  98    55 979
     6   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     7   AITKEN DA             J MED GENET                     17   187 980
     8   FASTH A               ACTA PAEDIATR SCAND             69   189 980
     9   STRATTON CJ           J CLIN CHEM CLIN BIOCHEM        19   852 981
    10   HARRIS A              CLIN GENET                      20   315 981
    11   JAKEL HP              BIOL ZENTRALBL                 100   273 981
    12   HOSLI P               EUR J PEDIATR                  137   116 981
    13   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    14   LEGGE M               CHIN MED J                      97   671 984
    15   AITKEN DA             PRENAT DIAGN                     5   119 985
    16   PINO JA               ANAL CHEM                       57   295 985

PN 78093
RN 00874 
AN 78192839
AU Schiotz-P-O.  Hoiby-N.  Morling-N.  Sorensen-H.
TI C3 polymorphism in a Danish cystic fibrosis population and its
   possible association with antibody response.
SO Hum-Hered. 1978. 28(4). P 293-300.
MJ ANTIBODIES-BACTERIAL.  COMPLEMENT-3: ge.  CYSTIC-FIBROSIS: im.
   POLYMORPHISM-GENETICS.
MN ADOLESCENCE.  ADULT.  ANTIBODIES-BACTERIAL: an.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg.  DENMARK.  FEMALE.
   GENE-FREQUENCY.  HUMAN.  INFANT.  INFANT-NEWBORN.  MALE.  PHENOTYPE.
   PSEUDOMONAS-INFECTIONS: im.
AB The C3 types of human serum are reported for a material of 113 Danish
   cystic fibrosis patients, age 0-30 years. The frequency of the C3F
   gene was 0.2832 which was significantly higher (p less than 0.0005)
   than the frequency found in a control group of 224 healthy babies
   (C3F = 0.1585). It also differed significantly (p less than 0.01)
   from the C3F gene frequency of 0.1780 found in 177 blood donors, age
   20-24 years. A significant association between any of the C3
   phenotypes and the most serious infection in cystic fibrosis, chronic
   mucoid P. aeruginosa infection, or the antibody response against
   these bacteria was not found.
RF 001   BRONNESTAM R          HUM HERED                       23   206 973
   002   BRONNESTAM R          HUM HERED                       23   214 973
   003   BURNS MW              LANCET                           1   270 968
   004   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   005   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   006   DOGGETT RG            INFECT IMMUN                     6   628 972
   007   FARHUD DD             HUMANGENETIK                    17    57 972
   008   GIBSON LE             PEDIATRICS                      23   545 959
   009   HOFF GE               SCAND J INFECT DIS               6   333 974
   010   HOLZHAUER RJ          AM J HUM GENET                  28   602 976
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   83   549 975
   015   HOIBY N               SCAND J RESPIR DIS              58    65 977
   016   LEDERBERG S           AM J HUM GENET                  28   597 976
   017   SHWACHMAN H           CLIN PEDIATR                    14  1115 975
   018   SORENSEN H            HUM HERED                       25   279 975
   019   SORENSEN H            HUM HERED                       25   284 975
   020   TEISBERG P            VOX SANG                        19    47 970
CT   1   SCACCHI R             HUM HERED                       31   183 981
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     3   BERNAL JE             HUM HERED                       36    97 986
     4   SCHUR PH              ANNU REV MED                    37   333 986

PN 78094
RN 00875 
AN 79217453
AU Boat-T-F.  Cheng-P.
TI Mucous glycoproteins in cystic fibrosis.  pp.  108-21.
SO In: Walborg EF, ed. Glycoproteins and glycolipids in disease
   processes. Washington, American Chemical Society, 1978. QU 55 S9801g
   1978. (REVIEW).
MJ CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: me.  MUCUS: me.
MN ANIMAL.  CARBOHYDRATES: an.  CELLS-CULTURED.  HUMAN.  MONOGRAPH.
   RABBITS.  REVIEW.  SULFURIC-ACIDS: me.  TRACHEA: me.
   SUPPORT-U-S-GOVT-P-H-S.
EX Cystic fibrosis, the most common lethal genetic trait of Caucasians,
   causes much of the chronic progressive lung disease in children and
   young adults.  It is also responsible for intestinal obstruction at
   birth (meconium ileus), pancreatic insufficiency with maldigestion
   and failure to grow, and obstructive liver disease in this age group.
   Furthermore, obliteration of the vas deferens causes aspermia and
   infertility in most males with CF.  Individuals with CF secrete sweat
   which contains excessive amounts of chloride and sodium.  Diagnostic
   criteria include detection of elevated chloride levels in sweat of
   individuals with typical pulmonary, gastrointestinal, or genital
   manifestations of the disease.  There are several, well documented
   alterations in the mucous secretions of individuals with cystic
   fibrosis, any of which alone or in combination, may interfere with
   mucous clearance from the lung or from passageways of other organs.
   It seems clear that additional studies to define basic aspects of
   normal mucous biochemistry, physiology and pharmacology must precede
   or parallel studies of CF mucous secretions if data pertinent to CF
   pathophysiology are to be generated.  Particular needs include an
   understanding of the chemical determinants of physical and
   rheological properties of these secretions, and elucidation of
   mechanisms for control of sulfated glycoprotein biosynthesis.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   MAYO BJ               TEX REP BIOL MED                34   107 976
   004   CONOD EJ              PEDIATR RES                     11    45 977
   005   MANGOS JA             PEDIATR RES                      2   378 968
   006   DEARBORN DG           IN: MORRIS D                         273 978
   007   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   008   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   009   RAO GJS               PEDIATR RES                      9   739 975
   010   SHAPIRA E             J BIOL CHEM                    252  7923 977
   011   DAVIS SS              BULL PHYSIOPATH RESPIR NANCY     9    47 973
   012   POTTER JL             AM REV RESPIR DIS               99   909 969
   013   KHAN MA               BIOCHIM BIOPHYS ACTA           444   369 976
   014   REID L                MOD PROBL PEDIATR               10   195 967
   015   ZUELZER WW            PEDIATRICS                       4    53 949
   016   REID L                IN: PORTER R                    32    45 968
   017   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   018   BOWMAN BH             SCIENCE                        164   325 969
   019   BOGART BI             PEDIATR RES                     11   131 977
   020   CZEGLEDY-NAGY E       LAB INVEST                      35   588 976
   021   BOAT TF               AM REV RESPIR DIS              110   428 974
   022$  BAKER AP              GAP CONF REP                             976
   023   BOAT TF               MOD PROBL PEDIATR               19   141 977
   024   BAKER AP              AM REV RESPIR DIS              115   811 977
   025   BAKER AP              ARCH BIOCHEM BIOPHYS           165   597 974
   026   BOAT TF               IN: MANGOS JA                        165 976
   027   NEUTRA MR             LAB INVEST                      36   535 977
   028   STURGESS JM           CLIN SCI                        43   533 972
   029   DEARBORN DG           IN: MANGOS JA                        179 976
   030   WOOD RE               AM REV RESPIR DIS              111   733 975
   031   FORSTNER JF           PEDIATR RES                     10   609 976
   032   GUGLER EC             J PEDIATR                       71   585 967
   033   BOAT TF               PEDIATR RES                      8   531 974
   034   BAILLEUL V            CLIN CHIM ACTA                  74   115 977
   035   DEGAND P              BULL PHYSIOPATH RESPIR NANCY     9   199 973
   036   ROBERTS GP            ARCH BIOCHEM BIOPHYS           173   528 976
   037   SHIH CK               AM REV RESPIR DIS              115   989 977
   038   SNARY D               BIOCHEM BIOPHYS RES COMMUN      40   844 970
   039   HILL HD               J BIOL CHEM                    252  3791 977
   040   BOAT TF               ARCH BIOCHEM BIOPHYS           177    95 976
   041   ROUSSEL P             J BIOL CHEM                    250  2114 975
   042   CHENG PW              FED PROC                        35  1444 976
   043   LOPEZ-VIDRIERO MT     IN: BRAIN JD                         289 977
   044   GOTTSCHALK A          BIOCHIM BIOPHYS ACTA            46    91 961
   045   MEYER FA              BIOCHIM BIOPHYS ACTA           392   223 975
   046   DEMAN J               BIOCHIM BIOPHYS ACTA           297   486 973
   048   LAMBLIN G             BULL EUR PHYSIOPATH RESP        13   175 977
   050   DISCHE Z              PEDIATRICS                      24    74 959
   051   ABLETT S              IN: RESING H                         344 976
   052   JEFFERY PK            IN: BRAIN JD                     5   193 977
   053   BOAT TF               IN: MANGOS JA                        165 976
   055   CHENG PW              ANAL BIOCHEM                    85   276 978
   056   BOAT TF               CHEST                           67   325 975
CT   1   MORIARTY CM           J MED                           13   257 982
     2   LITIN BS              BIOL NEONATE                    42   228 982
     3   BENYOSEPH Y           BIOCHIM BIOPHYS ACTA           718   172 982
     4   SLOMIANY A            J BIOL CHEM                    258  8535 983
     5   RUDICK VL             J CELL PHYSIOL                 118    67 984

PN 78095
RN 00876 
AN 78241012
AU Sahu-S.  Lynn-W-S.
TI Lipid composition of sputum from patients with asthma and patients
   with cystic fibrosis.
SO Inflammation. 1978 Mar. 3(1). P 27-36.
MJ ASTHMA: me.  CYSTIC-FIBROSIS: me.  LIPIDS: an.  SPUTUM: an.
MN ADOLESCENCE.  ADULT.  CHILD.  FATTY-ACIDS: an.  GLYCOLIPIDS: an.
   HUMAN.  PHOSPHOLIPIDS: an.  PULMONARY-SURFACTANT: an.
   SUPPORT-U-S-GOVT-P-H-S.
AB Lipids from the sputum of patients with asthma and with cystic
   fibrosis were isolated and characterized. In both cases, lipids
   constituted approximately 30% of the dry material.
   Phosphatidlycholine was the most abundant lipid, Significant amounts
   of phosphatidylethanolamine and phosphatidylglycerol were present.
   Hexosyl ceramides, sphingomyelin, phosphatidylinositol,
   lysophosphatidylcholine, and lysophosphatidylethanolamine were
   present as minor lipid components. Apperciable quantities of neutral
   lipids were present, of which triglycerides and cholesterol were the
   main constituents. Phosphatidylcholine, sphingomyelin, and
   phosphatidylgycerol were highly saturated. Large amounts of
   phosphatidylcholine containing mostly palmitic acid, particularly in
   the asthmatic sputum, suggest htat this highly saturated. Large
   amounts of phosphatidylcholine containing mostly palmitic acid,
   particularly in the asthmatic sputum, suggests that this highly
   saturated phospholipid is synthesized in the upper airways for
   reasons other than its beneficial surface-active properties in the
   alveoli.
RF 001   CHERNICK WS           PEDIATRICS                      24   739 959
   002   MATTHEWS LW           AM REV RESPIR DIS               88   199 963
   003   RAMIREZ RJ            AM J MED                        45   502 968
   004   LEWIS RW              LIPIDS                           6   859 971
   005   SAHU S                AM REV RESPIR DIS              114   177 976
   006   SAHU S                AM REV RESPIR DIS              115   233 977
   007   GALLAI-HATCHARD JJ    BIOCHIM BIOPHYS ACTA           116   532 966
   008   ADAMS EP              CHEM PHYS LIPIDS                 1   368 967
   009   FOLCH J               J BIOL CHEM                    226   497 957
   010   ROUSER G              IN: MARINETTI GV                 1    99 967
   011   ESSELMAN WJ           METHODS ENZYMOL                 28   140 972
   012   VIOQUE E              J AM OIL CHEM SOC               39    63 962
   013   SKIPSKI VP            METHODS ENZYMOL                 14   530 969
   014   DITMER JC             METHODS ENZYMOL                 14   482 969
   015   ROONEY SA             J LIPID RES                     16   418 975
   016   TARLOV AR             J BIOL CHEM                    240    49 965
   017   BARTLETT GR           J BIOL CHEM                    234   466 959
   018   FARKAS J              J LIPID RES                     14   344 973
   019   VANHANDEL E           J LAB CLIN MED                  50   152 957
   020   RUDEL LL              J LIPID RES                     14   364 973
   021   LAUTER CJ             J LIPID RES                      3   136 962
   022   TAO RVP               J LIPID RES                     14    16 973
   023   BAXTER CF             LIPIDS                           4   243 969
   024   HEPPLESTON AG         BR J EXP PATHOL                 55   384 974
   025   BODY DR               LIPIDS                           6   625 971
   026   HURST DJ              RESPIR PHYSIOL                  17    72 973
   027   ROONEY SA             BIOCHIM BIOPHYS ACTA           360    56 974
   028   GRAY GM               BIOCHIM BIOPHYS ACTA           144   519 967
   029   HENDERSON RF          LIPIDS                           7   492 972
   030   KING RJ               AM J PHYSIOL                   224   788 973
   031   GODINEZ RI            BIOCHEMISTRY                    14   830 975
   032   HALLMAN M             J LIPID RES                     17   257 976
   033   KLAUS MH              PROC NAT ACAD SCI USA           47  1858 961
   034   CLEMENTS JA           SCIENCE                        169   603 970
CT   1   GALABERT C            CLIN RESP PHYSIOL               17   197 981
     2   HARPER TB             AM REV RESPIR DIS              126   540 982
     3   SLAYTER HS            EUR J BIOCHEM                  142   209 984

PN 78096
RN 00877 
AN 79129714
AU Ten-Kate-L-P.  Feenstra-de-Gooyer-I.  Ploeg-de-Groot-G.  Gouw-W-L.
   Anders-G-J.
TI Should we screen all newborns for cystic fibrosis?.
SO Int-J-Epidemiol. 1978 Dec. 7(4). P 323-30.
MJ CYSTIC-FIBROSIS: oc.  MASS-SCREENING.
MN ALBUMINS: an.  ATTITUDE-OF-HEALTH-PERSONNEL.
   FALSE-NEGATIVE-REACTIONS.  FALSE-POSITIVE-REACTIONS.  HUMAN.
   INFANT-NEWBORN.  MECONIUM: an.  NETHERLANDS.  PEDIATRICS.
   QUESTIONNAIRES.
AB To assess the value of detecting albumin in meconium as a screening
   procedure for cystic fibrosis [CF] 68,000 meconium samples were
   examined by BM Meconium Test, single radial immunodiffusion and
   benzidine reaction. The specificity and sensitivity of this
   combination of tests were 99.67% and 78.57% respectively. The
   prevalence of CF at birth was confirmed as 1:3600 in this country.
   This low prevalence resulted in a relatively high number of false
   positives. Therefore, a positive test result has a low predictive
   value [3.39%] and this is a serious drawback of the method. The
   experiences and opinions of 37 local paediatricians about the
   screening programme were evaluated by a simple questionnaire. Gold's
   decision rule was applied. The least relative cost of
   misclassification justifying a mass-screening programme was 3 times
   higher than the actual relative cost as suggested by the aggregate
   opinion of paediatricians in the region. These results support the
   view that with the methods used screening may have more disadvantages
   than not screening.
RF 001   TEN KATE LP           INT J EPIDEMIOL                  6    23 977
   002   BRIMBLECOMBE FSW      LANCET                           2  1428 973
   003   GOLD RJM              ANN HUM GENET                   37   315 974
   004   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   005   BULL FE               ARCH DIS CHILD                  49   602 974
   006   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   007   STEPHAN U             PEDIATRICS                      55    35 975
   008   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   009   PROSSER R             ARCH DIS CHILD                  49   597 974
   010   GALEN RS              BEYOND NORMALITY THE PREDICTI            975
   011   TINSCHMANN P          PROC EWGCF 5TH ANNU MTG                  974
   012   GRIFFITHS AD          ARCH DIS CHILD                  51   321 976
   013   HUANG NN              AM J DIS CHILD                 120   289 970
   014   SHWACHMAN H           PEDIATRICS                      46   335 970
   015   WOOD RE               AM REV RESPIR DIS              113   833 976
   016   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   017   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   018   ANTONOWICZ I          PEDIATRICS                      56   782 975
   019   ANTONOWICZ I          LANCET                           1   746 976
   020   CROSSLEY JR           LANCET                           2  1093 977
CT   1   ANDERS GJPA           J GENET HUM                     29    23 981
     2   SZIBOR R              Z KLIN MED                      40   313 985
     3   DANKERTROELSE JE      LANCET                           1   326 986
     4   DANKERTROELSE JE      ACTA PAEDIATR SCAND             76   209 987

PN 78097
RN 00878 
AN 79108929
AU Ekvall-S.  Mitchell-A.
TI The effect of supplemental vitamin E on vitamin A serum levels in
   cystic fibrosis.
SO Int-J-Vitam-Nutr-Res. 1978. 48(4). P 324-32.
MJ CYSTIC-FIBROSIS: dt.  VITAMIN-A: bl.  VITAMIN-E: tu.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CREATINE: ur.  CREATININE: ur.
   CYSTIC-FIBROSIS: me, ur.  DRUG-THERAPY-COMBINATION.  FEMALE.
   HUMAN.  MALE.  VITAMIN-A: tu.  VITAMIN-E: bl.
AB Effects of the ingestion of vitamin E with vitamin A on the serum
   levels of these vitamins and the urinary creatine to creatinine
   ratios of 18 children with cystic fibrosis disease of the pancreas
   (CF) was studied. After the daily ingestion for two months of a
   specially prepared capsule containing 5000 IU vitamin A palmitate and
   100 mg d alpha-tocopherol acetate in aqueous dispersible form there
   was a significant increase in vitamin A as well as vitamin E levels
   of serum taken 3 1/2 hr postprandially. Creatine to creatinine ratios
   in single voiding of urine decreased.
RF 001   BAKER H               AM J CLIN NUTR                  20   850 967
   002   BAUERNFEIND JC        AM J CLIN NUTR                  27   234 974
   003   BIERI JG              PROC SOC EXP BIOL MED          117   131 964
   004   BLANC WA              PEDIATRICS                      22   494 958
   005   BONSNES RW            J BIOL CHEM                    158   581 945
   006   CLARK LC JR           AM J DIS CHILD                  81   774 951
   007   DAVIES AW             NATURE                         147   794 941
   008   GOLDBLOOM RB          PEDIATRICS                      32    36 963
   009   GORDON HH             PEDIATRICS                      21   673 958
   010   GREEN J               NUTR ABSTR REV                  38   321 969
   011   KATZ LN               EXPERIMENTAL ATHEROSCLEROSIS             953
   012   KERNER I              AM J DIS CHILD                  99   597 960
   013   LEWIS JS              AM J CLIN NUTR                  26   136 973
   014   MAJAJ AS              AM J CLIN NUTR                  12   374 963
   015   MEDWADOWSKI B         THESIS                                   964
   016   NEELD JB              J NUTR                          79   454 963
   017   NITOWSKY HM           AM J CLIN NUTR                  10   368 962
   018   RIVERS JPW            LANCET                           2   642 975
   019   RODRIQUEZ MS          J NUTR                         102   908 972
   020   UNDERWOOD BA          BULL NY ACAD MED                47    34 971
   021   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   022   WO CKW                AM J CLIN NUTR                  28   808 975
CT   1   WOODRUFF CW           AM J CLIN NUTR                  44   384 986

PN 78098
RN 00879 
AN 78170950
AU OHalloran-E-T.
TI Cystic fibrosis--an eleven year survey.
SO Ir-Med-J. 1978 Apr 21. 71(6). P 184-7.
MJ CYSTIC-FIBROSIS.
MN CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di, oc, th.  FEMALE.
   HUMAN.  INFANT.  IRELAND.  MALE.  PROGNOSIS.  TIME-FACTORS.
EX The purpose of this communication is to review our experiences with
   children with cystic fibrosis seen from January 1964 to January 1975
   and to analyse the factors which have contributed to the improved
   prognosis which has occurred in this period.  The numbers of new
   patients have increased from six in 1964 to 12 in 1974.  Both sexes
   have been equally affected.  Respiratory infections, failure to
   thrive and diarrhoea were the predominant presenting features in that
   order, and thus any one of these presenting features should indicate
   that cystic fibrosis should at least be considered and excluded.
   Each patient was assessed monthly at the clinic during which
   attendance formal physiotherapy was carried out and the parents were
   instructed in the techniques of percussion and drainage.  Forty-two
   of our sixty-four patients are still alive and thirty-three of those
   fall into the excellent category, seven into the good and one each
   into the fair and poor.  During the period of this review there has
   been an obvious improvement with a fall in morbidity and mortality
   and with the increasing proportion of patients now in the "excellent"
   group.  We attribute these facts to earlier diagnosis, regular and
   careful follow-up and a supervised therapeutic programme including
   parent education and participation.  It would seem, therefore, that
   early diagnosis and active treatment prolong life and give better
   health.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   ANDERSEN DH           PEDIATRICS                       3   406 949
   003   DODGE JA              BR MED J                         2   192 975
   004   GEORGE L              ARCH DIS CHILD                  46   139 971
   005   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   006   MEARNS MB             ARCH DIS CHILD                  46   139 972
   007   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   008   SHWACHMAN H           ADV PEDIATR                      7   249 955
   009   SHWACHMAN H           PEDIATRICS                      46   335 970
   010   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   011   WARWICK WJ            MOD PROBL PEDIATR               10   353 967

PN 78099
RN 00880 
AN 78170976
AU Katznelson-D.  Ben-Yishay-M.
TI Cystic fibrosis in Israel: clinical and genetic aspects.
SO Isr-J-Med-Sci. 1978 Feb. 14(2). P 204-11.
MJ CYSTIC-FIBROSIS.
MN ADOLESCENCE.  AUTOPSY.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di, fg, oc.  ETHNIC-GROUPS.  FAMILY-PLANNING.
   GENETIC-COUNSELING.  HUMAN.  INFANT.  ISRAEL.
AB A total of 140 cases of cystic fibrosis in 110 families was
   identified in Israel during the years 1946--75, and there was reason
   to suspect inadequate ascertainment. Cystic fibrosis is frequent
   among the Ashkenazic and Arab populations with an incidence
   approximating that for Caucasians of European ancestry (1:1,800 to
   1:4,000 live births). It is about half as frequent in the Sephardim,
   rare in the Iraqi or Yemenite Jews and perhaps absent in Iranian
   Jews. The clinical picture of cystic fibrosis in Israel in all the
   ethnic groups was found to be the same as elsewhere in the world. In-
   depth.interviews of 50 families were conducted to assess their
   understanding of the genetics of the disease and their attitude
   toward family planning.
RF 001   LEVIN S               IN: GOLDSCHMIDT E                    294 963
   002   STEPHAN U             PEDIATRICS                      55    35 975
   003   PUGH RJ               ARCH DIS CHILD                  42   544 967
   004   ANON                  FACTS ABOUT ISRAEL 1975                  975
   005   ANON                  STATISTICAL ABST OF ISRAEL               975
   006   GOLDSCHMIDT AE        ANN HUM GENET                   24   191 960
   007   BEARN AG              CLIN RES                        17   462 969
   008   SHWACHMAN H           PEDIATRICS                      46   335 970
   009   WING JP               HUM HERED                       24   323 974
   010   ADAM A                ISR J MED SCI                    9  1383 973
   011   CARTER CO             LANCET                           1   281 971
   012   LEONARD CO            N ENGL J MED                   287   433 972
CT   1   SCHAAP T              ISR J MED SCI                   14   201 978
     2   KATZNELSON D          ISR J MED SCI                   17   687 981
     3   KATZNELSON D          LANCET                           1   112 982
     4   HOLLANDER DH          MED HYPOTHESES                   8   191 982
     5   STURGESS JM           AM J MED GENET                  22   383 985
     6   KOLLBERG H            J TROP PEDIATR                  32   293 986
     7   NAZER H               TRANS R SOC TROP MED HYG        80   348 986

PN 78100
RN 00881 
AN 78170975
AU Schaap-T.  Hodes-M-E.  Cohen-M-M.
TI Cystic fibrosis--problems and prospects [editorial].
SO Isr-J-Med-Sci. 1978 Feb. 14(2). P 201-3.
MJ CYSTIC-FIBROSIS: fg.
MN CYSTIC-FIBROSIS: di.  HUMAN.  LINKAGE-GENETICS.  RESEARCH.
EX Cystic fibrosis, an autosomal recessive trait, is the most common
   hereditary lethal condition among Caucasians, approximating a
   prevalence of 1 per 2500 births with a carrier frequency of 1:25 in
   populations originating from West Europe.  The markedly elevated
   frequency of CF in a considerable proportion of the human race
   presents a genetic enigma for which several solutions have been
   proposed.  Genetic heterogeneity, heterozygote advantage, reduced
   penetrance, genetic drift, and linkage or epistasis are discussed.
   The basic defect in CF and its fundamental biochemical and
   physiological ramifications are unknown.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   BEARN AG              CLIN GASTROENTEROL               2   515 973
   003   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   004   KATZNELSON D          ISR J MED SCI                   14   204 978
   005   POLLEY MJ             J MED GENET                     11   249 974
   006   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   007   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   008   FEINGOLD J            ANN GENET (PARIS)               17   257 974
   009   CROW JF               IN: NEEL JV                           23 965
   010   STUART AB             LANCET                           2  1521 974
   011   SUPER M               S AFR MED J                     49   818 975
   012   RAO DC                AM J HUM GENET                  25   594 973
   013   WAGENER DK            AM J HUM GENET                  27   348 975
   014   MANGOS JA             PEDIATR RES                      1   436 967
   015   SPOCK A               PEDIATR RES                      1   173 967
   016   BOWMAN BH             SCIENCE                        164   325 969
   017   WOOD RE               LANCET                           2  1452 973
   018   BENKE PJ              IN: MANGOS JA                        157 976
   019   WILSON GB             CLIN CHIM ACTA                  49    79 973
   020   THOMAS JM             PEDIATR RES                     11  1148 977
   021   RAO GJS               PEDIATR RES                      9   739 975
   022   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   023   SHAPIRA E             PEDIATR RES                     10   812 976

PN 78101
RN 00882 
AN 79067429
AU Pinney-M-A.
TI Review of cystic fibrosis.
SO Issues-Compr-Pediatr-Nurs. 1978 Aug. 3(2). P 54-65.
MJ CYSTIC-FIBROSIS.
MN CHILD.  CYSTIC-FIBROSIS: di, th.  HUMAN.  PARENTS.
   PEDIATRIC-NURSING.  RESPIRATORY-THERAPY.
EX Cystic fibrosis is an inherited disease affecting mainly Caucasians.
   All exocrine glands are obstructed, causing multiple manifestations.
   The most lethal aspect is the pulmonary involvement.  Early diagnosis
   and treatment influence prognosis.  The sweat test is the diagnostic
   tool; it must be done in a center where it is performed frequently
   and where quality control is available.  Specific therapy varies from
   center to center, but all agree on a consistent, comprehensive
   approach to management.  One must be acutely aware of the
   psychosocial aspects when caring for children with cystic fibrosis.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   LEVISON H             IN: MANGOS JA                          3 976
   004   WAGGET J              J PEDIATR                       77   407 970
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   MELLINS RB            AM REV RESPIR DIS SUPPL        110   137 974
   009   WARING WW             ADV PEDIATR                     23   401 976
   010   ROTHSTEIN RJ          J ALLERGY CLIN IMMUNOL          53   100 974
   011   DROTUR DA             PEDIATRICS                      56   710 975
   013   MATTSSON A            PEDIATRICS                      50   801 972
   014   DI SANTAGNESE PA      AM FAM PHYSICIAN                 7   102 973
   015   DOOLEY RR             AM J OBSTET GYNECOL            118   971 974

PN 78102
RN 00883 
AN 78067357
AU Reitman-A-A.  Faber-R-D.
TI A cephalometric study of patients with cystic fibrosis.
SO J-Am-Dent-Assoc. 1978 Jan. 96(1). P 83-7.
MJ CYSTIC-FIBROSIS.  MAXILLOFACIAL-DEVELOPMENT.
MN ADOLESCENCE.  ADULT.  CEPHALOMETRY.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  FEMALE.  HUMAN.  MALE.  SKULL: gd.
AB Children with cystic fibrosis have skeletal maturation and epiphyseal
   anomalies similar to those in children with nutritional problems.
   However, these patients have been found to have normal somatic
   development if treatment is begun early. In a group of children with
   cystic fibrosis undergoing medical treatment, cephalometric
   measurements compared favorably with those established by normal
   standards.
RF 001   HUANG NN              AM J DIS CHILD                 120   289 970
   002   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   003   GORLIN RJ             THOMAS ORAL PATHOLOGY                995 970
   004   SPROUL A              J PEDIATR                       65   664 964
   005   KREISSL T             Z KINDERHEILK                  113    93 972
   006   GREEN OC              ENDOCRINOL METAB J CLIN         27  1059 967
   007   MILUNSKY A            AM J DIS CHILD                 121    15 971
   008$  DENNIS JL             JAMA                            94   855 965
   009   SNODGRASS RM          AM J ROENTG RAD THER NUCL MED   74     6 955
   010   TAUSSIG LM            AM J DIS CHILD                 125   495 973

PN 78103
RN 00884 
AN 78217979
AU Govan-J-R.  Fyfe-J-A.
TI Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the
   mucoid from to carbenicillin, flucloxacillin and tobramycin and the
   isolation of mucoid variants in vitro.
SO J-Antimicrob-Chemother. 1978 May. 4(3). P 233-40.
MJ ANTIBIOTICS: pd.  CARBENICILLIN: pd.  CLOXACILLIN: aa.
   CYSTIC-FIBROSIS: mi.  FLOXACILLIN: pd.  PSEUDOMONAS-AERUGINOSA: ip.
   TOBRAMYCIN: pd.
MN CHEMISTRY-PHYSICAL.  DRUG-RESISTANCE-MICROBIAL.  HUMAN.
   POLYSACCHARIDES-BACTERIAL: an.  PSEUDOMONAS-AERUGINOSA: de.
AB Mucoid strains of Pseudomonas aeruginosa isolated from the sputa of
   patients with cystic fibrosis or in vitro through selection with
   phage were more resistant to carbenicillin, flucloxacillin and
   tobramycin and more sensitive to tetracycline than related
   non-mucoid strains.  The observations led to the development of a
   technique for the isolation of mucoid variants in vitro based on
   enhanced resistance to carbenicillin.  Mucoid variants were isolated
   from various strains of Ps. aeruginosa and the exopolysaccharide
   found to be similar to that obtained from mucoid Ps. aeruginosa
   isolated from patients with cystic fibrosis.
RF 001   BRUMFITT W            J ANTIMICROB CHEMOTHER           1   163 975
   002   DOGGETT RG            APPL MICROBIOL                  18   936 969
   003   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   004   DOGGETT RG            J PEDIATR                       68   215 966
   005   EVANS LR              J BACTERIOL                    116   915 973
   006   GOVAN JRW             J MED MICROBIOL                  8   513 975
   007   GOVAN JRW             J ANTIMICROB CHEMOTHER           2   215 976
   008   GOVAN JRW             IN: NORRIS JR                   10    59 978
   009   HOLLOWAY BW           BACT REV                        33   419 969
   010   IACOCCA VF            AM J DIS CHILD                 106   315 963
   011   LAWSON D              IN: WATT PJ                           69 970
   012   MCCRAE WM             J INFECT DIS SUPPL             134   191 976
   013   MARKS MI              J PEDIATR                       79   822 971
   014   MARTIN DR             J MED MICROBIOL                  6   111 973
   015   MAY JR                J MED MICROBIOL                  6    77 973
   016   PHILLIPS I            J MED MICROBIOL                  2     9 969
   017   RAEBURN JA            J ANTIMICROB CHEMOTHER           2   107 976
   018   SONNENSCHEIN C        ZENTRALBL BAKTERIOL            104   365 927
   019   STANISICH V           GENETICS                        61   327 969
   020   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   021   ZIERDT CH             J BACTERIOL                     87  1003 964
CT   1   HOLLOWAY BW           MICROBIOL REV                   43    73 979
     2   GOVAN JRW             J GEN MICROBIOL                110   229 979
     3   THOMASSEN MJ          J INFECT DIS                   140   873 979
     4   DEMKO CA              CURRENT MICROBIOL                4    69 980
     5   MARKOWITZ SM          J ANTIMICROB CHEMOTHER           6   251 980
     6   CHENG KJ              CAN J MICROBIOL                 26  1104 980
     7   LAM J                 INFECT IMMUN                    28   546 980
     8   LIEBERMAN MM          INFECT IMMUN                    29   489 980
     9   FYFE JAM              J GEN MICROBIOL                119   443 980
    10   BRISOU JF             C R ACAD SCI (D)(PARIS)        290  1421 980
    11   FICK RB               CLIN CHEST MED                   2    91 981
    12   SLACK MPE             LANCET                           2   502 981
    13   COSTERTON JW          CRC CRIT REV MICROBIOL           8   303 981
    14   IRVIN RT              ANTIMICROB AGENTS CHEMOTHER     19  1056 981
    15   CHENG KJ              CAN J MICROBIOL                 27   461 981
    16   BLACKWOOD LL          INFECT IMMUN                    32   443 981
    17   COSTERTON JW          ANNU REV MICROBIOL              35   299 981
    18   MARKS MI              J PEDIATR                       98   173 981
    19   GOVAN JRW             J GEN MICROBIOL                125   217 981
    20   BERGAN T              SCAND J INFECT DIS            1981     7 981
    21   BAKER NR              CURRENT MICROBIOL                7    35 982
    22   SLACK MPE             J ANTIMICROB CHEMOTHER          10   368 982
    23   PIGGOTT NH            EUR J APP MICROBIO BIOTECHNOL   16   131 982
    24   SUTHERLAND IW         ADV MICROB PHYSIOL              23    79 982
    25   BOYCE JR              INFECT IMMUN                    37   840 982
    26   OHMAN DE              INFECT IMMUN                    37   662 982
    27   HOOKE AM              INFECT IMMUN                    38   136 982
    28   MONTIE TC             INFECT IMMUN                    38  1296 982
    29   EXNER M               ZENTRALBL BAKT MIKROB HYG (B)  176   425 982
    30   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    31   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    32   COSTERTON JW          REV INFECT DIS                   5  S867 983
    33   GOVAN JRW             REV INFECT DIS                   5  S874 983
    34   OMBAKA EA             REV INFECT DIS                   5  S880 983
    35   COSTERTON JW          PROG FOOD NUTR SCI               7    91 983
    36   OLIVER AM             J CLIN LAB IMMUNOL              10   221 983
    37   TURNOWSKY F           FEMS MICROBIOL LETTERS          17   243 983
    38   HACKING AJ            J GEN MICROBIOL                129  3473 983
    39   DALHOFF A             ZENTRALBL BAKT MIKROB HYG (A)  254   379 983
    40   COSTERTON JW          REV INFECT DIS                   6  S608 984
    41   GRISTINA AG           ORTHOP CLIN NORTH AM            15   517 984
    42   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    43   NACUCCHIO MC          PEDIATR RES                     18   295 984
    44   CHAN R                J CLIN MICROBIOL                19     8 984
    45   WINGENDER J           FEMS MICROBIOL LETTERS          21    63 984
    46   COSTERTON JW          DEVELOP IND MICROBIOL           25   363 984
    47   TANNENBAUM CS         ANTIMICROB AGENTS CHEMOTHER     25   673 984
    48   LAMBE DW              CAN J MICROBIOL                 30   809 984
    49   MILLS J               INFECT IMMUN                    43   359 984
    50   HANSEN JB             APPL ENVIRON MICROBIOL          47   704 984
    51   VOGEL F               DTSCH MED WSCHR                109  1148 984
    52   FYFE JAM              J GEN MICROBIOL                130   825 984
    53   JARMAN TR             ARCH MICROBIOL                 137   231 984
    54   GOLDBERG JB           J BACTERIOL                    158  1115 984
    55   DARZINS A             J BACTERIOL                    159     9 984
    56   LINKER A              J BACTERIOL                    159   958 984
    57   LIEBERMAN MM          SURV SYNTH PATHOL RES            4   312 985
    58   MARTY N               MED MALAD INFECT                15   604 985
    59   SHABTAI J             DEVELOP IND MICROBIOL           26   291 985
    60   IRVIN RT              CAN J MICROBIOL                 31   268 985
    61   MARESZBABCZYSZYN J    ARCH IMMUNOL THER EXP           33   515 985
    62   SUTHERLAND IW         ANNU REV MICROBIOL              39   243 985
    63   MARCUS H              INFECT IMMUN                    47   723 985
    64   SHABTAI Y             APPL ENVIRON MICROBIOL          49   192 985
    65   LUZAR MA              INFECT IMMUN                    50   577 985
    66   KOMIYAMA K            ORAL SURG                       59   590 985
    67   WINKLER U             KLIN WSCHR                      63   490 985
    68   GRISTINA AG           J BONE JOINT SURG              67A   264 985
    69   DUMA RJ               AM J MED                        78   154 985
    70   GRISTINA AG           SURGERY                         98    12 985
    71   LORY S                CURR TOP MICROBIOL IMMUNOL     118    53 985
    72   PULLIAM L             J INFECT DIS                   151   153 985
    73   DARZINS A             J BACTERIOL                    161   249 985
    74   OHMAN DE              J BACTERIOL                    162  1068 985
    75   GOVAN JRW             MICROBIOL SCI                    3   302 986
    76   SCHMITT DD            J VASC SURG                      3   732 986
    77   WEBB LX               J VASC SURG                      4    16 986
    78   MCEACHRAN DW          J MICROBIOL METH                 5    99 986
    79   FLOURNOY DJ           METH FIND EXP CLIN PHARMACOL     8   391 986
    80   FRIEND PA             J INFECT                        13    55 986
    81   MACGEORGE J           J MED MICROBIOL                 21   331 986
    82   KRIEG DP              J CLIN MICROBIOL                24   986 986
    83   PITT TL               J ROY SOC MED                   79    13 986
    84   DERETIC V             J BACTERIOL                    165   510 986
    85   DERETIC V             BIO TECHNOL                      5   469 987
    86   GROSS M               J PHYTOPATH                    118   276 987

PN 78104
RN 00885 
AN 78129864
AU Lewis-S-M.  Evans-J-W.  Jalowayski-A-A.
TI Continuous distributions of specific ventilation recovered from
   inert gas washout.
SO J-Appl-Physiol. 1978 Mar. 44(3). P 416-23.
MJ NITROGEN.  RESPIRATION.
MN ADULT.  AGING.  CHILD.  CYSTIC-FIBROSIS: pp.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: pp.  LUNG: ph.  MATHEMATICS.
   RESPIRATORY-DEAD-SPACE.  TIDAL-VOLUME.  SUPPORT-U-S-GOVT-P-H-S.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB We describe a new technique for recovering continuous distributions
   of ventilation (V) as a function of tidal ventilation/volume ratio
   (V/V0) from the nitrogen washout. The analysis yields a continuous
   distribution of V as a function of V/V0 represented as fractional
   ventilations of 50 compartments plus dead space. The procedure was
   verified by recovering known distributions from data to which noise
   had been added. Using an apparatus to control the subject's tidal
   volume and FRC, mixed expired N2 data gave the following results: a)
   the distributions of young, normal subjects were narrow and unimodal
   with a mean ln standard deviation of 0.56 plus or minus 0.13; b)
   those of subjects over age 40 were broader (ln SD 0.86 plus or minus
   0.19) with more poorly ventilated units; c) patients with pulmonary
   disease of all descriptions showed enlarged dead space; d) patients
   with cystic fibrosis showed multimodal distributions with the bulk of
   the ventilation going to overventilated units; and e) patients with
   obstructive lung diseases fell into several classes, three of which
   are illustrated. These results suggest that our approach is well
   suited for clinical investigation.
RF 001   BECKLAKE MR           THORAX                           7   111 952
   002   BOUHUYS A             PHYSIOL REV                     39   731 959
   003   EVANS JW              BULL MATH BIOPHYS               32    59 970
   004   EVANS JW              BULL MATH BIOPHYS               29   711 967
   005   EVANS JW              J APPL PHYSIOL                  42   889 977
   006   FOWLER WS             J APPL PHYSIOL                   2   283 949
   007   GOMEZ DM              PROC NAT ACAD SCI USA           49   312 963
   008   GOMEZ DM              J APPL PHYSIOL                  19   683 964
   009$  GOMEZ DM              J EXP MED                      193   514 965
   010   GOMEZ DM              AM REV RESPIR DIS               93     1 966
   011   HASHIMOTO T           J APPL PHYSIOL                  23   203 967
   012   HEISE M               RESPIRATION                     31   310 974
   013$  JALAWALA SA           J CLIN INVEST                   53   188 975
   014   LAWSON CL             SOLVING LEAST SQUARES PROBLEM            974
   015   MARTIN CJ             RESPIR PHYSIOL                  21   157 974
   016   NAKAMURA T            J APPL PHYSIOL                  21   227 966
   017   NYE RE                J APPL PHYSIOL                  16   115 961
   018   OKUBO T               J APPL PHYSIOL                  24   658 968
   019   OLSZOWKA AJ           RESPIR PHYSIOL                  25   191 975
   020   PESLIN R              J APPL PHYSIOL                  30   462 971
   021   ROSSING RG            J APPL PHYSIOL                  21  1907 966
   022   SCHWARZL F            PHYSICA                         18   791 952
   023   TSUNODA S             J APPL PHYSIOL                  32   644 972
   024   WAGNER PD             J APPL PHYSIOL                  36   588 974
   025   YOUNG AC              J CLIN INVEST                   53  1178 974
CT   1   LEWIS SM              J APPL PHYSIOL                  44   424 978
     2   BUTLER JP             J APPL PHYSIOL                  46    47 979
     3   EVANS JW              MATH BIOSCI                     46   233 979
     4   WAGNER PD             J APPL PHYSIOL                  46   579 979
     5   MARTIN CJ             J APPL PHYSIOL                  47   319 979
     6   LAMEDICA G            RESPIRATION                     39   333 980
     7   WAGNER PD             ANNU REV PHYSIOL                42   235 980
     8   AZZARO SH             IEEE TRANS BIOMED ENG           28   755 981
     9   DEVRIES WR            J APPL PHYSIOL                  51  1122 981
    10   LEWIS SM              J APPL PHYSIOL                  51  1463 981
    11   PIMMEL RL             J APPL PHYSIOL                  51  1581 981
    12   OZANNE GM             ANESTHESIOLOGY                  54   413 981
    13   WAGNER PD             BULL EUR PHYSIOPATH RESP        18   361 982
    14   JALOWAYSKI AA         RESPIRATION                     43   249 982
    15   LEWIS SM              RESPIR PHYSIOL                  50   111 982
    16   HUTCHISON AA          AM REV RESPIR DIS              125    28 982
    17   BRONIKOWSKI TA        INT J BIOMEDICAL COMPUT         14   411 983
    18   MULLER E              BULL EUR PHYSIOPATH RESP        19  P100 983
    19   RUBIN DZ              J APPL PHYSIOL                  56   708 984
    20   BATES JHT             IEEE TRANS BIOMED ENG           32   478 985
    21   BRUNNER JX            J APPL PHYSIOL                  59  1008 985
    22   HARF A                AM REV RESPIR DIS              132   350 985
    23   BUCHANAN PR           CLIN PHYS PHYSIOL MEASURE        7   237 986
    24   CRAWFORD ABH          J APPL PHYSIOL                  61  2108 986
    25   BATES JHT             RADIAT RES                     107   307 986
    26   BUCHANAN PR           AM REV RESPIR DIS              133  A384 986
    27   BATES JHT             MED BIOL ENG COMPUT             25   131 987

PN 78105
RN 00886 
AN 78129865
AU Lewis-S-M.
TI Emptying patterns of the lung studied by multiple-breath N2 washout.
SO J-Appl-Physiol. 1978 Mar. 44(3). P 424-30.
MJ MODELS-BIOLOGICAL.  RESPIRATION.
MN ADULT.  AGING.  CHILD.  CYSTIC-FIBROSIS: pp.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: pp.  LUNG-VOLUME-MEASUREMENTS.
   LUNG: ph, pp.  NITROGEN.  RESPIRATORY-DEAD-SPACE.
   SUPPORT-U-S-GOVT-P-H-S.  SUPPORT-U-S-GOVT-NON-P-H-S.
AB Changes in the nitrogen concentration seen during the single-breath
   nitrogen washout reflect changes in relative flow (V) from units with
   differing ventilation/volume ratios (V/V0). The multiple-breath
   washout provides sufficient data for the V for units with varying
   V/V0 to be plotted as a function of the volume expired. Flow from the
   dead space may also be determined. In young normals the emptying
   patterns are narrow and unimodal throughout the alveolar plateau with
   little or no flow from the dead space at the end of the breath. Older
   normals show more flow from the dead space, particularly toward the
   end of the breath, and some show a high V/V0 mode early in the
   breath. Patients with obstructive lung disease have a high flow from
   the dead space which is present throughout the breath. A well
   ventilated mode at the end of the breath is seen in some obstructed
   subjects. Patients with cystic fibrosis showed a poorly ventilated
   mode appearing at the end of the breath as well as a very high dead
   space.
RF 001$  BAKER LG              RESPIR PHYSIOL                  21   119 974
   002   BALL WC JR            J CLIN INVEST                   41   519 962
   003   DOLLFUSS RE           RESPIR PHYSIOL                   2   234 967
   004   ENGEL LA              J APPL PHYSIOL                  35     9 973
   005   EVANS JW              BULL MATH BIOPHYS               32    59 970
   006   EVANS JW              BULL MATH BIOPHYS               29   711 967
   007   EVANS JW              J APPL PHYSIOL                  42   889 977
   008   FOWLER WS             AM J PHYSIOL                   154   405 948
   009   FOWLER WS             J APPL PHYSIOL                   2   283 949
   010   FOWLER WS             J CLIN INVEST                   31    40 952
   011   LEWIS SM              J APPL PHYSIOL                  44   416 978
   012   MCCARTHY DS           AM J MED                        52   747 972
   013   MARTIN CJ             RESPIR PHYSIOL                  21   157 974
   014   MILLETTE B            J APPL PHYSIOL                  27   587 969
   015   PAIVA M               J APPL PHYSIOL                  35   401 973
   016   POWER G               J APPL PHYSIOL                  27   701 969
   017   SCHERER PW            BULL MATH BIOPHYS               34   393 972
   018   SIKAND R              J APPL PHYSIOL                  21  1331 966
   019   SUDA Y                J APPL PHYSIOL                  29   480 970
   020   TSUNODA S             J APPL PHYSIOL                  32   644 972
   021   WAGNER PD             J APPL PHYSIOL                  36   588 974
   022   YOUNG AC              J CLIN INVEST                   53  1178 974
CT   1   LAMEDICA G            RESPIRATION                     39   333 980
     2   JALOWAYSKI AA         RESPIRATION                     43   249 982
     3   RUBIN DZ              J APPL PHYSIOL                  56   708 984
     4   CUMMING G             CLIN PHYSIOL                     5    33 985
     5   BUCHANAN PR           CLIN PHYS PHYSIOL MEASURE        7   237 986

PN 78107
RN 00887 
AN 79048678
AU Sparham-P-D.  Lobban-D-I.  Speller-D-C.
TI Isolation of Staphylococcus aureus from sputum in cystic fibrosis.
SO J-Clin-Pathol. 1978 Oct. 31(10). P 913-8.
MJ CYSTIC-FIBROSIS: mi.  SPUTUM: mi.  STAPHYLOCOCCUS-AUREUS: ip.
MN ADOLESCENCE.  BACTERIOLOGICAL-TECHNICS.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  CULTURE-MEDIA.  HUMAN.
   PSEUDOMONAS-AERUGINOSA: ip.  SONICATION.
AB The success in the isolation of Staphylococcus aureus of different
   methods of sputum processing was investigated in 60 specimens
   collected from 14 patients with cystic fibrosis during a seven-month
   period. Fifty specimens (83%) from 11 patients yielded Staph. aureus
   by one or more methods. Direct plating of purulent portions of sputum
   on to media designed for general use in respiratory infections gave
   unsatisfactory results (35% yield of Staph. aureus). Some increase in
   isolations was obtained with preliminary liquefaction of sputum; but
   the best results were given by the addition of a medium selective for
   staphylococci (mannitol salt agar, BBL) or by initial sonication of
   sputum (each 83% yield). Seven of the 11 strains of Staph. aureus
   were thymidine-dependent and otherwise atypical in laboratory
   characteristics; these were isolated from patients who had received
   co-trimoxazole.
RF 001   ALDER VG              J APPL BACT                     25   436 962
   002   BABER KG              J MED LAB TECH                  26   391 969
   003   CHRISTIE R            J PATHOL BACTERIOL              51   189 940
   004   CRUICKSHANK R         MEDICAL MICROBIOLOGY             2       975
   005   GEORGE RH             LANCET                           2  1081 977
   006   HUHTANEN CN           J DAIRY SCI                     49  1008 966
   007   MCINTOSH AF           PROCESS BIOCHEM                  6    22 971
   008   MAY JR                ARCH DIS CHILD                  47   908 972
   009   MEAD GR               TUBERCLE                        45   370 964
   010   MEARNS MB             ARCH DIS CHILD                  47   902 972
   011   MILES AA              J HYGIENE                       38   732 938
   012   PHILLIPS I            J MED MICROBIOL                  2     9 969
   013   RAWLINS GA            LANCET                           2   538 953
   014   WILKINSON PJ          J CLIN PATHOL                   30   417 977
   015   WILLIAMS RF           IN: WILLIAMS RF                       20 977
CT   1   WILLIAMS RF           CURR MED RES OPIN                6    43 979
     2   HOWDEN R              MED LAB SCI                     38    29 981
     3   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     4   FRIEND PA             J INFECT                        13    55 986

PN 78108
RN 00888 
AN 78152669
AU Morris-L-J.  Mascia-A-V.  Farnsworth-P-B.
TI Cystic fibrosis: making a correct and early diagnosis.
SO J-Fam-Pract. 1978 Apr. 6(4). P 749-56.
MJ CYSTIC-FIBROSIS: di.
MN ADOLESCENCE.  ADULT.  CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, fg.  DIABETES-MELLITUS: co.
   DIAGNOSIS-DIFFERENTIAL.  FEMALE.  HUMAN.  INFANT.
   MALABSORPTION-SYNDROMES: di.  MALE.  RECTAL-PROLAPSE: et.
AB Cystic fibrosis is detected with increasing frequency in older
   children, adolescents, and even young adults. The quality of life and
   longevity in patients with cystic fibrosis is more favorable the
   earlier a diagnosis is made and a therapeutic regimen begun. This
   report presents and reviews five cases in chich the diagnosis of
   cystic fibrosis was made after the age of six years. Emphasis is
   placed on the variability of presenting signs and symptoms and the
   problems that can arise in confirming a suspected diagnosis of cystic
   fibrosis.
RF 001   DOERSHUK CF           PEDIATRICS                      36   675 965
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   003   STEINBERG AG          AM J HUM GENET                  12   416 960
   004   DI SANTAGNESE PA      JAMA                           172  2065 960
   005   ANDERSON CM           ARCH DIS CHILD                  35   581 960
   006   DARLING RC            AM J MED SCI                   225    67 953
   007   WOOD RE               AM REV RESPIR DIS              113   833 976
   008   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   009   SHWACHMAN H           PEDIATRICS                      30   389 962
   010   MCCOLLUM AT           J PEDIATR                       77   571 970
   011   GIBSON LE             J PEDIATR                       81   193 972
   012   ELIAN E               N ENGL J MED                   264    13 961
   013   SHWACHMAN H           ANN NY ACAD SCI                 93   600 962
   014   GIBSON LE             PEDIATRICS                      23   545 959
   015   KULCZYCKI LL          N ENGL J MED                   259   409 958
   016   TOMASHEFSKI JF        CHEST                           57    28 970
   017   MILUNSKY A            PEDIATRICS                      42   501 968
   018   HIDE DW               ARCH DIS CHILD                  44   533 969
   019   GOODCHILD MC          ARCH DIS CHILD                  48   684 973
   020   TAYLOR BW             ARCH DIS CHILD                  48   692 973
   021   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   022   MEARNS MB             ARCH DIS CHILD                  47   902 972
   023   SHWACHMAN H           PEDIATRICS                      55    86 975
   024   ROSAN RC              AM J DIS CHILD                 104   625 962
   025   GEORGE L              ARCH DIS CHILD                  46   139 971
   026   GREEN MN              PEDIATRICS                      41   989 968
   027   STEPHAN U             PEDIATRICS                      55    35 975
   028   SHWACHMAN H           PEDIATRICS                      30   167 962
CT   1   WARWICK WJ            J CHRON DIS                     33   685 980
     2   CHINO ES              AM SURGEON                      50    70 984

PN 78109
RN 00889 
AN 78152730
AU Cloutier-M-M.  Mangos-J-A.
TI The challenges of cystic fibrosis.
SO J-Fla-Med-Assoc. 1978 Apr. 65(4). P 259-63.
MJ CYSTIC-FIBROSIS.
MN CYSTIC-FIBROSIS: di, fg, th.  HUMAN.
AB Cystic fibrosis is an autosomal recessive genetic disorder of the
   exocrine glands which has a frequency of approximately 1:1,500 live
   births.  This disease presents challenges to the physician and the
   health care team.  The Pediatric Pulmonary Center of the University
   of Florida in Gainesville, in coordination with Cystic Fibrosis
   Centers and clinics throughout the state, is helping physicians and
   patients to recognize and manage this chronic disease.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   003   DI SANTAGNESE PA      AM J MED                        15   777 953
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   BAU SK                PEDIATRICS                      48   605 971
   006   DUDLEY JP             CF CLUB ABST                             976
   007   LANDAU LI             J PEDIATR                       82   863 973
   008   MANGOS JA             PEDIATR RES                      2   378 968
   009   SPOCK A               PEDIATR RES                      1   173 967
   010   BOWMAN BH             SCIENCE                        164   325 969

PN 78110
RN 00890 
AN 78243783
AU Klinger-J-D.  Straus-D-C.  Hilton-C-B.  Bass-J-A.
TI Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in
   patients with cystic fibrosis: Demonstration by radioimmunoassay.
SO J-Infect-Dis. 1978 Jul. 138(1). P 49-8.
MJ ANTIBODIES-BACTERIAL: ip.  CYSTIC-FIBROSIS: im.  EXOTOXINS: im.
   PEPTIDE-HYDROLASES: im.  PSEUDOMONAS-AERUGINOSA: im.
   PSEUDOMONAS-INFECTIONS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CHRONIC-DISEASE.
   FEMALE.  HUMAN.  INFANT.  MALE.  PSEUDOMONAS-AERUGINOSA: en, py.
   RADIOIMMUNOASSAY.  VIRULENCE.
AB Sera from 33 patients with cystic fibrosis and two pediatric patients
   being treated for chronic pulmonary infections not related to cystic
   fibrosis and six sera or serum pools from uninfected individuals were
   tested with a microtiter radioimmunoassay for reactivity against
   exotoxin A and two proteases from Pseudomonas aeruginosa. Exotoxin A
   was purified from a low-protease strain of P. aeruginosa and shown to
   have adenosine diphosphate-ribose transferase activity and mouse
   lethality. Proteases were purified from an isolate of P. aeruginosa
   from a patient with cystic fibrosis and had proteolytic activity
   against elastin and collagen in an assay employing dimethylated
   protein substrates. The antibody responses of the patients detected
   using 125I-labeled antibody to human immunoglobulin were correlated
   with clinical evaluations expressed as a composite score based on
   pulmonary findings, case histories, growth and nutrition, and chest X
   rays. Values in the radioimmunoassay for patients' sera were compared
   with those of a control serum pool and expressed as the ratio of
   counts per minute (cpm) in patient serum to the cpm in the control
   pool. Inverse correlations were found between these ratios for each
   of the pseudomonas exoproducts and clinical scores; highest ratios
   occurred in patients showing the lowest clinical scores. These
   results confirm that proteases and exotoxin A of P. aeruginosa are
   produced in cystic fibrosis pulmonary infections due to P. aeruginosa
   and suggest that they may serve as significant virulence factors in
   these chronic infectious states.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   IACOCCA VF            AM J DIS CHILD                 106   315 963
   003   MAY JR                ARCH DIS CHILD                  47   908 972
   004   MEARNS MB             ARCH DIS CHILD                  47   902 972
   005   HOIBY N               ACTA PAEDIATR SCAND             63   843 974
   006   MARKS MI              J PEDIATR                       79   822 971
   007$  ELLER JJ              AM J MED SUPPL                  62   179 977
   008   KREGER AS             INFECT IMMUN                     9   828 974
   009   SCHULTZ DR            INFECT IMMUN                    10   128 974
   010   PAVLOVSKIS OR         IN: SCHLESSINGER D                   252 975
   011   PAVLOVSKIS OR         J INFECT DIS                   133   253 976
   012   MIDDLEBROOK JL        CAN J MICROBIOL                 23   183 977
   013   BURNS MW              LANCET                           1   270 968
   014   DIAZ F                J INFECT DIS                   121   269 970
   015   HABBOUSHE C           PEDIATRICS                      48   973 971
   016   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   83   459 975
   017   SEIDMON EJ            J PEDIATR                       87   528 975
   018   POLLACK M             INFECT IMMUN                    14   942 976
   019   POLLACK M             J CLIN MICROBIOL                 6    58 977
   020   LIU PV                J INFECT DIS                   128   514 973
   021   IGLEWSKI BH           INFECT IMMUN                    15   138 977
   022   MORIHARA K            J BIOL CHEM                    240  3295 965
   023   PURCELL RH            APPL MICROBIOL                  26   478 973
   024   ROSENTHAL JD          J IMMUNOL                      109   171 972
   025   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   026   DOWNIE NM             BASIC STATISTICAL METHODS                970
   027   COLLIER RJ            J BIOL CHEM                    246  1496 971
   028   VASIL ML              INFECT IMMUN                    16   353 977
   029   FREDRICK JF           ANN NY ACAD SCI                121   305 964
   030   LIN Y                 J BIOL CHEM                    244   789 969
   031   LIU PV                J INFECT DIS                   116   481 966
   032   IGLEWSKI BH           PROC NAT ACAD SCI USA           72  2284 975
   033   MORIHARA K            INFECT IMMUN                    15   679 977
   034   CARRICK L JR          BIOCHIM BIOPHYS ACTA           391   422 975
CT   1   GRAY L                INFECT IMMUN                    23   150 979
     2   MORIHARA K            INFECT IMMUN                    24   188 979
     3   CASH HA               AM REV RESPIR DIS              119   453 979
     4   KOSTIALA AAI          J MED MICROBIOL                 13   201 980
     5   BERDISCHEWSKY M       PEDIATR RES                     14   830 980
     6   JENSEN SE             CAN J MICROBIOL                 26    77 980
     7   JENSEN SE             CAN J MICROBIOL                 26    87 980
     8   HOMMA JY              JAP J EXP MED                   50   149 980
     9   BEAUDRY PH            J PEDIATR                       97   144 980
    10   SANAI Y               FEBS LETTERS                   120   131 980
    11   CROSS AS              J INFECT DIS                   142   538 980
    12   JENSEN SE             J BACTERIOL                    144   844 980
    13   FICK RB               CLIN CHEST MED                   2    91 981
    14   BLACKWOOD LL          INFECT IMMUN                    32   443 981
    15   CRYZ SJ               INFECT IMMUN                    32   759 981
    16   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    17   WOODS DE              J CLIN INVEST                   68  1435 981
    18   MARKS MI              J PEDIATR                       98   173 981
    19   WOODS DE              J INFECT DIS                   143   784 981
    20   DORING G              ZENTRALBL BAKT MIKROB HYG (A)  249    89 981
    21   OBERNESSER HJ         ZENTRALBL BAKT MIKROB HYG (A)  249    76 981
    22   WRETLIND B            SCAND J INFECT DIS            1981    13 981
    23   CROWE KE              J CLIN MICROBIOL                15   115 982
    24   JAGGER KS             J CLIN MICROBIOL                15  1054 982
    25   BAKER NR              IN VITRO                        18   369 982
    26   BAKER NR              CAN J MICROBIOL                 28   248 982
    27   WOODS DE              INFECT IMMUN                    36  1223 982
    28   WEINER RN             EXP MOL PATH                    37   249 982
    29   DORING G              ZENTRALBL BAKT MIKROB HYG (A)  252   239 982
    30   OBERNESSER HJ         ZENTRALBL BAKT MIKROB HYG (A)  252   248 982
    31   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
    32   POLLACK M             REV INFECT DIS                   5  S979 983
    33   WOODS DE              REV INFECT DIS                   5  S715 983
    34   WRETLIND B            REV INFECT DIS                   5  S998 983
    35   JAGGER KN             J CLIN MICROBIOL                17    55 983
    36   BRYAN LE              J CLIN MICROBIOL                18   276 983
    37   CUKOR G               J CLIN MICROBIOL                18   457 983
    38   CASH HA               CAN J MICROBIOL                 29   448 983
    39   KLINGER JD            INFECT IMMUN                    39  1377 983
    40   LYERLY DM             INFECT IMMUN                    40   113 983
    41   DORING G              INFECT IMMUN                    42   197 983
    42   DORING G              J INFECT DIS                   147   744 983
    43   CAPLAN DB             REV INFECT DIS                   6  S705 984
    44   SPEERT DP             PEDIATR RES                     18   431 984
    45   BOROWSKI RS           J CLIN MICROBIOL                19   736 984
    46   LONDON CJ             APPL ENVIRON MICROBIOL          47    75 984
    47   GRANSTROM M           ACTA PAEDIATR SCAND             73   772 984
    48   DORING G              ACTA PATH MICROB IMMU SCA (C)   92   307 984
    49   WOOTEN MW             J CELL PHYSIOL                 121   490 984
    50   HANCOCK REW           J INFECT DIS                   149   220 984
    51   PARMELY MJ            J EXP MED                      160  1338 984
    52   GRANSTROM M           EUR J CLIN MICROBIOL             4   197 985
    53   KLINGER KW            EUR J CLIN MICROBIOL             4   201 985
    54   PITT TL               EUR J CLIN MICROBIOL             4   190 985
    55   SAELINGER CB          EUR J CLIN MICROBIOL             4   170 985
    56   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    57   DORING G              INFECT IMMUN                    49   557 985
    58   LUZAR MA              INFECT IMMUN                    50   577 985
    59   WINKLER U             KLIN WSCHR                      63   490 985
    60   LORY S                CURR TOP MICROBIOL IMMUNOL     118    53 985
    61   BRUCE MC              AM REV RESPIR DIS              132   529 985
    62   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    63   WOODS DE              CLIN INVEST MED                  9   108 986
    64   BALTIMORE RS          PEDIATR RES                     20  1085 986
    65   WOODS DE              J CLIN MICROBIOL                24   260 986
    66   HINGLEY ST            INFECT IMMUN                    54   379 986
    67   PITT TL               J ROY SOC MED                   79    13 986
    68   VASIL ML              J PEDIATR                      108   800 986
    69   MOSS RB               AM REV RESPIR DIS              133   648 986
    70   PARMELY MJ            J IMMUNOL                      137   988 986
    71   DASGUPTA MK           J CLIN IMMUNOL                   7    51 987
    72   DORING G              INFECTION                       15    47 987

PN 78111
RN 00891 
AN 80076215
AU Dann-L-G.  Blau-K.
TI Studies on the basic defect in cystic fibrosis: the kinin hypothesis.
SO J-Inherited-Metab-Dis. 1978. 1(4). P 179-81.
MJ CYSTIC-FIBROSIS: pp.  KININS: ph.
MN EXOCRINE-GLANDS: pp.  HUMAN.  MODELS-BIOLOGICAL.
EX It is our hypothesis that in cystic fibrosis there is a genetically
   determined specific deficiency in the activity of either the
   glandular kallikrein or in its activating enzyme, and that this
   defect is the primary defect in the disease.  The immediate
   consequence of either of these defects is the absence of kallidin and
   the resulting failure of reabsorption.  The fact that there may be
   mutations affecting distinct enzymes could account for the genetic
   heterogeneity of cystic fibrosis.  A consequence of a defective
   kallikrein system would be accumulation of a precursor related to the
   low molecular weight kininogen and we propose that this compound is
   the ciliary-dyskinesia factor.
RF 001   BENKE PJ              IN: MANGOS JA                        157 976
   002   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   003   DANN LG               LANCET                           2   405 978
   004   DIETL T               HOPPE SEYLERS Z PHYSIOL CHEM   359   499 978
   005   EMRICH HM             PEDIATR RES                      2   464 968
   006   GARRETT JR            ARCH ORAL BIOL                  12  1417 967
   007   KAISER D              LANCET                           1  1003 970
   008   LOBECK CC             IN: STANBURY JB                     1605 972
   009   MCKUSICK VA           MENDELIAN INHERIT IN MAN             468 978
   010   MANGOS JA             AM J PHYSIOL                   224  1235 973
   011   MANGOS JA             PEDIATR RES                      2   378 968
   012   MANGOS JA             IN: MANGOS JA                        311 976
   013   MUNGER BL             J BIOPHYS BIOCHEM CYTOL         11   385 961
   014   NUSTAD K              GEN PHARMAC                      9     1 978
   015   ORSTAVIK TB           ACTA HISTOCHEM                  54   183 975
   016   POTTER JL             ANN NY ACAD SCI                106   692 963
   017   RAO GJS               PEDIATR RES                      9   739 975
   018   SELINGER Z            IN: CARAFOLI E                       139 975
   019   SCHRAMM M             J CYCLIC NUCLEOTIDES RES         1   181 975
   020   SUTCLIFFE CH          PROC R SOC MED                  61   297 968
   021   ULLRICH KJ            IN: THORN NA                         423 974
   022   WEBSTER ME            BIOCHEM PHARMACOL               12   511 963

PN 78112
RN 00892 
AN 78243862
AU Wilson-G-B.  Fudenberg-H-H.
TI Separation of ciliary dyskinesia substances found in serum and
   secreted by cystic fibrosis leukocytes and lymphoid cell lines,
   using protein A--Sepharose CL-4B.
SO J-Lab-Clin-Med. 1978 Sep. 92(3). P 463-82.
MJ BACTERIAL-PROTEINS.  CILIA: an.  CYSTIC-FIBROSIS: bl.  LEUKOCYTES: se.
MN CELL-LINE.  CELL-MOVEMENT.  CELLS-CULTURED.  CILIA: ph.  GENOTYPE.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  HYDROGEN-ION-CONCENTRATION.
   IGG: me.  IN-VITRO.  PROTEIN-BINDING.  SERUM-ALBUMIN.
   SERUM-ALBUMIN-BOVINE.  STAPHYLOCOCCUS.  SUPPORT-U-S-GOVT-P-H-S.
AB Cell-free culture medium from PHA-stimulated PBL cultures or
   long-term lymphoid cell lines from CF homozygotes or obligate
   heterozygotes, as well as serum from such individuals, can produce
   three distinct changes in the ciliary beat of rabbit tracheal
   ciliated epithelium: (1) increased beat frequency, (2) CD, and (3)
   ciliostasis.  The ability to produce both 1 and 2 seems to be
   characteristic for leukocyte cultures from CF genotypes: 46 of 49 CF
   cultures produced both effects, as compared with none of 16 cultures
   from normal controls and 1 of 10 from non-CF patient controls with
   bronchial asthma.  CTA was not specific for CF PBL cultures, since
   13% of normal control and 60% of the non-CF patient control cultures
   produced ciliostasis.  Similar findings were obtained when serum from
   the same individuals or culture medium from long-term lymphoid cell
   lines was tested.  Using protein A from Staphylococcus aureus
   covalently coupled to Sepharose CL-4B as a reagent, we separated the
   CDAs present in serum and in culture medium from PBL and lymphoid
   cultures.  Protein A specifically adsorbs IgG and binds it under mild
   conditions at physiological pH.  The CDAs are noncovalently bound to
   IgG at physiological pH and can be co-purified with IgG.  The IgG-CDA
   complexes can be readily desorbed from protein A-Sepharose CL-4B at
   pH 3.0, and under these conditions the CDAs are dissociated from IgG,
   retain all their activity, and can be separated by chromatography on
   Bio-Gel P-10 or Sephadex G-200.  Three distinct activities were
   removed from serum or PBL cultures which showed both CDA and CTA, and
   two were obtained from samples which showed only CDA.  One CDA
   believed to be specific for CF (CF-CDA) was separated from CF serum
   and PBL or lymphoid cell culture medium.  This CF-CDA was complexed
   noncovalently to IgG (not subclass IgG3), had a molecular weight of
   4000 to 6000, was stable as acid pH, was found in biological fluids
   from both homozygotes and heterozygotes for CF, was shown not to be
   C3a (anaphylatoxin), did not require IgG for activity, and was
   positively charged at pH values more acidic than 8.0.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   WOOD RE               AM REV RESPIR DIS              111   733 975
   004   WOOD RE               AM REV RESPIR DIS              113   833 976
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   BESLEY GTN            J MED GENET                      6   278 969
   007   BERATIS NG            PEDIATR RES                      7   958 973
   008   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   009   DANES BS              J EXP MED                      136  1313 972
   010   CONOVER JH            PEDIATR RES                      7   224 973
   011   DANES BS              CLIN GENET                       7   128 975
   012   WILSON GB             CLIN RES                        25    34 977
   014   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   015   DANES BS              J EXP MED                      137  1538 973
   016   DANES BS              TEX REP BIOL MED                34   135 976
   017   WILSON GB             PEDIATR RES                     11   317 977
   018   CONOD EJ              PEDIATR RES                     11    45 977
   019   GLADE PR              AM J PATHOL                     60   483 970
   020   CONOVER JH            LANCET                           2  1501 973
   021   CONOVER JH            PEDIATR RES                      7   220 973
   022   WILSON GB             PEDIATR RES                     11   143 977
   023   WILSON GB             IN: RADOLA BJ                        337 977
   024   WILSON GB             NATURE                         266   463 977
   025   HJELM H               FEBS LETTERS                    28    73 972
   026   WILSON GB             PEDIATR RES                      9   635 975
   027   WILSON GB             PEDIATR RES                     11   139 977
   028   POLET H               J EXP MED                      142   949 975
   029   BOYUM A               SCAND J CLIN LAB INVEST SUPPL   97    77 968
   030   BRODER SW             BLOOD                           35   539 970
   032   GRABAR P              BIOCHIM BIOPHYS ACTA            10   193 953
   033   LAURELL CB            ANAL BIOCHEM                    15    45 966
   034   FUDENBERG HH          BASIC IMMUNOGENETICS                     977
   035   VYAS GN               J IMMUNOL                      100   274 968
   036   PANDEY JP             J IMMUNOGENET                    5   122 978
   037   BOHLEN P              ARCH BIOCHEM BIOPHYS           155   213 973
   038   KRONVALL G            J IMMUNOL                      103   828 969
   040   SPRAGG J              ANN NY ACAD SCI                209   372 973
   041   AMAUD P               TRANS ASSOC AM PHYSICIANS       39   205 976
   042   CONOVER JH            LIFE SCI                        14   253 974
   043   CONOD EJ              PEDIATR RES                      9   724 975
   044   VALLOTA EH            J EXP MED                      137  1109 973
   045   BARNETT DR            TEX REP BIOL MED                31   709 973
   046   WILSON GB             PEDIATR RES                     10    87 976
   047   SHAPIRA E             J BIOL CHEM                    252  7923 977
CT   1   WILSON GB             PEDIATR RES                     13  1079 979
     2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     3   WILSON GB             J CLIN INVEST                   66  1010 980
     4   MOSS RB               AM REV RESPIR DIS              121    23 980
     5   WILSON GB             PROC SOC EXP BIOL MED          164   105 980
     6   ROOMANS GM            ULTRASTRUCTURAL PATHOL           2    53 981
     7   WILSON GB             J CLIN INVEST                   68   171 981
     8   WILSON GB             CLIN GENET                      26   331 984

PN 78113
RN 00893 
AN 79049543
AU Moller-N-E.  Thomsen-J.
TI Mucocele of the paranasal sinuses in cystic fibrosis.
SO J-Laryngol-Otol. 1978 Nov. 92(11). P 1025-7.
MJ CYSTIC-FIBROSIS: co.  MUCOCELE: et.  PARANASAL-SINUS-DISEASES: et.
MN CASE-REPORT.  CHILD.  FEMALE.  HUMAN.  MALE.
AB Two children below 9 years of age with mucocele and cystic fibrosis
   are reported. Mucocele in this age-group is very rare and is probably
   pathognomonic of cystic fibrosis.
RF 001   CARDESA               CITED IN: ACTA OTO RINO LARIN    3   251 970
   002   DAWES JDK             IN: SCOTT-BROWN                  3   266 971
   003   MENDELSOHN RS         ARCH OTOLARYNGOL                79   312 964
   004   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   005   RITTER FN             IN: COATES GM                    3    15 955
   006   ROBERTSON DM          AM J OPHTHALMOL                 68   845 969
   007   RULON JT              ARCH OTOLARYNGOL                78   192 963
   008   STOOL S               TRANS AM ACAD OPHTHALMOL OTOL   70   811 966
   009   TALLENT A             CAHIERS OTO RHINO LARYNGOL       5     7 970
CT   1   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 78114
RN 00894 
AN 78201635
AU Calbreath-D-F.
TI Screening for cystic fibrosis.
SO J-Nurs-Care. 1978 Jul. 11(7). P 8.
MJ CYSTIC-FIBROSIS: di.
MN HUMAN.  INFANT-NEWBORN.
EX Cystic fibrosis is a great unknown.  There is a lot of information
   about the disease, but no common denominator, nothing to pull all the
   pieces together.  It represents both a diagnostic and a therapeutic
   challenge.  Progress is being made and perhaps someday we will be
   able to understand this complex entity.

PN 78115
RN 00895 
AN 79153473
AU Morrissey-S-M.  Tymvios-M-C.
TI Acid mucins in human intestinal goblet cells.
SO J-Pathol. 1978 Dec. 126(4). P 197-208.
MJ CYSTIC-FIBROSIS: me.  INFANT-NEWBORN-DISEASES: me.
   INTESTINE-SMALL: me.  MUCINS: me.
MN CELL-COUNT.  CYSTIC-FIBROSIS: pa.  DUODENUM: me.  HISTOCYTOCHEMISTRY.
   HUMAN.  ILEUM: me.  INFANT.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: pa.  INTESTINE-SMALL: pa.  JEJUNUM: me.
AB Acid mucins in goblet cells of the duodenum, jejunum and ileum of
   neonates and infants with cystic fibrosis (CF) and without CF were
   measured by scanning microdensitometry after alcian blue staining
   according to the protocol of McCarthy and Reid (1963) which
   characterises four groups of acidic mucins. In CF infants over 6 mth
   of age, but not in controls, there was an increase along the gut from
   duodenum to ileum of both weakly acidic and strongly acidic
   sulphomucins. In the ileum the increase was in total mucins from 6
   mth previously in the same CF patients and this difference could be
   accounted for by an increase of sialidase-resistant mucins. The
   increase in sulphomucins was more marked at the tip than at the base
   of the villi. In CF neonates there was significant difference in the
   quantities of acidic mucins. The question whether the mucins of CF
   are chemically abnormal or merely accumulated to an abnormal extent
   is probably best investigated by analysis of sialidase-resistant
   mucins and sulphomucins of the ileum and strongly acidic sulphomucins
   of the duodenum and jejunum in CF infants over 6 mth of age.
RF 001   ANDERSEN DH           ANN NY ACAD SCI                 93   500 962
   002   BAUER U               ANN PAEDIATR                   194   236 960
   003   BELANGER L            ANN NY ACAD SCI                106   364 963
   004   DISCHE Z              PEDIATRICS                      24    74 959
   005   FARBER S              J MICH MED SOC                  44   587 945
   006   FREYE HB              J PEDIATR                       64   575 964
   007   GIBBONS RA            EXCERPTA MED INT CONG SERIES   133   695 966
   008   GOTTSCHALK A          CHEM BIOL SIALIC ACID REL                960
   009$  GRAIG JM              IN: RESEARCH ON CF                    25 959
   010   GRECO V               GUT                              8   491 967
   011   JOHANSEN PG           ANN NY ACAD SCI                106   755 963
   012   JOHANSEN PG           J PATHOL                        99   299 969
   013   JONES R               HISTOCHEM J                      5    19 973
   014   KENT PW               BIOCHEM J                       87    38 963
   015   LAMB D                THESIS                                   969
   016   LAMB D                J PATHOL                        98   213 969
   017   LAMB D                HISTOCHEM J                      4    91 972
   018   LANDING BH            ROSS PAEDIATR RES CONF 18TH           63 956
   019   LEV R                 LAB INVEST                      14  2080 966
   020   LEV R                 AM J PATHOL                     46    23 965
   021   MCCARTHY C            Q J EXP PHYSIOL                 49    81 964
   022   PALLAVICINI JC        ANN NY ACAD SCI                106   330 963
   023   POTTER JL             ANN NY ACAD SCI                106   692 963
   024   ROELFS RE             AM J DIS CHILD                 113   419 967
   025   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   026   SCHRAGER J            NATURE                         201   702 964
   027   SHACKLEFORD JM        J HISTOCHEM CYTOCHEM            12   512 964
   028   SPICER SS             AM J CLIN PATHOL                33   453 970
   029   THOMAIDIS TS          J PEDIATR                       63   444 963
   030   WAGNER BM             AM J DIS CHILD                  99    61 960
CT   1   HOUGH L               J PHYSIOL (LOND)               291  P  9 979
     2   MORRISSEY SM          GUT                             22   788 981
     3   ADLER KB              LAB INVEST                      45   372 981
     4   FORSTNER G            ADV EXP MED BIOL               144   199 982
     5   WESLEY A              PEDIATR RES                     17    65 983
     6   MORRISSEY SM          GUT                             24   909 983
     7   REID L                INT REV EXP PATHOL              24   335 983
     8   JACOBS LR             DIG DIS SCI                     28   422 983
     9   JEFFREY I             J CLIN PATHOL                   36  1292 983
    10   HOLLANDERS D          BR J CLIN PRACT                 37   112 983
    11   SLOMIANY A            BIOCHIM BIOPHYS ACTA           750   253 983
    12   REID PE               HISTOCHEM J                     16   253 984
    13   JEFFREY I             J CLIN PATHOL                   37   957 984
    14   HOLLANDERS D          J PHYSIOL (LOND)               348  P  8 984
    15   CLEGHORN GJ           LANCET                           1     8 986
    16   MORRISSEY SM          DIGESTION                       34    28 986
    17   HOLLANDERS D          BR J CLIN PRACT                 40    74 986

PN 78116
RN 00896 
AN 78153026
AU Buts-J-P.  Morin-C-L.  Roy-C-C.  Weber-A.  Bonin-A.
TI One-hour blood xylose test: a reliable index of small bowel function.
SO J-Pediatr. 1978 May. 92(5). P 729-33.
MJ INTESTINAL-MUCOSA: pp.  INTESTINE-SMALL: pp.  XYLOSE: du.
MN CELIAC-DISEASE: di.  CYSTIC-FIBROSIS: pp.  FECES: an.  HUMAN.
   INTESTINAL-DISEASES: di.  LIPIDS: an.  MALABSORPTION-SYNDROMES: di.
   RETROSPECTIVE-STUDIES.  TIME-FACTORS.  XYLOSE: bl.
AB A retrospective analysis of oral D-xylose tolerance tests in 435
   pediatric patients was performed. A significant difference was found
   between 126 normal subjects and 47 untreated children with celiac
   disease one hour after load. The one-hour value was found to be more
   reliable than was fecal fat analysis in screening children for celiac
   disease. Sex, age, weight, and body surface did not influence the
   results of the one-hour value in the control subjects. Forty-eight
   children with cystic fibrosis had one-hour xylose levels within the
   normal range, but the means at 90, 120, and 180 minutes after load
   exceeded significantly (P less than 0.01) those of the controls. In a
   nonceliac group of 63 children with abnormally low xylose levels,
   almost all were found to have clinical conditions compatible with
   upper small bowel mucosal impairment. This study shows that a single
   estimation of xylose in blood one hour after load is a reliable index
   of small bowel mucosal function. It is a good screening test for
   celiac disease and small bowel disorders producing malabsorption in
   children.
RF 001   HAWKINS KI            CLIN CHEM                       16   749 970
   002   JONES WO              J PEDIATR                       62    50 963
   003   MEEUWISSE GW          ACTA PAEDIATR SCAND             54    33 965
   004   MCCRAE WM             ARCH DIS CHILD                  38   571 963
   005   SAMMONS HG            GUT                              8   348 967
   006   FINLAY JM             ANN INTERN MED                  61   411 964
   007   BENSON JA JR          N ENGL J MED                   256   335 957
   008   ROLLES CJ             LANCET                           2  1043 973
   009   ROLLES CJ             ARCH DIS CHILD                  50   359 975
   010   SLADEN GE             BR MED J                         3   223 973
   011   LAMABADUSURIYA SP     ARCH DIS CHILD                  50    34 975
   012   GOLDMAN AS            PEDIATRICS                      32   425 963
   013   DAVIDSON M            J PEDIATR                       69  1027 966
   014   ROE JH                J BIOL CHEM                    173   507 948
   015   LANZKOWSKY P          JAMA                           186   517 963
   016   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   017   SHMERLING DH          PEDIATRICS                      46   690 970
   018   FORDTRAN JS           N ENGL J MED                   267   274 962
   019   BUTTERWORTH CE JR     N ENGL J MED                   261   157 959
   020   SEGAL S               J CLIN INVEST                   38   407 959
   021   CASPARY WF            GASTROENTEROLOGY                63   531 972
   022   GLUCKMAN RF           GASTROENTEROLOGY                44   828 963
   023   KENDALL MJ            BR MED J                         1   533 971
   024   JACOBSON ED           AM J MED                        28   524 960
   025   EGAN-MITCHELL B       ARCH DIS CHILD                  47   238 972
   026   OPPENHEIMER EH        J PEDIATR                       86   683 975
   027   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   028   WYNGAARDEN JB         J CLIN INVEST                   36  1395 957
   029   BRIEN FS              GASTROENTEROLOGY                20   287 952
   030   SANTIAGO-BORRERO PJ   PEDIATRICS                      48    59 971
   031   GOLDSTEIN F           GASTROENTEROLOGY                59   380 970
   032   ROBILLARD JE          UNION MED CAN                  102  1496 973
CT   1   MORIN CL              LANCET                           1  1102 979
     2   CHRISTIE DL           J PEDIATR                       94   509 979
     3   LIEBMAN WM            J PEDIATR                       94   508 979
     4   MORIN CL              J PEDIATR                       94   509 979
     5   COBDEN I              GUT                             21   512 980
     6   PARK RW               GASTROENTEROLOGY                81  1143 981
     7   LEBENTHAL E           J PEDIATR                       98   681 981
     8   KEKOMAKI M            J PEDIATR GASTROENTEROL NUTR     1   369 982
     9   MONTGOMERY RD         TRANS R SOC TROP MED HYG        76    25 982
    10   RYAN ME               CLIN GASTROENTEROL              12   533 983
    11   SAVILAHTI E           ARCH DIS CHILD                  58   246 983
    12   PERKKIO M             ACTA PAEDIATR SCAND             73   680 984
    13   FITZGERALD JF         PEDIATR INFECT DIS               4     6 985
    14   BONAMICO M            RIV ITAL PEDIATR                11   172 985
    15   CHATTI N              UNION MED CAN                  114    60 985
    16   LOMBARD KA            PEDIATRICS                      77   396 986
    17   LEVINE JJ             AM J DIS CHILD                 141   435 987

PN 78117
RN 00897 
AN 79069434
AU Davidson-G-P.  Hassel-F-M.  Crozier-D.  Corey-M.  Forstner-G-G.
TI Iatrogenic hyperuricemia in children with cystic fibrosis.
SO J-Pediatr. 1978 Dec. 93(6). P 976-8.
MJ CYSTIC-FIBROSIS: bl.  URIC-ACID: bl.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  CHILD.  CYSTIC-FIBROSIS: dt.
   HUMAN.  PANCREAS: en.  PANCREATIC-EXTRACTS: ae, tu.  PURINES: ae.
EX We report the frequent presence of hyperuricemia in a group of
   children with cystic fibrosis who were known to be consuming large
   dosages of pancreatic extract as part of their therapy.
   Hyperuricemia was more common in older patients who had been treated
   for a longer period of time.  Clarification of the role of renal
   function and other factors in the production of hyperuricemia awaits
   a careful study of the relationship of purine load to urate excretion
   at various ages in these patients.
RF 001   STAPLETON FB          N ENGL J MED                   295   246 976
   002   NOUSIA-ARVANITAKIS S  J PEDIATR                       90   302 977
   003   COREY M               AM REV RESPIR DIS              114  1085 976
   004   HARKNESS RA           ARCH DIS CHILD                  44   773 969
   005   ENDOZIEN JC           NATURE                         228   180 970
   006   STAPLETON FB          PEDIATR RES                     11   558 977
   007   KAUFMAN JM            J PEDIATR                       73   583 968
   008   WINBERG J             ACTA PAEDIATR SCAND             48   443 959
   009   GUTMAN AB             TRANS ASSOC AM PHYSICIANS       74   353 961
   010   KLINENBERG J          NEPHRON                         14    88 975
CT   1   GAHL WA               J PEDIATR                       95   330 979
     2   ROBB TA               LANCET                           2   544 980
     3   BELL L                J CAN DIET ASSOC                42    62 981
     4   BOHLES H              HELV PAEDIATR ACTA              37   267 982
     5   MISCHLER EH           AM J DIS CHILD                 136  1060 982
     6   CHEN YT               N ENGL J MED                   311   128 984
     7   PERRY RS              CLIN PHARMACY                    4   161 985
     8   ZENTLERMUNRO PL       GUT                             26   892 985
     9   SPINO M               J PEDIATR                      107    64 985
    10   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    11   GOODCHILD MC          J ROY SOC MED                   79    32 986
    12   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 78118
RN 00898 
AN 78153070
AU Kulczycki-L-L.  Schauf-V.
TI Incidence of cystic fibrosis in black children--revisited [letter].
SO J-Pediatr. 1978 May. 92(5). P 855.
MJ CYSTIC-FIBROSIS: oc.
MN BLACKS.  CHILD.  DISTRICT-OF-COLUMBIA.  HUMAN.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: oc.  NEW-YORK-CITY.
EX In the February, 1977, issue of The Journal, Dr. Heffer comments on
   publications concerning the occurrence of cystic fibrosis (CF) in
   black children.  He "feels" that CF occurs more frequently than we
   have reported.  Our ten-year search in the Washington, D.C., area
   shows a minimum incidence of cystic fibrosis among black newborn
   infants as one per 17,000.  Since 1972, we have identified an
   additional four black patients with cystic fibrosis in black
   children.  This is consistent with the previously reported incidence
   of one in 17,000.  Therefore, we disagree with Heffer, that this is a
   common disease among blacks.
RF 001   HEFFER ET             J PEDIATR                       90   324 977
   002   HEFFER ET             NY STATE J MED                  74  2355 974
   003   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   004   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   005   STERN RC              J PEDIATR                       89   412 976
   006   DI SANTAGNESE PA      ANN INTERN MED                  54   482 961

PN 78119
RN 00899 
AN 78153027
AU Nousia-Arvanitakis-S.  Arvanitakis-C.  Desai-N.  Greenberger-N-J.
TI Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by
   the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid.
SO J-Pediatr. 1978 May. 92(5). P 734-7.
MJ P-AMINOBENZOIC-ACID: du.  AMINOBENZOIC-ACIDS: du.
   CYSTIC-FIBROSIS: co.  PANCREATIC-DISEASES: di.
MN P-AMINOBENZOIC-ACID: aa, ur.  ADOLESCENCE.  ADULT.  CHILD.
   CHILD-PRESCHOOL.  CHYMOTRYPSIN: me.  FECES: an, en.  HUMAN.
   LIPIDS: an.  PANCREATIC-DISEASES: et, ur.  SUPPORT-U-S-GOVT-P-H-S.
AB The synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid is
   specifically cleaved by chymotrypsin to Bz-Ty and PABA. The liberated
   PABA is absorbed and excreted in the urine. Accordingly, PABA
   recovery reflects intraluminal chymotrypsin activity and is an index
   of exocrine pancreatic function. This test was evaluated in 24
   patients with cystic fibrosis to determine its role in the diagnosis
   of exocrine pancreatic insufficiency. Cumulative percent PABA
   recovery in six hours was significantly lower in CF patients compared
   with the control group. No overlap was noted between the two groups.
   There was good correlation between PABA recovery, fecal chymotrypsin
   activity, and coefficient of fat absorption. These findings indicate
   that PABA recovery is significantly reduced in patients with CF and
   steatorrhea and may prove a practical and reliable test of pancreatic
   insufficiency.
RF 001   KOPEL FB              GASTROENTEROLOGY                62   483 972
   002   STAPLETON FB          N ENGL J MED                   295   246 976
   003   IMONDI AR             GUT                             13   726 972
   004   ARVANITAKIS C         LANCET                           1   663 976
   005   GYR K                 GUT                             17    27 976
   006   BORNSCHEIN W          CLIN CHIM ACTA                  67    21 976
   007   TAUSSIG LM            J PEDIATR                       82   380 973
   008   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   009   IMONDI AR             ANAL BIOCHEM                    54   199 973
   010   BRATTON AC            J BIOL CHEM                    128   537 939
   011   SMITH HW              J CLIN INVEST                   24   388 945
   012   BARBERO GJ            AM J DIS CHILD                 112   536 966
   013   DYCK WP               AM J DIG DIS                    12   310 967
   014   GREENGARD P           IN: GOODMAN LS                      1661 970
   015   ZAROFONETIS CJD       J INVEST DERMATOL               11   359 948
CT   1   IMONDI AR             DIG DIS SCI                     24   214 979
     2   MALIS F               J PEDIATR                       94   942 979
     3   SACHER M              J PEDIATR                       94   159 979
     4   LANKISCH PG           DTSCH MED WSCHR                105  1418 980
     5   LANG C                SCHWEIZ MED WOCHENSCHR         110   522 980
     6   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   746 980
     7   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   301 980
     8   OSSWALD P             MONATSSCHR KINDERHEILKD        128   340 980
     9   SCHONBERGER W         MONATSSCHR KINDERHEILKD        128   195 980
    10   HOEK FJ               GUT                             22     8 981
    11   LANKISCH PG           HEPATOGASTROENTEROLOGY          28   333 981
    12   LANG C                BR J SURG                       68   771 981
    13   PARK RW               GASTROENTEROLOGY                81  1143 981
    14   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
    15   WOLF C                SCHWEIZ MED WOCHENSCHR         111   343 981
    16   LIBEER JC             CLIN CHIM ACTA                 115   119 981
    17   KAI H                 J PEDIATR GASTROENTEROL NUTR     1   445 982
    18   LANKISCH PG           GUT                             23   777 982
    19   RYAN ME               CLIN GASTROENTEROL              12   533 983
    20   DELCHIER JC           GUT                             24   318 983
    21   HEELEY AF             CLIN CHEM                       29  2011 983
    22   TOSKES PP             GASTROENTEROLOGY                85   565 983
    23   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             2   249 984
    24   TOSKES PP             PHARMACOTHERAPY                  4    74 984
    25   LANKISCH PG           CLIN GASTROENTEROL              13   717 984
    26   HUBBARD VS            DIG DIS SCI                     29   881 984
    27   GILLARD BK            AM J DIS CHILD                 138   577 984
    28   BELLENTANI S          EUR J PEDIATR                  143   145 984
    29   ORENSTEIN DM          SEM RESPIR MED                   6   252 985
    30   SCOTTA MS             CLIN BIOCHEM                    18   233 985
    31   BORNSCHEIN W          Z GASTROENTEROL                 23   247 985
    32   KOREN G               DIG DIS SCI                     30   928 985
    33   RIEU D                ANN PEDIATR (PARIS)             32   205 985
    34   SCHIOTZ PO            ACTA PAEDIATR SCAND             74   460 985
    35   NIEDERAU C            GASTROENTEROLOGY                88  1973 985
    36   HEYMAN MB             GASTROENTEROLOGY                89   685 985
    37   WEIZMAN Z             GASTROENTEROLOGY                89   596 985
    38   SCHARPE S             CLIN CHEM                       33     5 987
    39   SARLES J              ARCH FR PEDIATR                 44   311 987

PN 78120
RN 00900 
AN 79069407
AU Vitullo-B-B.  Rochon-L.  Seemayer-T-A.  Beardmore-H.  de-Belle-R-C.
TI Intrapancreatic compression of the common bile duct in cystic
   fibrosis.
SO J-Pediatr. 1978 Dec. 93(6). P 1060-1.
MJ COMMON-BILE-DUCT.  CYSTIC-FIBROSIS: co.
MN AUTOPSY.  CASE-REPORT.  CHOLESTASIS: et.  COMMON-BILE-DUCT: pa.
   CYSTIC-FIBROSIS: pa.  HUMAN.  INFANT.  MALE.  PRESSURE.
AB We report an infant with cystic fibrosis presenting at birth with
   meconium ileus who developed prolonged cholestatic jaundice from
   compression of the common bile duct and the pancreatic duct by
   advanced pancreatic fibrosis.  Extrahepatic biliary obstruction of
   this nature has not been previously described in cystic fibrosis.
RF 001   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   002   OPPENHEIMER EH        J PEDIATR                       86   683 975
   003   TALAMO RC             AM J DIS CHILD                 115    74 968
   004   JEAN R                ARCH FR PEDIATR                 27   849 970
   005   VALMAN HB             ARCH DIS CHILD                  46   805 971
CT   1   LAMBERT JR            GASTROENTEROLOGY                80   169 981
     2   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     3   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     4   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     5   TEDESCO FJ            GASTROINTEST ENDOSC             32    25 986
     6   PATRICK MK            J PEDIATR                      108   101 986

PN 78121
RN 00901 
AN 78088954
AU Antonowicz-I.  Lebenthal-E.  Schwachman-H.
TI Disaccharidase activities in small intestinal mucosa in patients
   with cystic fibrosis.
SO J-Pediatr. 1978 Feb. 92(2). P 214-9.
MJ CYSTIC-FIBROSIS: en.  DISACCHARIDASES: me.  INTESTINAL-MUCOSA: en.
   INTESTINE-SMALL: en.
MN ALPHA-GLUCOSIDASES: me.  ATROPHY.  BETA-GALACTOSIDASES: me.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pa.  HUMAN.  INTESTINAL-MUCOSA: pa.
   INTESTINE-SMALL: pa.
AB The disaccharidase activities in small intestinal biopsies were
   related to the morphology of the mucosa and the ages of 63 patients
   with cystic fibrosis and 177 healthy control subjects of Caucasian
   origin. In patients with CF and in the healthy control subjects under
   5 years of age with normal intestinal mucosa, no low lactase activity
   was found. In those patients with CF who were over 5 years of age,
   one group had high and one group had low lactase activity, as occurs
   in healthy Caucasian control subjects of the same age. This finding
   supports the view that in patients with CF, lactase deficiency is not
   related to the disease entity. In patients with or without CF who had
   the same degree of mucosal atrophy, the decrease of disaccharidase
   activities followed the same pattern, indicating that enzyme
   activities are affected to the same extent by the damage of the
   mucosa. In patients with CF with pancreatic insufficiency, the
   disaccharidase activities were significantly (P less than 0.001)
   higher when compared to those in control subjects of the same age and
   ethnic group, although the increase was not uniform in all patients
   with cystic fibrosis.
RF 001   AURICCHIO S           LANCET                           2   324 963
   002   WESER E               N ENGL J MED                   273  1070 965
   003   ANDERSON AFR          AM J DIG DIS                     9    91 942
   004   CHALFIN D             AM J DIG DIS                    12    81 967
   005   SHEEHY TW             LANCET                           2     1 965
   006   BINDER HJ             AM J DIG DIS                    11   858 966
   007   FRAZER AC             LANCET                           1   503 966
   008   LITMAN A              ISR J MED SCI                    4   110 968
   009   KOJECKY Z             AM J PROCTOL                    19   204 968
   010   NORDIO S              ANN PAEDIATR                   206   287 966
   011   PETERNAL WW           GASTROENTEROLOGY                48   299 965
   012   COZZETTO FJ           PEDIATRICS                      32   228 963
   013   GRYBOSKI JD           GASTROENTEROLOGY                45   633 963
   014   JONES RHT             LANCET                           2   120 964
   015   ANTONOWICZ I          PEDIATRICS                      42   492 968
   016   CUATRECASAS P         LANCET                           1    14 965
   017   COOK GC               LANCET                           1   725 966
   018   GILAT T               AM J DIG DIS                    15   895 970
   019   KRETCHMER N           LANCET                           2   392 971
   020   HUANG SS              SCIENCE                        160    83 966
   021   BAYLESS TM            JAMA                           197   968 966
   022   BAYLESS TM            JOHNS HOPKINS MED J            121    54 967
   023   ALZATE H              AM J CLIN NUTR                  22   122 969
   024   REDDY V               AM J CLIN NUTR                  25   114 972
   025   LEBENTHAL E           GASTROENTEROLOGY                67   807 974
   026   WELSH JD              MEDICINE (BALTIMORE)            49   257 970
   027   SIMMONS FJ            AM J DIG DIS                    18   595 973
   028   JOHNSON JD            ADV PEDIATR                     22   197 975
   029   DAHLQVIST A           BIOL SOC TRANS                   3   227 975
   030   LEBENTHAL E           AM J CLIN NUTR                  28   595 975
   031   ALPERS DH             BIOCHIM BIOPHYS ACTA           401    28 975
   032   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   033   DAHLQVIST A           ANAL BIOCHEM                     7    18 964
   034   TOWNLEY RRW           PEDIATRICS                      36   911 965
   035   LOWRY OH              J BIOL CHEM                    193   265 951
   036   EGGSTEIN M            KLIN WOCHENSCHR                 33   879 955
   037   PENA AS               GUT                             10  1052 969
   038   GUDMAND-HOYER E       GUT                             11   338 970
   039   TANDON R              AM J DIG DIS                    16   845 971
   040   PENA AS               GASTROENTEROLOGY                64   400 973
   041   GUDMAND-HOYER E       SCAND J GASTROENTEROL           10   209 975
   042   ARVANITAKIS C         AM J DIG DIS                    19   417 974
   043   SEETHARAM B           LIFE SCI                        18    89 976
   044   ANTONOWICZ I          PEDIATRICS                      56   782 975
CT   1   SCHMIDT E             CLIN BIOCHEM                    12   247 979
     2   SCHMIDT E             J CLIN CHEM CLIN BIOCHEM        17   693 979
     3   KEDINGER M            ENZYME                          24    96 979
     4   COX KL                J PEDIATR                       94   488 979
     5   LEBENTHAL E           AM J DIS CHILD                 133    21 979
     6   BROWN KH              AM J CLIN NUTR                  33  1054 980
     7   MITCHELL EA           AUST PAEDIATR J                 17    89 981
     8   BRANSKI D             DIGESTION                       22     8 981
     9   MCNAMARA D            BIOMEDICINE EXPRESS             35   122 981
    10   LEBENTHAL E           PEDIATRICS                      67   828 981
    11   PARK RW               GASTROENTEROLOGY                81  1143 981
    12   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    13   CATALA J              DIGESTION                       24   234 982
    14   BOUNOUS G             GASTROENTEROLOGY                82  1457 982
    15   GUTSCHMIDT S          J PEDIATR GASTROENTEROL NUTR     2   677 983
    16   ROSSI E               ANN ALLERGY                     53   649 984
    17   SCHWARTZ M            PRENAT DIAGN                     5   145 985
    18   CREUTZFELDT W         SCAND J GASTROENTEROL           20    45 985
    19   FRASE LL              GASTROENTEROLOGY                88   478 985
    20   RUBINSTEIN S          PEDIATRICS                      78   473 986

PN 78122
RN 00902 
AN 78132308
TI Pancreatitis in children [letter].
SO J-Pediatr. 1978 Apr. 92(4). P 685-6.
MJ PANCREATITIS: fg.
MN AMYLASES: bl.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co, di.
   FEMALE.  HUMAN.  INFANT.  PANCREATITIS: et.  PREGNANCY.
EX "Hereditary pancreatitis" is important for at least three reasons:
   (1) It is probably not an uncommon form of pancreatitis in children
   and young adults; (2) the course of the disorder may be chronic, with
   substantial long-term morbidity, including an apparently increased
   risk for pancreatic cancer; and (3) once having made the correct
   diagnosis, occurrence among siblings and/or offspring (and perhaps
   other relatives) of the proband may be expected.  Hereditary
   pancreatitis is an autosomal dominant trait with apparently complete
   penetrance, though markedly variable expressivity.  It would be
   reasonable to point out that hereditary pancreatitis should be
   entertained whenever an alternative diagnosis is not documented, even
   without a positive family history. - We agree with the statement by
   Jordan and Ament in a recent article that "acute pancreatitis is one
   of the rarer causes of abdominal pain in children and is among the
   least reported and characterized."  However, their discussion of this
   problem is surprisingly incomplete.  Familial pancreatitis, one of
   the most important causes of pancreatitis in childhood, is not even
   mentioned; cystic fibrosis is barely acknowledged.  These two
   conditions as well as hypolipoproteinemia and ascariasis (also not
   mentioned) should be included in the differential diagnosis of
   pancreatitis in children and of otherwise unexplained abdominal pain
   in this age group. - We appreciate the concern that we did not
   diagnose hereditary pancreatitis in any of our patients.  None of the
   ten patients with "idiopathic pancreatitis" had a family history of
   pancreatitis documented in their charts.  Cystic fibrosis (CF) is not
   a common cause of pancreatitis in our center.  We chose to omit
   ascariasis from our differential diagnosis because in the developed
   countries it is unlikely to be a common cause of pancreatitis.
RF 001   JORDAN SC             J PEDIATR                       91   211 977
   002   RICCARDI VM           ARCH INTERN MED                135   822 975
   003   KATTWINKEL J          PEDIATRICS                      51    55 973
   003   DI SANTAGNESE PA      IN: VAUGHAN VC III                   903 975
   004   SCRIVER CR            AMINO ACID METABOL DISORDERS             973
   004   SHWACHMAN H           PEDIATRICS                      55    86 975
   005   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   006   TYE JG                J MED GENET                     13    96 976
   007   WOLF RO               J LAB CLIN MED                  87   164 976
   008   SKUDE G               ACTA PAEDIATR SCAND             65   145 976
   009   SCHIOTZ PO            CLIN GENET                      11    43 977
CT   1   WOLF RO               PEDIATR RES                     13  1076 979
     2   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     3   MASARYK TJ            DIG DIS SCI                     28   874 983

PN 78123
RN 00903 
AN 79007007
AU Buescher-E-S.  Winkelstein-J-A.
TI The ability of bacteria to activate the terminal complement
   components in serum of patients with cystic fibrosis.
SO J-Pediatr. 1978 Sep. 93(3). P 530-1.
MJ BACTERIA.  COMPLEMENT.  CYSTIC-FIBROSIS: im.
MN CYSTIC-FIBROSIS: co, mi.  HUMAN.  IN-VITRO.  LUNG-DISEASES: et.
   PSEUDOMONAS-AERUGINOSA.  RECURRENCE.  STAPHYLOCOCCUS-AUREUS.
   SUPPORT-U-S-GOVT-P-H-S.
EX The terminal complement components, C3 to C9, contribute to the
   host's defense against infection.  This study was performed to
   determine if defective activation of C3 to C9 by bacteria contributes
   to the pathogenesis of the recurrent pulmonary infections in cystic
   fibrosis.  When each of the bacteria was incubated in the serum of
   patients with cystic fibrosis for 30 minutes, the consumption of
   available C3 was the same as in the sera of the control patients and
   of the two patients with chronic, severe bronchiectasis.  Based on
   the results of the present study, it is unlikely that defective
   activation of C3 to C9 contributes to the pathogenesis of the
   increased susceptibility to pulmonary infections of these patients.
RF 001   TALAMO RC             IN: MANGOS JA                        195 976
   002   POLLEY MJ             J MED GENET                     11   249 974
   003   LYRENE RK             J PEDIATR                       91   681 977
   004   WINKELSTEIN JA        J IMMUNOL                      108  1681 972
CT   1   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979
     2   HODSON ME             THORAX                          35   801 980
     3   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     4   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985

PN 78124
RN 00904 
AN 79049980
AU Mitchell-I.  Corey-M.  Woenne-R.  Krastins-I-R.  Levison-H.
TI Bronchial hyperreactivity in cystic fibrosis and asthma.
SO J-Pediatr. 1978 Nov. 93(5). P 744-8.
MJ ASTHMA: pp.  BRONCHI: de.  CYSTIC-FIBROSIS: pp.
   METHACHOLINE-COMPOUNDS: pd.
MN ADOLESCENCE.  ADULT.  ASTHMA: im.  BRONCHI: im, pp.  CHILD.
   CYSTIC-FIBROSIS: fg, im.  DOSE-RESPONSE-RELATIONSHIP-DRUG.  FEMALE.
   FORCED-EXPIRATORY-VOLUME.  HISTAMINE: pd.  HUMAN.  MALE.
AB We studied 113 patients with CF and compared their responsiveness to
   inhaled methacholine to that of 50 asthmatic children and 26 normal
   children. Positive responses to MCh occurred in 51% of the patients
   with CF and 98% of those with asthma. There was a significant
   correlation between a positive response to MCh in CF and poor
   pulmonary function. There was no relationship between allergic
   rhinitis or positive allergen skin tests and a positive MCh response.
   Dose-response curves and time course to MCh challenge differed in CF
   and asthma. Bronchial hyperreactivity is thus common in CF but is
   different from that in asthma.
RF 001   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   002   WARNER JO             ARCH DIS CHILD                  51   507 976
   003   LANDAU LI             J PEDIATR                       82   863 973
   004   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   005   CHAI H                J ALLERGY CLIN IMMUNOL          56   323 975
   006   ROTHSTEIN RJ          J ALLERGY CLIN IMMUNOL          53   100 974
   007   MELLIS CM             PEDIATRICS                      61   446 978
   008   MERCER TT             ANN ALLERGY                     23   314 965
   009   WENG TR               AM REV RESPIR DIS               99   879 969
   010   NIE NH                STAT PACKAGE FOR THE SOCIAL S            975
   011   SNEDECOR GW           STATISTICAL METHODS                      967
   012   HALUSZKA J            RESPIRATION                     32   217 975
   013   EMPEY DW              AM REV RESPIR DIS              113   131 976
   014   RUBINFELD AR          AM REV RESPIR DIS              115   381 977
   015   SWIFT DL              IN: LAWSON D PROC 5TH INT CF             969
   016   DOLOVICH MB           J APPL PHYSIOL                  40   468 976
   017   NELSON LA             CF CLUB ABST                    18       977
CT   1   ANON                  LANCET                           1   708 979
     2   MIHALAS LS            J PEDIATR                       94  1013 979
     3   MILLIGAN DWA          J PEDIATR                       95    24 979
     4   KATTAN M              N ENGL J MED                   301   664 979
     5   BURDON JGW            MED J AUST                       2    77 980
     6   SLY PD                AUST PAEDIATR J                 16   205 980
     7   KATTAN M              THORAX                          35   531 980
     8   ORMEROD LP            THORAX                          35   768 980
     9   TOBIN MJ              THORAX                          35   807 980
    10   MOSS RB               AM REV RESPIR DIS              121    23 980
    11   GURWITZ D             AM REV RESPIR DIS              122    95 980
    12   LARSEN GL             AM J DIS CHILD                 134  1143 980
    13   DAVIS PB              N ENGL J MED                   302  1453 980
    14   FANTA CH              MED CLIN NORTH AM               65   473 981
    15   GALANT SP             J CLIN INVEST                   68   253 981
    16   GURWITZ D             J PEDIATR                       98   551 981
    17   MOSS RB               J PEDIATR                       99   215 981
    18   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
    19   VANASPEREN P          AM J DIS CHILD                 135   815 981
    20   RUSSELL NJ            BR J DIS CHEST                  76    35 982
    21   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    22   WONNE R               ATEMWEGS LUNGENKRANKH            9   104 983
    23   NEIJENS HJ            PEDIATR CLIN NORTH AM           30   829 983
    24   DAVIS PB              J CHRON DIS                     36   269 983
    25   SCHEINMANN P          SEM HOP PARIS                   59  2969 983
    26   LEWIS MI              S AFR MED J                     65   641 984
    27   MCFADDEN ER           J ALLERGY CLIN IMMUNOL          73   413 984
    28   DAVIS PB              AM REV RESPIR DIS              129   911 984
    29   SELTZER J             AM REV RESPIR DIS              129   790 984
    30   MISCHLER EH           SEM RESPIR MED                   6   271 985
    31   WONNE R               CLIN ALLERGY                    15   455 985
    32   MITCHELL I            ANN ALLERGY                     54   233 985
    33   HORDVIK NL            AM REV RESPIR DIS              131   889 985
    34   DARGA LL              PEDIATR PULMONOL                 2    82 986
    35   MACLUSKY IB           PEDIATR PULMONOL                 2    94 986
    36   DAVIS PB              HORM METAB RES                  18   217 986
    37   DAVIES RJ             J ALLERGY CLIN IMMUNOL          78  1031 986
    38   SULLIVAN MM           CHEST                           90   239 986
    39   BARNES PJ             AM REV RESPIR DIS              134  1289 986
    40   STEAD RJ              PROSTAGLANDINS LEUKOTR MED      26    91 987
    41   GALVEZ RA             J ALLERGY CLIN IMMUNOL          79   331 987

PN 78125
RN 00905 
AN 78220043
AU Sorensen-R-U.  Stern-R-C.  Polmar-S-H.
TI Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic
   fibrosis: Relationship to status of pulmonary disease in sibling
   pairs.
SO J-Pediatr. 1978 Aug. 93(2). P 201-5.
MJ CYSTIC-FIBROSIS: im.  LYMPHOCYTES: im.  LYMPHOPENIA: et.
   PNEUMONIA: im.  PSEUDOMONAS-INFECTIONS: im.
MN ADOLESCENCE.  ADULT.  AGGLUTINATION-TESTS.  ANTIGENS-BACTERIAL.
   CHILD.  CYSTIC-FIBROSIS: fg.  FEMALE.  HUMAN.  IMMUNITY-CELLULAR.
   IN-VITRO.  LYMPHOPENIA: im.  MALE.  PNEUMONIA-STAPHYLOCOCCAL: im.
   PSEUDOMONAS-AERUGINOSA: im.  STAPHYLOCOCCAL-INFECTIONS: im.
   STAPHYLOCOCCUS-AUREUS: im.  SUPPORT-U-S-GOVT-P-H-S.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB Lymphocyte proliferative responses to Pseudomonas aeruginosa and
   Staphylococcus aureus were evaluated in six sibling pairs with cystic
   fibrosis. In each pair, one sibling had advanced clinical disease,
   whereas the other sibling was in good clinical condition. Three in
   this latter group had no clinically apparent Pseudomonas bronchitis.
   In all cases, the average responses to Pseudomonas isolated from each
   sibling pair were lower in the sibling with advanced clinical
   disease. This difference was not observed in the responses to
   Staphylococcus. Normal plasma or plasma from patients with CF in good
   clinical condition does not restore the responses in patients with
   advanced clinical disease. However, plasma from patients with low or
   no responses to Pseudomonas inhibits the responses of responding
   siblings. A progressive specific lymphocyte unresponsiveness to
   Pseudomonas may play an important role in the increasing
   destructiveness of chronic pulmonary Pseudomonas infection in cystic
   fibrosis.
RF 001   TALAMO RC             IN: MANGOS JA                        195 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   004   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   005   THOMASSEN MJ          J RETICULOENDOTHEL SOC          22   38A 977
   006   HANN S                INFECT IMMUN                    14   114 976
   007   HOIBY N               SCAND J RESPIR DIS              56    38 975
   008   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   009   SOUTH MA              J PEDIATR                       71   645 967
   010   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   011   GREEN GM              AM REV RESPIR DIS              102   691 970
   012   GREEN GM              J EXP MED                      119   167 964
   013   KALTREIDER HB         AM REV RESPIR DIS              113   347 976
   014   WARR GA               AM REV RESPIR DIS              108   371 973
   015   SORENSEN RU           INFECT IMMUN                    18   735 977
   016   THORSBY E             HISTOCOMPATIBILITY TESTING           655 970
   017   DOERSHUK CF           J PEDIATR                       65   677 964
   018   SHWACHMAN H           AM J DIS CHILD                  96     6 958
CT   1   THOMASSEN MJ          PEDIATR RES                     13  1085 979
     2   CHURCH JA             J PEDIATR                       95   272 979
     3   MCCARTHY MM           CLIN PEDIATR                    19   746 980
     4   HODSON ME             THORAX                          35   801 980
     5   CHURCH JA             ANN ALLERGY                     45   217 980
     6   BEAUDRY PH            J PEDIATR                       97   144 980
     7   MOSS RB               AM REV RESPIR DIS              121    23 980
     8   BALTIMORE RS          J INFECT DIS                   141   238 980
     9   HARPER TB             LUNG                           157   219 980
    10   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
    11   SORENSEN RU           PEDIATR RES                     15    14 981
    12   RUBIN HR              CELL IMMUNOL                    57   307 981
    13   MARKS MI              J PEDIATR                       98   173 981
    14   MOSS RB               J PEDIATR                       99   215 981
    15   SORENSEN RU           AM REV RESPIR DIS              123    37 981
    16   FROLAND SS            SCAND J INFECT DIS            1981    72 981
    17   VANGEFFEL R           ANN IMMUNOL (PARIS)           D133   293 982
    18   VANGEFFEL R           IMMUNOL LETTERS                  5   155 982
    19   SEALE TW              ANN CLIN LAB SCI                12   415 982
    20   GOTZ M                CLIN EXP IMMUNOL                50   178 982
    21   HARPER TB             AM REV RESPIR DIS              126   540 982
    22   PORWOLL JM            INFECT IMMUN                    40   670 983
    23   CAPLAN DB             REV INFECT DIS                   6  S705 984
    24   PARMELY MJ            J EXP MED                      160  1338 984
    25   LIEBERMAN MM          SURV SYNTH PATHOL RES            4   312 985
    26   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    27   DAVIS PB              SEM RESPIR MED                   6   261 985
    28   KURLAND G             PEDIATRICS                      78  1097 986
    29   PIEDRA P              J PEDIATR                      108   817 986

PN 78126
RN 00906 
AN 78220060
AU Rosenstein-B-J.  Plotnick-L-P.  Blasco-P-A.
TI Iodide-induced hypothyroidism without a goiter in an infant with
   cystic fibrosis.
SO J-Pediatr. 1978 Aug. 93(2). P 261-2.
MJ CYSTIC-FIBROSIS: co.  HYPOTHYROIDISM: ci.  POTASSIUM-IODIDE: ae.
MN CASE-REPORT.  CYSTIC-FIBROSIS: dt.  FEMALE.  HUMAN.  INFANT.
   INFANT-NEWBORN.  POTASSIUM-IODIDE: tu.  SUPPORT-U-S-GOVT-NON-P-H-S.
AB It has been suggested that patients with cystic fibrosis may have an
   intrinsic abnormality of thyroid function that may be enhanced by
   the administration of iodides.  We wish to report an infant with CF
   in whom hyperthyroidism developed, in the absence of a goiter,
   following short-term iodide therapy.
RF 001   DOLAN TF JR           J PEDIATR                       79   684 971
   002   AZIZI F               TRANS ASSOC AM PHYSICIANS       87   111 974
   003   BEGG TB               Q J MED                         32   351 963
   004   SEGALL-BLANK M        CF CLUB ABST                          21 977
   005   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   CHABROLLE JP          ARCH FR PEDIATR                 36    80 979

PN 78127
RN 00907 
AN 78220113
AU Rich-R-H.  Warwick-W-J.  Leonard-A-S.
TI Open thoracotomy and pleural abrasion in the treatment of
   spontaneous pneumothorax in cystic fibrosis.
SO J-Pediatr-Surg. 1978 Jun. 13(3). P 237-42.
MJ CYSTIC-FIBROSIS: co.  PLEURA: su.  PNEUMOTHORAX: su.  THORAX: su.
   THORACIC-SURGERY.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.
   INTUBATION.  MALE.  METHODS.  PNEUMOTHORAX: dt, et.  QUINACRINE: tu.
   RETROSPECTIVE-STUDIES.
AB The various treatments of spontaneous pneumothorax in cystic fibrosis
   are examined over a 15-yr period. Open thoracotomy with pleural
   abrasion is compared to observation, tube thoracostomy, and tube
   thoracostomy with instillation of quinacrine. Open thoracotomy with
   pleural abrasion has been performed 31 times in 20 patients.
   Discussion centers around selection of patients, preoperative
   preparation, operative technique, and postoperative care and follow-
   up, including analysis of pulmonary function studies. In our
   experience, open thoracotomy with pleural abrasion is a safe and
   effective method that should be utilized in the management of
   pneumothorax in patients with cystic fibrosis.
RF 001   GRAHAM WP 3RD         SURG GYNECOL OBSTET            122   373 966
   002   SCHUSTER SR           J THORAC CARDIOVASC SURG        48   750 964
   003   HOLSCLAW DS           CLIN PEDIATR                     9   346 970
   004   HOLSCLAW DS           MINN MED                        52  1547 969
   005   MEARNS MB             ARCH DIS CHILD                  47   499 972
   006   GIBBS GE              MINN MED                        52  1433 969
   007   WYLIE RH              J THORAC CARDIOVASC SURG        48   770 964
   008   LIFSCHITZ MI          AM J DIS CHILD                 116   633 968
   009   BOAT TF               JAMA                           209  1498 969
   010   SHWACHMAN H           MINN MED                        52  1521 969
   011   JONES RE              AM J DIS CHILD                 130   777 976
   012   KATTWINKEL J          JAMA                           226   557 973
   013   BROOKS JW             ANN SURG                       177   798 973
   014   SAHA SP               ANN THORAC SURG                 19   561 975
   015   MITCHELL-HEGGS PF     THORAX                          25   165 970
   016   STOWE SM              AM REV RESPIR DIS              111   611 975
CT   1   SCHUSTER SR           J PEDIATR SURG                  18   492 983
     2   WEEDEN D              THORAX                          38   737 983
     3   ROBB KL               J ECON ENTOMOL                  77  1288 984
     4   MISRA M               BULL INST ZOOL ACAD SINICA      24    85 985

PN 78128
RN 00908 
AN 78244407
AU Flanigan-R-C.  Stern-R-C.  Izant-R-J-Jr.  Filston-H-C.
TI Cystic fibrosis in a black infant: presentation with meconium ileus
   and volvulus.
SO J-Pediatr-Surg. 1978 Aug. 13(4). P 435-6.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: su.
   INTESTINE-SMALL: su.  MECONIUM.
MN CASE-REPORT.  COLON: ab.  DUCTUS-ARTERIOSUS-PATENT: co.  FEMALE.
   HUMAN.  ILEOSTOMY.  ILEUM: su.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-OBSTRUCTION: co.  JEJUNUM: su.  NEGROID-RACE.  PREGNANCY.
AB This is a case report of meconium ileus complicated by intestinal
   volvulus and infarction in a black infant.
RF 001   STERN RC              J PEDIATR                       89   412 976
   002   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   003   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   004   WAGGET J              J PEDIATR SURG                   5   649 970
   005   KALAYOGLU M           J PEDIATR SURG                   6   290 971
   006   BISHOP HC             ANN SURG                       145   410 957
CT   1   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981

PN 78129
RN 00909 
AN 79050049
AU Shigemoto-H.  Endo-S.  Isomoto-T.  Sano-K.  Taguchi-K.
TI Neonatal meconium obstruction in the ileum without mucoviscidosis.
SO J-Pediatr-Surg. 1978 Oct. 13(6). P 475-9.
MJ CYSTIC-FIBROSIS.  ILEUM.  INFANT-NEWBORN-DISEASES: th.
   INTESTINAL-OBSTRUCTION: th.  MECONIUM.
MN CASE-REPORT.  CONTRAST-MEDIA: tu.  ENEMA.  FEMALE.  HUMAN.
   HYPERTONIC-SOLUTIONS.  HYPERTROPHY: et.  ILEUM: pa.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: et, pa.  INTESTINAL-MUCOSA: se.
   INTESTINAL-OBSTRUCTION: et, pa.  MALE.  MUCUS: se.
AB Two newborns with intestinal obstruction of the terminal ileum
   without mucoviscidosis were cured by Gastrografin enema. A further
   case of a premature infant showed, at autopsy, a large intestine
   containing normal meconium, but an ileum which was plugged with
   tenacious meconium containing PAS-positive and alcian blue-negative
   mucus. Our 3 cases were similar to cases of "meconium disease"
   reported by Rickham and of "meconium plug in the small intestine"
   reported by Emery. The primary cause of this disease lies in the
   large amount of PAS-positive mucus secreted from goblet cells of the
   ileal mucosa and the hypertrophy of lymph nodules in the ileal
   submucosa.
RF 001   LEUBNER H             PEDIATRICS                      15   135 955
   002   DI SANTAGNESE PA      PEDIATRICS                      22   507 958
   003   BERTI G               ARCH KINDERHEILK                24   463 898
   004   CLATWORTHY HW         SURGERY                         39   131 956
   005   RICKHAM PP            AM J SURG                      109   173 965
   006   KORNBLITH BA          AM J PATHOL                      5   249 929
   007   HURWITT ES            AM J DIS CHILD                  64   443 942
   008   EMERY JL              ARCH DIS CHILD                  32    17 957
   009   ZACHARY RB            ARCH DIS CHILD                  32    22 957
   010   DOLAN TF JR           J PEDIATR SURG                   9   821 974
CT   1   SIEGEL MJ             RADIOLOGY                      132    79 979
     2   YOSHIKAWA Y           ACTA PATHOL JAP                 31   845 981
     3   HILLEMEIER AC         PEDIATRICS                      69   325 982
     4   TAL A                 CLIN PEDIATR                    24   460 985
     5   SAMUEL N              J ULTRASOUND MED                 5   425 986
     6   KING A                PEDIATR RES                     20   536 986

PN 78130
RN 00910 
AN 78221008
AU Lloyd-Still-J-D.
TI Assisted ventilation in cystic fibrosis [letter].
SO JAMA. 1978 Aug 25. 240(8). P 739.
MJ CYSTIC-FIBROSIS: co.  RESPIRATION-ARTIFICIAL.
   RESPIRATORY-INSUFFICIENCY: th.
MN HUMAN.  INFANT.  RESPIRATORY-DISTRESS-SYNDROME: th.
   RESPIRATORY-INSUFFICIENCY: et.
EX My colleagues and I reviewed the diagnosis, management, and prognosis
   in 17 cases of infants with cystic fibrosis and severe respiratory
   distress who were admitted to the Children's Hospital Medical Center,
   Boston, between 1968 and 1972.  There was a 60% mortality overall.
   Six of the 17 infants were treated with assisted ventilation, of whom
   only one survived.  Our subsequent experience with assisted
   ventilation has shown no improvement in the survival of these
   infants.
RF 000   DAVIS PB              JAMA                           239  1851 978
   001   LLOYD-STILL JD        PEDIATRICS                      53   678 974

PN 78131
RN 00911 
AN 79050797
AU Garrison-D-W.
TI Parents' understanding of genetic risk data in genetic counseling
   [letter].
SO JAMA. 1978 Dec 8. 240(24). P 2631-2.
MJ CYSTIC-FIBROSIS: fg.  GENETIC-COUNSELING.
MN HUMAN.  RISK.
EX Relatively little has been published on the parents' ability to grasp
   the importance of empirical risk data and Mendelian-type
   probabilities.  The basic problem is that for many reasons, consumers
   do not know what the recurrent risks are for the various genetic
   diseases, not only cystic fibrosis.  As is so often the problem in
   health care, the most effective means to communicate health care
   information is not used or even known.  Until the problem of
   communication of probability can be worked out, I would like to make
   some suggestions in trying to help those who are provided with
   probability data.  Always record probability values discussed in the
   genetic counseling session.  If dealing with a family physician, the
   information should become a part of the medical history for future
   reference.  When providing documentation of probabilities, always
   include the interpretation of such probabilities through diagrams,
   charts, and other simple means.  Use available pamphlets and
   brochures provided by various organizations such as foundations and
   departments of health.
RF 000   CHECK W               JAMA                           240   819 978
   001   LEONARD CO            N ENGL J MED                   287   433 972
   002   CARTER CO             LANCET                           1   281 971
CT   1   WHITTEN CF            AM J HUM GENET                  33   802 981

PN 78132
RN 00912 
AN 78197203
AU Kulczycki-L-L.  Murphy-T-M.  Bellanti-J-A.
TI Pseudomonas colonization in cystic fibrosis.  A study of 160
   patients.
SO JAMA. 1978 Jul 7. 240(1). P 30-4.
MJ BRONCHI: mi.  CARRIER-STATE: mi.  CYSTIC-FIBROSIS: co.
   PSEUDOMONAS-AERUGINOSA: ip.  PSEUDOMONAS-INFECTIONS: co.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: pd, tu.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: mi.  DISEASE-SUSCEPTIBILITY.
   DRUG-RESISTANCE-MICROBIAL.  FOLLOW-UP-STUDIES.  HUMAN.  INFANT.
   PSEUDOMONAS-AERUGINOSA: de, gd.  PSEUDOMONAS-INFECTIONS: dt.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB We investigated the role of Pseudomonas aeruginosa colonization in
   the respiratory tracts of cystic fibrosis (CF) patients to relate the
   effect of this colonization to progression of bronchial airway
   pathologic conditions and to the patients' clinical progress, and to
   identify predisposing factors to persistence of P aeruginosa
   colonization and bronchial tree damage. Half of 160 CF patients
   studied had persistent P aeruginosa respiratory tract colonization;
   the other half had none. Pseudomonas aeruginosa seems to have an
   exclusive propensity for the respiratory tract and may appear at any
   age. Treatment with antibiotics, including aminoglycosides, failed to
   eradicate P aeruginosa. The continuous use of antibiotics seemed to
   contribute to the persistence of P aeruginosa and the appearance of
   mucoid strains of P aeruginosa.
RF 001   REYNOLDS HY           JAMA                           236  2190 976
   002   ELSTON HR             AM J CLIN PATHOL                48   519 967
   003   HARRISON GM           CF CLUB ABST                    16    42 975
   004   LARAYA-CUASAY LR      J PEDIATR                       89    23 976
   005   GIBSON LE             PEDIATRICS                      23   545 959
   006   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   007   ALTMAN RP             J PEDIATR SURG                   8   809 973
   008   WARING WW             PEDIATRICS                      39   166 967
   009   DOGGETT RG            LANCET                           1   236 971
   010   REYNOLDS HY           ANN INTERN MED                  82   819 975
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   012   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
   013   BELLANTI JA           PROC INT CF CONG 7TH                  20 976
   014   PENNINGTON JE         J INFECT DIS                   131   158 975
   015   MILLIS RM             CHEST                           71   508 977
   016   DI SANTAGNESE PA      AM J DIS CHILD                  72    17 946
   017   HUANG NN              J PEDIATR                       59   512 961
   018   BURNS MW              LANCET                           1   270 968
   019   DOERSHUK CF           IN: MANGOS JA                            976
CT   1   KULCZYCKI LL          MONOGR PAEDIATR                 10    27 979
     2   LOENINGBAUCKE VA      J PEDIATR                       95   630 979
     3   MCCARTHY MM           CLIN PEDIATR                    19   746 980
     4   LAM J                 INFECT IMMUN                    28   546 980
     5   BEAUDRY PH            J PEDIATR                       97   144 980
     6   WIENTZEN R            AM J DIS CHILD                 134  1134 980
     7   BALTIMORE RS          J INFECT DIS                   141   238 980
     8   CARLONE S             MICROBIOLOGICA                   4   215 981
     9   KOEPP LH              CURRENT MICROBIOL                6   383 981
    10   MOSS RB               J PEDIATR                       99   215 981
    11   BAKER NR              CURRENT MICROBIOL                7    35 982
    12   BAKER NR              IN VITRO                        18   369 982
    13   SORDELLI DO           CLIN IMMUNOL IMMUNOPATHOL       22   153 982
    14   BAKER NR              CAN J MICROBIOL                 28   248 982
    15   BALTIMORE RS          HELV PAEDIATR ACTA              37   547 982
    16   BOYCE JR              INFECT IMMUN                    37   695 982
    17   BOYCE JR              INFECT IMMUN                    37   840 982
    18   OHMAN DE              INFECT IMMUN                    37   662 982
    19   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    20   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    21   BODEY GP              REV INFECT DIS                   5   279 983
    22   CROSS A               REV INFECT DIS                   5  S837 983
    23   GOVAN JRW             REV INFECT DIS                   5  S874 983
    24   BALTIMORE RS          PEDIATR RES                     17   952 983
    25   CUKOR G               J CLIN MICROBIOL                18   457 983
    26   BOYD RL               INFECT IMMUN                    39  1403 983
    27   HASTIE AT             INFECT IMMUN                    40   506 983
    28   DORING G              INFECT IMMUN                    42   197 983
    29   PENKETH A             AM REV RESPIR DIS              127   605 983
    30   HACKING AJ            J GEN MICROBIOL                129  3473 983
    31   BOUCHER RC            LUNG                           161     1 983
    32   ADLER KB              JAMA                           249  1615 983
    33   CHAN R                J CLIN MICROBIOL                19     8 984
    34   PENKETH A             THORAX                          39   299 984
    35   BUCKMIRE FLA          MICROBIOS                       41    49 984
    36   KUHN RJ               CLIN PHARMACY                    4   555 985
    37   EFTIMIADI C           DRUGS UNDER EXP CLIN RES        11   241 985
    38   OLIVER AM             J CLIN LAB IMMUNOL              17    85 985
    39   IRVIN RT              CAN J MICROBIOL                 31   268 985
    40   STACK BHR             THORAX                          40   358 985
    41   JACQUOT J             INFECT IMMUN                    47   555 985
    42   MARCUS H              INFECT IMMUN                    47   723 985
    43   SORDELLI DO           INFECT IMMUN                    49   265 985
    44   WINKLER U             KLIN WSCHR                      63   490 985
    45   LINDEMANN RA          J DENT RES                      64    54 985
    46   SORDELLI DO           EUR J RESPIR DIS                67   118 985
    47   TABLAN OC             J PEDIATR                      107   382 985
    48   BROWN J               AM J DIS CHILD                 139   836 985
    49   GOVAN JRW             MICROBIOL SCI                    3   302 986
    50   FRIEND PA             J INFECT                        13    55 986
    51   PADGETT PJ            CURRENT MICROBIOL               14   187 986
    52   PEDERSEN SS           J ANTIMICROB CHEMOTHER          17   505 986
    53   PEDERSEN SS           ACTA PAEDIATR SCAND             75   840 986
    54   ADLER KB              AM J PATHOL                    125   501 986
    55   STUTTS MJ             AM REV RESPIR DIS              134    17 986
    56   LONNQVIST B           J INFECT DIS                   153   175 986
    57   DUNNE WM              DIAGN MICROBIOL INFECT DIS       6   165 987
    58   BOUCHER RC            TOXICOL APPL PHARMACOL          87   264 987
    59   GOLDBERG JB           J BACTERIOL                    169  1349 987

PN 78133
RN 00913 
AN 78174206
AU Stern-R-C.  Boat-T-F.  Abramowsky-C-R.  Matthews-L-W.  Wood-R-E.
   Doershuk-C-F.
TI Intermediate-range sweat chloride concentration and Pseudomonas
   bronchitis.  A cystic fibrosis variant with preservation of exocrine
   pancreatic function.
SO JAMA. 1978 Jun 23. 239(25). P 2676-80.
MJ BRONCHITIS: co.  CHLORIDES: an.  CYSTIC-FIBROSIS: fg.
   PSEUDOMONAS-INFECTIONS: co.  SWEAT: an.
MN ADOLESCENCE.  BRONCHITIS: et.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, di.  DIAGNOSIS-DIFFERENTIAL.  FEMALE.  GENES.
   HUMAN.  MALE.  PEDIGREE.  SUPPORT-U-S-GOVT-P-H-S.
AB We studied the clinical and laboratory characteristics of seven
   patients with sweat chloride concentration consistently between 40
   and 60 mEq/liter. Each has chronic Pseudomonas bronchitis, and all
   lack digestive symptoms. Laboratory findings indicate the
   preservation of exocrine pancreatic function. The patients include
   two of five children in one family and two of four in another. In a
   third family, one of five siblings has an intermediate sweat chloride
   concentration, but another has a typical fibrosis value (105
   mEq/liter). One patient died of respiratory failure; results of an
   autopsy showed bronchiolectasis typical of cystic fibrosis, but
   minimal pancreatic changes. The data suggest a genetic basis for this
   variant of cystic fibrosis. These patients may be homozygous for a
   portion of a closely linked multigene cystic fibrosis locus or may
   have modifier genes that ameliorate the pancreatic and sweat lesions.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   SHWACHMAN H           ADV PEDIATR                      7   249 955
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   WOOD RE               AM REV RESPIR DIS              113   833 976
   005   COGSWELL JJ           ARCH DIS CHILD                  49   520 974
   006   SARSFIELD JK          ARCH DIS CHILD                  50   463 975
   007   OTSUKI M              CLIN CHIM ACTA                  22   439 976
   008   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   009   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   010   LOBECK CC             PEDIATRICS                      30   172 962
   011   SHWACHMAN H           PEDIATRICS                      36   689 965
   012   TAUSSIG LM            PEDIATRICS                      54   229 974
   013   SHWACHMAN H           PEDIATRICS                      55    86 975
   014   DENNING CR            PEDIATRICS                      41     7 968
   015   ANDERSON CM           ARCH DIS CHILD                  35   581 960
   016   GHARIB R              AM J DIS CHILD                 108   499 964
   017   LARAYA-CUASAY LR      J PEDIATR                       89    23 976
   018   KISSMEYER-NIELSEN F   NATURE                         224    75 969
   019   FAGERHOL MK           PROG MED GENET                   7    96 970
   020   GALDSTON M            AM REV RESPIR DIS              107   718 973
CT   1   ANON                  LANCET                           2  1032 978
     2   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
     3   DAVIS PB              AM J MED                        69   643 980
     4   SHWACHMAN H           ARCH DIS CHILD                  56   137 981
     5   COLTEN HR             N ENGL J MED                   304   831 981
     6   STERN RC              LANCET                           1  1401 982
     7   BARBERO GJ            J PEDIATR                      100   914 982
     8   GASKIN K              J PEDIATR                      100   857 982
     9   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    10   GUIDOTTI TL           RESPIRATION                     44   351 983
    11   BLYTHE SA             CLIN BIOCHEM                    17   277 984
    12   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    13   FISHER JH             AM REV RESPIR DIS              132  1149 985
    14   MCCARTHY VP           PEDIATR INFECT DIS               5   256 986
    15   BROWN RF              SOUTH MED J                     79  1430 986
    16   ROSENSTEIN BJ         SOUTH MED J                     79   319 986
    17   FERNALD GW            SEM ROENTGENOL                  22    87 987

PN 78134
RN 00914 
AN 78153979
AU Davis-P-B.  di-SantAgnese-P-A.
TI Assisted ventilation for patients with cystic fibrosis.
SO JAMA. 1978 May 5. 239(18). P 1851-4.
MJ CYSTIC-FIBROSIS: th.  RESPIRATION-ARTIFICIAL.
MN ACUTE-DISEASE.  ADOLESCENCE.  ADULT.  AGE-FACTORS.  CHILD.
   CHILD-PRESCHOOL.  CHRONIC-DISEASE.  COMPARATIVE-STUDY.  HUMAN.
   INFANT.  LUNG-DISEASES-OBSTRUCTIVE: th.  REMISSION-SPONTANEOUS.
   RESPIRATORY-INSUFFICIENCY: th.  TIME-FACTORS.
AB Forty-six patients with cystic fibrosis (CF), 1 month to 32 years of
   age, had 51 episodes of assisted ventilation. Thirty-five (69%) died
   after 1 to 395 days of mechanical ventilation and six others (12%)
   died in the hospital 1 to 42 days after assisted ventilation therapy
   was discontinued. Only three patients survived longer than one year
   after discharge. These results are much poorer than those reported
   for patients with chronic obstructive pulmonary disease of other
   causes probably because of the different natural history and response
   to therapy in CF. Patients with CF whose conditions progressively
   deteriorated despite optimal therapy and no longer respond to
   antibiotic and physical therapy are not good candidates for
   mechanical ventilation. The occasional patient with good baseline
   status in whom acute respiratory failure develops should be
   considered for assisted ventilation.
RF 001   ZWILLICH CW           AM J MED                        57   161 974
   002   PETTY TL              JAMA                           233    34 975
   003   ROGERS RM             CHEST SUPPL                     62    95 972
   004   ODONOHUE WJ           CHEST                           58   603 970
   005   JESSEN O              LANCET                           2     9 967
   006   WEISS EB              ANN INTERN MED                  67   556 967
   007   BRADLEY RD            LANCET                           1   854 964
   008   ANON                  GAP CONF REP PULMONARY COMPLI         10 972
   009   ANON                  GAP CONF REP CHRON BRONC CF           17 977
   010   SHWACHMAN H           N ENGL J MED                   296  1519 977
   011   BIGELOW DB            IN: PETTY TL                         240 974
   012   DI SANTAGNESE PA      IN: DOWNEY JA                         25 974
   013   DAVIS PB              AM REV RESPIR DIS SUPPL        115   278 977
   014   DI SANTAGNESE PA      IN: VAUGHAN VC III                   903 975
   015   ALBERTINI RE          CHEST                           67   134 975
   016   SALISBURY BG          THORAX                          30   441 975
   017   ROGERS RM             N ENGL J MED                   286  1230 972
CT   1   SANTAGNESE PAD        AM J MED                        66   121 979
     2   WOOD RE               SOUTH MED J                     72   189 979
     3   PETTY TL              SEM RESPIR MED                   3   263 982
     4   KNAUS WA              JAMA                           249  1059 983
     5   NUSSBAUM E            CLIN PEDIATR                    24   379 985
     6   SCOGGIN CH            POSTGRAD MED                    77   243 985
     7   MAKE BJ               CLIN CHEST MED                   7   679 986
     8   ODONOHUE WJ           CHEST                           90  S  1 986

PN 78135
RN 00915 
AN 79007746
AU Bonforte-R-J.
TI Variability in cystic fibrosis [letter].
SO JAMA. 1978 Oct 20. 240(17). P 1855.
MJ CYSTIC-FIBROSIS: fg.
MN CYSTIC-FIBROSIS: di.  DIAGNOSIS-DIFFERENTIAL.  HUMAN.
EX All of us who care for patients with cystic fibrosis (CF) are well
   aware of the varying degrees of clinical involvement they have.  It
   has long been known that whereas the most patients have pulmonary
   involvement of one degree or another, approximately 15% to 20% of
   patients will not have any pancreatic involvement.  In the 80% to 85%
   of patients with pancreatic involvement, the degree of involvement
   can vary greatly.  If we can accept the concept of clinical
   heterogeneity for the pulmonary and gastrointestinal systems, there
   is no reason why we should doubt the existence of clinical
   variability for the other major organ system affected by this
   disease, the sweat glands.
RF 000   STERN RC              JAMA                           239  2676 978

PN 78136
RN 00916 
AN 79007795
AU Rosenstein-B-J.  Langbaum-T-S.  Gordes-E.  Brusilow-S-W.
TI Cystic fibrosis.  Problems encountered with sweat testing.
SO JAMA. 1978 Oct 27. 240(18). P 1987-8.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHLORIDES: an.  FALSE-NEGATIVE-REACTIONS.  FALSE-POSITIVE-REACTIONS.
   HUMAN.  IONTOPHORESIS.  PILOCARPINE: du.  SPECIMEN-HANDLING: st.
AB The sweat test is the only practical and reliable laboratory test for
   confirmation of the diagnosis of cystic fibrosis. Among 234 patients
   referred to The Johns Hopkins Hospital for sweat testing, 62 had had
   a previous test; 29 tests had been reported as negative, and 33 tests
   had been reported as positive. Results of quantitative pilocarpine-
   iontophoresis sweat tests at this center led to a change in diagnosis
   in 27 (43.5%) of these 62 patients. Most of the errors were false-
   positive.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   DARLING RC            AM J MED SCI                   225    67 953
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   ANON                  J PEDIATR                       88   711 976
   005   KOPITO L              PEDIATRICS                      43   794 969
   006   SHWACHMAN H           J PEDIATR                       66   432 965
   007   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   008   MACLEAN WC JR         J PEDIATR                       83    86 973
   009   GIBSON LE             CLIN PEDIATR                    12   450 973
   010   BRAY PT               CLIN CHIM ACTA                  80   333 977
   011   WARING WW             ADV PEDIATR                     23   401 976
CT   1   PRIEST JB             JAMA                           242  1970 979
     2   SCHWACHMAN H          J PEDIATR                       98   576 981
     3   WONG LTK              GUT                             23   744 982
     4   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     5   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983
     6   KIRK JM               ANN CLIN BIOCHEM                20   369 983
     7   ORENSTEIN DM          SEM RESPIR MED                   6   252 985
     8   CHRISTOFFEL KS        J PEDIATR                      107   231 985
     9   TAGLE S               REV MED CHIL                   113   758 985
    10   ROSENSTEIN BJ         CLIN PEDIATR                    26    78 987

PN 78137
RN 00917 
AN 79175879
AU Cho-Y-J.  Oh-Y-H.  Abe-C.  Homma-J-Y.  Usui-M.  Matuhasi-T.
TI IgE antibody production to exoenzymes and common antigen (OEP) of
   Pseudomonas aeruginosa in mice.
SO Jpn-J-Exp-Med. 1978 Dec. 48(6). P 491-6.
MJ ANTIBODY-FORMATION.  IGE: bi.  PANCREATOPEPTIDASE: im.
   PEPTIDE-HYDROLASES: im.  PSEUDOMONAS-AERUGINOSA: im.
MN ANIMAL.  ANTIBODIES-BACTERIAL: im.  ANTIGENS-BACTERIAL: im.
   CYSTIC-FIBROSIS: im.  ENDOTOXINS: an.  FEMALE.  HUMAN.  MALE.  MICE.
   PSEUDOMONAS-AERUGINOSA: en.  TOXOIDS: im.
AB IgE antibody production to exoenzymes and common antigen (OEP) of P.
   aeruginosa was studied in mice that were injected with the antigens
   incorporated into water-in-oil-in-water (w/o/w) emulsion or Al(OH)3
   gel. OEP and protease toxoid (PT) elicited IgE antibody response but
   elastase toxoid (ET) did not. Capacity of the OEP to produce IgE
   antibody was reduced remarkably by it's protease treatment, which
   suggested that the capacity lies in the protein portion of OEP. The
   w/o/w emulsion was less effective than Al(OH)3 gel in adjuvanticity
   to elicit IgE antibody response, but the emulsion enhanced the IgM
   and/or IgG antibody response to PT and maintained a constant level
   for a long period. These findings may suggest that IgE antibody
   response to some components of P. aeruginosa could be induced in man.
   High serum level of IgE was observed in some cases of cystic fibrosis
   caused by P. aeruginosa infection, although the IgE antibody activity
   has not yet been determined.
RF 001   SORENSEN RU           INFECT IMMUN                    18   735 977
   002   HOMMA JY              JAPAN J EXP MED                 45   361 975
   003   DANNEMAN PJ           INFECT IMMUN                    14   694 976
   004   MATUHASI T            NATURE NEW BIOL                245   213 973
   005   HOMMA JY              ANIMAL PLANT MICROBIOL TOXINS    1   499 976
   006   ABE C                 JAPAN J EXP MED                 47   393 977
   007   TANAMOTO K            J BIOCHEM (TOKYO)               83   711 978
   008   MORIHARA K            BIOCHIM BIOPHYS ACTA            73   113 963
   009   MORIHARA K            J BIOL CHEM                    240  3295 965
   010   MORIHARA K            AGRIC BIOL CHEM                 39  1123 975
   011   HOMMA JY              JAPAN J EXP MED                 48   111 978
   012   MOTA I                LIFE SCI                         8   813 969
   013   TOMIYAMA T            JAPAN J EXP MED                 43   185 973
   014   KIMURA J              JAPAN J EXP MED                 48   149 978
CT   1   ABE C                 JAP J EXP MED                   51    71 981
     2   PAUWELS R             ALLERGY                         38   239 983
     3   HOMMA JY              J CLIN MICROBIOL                20   855 984

PN 78138
RN 00918 
AN 79155504
AU Araki-H.  Nakamura-K.
TI Effect of sera from cystic fibrosis homozygotes and heterozygotes on
   glucose metabolism in Vero cells.
SO Lancet. 1978 Apr 15. 1(8068). P 793-4.
MJ CYSTIC-FIBROSIS: bl.  GLUCOSE: me.
MN ANIMAL.  CARBON-DIOXIDE.  CELL-LINE.  CYSTIC-FIBROSIS: fg.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  KIDNEY.  ANTHROPOIDEA.
AB The effect on intracellular production of carbon dioxide from glucose
   of sera from cystic fibrosis (C.F.) homozygotes and heterozygotes was
   determined in an established cell line (Vero cell) by a double-blind
   assay. CO2 production was reduced when cells were incubated with an
   ammonium-sulphate-precipitated fraction of sera from C.F. homozygotes
   and heterozygotes but not by a similar fraction from sera of healthy
   donors.
RF 001   BALFE JW              SCIENCE                        162   689 968
   002   MANGOS JA             PEDIATR RES                      2   378 968
   003   SPOCK A               PEDIATR RES                      1   173 967
   004   LAPEY A               PEDIATR RES                      5   446 971
   005   FEIG SA               PEDIATR RES                      8   594 974
   006   FITZPATRICK DF        NATURE NEW BIOL                235   173 972
   007   DUFFY MJ              NATURE NEW BIOL                246   151 973
   008   ARAKI H               PEDIATR RES                      9   932 975
   009   YASUMURA T            NIPPON RINSHO                   21  1201 963
   010   WARSHAW JB            CELL BIOL                       52   283 972
   011   GOLDNER AM            J GEN PHYSIOL                   53   362 969
   012   ARAKI H               PROC INT CF CONG 7TH                  28 976
   013$  BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      14   253 975
   014   DANES BS              J EXP MED                      137  1538 973
CT   1   NAKAMURA K            J NATL CANCER INST              77  1035 986

PN 78139
RN 00919 
AN 78245770
AU Dodge-J-A.  Hamdi-I.
TI Abnormal levels of prostaglandins and fatty acids in cystic fibrosis
   [letter].
SO Lancet. 1978 Aug 26. 2(8087). P 475.
MJ CYSTIC-FIBROSIS: me.  LINOLEIC-ACIDS: df.  PROSTAGLANDINS-E: bi.
   PROSTAGLANDINS-F: bi.
MN HUMAN.
EX Like Dr Chase and Dr Dupont we have found essential fatty-acid
   deficiency, usually subclinical, in cystic fibrosis patients.
   However, we feel that their data on prostaglandin synthesis may have
   other interpretations.  In patients with deficiency of linoleic
   acid, oleic acid is used an alternative substrate; and instead of
   dihomogammalinoleic acid, an alternative 20:3 fatty acid is produced.
   We have found increased amounts of this substance in the plasma of
   patients with cystic fibrosis.  We agree with the authors' conclusion
   that levels of linoleic acid are specifically related to P.G.
   production in children with cystic fibrosis.  It remains to be shown
   whether children with cystic fibrosis have a primary abnormality of
   fatty-acid metabolism or whether the observed disturbances of
   prostaglandin metabolism are secondary to malabsorption of dietary
   essential fatty acids.  In either case, certain clinical features of
   the disease may well be explained by prostaglandin disturbances.
RF 000   CHASE HP              LANCET                           2   236 978
   001   YASSA JG              PROC INT CF CONG 7TH                 323 976
   002   ROBINSON PG           PROC INT CF CONG 7TH                 107 976
   003   VAN EVERT WE          PROSTAGLANDINS                  15   268 978
   004   LEMEN RJ              AM REV RESPIR DIS              117   639 978
CT   1   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986

PN 78140
RN 00920 
AN 78245706
AU Smalley-C-A.  Addy-D-P.  Anderson-C-M.
TI Does that child really have cystic fibrosis?.
SO Lancet. 1978 Aug 19. 2(8086). P 415-7.
MJ CYSTIC-FIBROSIS: di.
MN AMYLASES: an.  BICARBONATES: an.  CHILD.  CHILD-PRESCHOOL.
   CHLORIDES: an.  CHOLECYSTOKININ: du.  EVALUATION-STUDIES.
   FALSE-POSITIVE-REACTIONS.  HUMAN.  LIPASE: an.  PANCREAS: pp.
   SECRETIN: du.  SODIUM: an.  SWEAT: an.  TRYPSIN: an.
AB A diagnosis of cystic fibrosis was incorrectly made after false-
   positive sweat tests in 14 children. 13 of these children had been
   tested at hospitals where it seems likely that sweat tests were not
   done very often. All the children had normal sweat-electrolyte values
   when the test was repeated at a regional paediatric centre where
   approximately 250 sweat tests are done each year. In 5 cases,
   detailed testing of pancreatic function was normal. None of the
   children had typical chest disease and only 2 had gastrointestinal
   symptoms. In the absence of the typical clinical features of the
   disease a diagnosis of cystic fibrosis should be made with extreme
   caution and only after meticulous testing of both sweat electrolytes
   and pancreatic function.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   SCHWARZ V             IN: DAVIS JA                         545 974
   003   GIBSON LE             J PEDIATR                       81   193 972
   004   SCHWARZ V             ARCH DIS CHILD                  52   870 977
   005   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   006   ANON                  J PEDIATR                       88   711 976
   007   GIBSON LE             PEDIATRICS                      23   545 959
   008   SCHALES O             J BIOL CHEM                    140   879 941
   009   HADORN B              J PEDIATR                       73    39 968
   010   SCHWERT GW            J BIOL CHEM                    172   221 948
   011   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   012   HADORN B              CAN MED ASSOC J                 98   377 968
   013   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
CT   1   ANON                  LANCET                           2  1032 978
     2   STAGG BH              ANN CLIN BIOCHEM                16   147 979
     3   DANDONA P             THORAX                          36    60 981
     4   ANON                  LANCET                           2  1196 982
     5   DAVID TJ              LANCET                           2  1204 982
     6   GASKIN KJ             PEDIATR RES                     16   554 982
     7   WONG LTK              GUT                             23   744 982
     8   BROWN RC              J CLIN PATHOL                   35   547 982
     9   HEELEY AF             CLIN CHEM                       29  2011 983
    10   LITTLEWOOD JM         BR MED J                       287   501 983
    11   CARTER EP             ARCH DIS CHILD                  59   919 984
    12   PERINI JM             BULL EUR PHYSIOPATH RESP        21   569 985
    13   GREEN A               ANN CLIN BIOCHEM                22   171 985
    14   CUMMING JGR           ARCH DIS CHILD                  61   573 986
    15   LITTLEWOOD JM         ARCH DIS CHILD                  61  1041 986
    16   DAVIDSON GP           ACTA PAEDIATR SCAND             75   145 986
    17   ROSENSTEIN BJ         CLIN PEDIATR                    26    78 987

PN 78141
RN 00921 
AN 78245699
AU Dann-L-G.  Blau-K.
TI Exocrine-gland function and the basic biochemical defect in cystic
   fibrosis.
SO Lancet. 1978 Aug 19. 2(8086). P 405-7.
MJ CYSTIC-FIBROSIS: et.  SALIVARY-GLANDS: me.
MN ABSORPTION.  ARGININE.  CALCIUM: me.  CELL-MEMBRANE: me.
   CHLORINE: me.  CYSTIC-FIBROSIS: en, me.  ESTERASES: df.  HUMAN.
   KININS: bi.  MODELS-BIOLOGICAL.  SALIVARY-GLANDS: pa, se.  SODIUM: me.
AB A biochemical link is proposed between secretion and reabsorption in
   exocrine glands, in the form of a factor (kinin E) which initiates
   ion reabsorption. Activation of this factor involves arginine
   esterases, and in cystic fibrosis these may be defective, preventing
   the formation of kinin E. In cystic fibrosis stimulation of exocrine
   glands produces abnormal reabsorption of ions, leading to the
   physiological abnormalities and clinical manifestations of the
   disease.
RF 001   PETERSEN OH           PHIL TRANS R SOC LOND BIOL     262   307 971
   002   GARRETT JR            ARCH ORAL BIOL                  12  1417 967
   003   FOX RH                J PHYSIOL (LOND)               142  2119 958
   004   ULLRICH KJ            IN: THORN NA                         423 974
   005   MANGOS JA             AM J PHYSIOL                   224  1235 973
   006   SUTCLIFFE CH          PROC R SOC MED                  61   297 968
   007   MANGOS JA             IN: MANGOS JA                        311 976
   008   RAO GJS               SCIENCE                        177   610 972
   009   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   010   COBURN MD             AM REV RESPIR DIS              110   368 974
   011   RAO GJS               PEDIATR RES                      8   684 974
   012   RAO GJS               PEDIATR RES                      9   739 975
   013   NUSTAD K              GEN PHARMAC                      9     1 978
   014   FRAKI JE              ACTA DERM VENEREOL (STOCKH)     50   321 970
   015   BEILENSON S           J PHYSIOL (LOND)               199   303 968
   016   GARRETT JR            IN: THORN NA                         487 974
   017$  FINK E                ANAL CHEM                      290   183 978
   018   BOWMAN BH             CLIN GENET                      12   333 977
   019   MANGOS JA             SCIENCE                        158   135 967
   020   MANGOS JA             PEDIATR RES                      2   378 968
   021   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   022   MARTINEZ JR           PEDIATR RES                      9   470 975
   023   WHITELAW A            LANCET                           2  1288 977
   024   POTTER JL             ANN NY ACAD SCI                106   692 963
   025   GUGLER EC             J PEDIATR                       71   585 967
CT   1   BROCK DJH             LANCET                           1  1245 979
     2   DANN LG               LANCET                           2   907 979
     3   WILSON GB             PEDIATR RES                     13  1079 979
     4   TARNOKY AL            J ROY SOC MED                   73    73 980
     5   DUFFY MJ              CLIN CHIM ACTA                 103   233 980
     6   STEGMAYR B            ULTRASTRUCTURAL PATHOL           2   357 981
     7   HALLINAN F            MED HYPOTHESES                   7   793 981
     8   BURY AF               PEDIATR RES                     16   613 982
     9   GREEN JR              EUR J PEDIATR                  139    35 982
    10   HEELEY AF             CLIN CHEM                       29  2011 983
    11   HARE ER               PEDIATR RES                     19   938 985
    12   RUPP GM               MED HYPOTHESES                  20   245 986

PN 78142
RN 00922 
AN 78112941
AU Kilbourn-J-P.
TI Bacterial content and ionic composition of sputum in cystic fibrosis
   [letter].
SO Lancet. 1978 Feb 11. 1(8059). P 334.
MJ BACTERIA.  CYSTIC-FIBROSIS.  ELECTROLYTES.  SPUTUM.
MN BACTERIA: ip.  CALCIUM: an.  CANDIDA-ALBICANS: ip.
   CYSTIC-FIBROSIS: mi.  ELECTROLYTES: an.  HUMAN.  POTASSIUM: an.
   SODIUM: an.  SPUTUM: an, mi.
EX Burns and May proposed the following pattern for the bacteriology of
   cystic fibrosis: (1) Staphylococcus aureus is the initial bacterial
   pathogen, and damage caused by it renders the lungs susceptible to
   infection by other species.  (2) Control of S. aureus by antibiotics
   allows the influx of Haemophilus influenzae.  (3) Pseudomonas
   aeruginosa is introduced and continued chemotherapy encourages its
   establishment.  (4) P. aeruginosa supplants S. aureus and H.
   influenzae, becoming the sole pathogen.  I have examined these ideas
   by quantitative culture of sputum from 20 patients seen at the Cystic
   Fibrosis Treatment and Research Center, University of Oregon Health
   Sciences Center from 1965 to 1977.  The results accord with the
   original hypothesis of Burns and May.  In 13 of 20 patients the
   sputum bacterial flora changed as the hypothesis of Burns and May
   predicted.  This preliminary data suggests that one of the primary
   sputum abnormalities in cystic fibrosis may be increased Ca++ which
   makes the sputum susceptible to colonisation by S. aureus.  After
   infection the Ca++ concentration is reduced and the lung becomes
   susceptible to colonisation by other microorganisms including H.
   influenzae, P. aeruginosa, and Escherichia coli.
RF 001   BURNS MW              LANCET                           1   270 958
   002   MAY JR                ARCH DIS CHILD                  47   908 972
   003   KILBOURN JP           AM REV RESPIR DIS               98   810 968
   004   KILBOURN JP           LANCET                           2   878 970
   005   KILBOURN JP           LANCET                           1   405 974
   006   MATTHEWS LW           AM REV RESPIR DIS               88   199 963
   007   POTTER JL             AM REV RESPIR DIS               96    83 967
   008   POTTER JL             ANN NY ACAD SCI                106   692 963
   009   CHERNICK WS           PEDIATRICS                      24   739 959
CT   1   BOYCE JR              LANCET                           2   268 980
     2   KILBOURN JP           PEDIATR RES                     14   259 980
     3   LINKE HAB             MICROBIOS                       27   107 980
     4   BOYCE JR              INFECT IMMUN                    37   695 982
     5   BOYCE JR              INFECT IMMUN                    37   840 982
     6   PIER GB               J INFECT DIS                   147   494 983
     7   KILBOURN JP           CURRENT MICROBIOL               11    19 984
     8   MULLER RM             SCANN ELECTRON MICROSC        1985  1583 985

PN 78143
RN 00923 
AN 78091015
AU Sparham-P-D.  Lobban-D-I.  Speller-D-C.
TI Thymidine-requiring Staphylococcus aureus [letter].
SO Lancet. 1978 Jan 14. 1(8055). P 104-5.
MJ STAPHYLOCOCCUS-AUREUS: gd.  THYMIDINE.
MN CYSTIC-FIBROSIS: mi.  DRUG-RESISTANCE-MICROBIAL.  HUMAN.
   TRIMETHOPRIM: ad.
EX We confirm that thymidine-requiring (thy-) Staphylococcus aureus
   strains are common in patients with cystic fibrosis.  In 7 months, we
   isolated Staph. aureus from 11 of 14 patients with C.F.  Despite
   long-term co-trimoxazole Staph. aureus tends to persist in the sputum
   even though isolates do not require thymidine at first and are
   trimethoprim-sensitive in vitro.  Staph. aureus is less commonly
   isolated, and of less significance, in most other chest conditions
   for which co-trimoxazole is given.  These factors may explain why
   thy- staphylococci are recognised more frequently in C.F. than in
   other diseases.
RF 000   GEORGE RH             LANCET                           2  1081 977
   002   WILLIAMS RF           PROC EWGCF 6TH ANNU MTG                4 975
CT   1   WILLIAMS RF           CURR MED RES OPIN                6    43 979
     2   STURM AW              ANT V LEEUW J MICROBIOL SEROL   47    92 981
     3   LACEY RW              J MED MICROBIOL                 15   403 982
     4   KING CH               J CLIN MICROBIOL                18    79 983

PN 78144
RN 00924 
AN 78222230
AU Chase-H-P.  Dupont-J.
TI Abnormal levels of prostaglandins and fatty acids in blood of
   children with cystic fibrosis.
SO Lancet. 1978 Jul 29. 2(8083). P 236-8.
MJ CYSTIC-FIBROSIS: bl.  LINOLEIC-ACIDS: bl.  PROSTAGLANDINS-E: bl.
   PROSTAGLANDINS-F: bl.
MN CHILD.  CLINICAL-TRIALS.  CYSTIC-FIBROSIS: dt, pp.  FEMALE.  HUMAN.
   LINOLEIC-ACIDS: pd, tu.  MALE.  PROSTAGLANDINS-E: bi.
   PROSTAGLANDINS-F: bi.  STIMULATION-CHEMICAL.
AB 12 children with cystic fibrosis (C.F.) had lower levels of the
   essential fatty acid, linoleic acid, in plasma and in red blood
   cells, than did control children, and production of prostaglandin
   F2alpha (P.G.F2alpha) was higher than in controls. After 10 months of
   oral linoleic-acid supplementation in 6 of the children with C.F.,
   the linoleic-acid levels in plasma, red cells, and platelets were
   higher and P.G.F2alpha production was lower than in the 6 children
   with C.F. who received a placebo lipid. Prostaglandin F2alpha is
   associated with bronchoconstriction and its increased production in
   children with C.F. might be causally related to their chronic
   pulmonary disease.
RF 001   KUO PT                J PEDIATR                       60   394 962
   002   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   003   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   004   RIVERS JPW            LANCET                           2   642 975
   005   HUBBARD VS            LANCET                           2  1302 977
   006   ELLIOTT RB            PEDIATRICS                      57   474 976
   007   SILVER MJ             J PROSTAGLANDINS                 1   429 972
   009   PASARGIKLIAN M        IN: SAMUELSSON B                 1   461 976
   010   NELSON GJ             IN: NELSON GJ                         10 972
   012   MCCOSH FJ             J PROSTAGLANDINS                12   471 976
   013   DUPONT J              FED PROC                        37   445 978
   014   PACE-ASCIAK C         BIOCHIM BIOPHYS ACTA           152   784 968
CT   1   HORROBIN DF           MED HYPOTHESES                   5   599 979
     2   HORROBIN DF           MED HYPOTHESES                   5   365 979
     3   CHASE HP              PEDIATRICS                      64   207 979
     4   CHASE HP              J PEDIATR                       95   337 979
     5   HORROBIN DF           MED HYPOTHESES                   6   277 980
     6   GALEY WR              PEDIATR RES                     14  1269 980
     7   CHASE HP              METABOLISM                      29   365 980
     8   HUBBARD VS            J PEDIATR                       96   421 980
     9   SHEPHERD R            J PEDIATR                       97   351 980
    10   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
    11   ROGIERS V             CLIN CHIM ACTA                 105   105 980
    12   OLLEY PM              AM J DIS CHILD                 134   688 980
    13   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
    14   RIVERS JPW            BR MED BULL                     37    59 981
    15   PARK RW               GASTROENTEROLOGY                81  1143 981
    16   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
    17   ALLING C              EUR J PEDIATR                  137   197 981
    18   CHASE HP              J PEDIATR GASTROENTEROL NUTR     1    49 982
    19   LEVI N                RIV ITAL PEDIATR                 8   695 982
    20   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    21   ROGIERS V             PEDIATR RES                     16   761 982
    22   HARPER TB             AM REV RESPIR DIS              126   540 982
    23   HUBBARD VS            EUR J PEDIATR                  141    68 983
    24   ROGIERS V             EUR J PEDIATR                  141    39 983
    25   HUANG YS              PROSTAGLANDINS LEUKOTR MED      15   223 984
    26   ROGIERS V             PEDIATR RES                     18   704 984
    27   HORROBIN DF           BIOMED BIOCHIM ACTA             43  S114 984
    28   MANSELL AL            J PEDIATR                      104   700 984
    29   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    30   HUBBARD VS            SEM RESPIR MED                   6   308 985
    31   FARRELL PM            PEDIATR RES                     19   104 985
    32   CHRISTOPHE A          ANN NUTR METAB                  29   239 985
    33   MAAK B                Z KLIN MED                      40  1115 985
    34   WILSON DO             AM REV RESPIR DIS              132  1347 985
    35   GALLAND L             J AM COLL NUTR                   5   213 986
    36   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    37   MISCHLER EH           PEDIATR RES                     20    36 986
    38   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    39   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986
    40   CARLSTEDTDUKE J       PROC NAT ACAD SCI USA           83  9202 986
    41   DUPONT J              N ENGL J MED                   314   718 986
    42   HARE WR               BIOCHEM SOC TRANS               15   497 987
    43   HUBBARD VS            LIPIDS                          22   424 987
    44   STEAD RJ              PROSTAGLANDINS LEUKOTR MED      26    91 987
    45   YOUNGBERG  CA         DIG DIS SCI                     32   472 987

PN 78145
RN 00925 
AN 78155356
AU Lieberman-J.
TI Lectins and cystic fibrosis [letter].
SO Lancet. 1978 May 6. 1(8071). P 985-6.
MJ CONCANAVALIN-A.  CYSTIC-FIBROSIS: pp.
MN ANIMAL.  CYSTIC-FIBROSIS: et.  EXOCRINE-GLANDS: se.  HUMAN.
   MUCUS: se.  RATS.
EX Dr Freed and Dr Buckley have shown that a lectin, concanavalin A (Con
   A), causes severe rhinitis, sinusitis, and increased mucus secretion
   when inhaled by man or small-intestinal colic, foul-smelling flatus,
   and mucus-coated stools if ingested.  It is somewhat surprising that
   the authors suggest that a suitable inhaled or ingested lectin may be
   useful in treating patients with cystic fibrosis, since the very
   symptoms produced by the ingested lectin resemble those associated
   with the disease.  A more attractive recommendation would be for
   patients with cystic fibrosis to avoid substances containing lectins
   such as Con A to avoid stimulating additional mucus release.  The
   underlying pathogenetic defect in cystic fibrosis may be
   inappropriate, excessive stimuli by lectin-like substances.  These
   observations suggest that the increase in the protein content of
   lymphocytes is stimulated by a plasma factor present in patients with
   cystic fibrosis and in carriers of the cystic fibrosis gene.  These
   observations, plus those of Freed and Buckley, might suggest that
   cystic fibrosis is a disease involving a plasma factor with lectin or
   Con A-like activity which stimulates the secretion of mucus and
   increases the enzyme content of circulating or cultured lymphocytes.
   - Professor Lieberman confuses cause with effect.  If there is
   excessive mucus production in cystic fibrosis we suggest that this is
   because the secretion is so difficult to remove from the mucosal
   surface.  Goblet cells and mucus glands become clogged with
   hyperviscid mucus which, not being removed, stimulates further mucus
   production.  To deprive the patient of the mucotractive value of his
   dietary lectins would be a therapeutic mischief equivalent to
   prescribing a cough-suppresant for a productive cough.
RF 000   FREED DLJ             LANCET                           1   585 978
   001   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   002   LIEBERMAN J           AM REV RESPIR DIS              116  1047 977
CT   1   LIEBERMAN J           J LAB CLIN MED                  97   646 981

PN 78146
RN 00926 
AN 79052016
TI Cystic-fibrosis variants--or variations?  [editorial].
SO Lancet. 1978 Nov 11. 2(8098). P 1032-3.
MJ CYSTIC-FIBROSIS: di.
MN BRONCHITIS: di.  CHLORIDES: an.  CHRONIC-DISEASE.
   DIAGNOSIS-DIFFERENTIAL.  HUMAN.  PANCREAS: pp.
   PSEUDOMONAS-INFECTIONS: di.  STAPHYLOCOCCAL-INFECTIONS: di.
   SWEAT: an.
EX Cystic fibrosis is inherited by single autosomal transmission.  That,
   at least, is the general view; but from time to time other
   suggestions are offered.  Stern et al. describe what they believe may
   be a genetic variant.  The affected patients, they suggest, are
   homozygous for a portion of a closely linked multigenic cystic
   fibrosis locus, or have modifier genes ameliorating the pancreatic
   and sweat lesions.  Do these patients really have CF?  And, if so,
   are Stern et al. justified in suggesting that they differ genetically
   from the "classic" CF patient?  This hypothesis may not be correct
   but, until we understand the basic fundamental defect, it may be
   unwise to divide CF into different genetic types on the basis of
   clinical variations.
RF 001   DANKS DM              ANN HUM GENET                   28   323 965
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   DANES BS              J EXP MED                      129   775 969
   004   STERN RC              JAMA                           239  2676 978
   005   HADORN B              CAN MED ASSOC J                 98   377 968
   006   ZOPPI G               ACTA PAEDIATR SCAND             59   692 970
   007   ANON                  J PEDIATR                       88   711 976
   008   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   009   SCHWARZ V             ARCH DIS CHILD                  52   870 977
   010   SMALLEY CA            LANCET                           2   415 978
   011   MANGOS JA             CF PROJECTIONS INTO THE FUTUR            976
   012   HIRSCHHORN K          IN: MANGOS JA                        305 976
   013   CONOVER JH            LIFE SCI                        14   253 974
CT   1   DAVIS PB              AM J MED                        69   643 980
     2   TARNOKY AL            J ROY SOC MED                   73    73 980

PN 78147
RN 00927 
AN 79052040
AU Kibel-M-A.
TI Sweat tests in cystic fibrosis [letter].
SO Lancet. 1978 Nov 11. 2(8098). P 1050.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHILD.  CHLORIDES: an.  ECZEMA: di.  FALSE-POSITIVE-REACTIONS.
   HUMAN.  SODIUM: an.
EX Dr Smalley and her colleagues rightly stress that the commonest
   reason for abnormally high sweat-electrolyte levels, apart from
   cystic fibrosis, is faulty technique.  A further cause of
   false-positive results, and potentially more important than the list
   of rare disorders usually cited, is atopic dermatitis.  Dr M. Ampola
   and I investigated ten children with eczema at the Tufts New England
   Medical Center, Boston, and found higher sodium and/or chloride
   levels in sweat obtained from affected skin than in sweat from normal
   skin in the same individuals.  In four of these atopic children,
   levels within the diagnostic range for cystic fibrosis were obtained
   (above 60 mmol/l).
RF 000   SMALLEY CA            LANCET                           2   415 978
   001   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   002   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   003   ANON                  J PEDIATR                       88   711 976
CT   1   DAVID TJ              LANCET                           2  1204 982
     2   RUDDY RM              CLIN PEDIATR                    26    83 987

PN 78148
RN 00928 
AN 79031281
AU Galabert-C.  Filliat-M.  Chazalette-J-P.
TI Fatty-acid composition of serum-lecithins in cystic-fibrosis
   patients without steatorrhoea [letter].
SO Lancet. 1978 Oct 21. 2(8095). P 903.
MJ CYSTIC-FIBROSIS: me.  FATTY-ACIDS-UNSATURATED: an.
   PHOSPHATIDYLCHOLINES: bl.
MN HUMAN.  PANCREAS: me.
EX We have investigated the fatty-acid composition of serum-lecithins
   from four groups of C.F. patients, defined by their pancreatic
   function evaluated by 72-h quantitative stool fat and determination
   of the coefficient of fat absorption.  C.F. patients without
   pancreatic insufficiency and not on pancreatic extract had
   significantly higher percentages of linoleic acid than did patients
   of any other group.  The altered fatty-acid composition of
   serum-lipid fractions seems to be a secondary consequence of the
   pancreatic insufficiency commonly associated with C.F. disease and
   not a direct metabolic defect as some have suggested.
RF 001   HUBBARD VS            LANCET                           2  1302 977
   002   KUO PT                J PEDIATR                       60   394 962
   003   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   004   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   005   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
CT   1   ROGIERS V             CLIN CHIM ACTA                 105   105 980
     2   ROGIERS V             PEDIATR RES                     16   761 982
     3   HARPER TB             AM REV RESPIR DIS              126   540 982
     4   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983
     5   HUBBARD VS            EUR J PEDIATR                  141    68 983
     6   ROGIERS V             EUR J PEDIATR                  141    39 983
     7   ROGIERS V             PEDIATR RES                     18   704 984
     8   FARRELL PM            PEDIATR RES                     19   104 985
     9   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986
    10   STEAD RJ              PROSTAGLANDINS LEUKOTR MED      26    91 987

PN 78149
RN 00929 
AN 79071612
AU Ellam-S-V.
TI Improvement on the safety of sweat-test equipment.
SO Med-Biol-Eng-Comput. 1978 Sep. 16(5). P 595-6.
MJ ACCIDENT-PREVENTION.  IONTOPHORESIS: is.  SAFETY.  SWEAT: an.
MN BURNS-ELECTRIC: pc.  CYSTIC-FIBROSIS: me.  HUMAN.
EX Patients with cystic fibrosis have a higher concentration of sodium
   and chloride in their sweat than normals.  This observation led to
   the introduction of an iontophoresis technique for stimulating the
   sweat glands with pilocarpine.  Occasionally, electrical burns result
   from defective equipment or from an incorrect or badly applied test
   procedure.  A new design of equipment is presented which eliminates
   the possibility of a burn during the test.
RF 001   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   SCHWARZ V             ARCH DIS CHILD                  43   695 968

PN 78150
RN 00930 
AN 79052693
AU Elliott-R-B.
TI Cystic fibrosis screening in the newborn [editorial].
SO Med-J-Aust. 1978 Jul 29. 2(3). P 95.
MJ CYSTIC-FIBROSIS: pc.  MASS-SCREENING: mt.
MN HUMAN.  INFANT-NEWBORN.
EX Many attempts have been made to establish a suitable screening test
   for cystic fibrosis for newborns.  Recently, a new method has been
   described by Crossley and her associates.  It is based on measuring
   pancreatic trypsin in a sample of faeces collected on to filter paper
   on the 4th or 5th day of life.  The false-negative rate of the new
   test has not yet been determined, but older children with CF and
   pancreatic achylia all gave abnormal results when tested.  The
   disadvantage of the test, as with the meconium albumin test, is that
   about 10% of children with CF are said not to have pancreatic
   achylia.  Whilst the method needs more extensive evaluation, it
   appears technically more satisfactory than others so far described.
RF 001   ELLIOTT RB            REC ADELAIDE CHILD HOSP          1   359 977
   002   PROSSER R             ARCH DIS CHILD                  49   597 974
   003   CROSSLEY JR           LANCET                           2  1093 977

PN 78151
RN 00931 
AN 79072550
AU Moses-R-G.  Bowen-T.  Edwards-R.
TI Cystic fibrosis and fast moving haemoglobin [letter].
SO Med-J-Aust. 1978 Aug 12. 2(4). P 160-1.
MJ CYSTIC-FIBROSIS: bl.  HEMOGLOBINS: an.
MN CHILD.  CHILD-PRESCHOOL.  HUMAN.  INFANT.
EX We have measured fast moving components of haemoglobin (FMH) in nine
   children with cystic fibrosis without any clinical evidence of
   diabetes mellitus.  The nine patients with cystic fibrosis had a mean
   FMH of 9.3 which differed significantly from 97 controls with a mean
   FMH of 7.6.  There was no correlation between FMH and age or FMH and
   duration of disease.  The above results raise the question as to what
   extent the FMH is a reflection of hyperglycaemia or insulinopenia.
RF 001   PAULSEN EP            DIABETES                        25   890 976
   002   KOENIG RJ             N ENGL J MED                   295   417 976
   003   MILNER AD             ARCH DIS CHILD                  44   351 969

PN 78152
RN 00932 
AN 78113434
AU Holzel-A.
TI Malabsorption.
SO Midwife-Health-Visit-Community-Nurse. 1978 Mar. 14(3). P 79-81.
MJ MALABSORPTION-SYNDROMES: pp.
MN CELIAC-DISEASE: pp.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pp.
   DIETARY-CARBOHYDRATES.  HUMAN.  INFANT.  LACTOSE-INTOLERANCE: pp.
   SUCROSE.
EX Malabsorption in infancy and childhood can roughly be defined as a
   condition of inadequate growth in spite of seemingly adequate
   nutrition and is accompanied by excessive excretion of food
   components in the stools.  Acquired lactase deficiency, the
   introduction of sugar in the diet, coeliac disease, and cystic
   fibrosis are discussed.

PN 78153
RN 00933 
AN 79093734
AU Watts-R-W.
TI Recent advances in screening for inborn errors of metabolism.
SO Monogr-Hum-Genet. 1978. 9. P 204-11.
MJ METABOLISM-INBORN-ERRORS: di.
MN ANEMIA-SICKLE-CELL: oc.  CRETINISM: oc.  CYSTIC-FIBROSIS: oc.
   HETEROZYGOTE-DETECTION.  HUMAN.  METABOLISM-INBORN-ERRORS: fg.
   PHENYLKETONURIA: oc.  TAY-SACHS-DISEASE: oc.
EX A screening test is any diagnostic procedure which we apply without
   a specific clinical indication from the point of view of the
   individual patient concerned.  Non-selective (whole population)
   screening for inborn errors of metabolism, selective screening for
   inborn errors of metabolism, screening for nonamino organic
   acidurias, and selective screening for inborn errors of metabolism
   because of genetic indications are discussed.  The main points which
   emerge for the future from this review are the need to develop
   multidisease screening programmes to detect the very rare diseases;
   that postnatal, prenatal and carrier screening should be considered
   and developed collectively; and there us an urgent needs to develop
   screening for thallasaemia, sickle cell disease, cystic fibrosis and
   congenital hypothyroidism.
RF 001   BROWN E               METABOLISM                      26  1047 977
   002   CHALMERS RA           CLIN CHEM                       22  1292 976
   003   CHALMERS RA           CLIN CHEM                       22  1288 976
   004   CHALMERS RA           ANN CLIN BIOCHEM                14   149 977
   005   CHILDS B              AM J HUM GENET                  28   537 976
   006   CHILDS B              AM J HUM GENET                  28   550 976
   007   EVANS PR              IN: RAINE DN                          93 977
   008   FISHER DA             J PEDIATR                       89   692 976
   009   GIBBS DA              ANN CLIN BIOCHEM                14   157 977
   011   KABACK MM             HUM HERED                       27   186 977
   012   KABACK MM             PROG MED GENET                  10   103 974
   013   KAN YW                LANCET                           1   269 977
   014   KOMROWER GM           PEDIATRICS                      53   182 974
   015   LAWSON AM             CLIN CHEM                       22  1283 976
   016   NATHAN DG             BR J HAEMATOL SUPPL             31   143 975
   017   PADEH B               HUM HERED                       27   200 977
   018   PURKISS P             PROC INT SYMP GLYCOCON 3RD            19 975
   019   SEEGMILLER JE         IN: NATELSON S                       291 974
   020   WATTS RWE             LANCET                           1   368 975
CT   1   HAIDER M              CLIN BIOCHEM CONTEM THEO TECH    2   145 982

PN 78154
RN 00934 
AN 79032102
AU Gordeuk-V.  Keeports-R.  Rexrode-W.
TI Cystic fibrosis in adults [letter].
SO N-Engl-J-Med. 1978 Nov 16. 299(20). P 1137.
MJ CYSTIC-FIBROSIS: oc.
MN ADULT.  AGE-FACTORS.  CASE-REPORT.  CYSTIC-FIBROSIS: di.  FEMALE.
   HUMAN.
EX Long considered a childhood disease, cystic fibrosis has been
   recognized with increasing frequency in adults.  In the case reported
   below the diagnosis was made in an adult.  The initial diagnosis of
   cystic fibrosis in patients over 30 years of age has rarely been
   reported.  Our patient, in whom the diagnosis of cystic fibrosis was
   first made at 48 years if age, serves to emphasize the point that
   physicians should consider cystic fibrosis in the differential
   diagnosis of adults with unexplained chronic obstructive lung
   disease.
RF 001   WARWICK WJ            JAMA                           238  2159 977
   002   SHWACHMAN H           N ENGL J MED                   296  1519 977
   003   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
CT   1   DAVIDSON AGF          N ENGL J MED                   300  1164 979

PN 78155
RN 00935 
AN 79053053
AU Bennion-L-J.  Grundy-S-M.
TI Risk factors for the development of cholelithiasis in man (second of
   two parts).
SO N-Engl-J-Med. 1978 Nov 30. 299(22). P 1221-7. (REVIEW).
MJ CHOLELITHIASIS: et.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  ANEMIA-HEMOLYTIC: co.  BILE: mi.
   CHOLELITHIASIS: ci, fg, oc.  CLOFIBRATE: ae.  CONTRACEPTIVES-ORAL: ae.
   CYSTIC-FIBROSIS: co.  DIET: ae.  ESTROGENS: ae.  FEMALE.
   GASTROINTESTINAL-DISEASES: co.  HUMAN.  INFECTION: co.
   LIVER-CIRRHOSIS-ALCOHOLIC: co.  MALE.  OBESITY: co.  PREGNANCY.
   REVIEW.  RISK.
EX The demographic characteristics of persons at high risk for pigment
   gallstones differ from those is whom cholesterol stones are likely to
   develop.  Conditions associated with pigment gallstones include
   hemolytic anemia, alcoholic cirrhosis, and infected bile.  Conditions
   associated with cholesterol gallstones include obesity, diet,
   blood-cholesterol-lowering drugs, disorders of the gastrointestinal
   tract, female sex hormones, and genetic and ethnic influences.
   Problem areas such as case finding and common disorders and pregnancy
   are discussed, along with clinical implications (diagnosis,
   prevention, and therapy).
RF 049   SAMPLINER RE          N ENGL J MED                   283  1358 970
   050   SIEVERS ML            JAMA                           182   570 962
   051   THISTLE JL            MAYO CLIN PROC                  46   603 971
   052   SUTOR DJ              GUT                             12    55 971
   053   GROSS DMB             J PATHOL BACTERIOL              32   503 929
   054   TROTMAN BW            AM J DIG DIS                    20   735 975
   055   MARINOVIC J           REV MED CHIL                   100  1320 972
   056   MIYAKE H              DIGESTION                        1   219 968
   057   YAGI T                TOHOKU J EXP MED                72   117 960
   058   NAKAYAMA F            AM J SURG                      120   794 970
   059   KAMEDA H              GASTROENTEROLOGY                46   109 964
   060   MATSUSHIRO T          GASTROENTEROLOGY                72   630 977
   061   GLENN F               ANN SURG                       153   411 961
   062   CAMERON JL            ANN SURG                       174   702 971
   063   MERENDINO KA          ANN SURG                       177   694 973
   064   TAMALET E             J MED FR                        21   159 932
   065   JORDAN RA             GASTROENTEROLOGY                33   952 957
   066   DEWEY KW              RADIOLOGY                       96   385 970
   067   BATES GC              GASTROENTEROLOGY                21   104 952
   068   BOUCHIER IAD          GUT                             10   705 969
   069   NICHOLAS P            GASTROENTEROLOGY                63   112 972
   070   VAN DER LINDEN W      ACTA CHIR SCAND SUPPL          269     1 961
   071   FRIEDMAN GD           J CHRON DIS                     19   273 966
   072   STURDEVANT RAL        N ENGL J MED                   288    24 973
   073   MABEE TM              SURGERY                         79   460 976
   074   SARLES H              SEM HOP PARIS                   33  3424 957
   075   SARLES H              AM J DIG DIS                    14   531 969
   076   SARLES H              AM J DIG DIS                    15   251 970
   077   SARLES H              SCAND J GASTROENTEROL            6   189 971
   078   SCHREIBMAN PH         AM SOC CLIN INVE 66TH ANN MTG        72A 974
   079   QUINTAO E             J LIPID RES                     12   233 971
   080   SARLES H              SCAND J GASTROENTEROL            5   603 970
   081   DAM H                 Z ERNAEHRUNGSWISS               10   178 971
   082   DENBESTEN L           SURGERY                         73   266 973
   083   MIETTINEN M           ANN CLIN RES                     8   111 976
   084   DAM H                 SCAND J CLIN LAB INVEST         19   367 967
   085   WATANABE N            ARCH SURG                       85   136 962
   086   GRUNDY SM             J CLIN INVEST                   55   269 975
   087   HEATON KW             CLIN GASTROENTEROL               2    67 973
   088   BURKITT DP            BR MED J                         1   274 973
   089   POMARE EW             AM J DIG DIS                    21   521 976
   091   RAYMOND TL            J CLIN INVEST                   60  1429 977
   092   ANON                  N ENGL J MED                   296  1185 977
   093   COOPER J              LANCET                           1  1083 975
   094   PERTSEMLIDIS D        GASTROENTEROLOGY                66   565 974
   095   THISTLE JL            GASTROENTEROLOGY                61   488 971
   096   HORLICK L             CIRCULATION                     43   299 971
   097   GRUNDY SM             J LIPID RES                     13   531 972
   098   WOOD PD               METABOLISM                      21   107 972
   099   DAM H                 Z ERNAEHRUNGSWISS               10   188 971
   100   MEIHOFF WE            J CLIN INVEST                   47   261 968
   101   HEATON KW             GASTROENTEROLOGY                55     5 968
   102   DOWLING RH            GUT                             13   415 972
   103   COHEN S               GASTROENTEROLOGY                60   237 971
   104   BAKER AL              AM J DIG DIS                    19   109 975
   105   MARKS JW              AM J DIG DIS                    22  1097 977
   106   HEATON KW             BR MED J                         3   494 969
   107   PELLERIN D            J PEDIATR SURG                  10    35 975
   108   ROVSING H             ACTA RADIOL DIAGN STOCKH        14   588 973
   109   ROY CC                N ENGL J MED                   297  1301 977
   110   WEBER AM              N ENGL J MED                   289  1001 973
   111   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   112   WATKINS JB            GASTROENTEROLOGY                67   835 974
   113   ANON                  LANCET                           1  1399 973
   114   ANON                  ORAL CONTRACEPTIVES AND HEALT         57 974
   115   STOLLEY PD            AM J EPIDEMIOL                 102   197 975
   116   ANON                  N ENGL J MED                   290    15 974
   117   BENNION LJ            N ENGL J MED                   294   189 976
   118   TRITAPEPE R           N ENGL J MED                   295   961 976
   119   ANON                  FDA DRUG BULL                    8    12 978
   120   NILSSON S             ACTA CHIR SCAND                132   275 966
   121   HORN G                BR MED J                         2   732 956
   122   BENNION LJ            METABOLISM                      27   961 978
   123   BENNION LJ            CLIN RES                        26  496A 978
   124   BENNION LJ            N ENGL J MED                   297   709 977
   125   NILSSON S             ACTA CHIR SCAND                133   648 967
   126   WILCOX LL             CLIN RES                        20   223 972
   127   ZAHOR Z               SCAND J GASTROENTEROL            9     3 974
   128   BILL K                N ENGL J MED                   284   694 971
   129   REDINGER RN           ARCH INTERN MED                130   618 972
   130   THISTLE JL            N ENGL J MED                   284   144 971
   131   JACKSON CD            SURGERY                         46   853 959
   132   VAN DER LINDEN W      ACTA GENET STATIST MED          15   159 965
   133   DANZINGER RG          MAYO CLIN PROC                  47   762 972
   134   BAINTON D             N ENGL J MED                   294  1147 976
   135   WILLIAMS CN           CAN MED ASSOC J                117   758 977
   136   BENNION LJ            N ENGL J MED                   296  1365 977
   137   KAYE MD               LANCET                           1  1228 971
   138   RIEGEL C              JAMA                           105  1343 935
   139   POTTER MG             JAMA                           106  1070 937
   140   LARGE AM              AM J MED SCI                   239   713 960
CT   1   BARKER DJP            BR MED J                         2  1389 979
     2   GRUNDY SM             EUR J CLIN INVEST                9   179 979
     3   AYUB A                SURG CLIN NORTH AM              59  1095 979
     4   REDINGER RN           POSTGRAD MED                    65    56 979
     5   ANDERSEN JM           GASTROENTEROLOGY                77  1146 979
     6   INGELFINGER FJ        N ENGL J MED                   300   917 979
     7   PADOVA CD             METH FIND EXP CLIN PHARMACOL     2   177 980
     8   CAPRON JP             GASTROENTEROL CLIN BIOL          4    63 980
     9   DEVORE GR             CLIN PERINATOL                   7   349 980
    10   HUIJBREGTS AWM        EUR J CLIN INVEST               10   443 980
    11   DIPADOVA C            EUR SURG RES                    12    57 980
    12   ANGELIN B             SCAND J GASTROENTEROL           15   849 980
    13   HONORE LH             J CLIN PHARMACOL                20   338 980
    14   DEMARQUEZ JL          AGRESSOLOGIE                    21   137 980
    15   PETERS H              INTERNIST                       21   559 980
    16   CADIER L              ANN RADIOL (PARIS)              23   428 980
    17   SHAFFER EA            CAN J SURG                      23   517 980
    18   HONORE LH             J REPROD MED                    25   187 980
    19   HONORE LH             J CHRON DIS                     33   465 980
    20   SCHLIERF G            ATHEROSCLEROSIS                 36   323 980
    21   DIEHL AK              J NATL CANCER INST              65  1209 980
    22   MCMICHAEL AJ          J NATL CANCER INST              65  1201 980
    23   DIEHL AK              SOUTH MED J                     73   438 980
    24   AHLBERG J             GASTROENTEROLOGY                79    90 980
    25   MOCK DM               J PEDIATR                       96   878 980
    26   HONORE LH             ARCH SURG                      115    62 980
    27   PAUMGARTNER G         MUNCH MED WOCHENSCHR           122  1223 980
    28   PAUMGARTNER G         MUNCH MED WOCHENSCHR           122  1001 980
    29   WILLIAMS CN           CAN MED ASSOC J                122   664 980
    30   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   551 980
    31   SCHWEIGHOFER S        AM J DIS CHILD                 134   622 980
    32   BRAVERMAN DZ          N ENGL J MED                   302   362 980
    33   COHEN S               N ENGL J MED                   302   397 980
    34   DIEHL AK              LANCET                           2   187 981
    35   DIPADOVA C            METH FIND EXP CLIN PHARMACOL     3   155 981
    36   ANGELIN B             SCAND J GASTROENTEROL           16  1015 981
    37   SCHLIERF G            DIGESTION                       21    44 981
    38   AHLBERG J             J LIPID RES                     22   404 981
    39   STEVEN MM             GUT                             22   592 981
    40   CAPRON JP             DIG DIS SCI                     26   523 981
    41   DIPADOVA C            DIG DIS SCI                     26  1095 981
    42   SOUSTEK Z             ACTA MORPHOL ACAD SCI HUNG      29   127 981
    43   RUDERMAN NB           AM J CLIN NUTR                  34  1617 981
    44   PIMSTONE NR           SURG CLIN NORTH AM              61   865 981
    45   KLATSKY AL            CIRCULATION                     64    32 981
    46   MOK HYI               GASTROENTEROLOGY                81   340 981
    47   LEE SP                SCIENCE                        211  1429 981
    48   TURLEY SD             J BIOL CHEM                    256  2438 981
    49   RUDERMAN NB           INT J OBES                       6   151 982
    50   TUCKER LE             INT J OBES                       6   247 982
    51   CHILDS B              AM J MED GENET                  13   319 982
    52   ZSIGMOND G            EUR SURG RES                    14   344 982
    53   LEISS O               SCAND J GASTROENTEROL           17   587 982
    54   HENEGOUWEN GPV        NETH J MED                      25    89 982
    55   USCANGA L             REV INVEST CLIN                 34   341 982
    56   TAKEUCHI N            ATHEROSCLEROSIS                 42   129 982
    57   PODDA M               ARCH DIS CHILD                  57   956 982
    58   BRAUN B               KLIN WSCHR                      60  1357 982
    59   EVERSON GT            GASTROENTEROLOGY                82   711 982
    60   HEUBI JE              GASTROENTEROLOGY                82  1295 982
    61   LOWENFELS AB          GASTROENTEROLOGY                83   672 982
    62   KRISHNAMURTHY GT      WEST J MED                     137    87 982
    63   SHUMAN WP             AM J ROENTGENOL                138     1 982
    64   KORENMAN SG           ARCH INTERN MED                142  1131 982
    65   SASTIC JW             SURG GYNECOL OBSTET            155   209 982
    66   KERN F                SEM LIVER DIS                    3    87 983
    67   ZAK RA                SEM LIVER DIS                    3   132 983
    68   BOUCHIER IAD          CLIN GASTROENTEROL              12    25 983
    69   DOWLING RH            CLIN GASTROENTEROL              12   125 983
    70   BORGNAPIGNATTI C      ITAL J GASTROENTEROL            15   228 983
    71   KESANIEMI YA          SCAND J GASTROENTEROL           18   897 983
    72   WHITING MJ            GUT                             24    11 983
    73   LEISS O               KLIN WSCHR                      61   579 983
    74   GILAT T               GASTROENTEROLOGY                84   242 983
    75   MESSING B             GASTROENTEROLOGY                84  1012 983
    76   TURLEY SD             GASTROENTEROLOGY                84   253 983
    77   LEISS O               FETTE SEIFEN ANSTRICHM          85   447 983
    78   MEDINA E              REV MED CHIL                   111   668 983
    79   MCMICHAEL AJ          AM J EPIDEMIOL                 118   620 983
    80   ADYE B                WEST J MED                     139   471 983
    81   BOUCHIER IAD          BR MED J                       286   415 983
    82   DOTY JE               J PARENT ENTERAL NUTR            8   263 984
    83   WHITING MJ            INT J OBES                       8   681 984
    84   ANGELIN B             EUR J CLIN INVEST               14    73 984
    85   FAED EM               DRUG METAB REV                  15  1213 984
    86   DIPADOVA C            SCAND J GASTROENTEROL           19   820 984
    87   BOUCHIER JAD          GUT                             25  1021 984
    88   WERNER D              GUT                             25   269 984
    89   ACALOVSCHI M          ACTA GASTROENTEROL BELG         47   381 984
    90   ADAMI HO              BR J CANCER                     49   235 984
    91   DEDERER YM            KLIN MED                        62    14 984
    92   ADAMTHWAITE DN        S AFR MED J                     65   572 984
    93   WHITING MJ            GASTROENTEROLOGY                86   243 984
    94   TURLEY SD             GASTROENTEROLOGY                87   284 984
    95   FRIED GM              SURGERY                         95   284 984
    96   VOGELBERG KH          DTSCH MED WSCHR                109  1712 984
    97   MULLIGAN SC           IR J MED SCI                   153   106 984
    98   SCRAGG RKR            BR MED J                       288  1113 984
    99   RHOMBERG HP           BR MED J                       289  1002 984
   100   MORRISON WB           VET PATHOL                      22   285 985
   101   BOLONDI L             GUT                             26   734 985
   102   SPITZ MR              J SURG ONCOL                    30     6 985
   103   DIEHL AK              J CHRON DIS                     38  1019 985
   104   LEISS O               KLIN WSCHR                      63  1163 985
   105   NILSELL K             GASTROENTEROLOGY                89   287 985
   106   BORTNICHAK EA         AM J EPIDEMIOL                 121    19 985
   107   PIXLEY F              BR MED J                       291    11 985
   108   EINARSSON K           N ENGL J MED                   313   277 985
   109   ABATE MA              DRUG INTEL CLIN PHARM           20   106 986
   110   DIDONATO P            GUT                             27    23 986
   111   TURLEY SD             J LIPID RES                     27   486 986
   112   OKOLICSANYI L         DRUGS                           31   430 986
   113   MARMON L              POSTGRAD MED                    79   181 986
   114   SANDLER RS            GASTROENTEROLOGY                91   157 986
   115   WYSOWSKI DK           AM J EPIDEMIOL                 123   532 986
   116   KEANE P               SURG GYNECOL OBSTET            163   555 986
   117   TURLEY SD             BIOCHIM BIOPHYS ACTA           879    28 986
   118   WINSHIP KA            ADVER DRUG REAC ACUT POIS REV    6    37 987
   119   HEATON KW             MOL ASP MED                      9    89 987
   120   LEE SS                J CLIN GASTROENTEROL             9    65 987
   121   PITT HA               AM J SURG                      153   233 987
   122   SCHULMAN A            RADIOLOGY                      162   425 987

PN 78156
RN 00936 
AN 78247032
AU Romeo-G.  Parsons-M.  Bossen-A.  Blessing-Moore-J.  Cavalli-Sforza-L.
TI Trypsin-binding IgG in cystic fibrosis.
SO Nature. 1978 Aug 31. 274(5674). P 909-11.
MJ ANTIBODIES: an.  CYSTIC-FIBROSIS: im.  TRYPSIN: im.
MN CYSTIC-FIBROSIS: th.  HUMAN.  IGG.  IMMUNOGLOBULINS-FAB.
   PANCREATIC-EXTRACTS: im, tu.  SUPPORT-U-S-GOVT-P-H-S.
EX It has been observed that most cystic fibrosis patients lack an
   alpha2 macroglobulin-protease complex and that binding of trypsin and
   other proteases to alpha2 macroglobulin is lower in plasma of CF
   patients than in that of normal controls.  We therefore decided to
   study the interaction of trypsin with plasma proteins of CF patients.
   Here we report that trypsin-binding IgG (TbIgG) is present in 80% of
   CF patients and in 30% of their mothers, but not in 97% of normal
   controls or in other relatives of CF patients.  Experimental evidence
   supports the antibody nature of TbIgG, which is presumably produced
   against the porcine trypsin ingested by CF patients as pancreatic
   extracts for substitutive enzyme therapy.
RF 001   WILSON GB             PEDIATR RES                     10    87 976
   002   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   003   HUNTER WM             NATURE                         194   495 962
   004   DAIGER S              PROC NAT ACAD SCI USA           72  2076 975
   005   STANWORTH DR          IN: WEIR DM                     10     1 973
   006   KOPITO LE             PEDIATR RES                     10   742 976
   007   TWAROG FJ             J ALLERGY CLIN IMMUNOL          59    35 977
   008   DOLAN TF JR           AM REV RESPIR DIS              110   812 974
   010   GENELL S              HOPPE SEYLERS Z PHYSIOL CHEM   358   115 977
   011   LIEBOW C              SCIENCE                        189   472 975
   012   ELIAS E               LANCET                           2    66 977
   013   AARON R               IMMUNOCHEMISTRY                  3   451 966
   014   ERICKSON RP           IMMUNOCHEMISTRY                 11    41 974
   015   RAO GJS               SCIENCE                        177   610 972
   016   RAO GJS               PEDIATR RES                      8   684 974
   017   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   018   TALAMO RC             PEDIATR RES                      6   430 972
   019   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   020   GOLDSMITH GH          J LAB CLIN MED                  89   131 977
   021   ROMEO G               AM J HUM GENET                  29   92A 977
CT   1   VANLEUVEN F           PEDIATR RES                     13  1384 979
     2   DAVIS PB              PEDIATR RES                     14    83 980
     3   DENARO M              PEDIATR RES                     14  1086 980
     4   TARNOKY AL            J ROY SOC MED                   73    73 980
     5   ROMEO G               J LAB CLIN MED                  95   116 980
     6   PARSONS M             CLIN CHIM ACTA                 100   215 980
     7   MOSS RB               AM REV RESPIR DIS              121    23 980
     8   SCHIDLOW DV           AM REV RESPIR DIS              121    31 980
     9   BLITZER MG            J PEDIATR GASTROENTEROL NUTR     1   289 982
    10   COX KL                J PEDIATR GASTROENTEROL NUTR     1   345 982
    11   DURIE PR              J PEDIATR GASTROENTEROL NUTR     1   337 982
    12   ROBERTS RC            PEDIATR RES                     16   416 982
    13   MOSS RB               CLIN EXP IMMUNOL                47   301 982
    14   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    15   LAROCHE D             J PEDIATR GASTROENTEROL NUTR     5   404 986
    16   MOORE DJ              CLIN BIOCHEM                    19   303 986
    17   GOLDSTEIN W           AM REV RESPIR DIS              134    49 986
    18   BLANDIN C             J BIOPHYS BIOMECAN              11     5 987

PN 78157
RN 00937 
AN 78248435
AU Phillips-B-M.
TI Cystic fibrosis: the challenge in research and management.
SO Nurs-Mirror. 1978 Aug 24. 147(8). P 13-5.
MJ CYSTIC-FIBROSIS: nu.
MN ADOLESCENCE.  CHILD.  CYSTIC-FIBROSIS: co, px.  HUMAN.  RESEARCH.
EX Cystic fibrosis is a common and serious disease, and presents a
   challenge in management to the paediatrician, nurse, dietitian,
   physiotherapist, and all other members of the caring team.  The
   outstanding research challenge is to discover the basic defect, and
   if this is not treatable to find a method of identifying carriers
   and affected infants in utero.  In this task, the work of the Cystic
   Fibrosis Research Trust, both in raising money for research and for
   supporting and advising patients, is much appreciated.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   SPOCK A               PEDIATR RES                      1   173 967
   003   WOLFSDORF J           PEDIATRICS                      43   799 969
   004   PARKS CR              AM REV RESPIR DIS              108   513 973

PN 78158
RN 00938 
AN 78248436
AU Duberley-J-D.  King-H.
TI Cystic fibrosis: the nurse-teacher and carer for mother and child.
SO Nurs-Mirror. 1978 Aug 24. 147(8). P 15-8.
MJ CYSTIC-FIBROSIS: nu.  PARENT-CHILD-RELATIONS.  PATIENTS: ed.
   PATIENT-EDUCATION.
MN CHILD.  HOME-NURSING.  HUMAN.  INTERPERSONAL-RELATIONS.
   NURSE-PATIENT-RELATIONS.  TERMINAL-CARE.
EX The authors explain the importance of nursing care being directed to
   all members of the family involved in the care of the cystic fibrosis
   child and, in particular, the mother.
RF 001   BIVALEC LM            NURS CLIN NORTH AM               2   109 976
   002   BURTON L              FAMILY LIFE OF SICK CHILDREN             975
   003   HARRISSON SP          FAMILIES IN STRESS                       977
   004   TURK J                PEDIATRICS                      34    67 964
   005   QUINT JC              NURSE AND THE DYING PATIE                967

PN 78159
RN 00939 
AN 78248437
AU Mallinson-B-M.
TI Cystic fibrosis: 7 rules for physiotherapy.
SO Nurs-Mirror. 1978 Aug 24. 147(8). P 18-9.
MJ CYSTIC-FIBROSIS: nu.  PHYSICAL-THERAPY.
MN CHILD.  HUMAN.  INFANT.  POSTURE.
EX The author explains why treatment, although time-consuming, must be
   carried out every day.

PN 78160
RN 00940 
AN 78248433
TI A positive approach to cystic fibrosis [editorial].
SO Nurs-Mirror. 1978 Aug 24. 147(8). P 1.
MJ CYSTIC-FIBROSIS: nu.
MN CHILD.  FAMILY.  HOME-NURSING.  HUMAN.
EX The child with cystic fibrosis presents a heart-breaking problem to
   parents, since the disease is inherited equally from both mother and
   father, and there is the possibility that other children will be
   similarly afflicted.  Perhaps the most valuable advice the nurse can
   give to parents is to adopt at all times a positive approach to their
   problem.

PN 78161
RN 00941 
AN 78136652
AU Russell-G.
TI Cystic fibrosis--1.  Clinical aspects.
SO Nurs-Times. 1978 Mar 23. 74(12). P 486-9.
MJ CYSTIC-FIBROSIS: di.
MN CYSTIC-FIBROSIS: th.  HUMAN.  INFANT.  PROGNOSIS.
EX Cystic fibrosis is a fatal inherited disease involving many different
   organs.  At one time most affected children died within a few years
   of birth but modern management has led to a marked improvement in
   prognosis and, of course, to an increase in the number of affected
   older children and young adults.  Cystic fibrosis is, therefore, no
   longer a disease encountered only in paediatric units, but with
   increasing survival into teens and twenties affected patients are now
   appearing in adult units.  The aetiology and pathology, the clinical
   picture, diagnosis, treatment, and prognosis are discussed.

PN 78162
RN 00942 
AN 78115481
AU Russell-G.
TI Cystic fibrosis--2: genetic and social aspects.
SO Nurs-Times. 1978 Mar 30. 74(13). P 538-41.
MJ CYSTIC-FIBROSIS: fg.
MN CYSTIC-FIBROSIS: di.  FEMALE.  GENETIC-COUNSELING.  HUMAN.
   INFANT-NEWBORN.  PARENTS: ed.  PREGNANCY.  PRENATAL-DIAGNOSIS.
   PROGNOSIS.  RESEARCH.
EX The inheritance of cystic fibrosis and its impact on the patient and
   on the community are examined.  Inheritance, genetic counseling,
   antenatal diagnosis, screening for cystic fibrosis, psychosocial
   aspects, employment prospects, and the Cystic Fibrosis Research Trust
   are discussed.
RF 001   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   002   BURTON L              PRACTITIONER                   210   247 973
   003   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   004   GIBBS GE              PAEDIATRICIAN                    1   133 972
   005   MCCRAE WM             IN: APLEY J                      4   157 974
   006   SHWACHMAN H           PEDIATRICS                      46   335 970

PN 78163
RN 00943 
AN 79115400
AU Lavy-U.  Bauer-C-H.
TI Pathophysiology of failure to thrive in gastrointestinal disorders.
SO Pediatr-Ann. 1978 Nov. 7(11). P 743-9.
MJ GASTROINTESTINAL-DISEASES: co.  GROWTH-DISORDERS: et.
MN ADOLESCENCE.  CELIAC-DISEASE: co.  CHILD.  COLITIS-ULCERATIVE: co.
   CYSTIC-FIBROSIS: co.  ENTERITIS: co.  ESOPHAGEAL-DISEASES: co.
   ESOPHAGUS: ab.  HUMAN.  INFANT.  INFANT-NEWBORN.  LIVER-DISEASES: co.
   MALABSORPTION-SYNDROMES: co.  MEGACOLON: co.
   MOUTH-ABNORMALITIES: co.  SYNDROME.
AB What will be our GI approach to a child with FTT syndrome? Detailed
   history and physical examination will give us the clue and often the
   probable diagnosis. Several laboratory tests are helpful in
   establishing the fact that there is malabsorption. Among them are a
   complete blood count with smear, quantitative stool fat excretion,
   serum protein and chemistry screen panel, prothrombin time, and oral
   tolerance and absorption--i.e., of glucose, iron, vitamin A, and
   xylose. Specialized procedures may be used to nail down the
   diagnosis: radiology, biopsy, duodenal intubation, etc. These should
   never be employed as routine screening tests, however. In outlining a
   comprehensive and successful therapy, the attending physician will
   find it helpful to consider the particular pathophysiologic
   mechanisms of a specific disease. Exact diagnosis makes the therapy
   both rational and effective.
RF 001   ANDERSON CM           IN: ANDERSON CM                          975
   002   BEEKEN WL             PEDIATRICS                      52    69 973
   003   CARRE IJ              CLIN PROC CHILD HOSP DC         25   123 969
   004   CASTLEMAN B           N ENGL J MED                   289   147 973
   005   DAVIDSON M            J PEDIATR                       69  1027 966
   006   DAVIDSON M            IN: BARNETT HL                           972
   007   DAVIDSON M            IN: SLEISENGER MH                        973
   008   KATTWINKEL J          PEDIATRICS                      51    55 973
   009   OLSEN WA              N ENGL J MED                   285  1358 971
   010   PRINSEN JE            J PEDIATR SURG                  10    97 975
   011   SHWACHMAN H           PEDIATRICS                      46   335 970
   012   SILVERBERG M          IN: BARNETT HL                           972
   013   SILVERBERG M          PEDIATR ANN                      6       977
   014   SMITH DW              RECOGNIZABLE PATTERNS OF HUMA            970
   015   TRIER JS              N ENGL J MED                   285  1470 971

PN 78164
RN 00944 
AN 78072649
AU Holsclaw-D-S-Jr.
TI Recognition and management of patients with cystic fibrosis.
SO Pediatr-Ann. 1978 Jan. 7(1). P 9-10, 12-6, 21-2 passim.
MJ CYSTIC-FIBROSIS.
MN ADOLESCENCE.  ADULT.  AIRWAY-OBSTRUCTION: th.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co, di, pa, th.  HUMAN.  INFANT.
   INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: et.  LIVER: pa.  LUNG: pa.
   MECONIUM.  MIDDLE-AGE.  PANCREAS: pa.
   RESPIRATORY-TRACT-INFECTIONS: dt.  INFERTILITY: et.
   SUPPORT-U-S-GOVT-P-H-S.  SUPPORT-U-S-GOVT-NON-P-H-S.
EX Cystic fibrosis is the most common lethal genetic disease in
   childhood, and the broad range of its clinical expression can involve
   practically every specialty of medicine.  The pathology of cystic
   fibrosis, its clinical features, diagnosis, and treatment are
   discussed.  The pediatrician will not want to attempt to provide
   exclusive care for the CF patient.  These patients require the many
   supports that only a specialized center will have.  Chest surgeons,
   pediatric surgeons, otolaryngologists, cardiologists,
   gastroenterologists - in fact, all fields of medicine and all medical
   specialties - may be needed for the various clinical problems
   associated with the disease.
RF 001   MCKUSICK VA           MENDELIAN INHERIT IN MAN                 975
   002   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   HOLSCLAW DS           CLIN PEDIATR                     9   346 970
   005   SHWACHMAN H           PEDIATRICS                      30   389 962
   006   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   007   CRAIG JM              AM J DIS CHILD                  93   357 957
   008   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   009   SHWACHMAN H           N ENGL J MED                   286  1300 972
   010   HOLSCLAW DS           J UROL                         106   568 971
   011   HOLSCLAW DS           PEDIATRICS                      48   442 971
   012   KOPITO LE             FERTIL STERIL                   24   512 973
   013   OPPENHEIMER EH        J PEDIATR                       77   991 970
   014   WOOD RE               AM REV RESPIR DIS              113   833 976
   015   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   016   DOGGETT RG            J PEDIATR                       68   215 966
   017   KULCZYCKI LL          N ENGL J MED                   259   409 958
   018   VALMAN HB             ARCH DIS CHILD                  46   805 971
   019   KESSLER WR            PEDIATRICS                       8   648 951
   020   ANON                  J PEDIATR                       88   711 976
   021   GIBSON LE             PROC FOR QUANTITATIVE ION                975
   022   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   023   WARING WW             ADV PEDIATR                     23   401 976
   024   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            974
   025   TECKLIN JS            PHYS THER                       55  1081 975
   026   STERN RC              CLIN PEDIATR                    11   521 972
   027   HANDWERGER S          N ENGL J MED                   281   451 969
   028   HOLSCLAW DS           J PEDIATR                       76   829 970
   029   HOLSCLAW DS           PEDIATRICS                      48    51 971
   030   SIASSI B              J PEDIATR                       78   794 971
   031   KELMINSON LL          PEDIATRICS                      39    24 967
   032   GAYTON WF             AM J DIS CHILD                 126   856 973
   033   GAYTON WF             PEDIATRICS                      59   888 977
   034   BOYLE IR              J PEDIATR                       88   318 976
   035   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
CT   1   CHO YW                J CLIN PHARMACOL                21   224 981
     2   STANGHELLE JK         ACTA PAEDIATR SCAND             72   935 983

PN 78165
RN 00945 
AN 78072646
AU Huang-N-N.
TI The use of new antibiotic agents for chronic pulmonary disease.
SO Pediatr-Ann. 1978 Jan. 7(1). P 56, 58-60, 62 passim.
MJ ANTIBIOTICS: tu.  BACTERIAL-INFECTIONS: dt.
   RESPIRATORY-TRACT-INFECTIONS: dt.
MN AGAMMAGLOBULINEMIA: co.  AMINOGLYCOSIDES: tu.  ASTHMA: co.
   CEPHALOSPORINS: tu.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: co.
   IMMUNOLOGIC-DEFICIENCY-SYNDROMES: co.  PENICILLINS: tu.
   PNEUMONIA-ASPIRATION: co.  RESPIRATORY-TRACT-INFECTIONS: et.
   SULFAMETHOXAZOLE: tu.  TETRACYCLINES: tu.  TRIMETHOPRIM: tu.
AB Modern advances in the development of antimicrobial agents and in
   chemotherapy have made available potent aminoglycoside antibiotics,
   with more effective ones to come. Their effectiveness against P.
   aeruginosa is a great contribution to patients with cystic fibrosis
   and other chronic disorders. The development of carbenicillin has
   augmented the effectiveness of the aminoglycoside antibiotics.
   Ticarcillin is similar to carbenicillin and will play a similar role
   in antibiotic therapy. The cephalosporins serve as alternative agents
   principally for their antistaphylococcal activity. We are urgently in
   need of a potent antibiotic agent against P. aeruginosa that can be
   given by the oral route. The TMP-SMX combination is a potent
   chemotherapeutic agent that can be administered by the oral route. It
   is effective in the treatment of P. carinii pneumonia, which is very
   common owing to the extended survival of patients with leukemia and
   other malignancies or with allografts who are prone to develop
   infections with immunosuppressive therapy.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   CUMMING WA            RADIOLOGY                      105   387 972
   003   BARTLETT JG           CHEST                           68   560 975
   004   KIM IG                LARYNGOSCOPE                    83   347 973
   005   GOSINK BB             AM J ROENTG RAD THER NUCL MED  117   816 973
   006   LARAYA-CUASAY LR      AM REV RESPIR DIS              109   703 974
   007   BAUER AW              AM J CLIN PATHOL                45   493 966
   008   STRATFORD BC          LANCET                           1   378 974
   009   MENDELSON J           ANTIMICROB AGENTS CHEMOTHER      9   633 976
   010   MEYERS RM             ARCH OTOLARYNGOL                92   160 970
   011   KOSSEK JC             J LAB INVEST                    30    48 974
   012   BOBROW SN             JAMA                           222  1546 972
   013   HOLMES RK             ANTIMICROB AGENTS CHEMOTHER      6   253 974
   014   HOUANG ET             LANCET                           1   423 976
   015   NEU HC                J INFECT DIS SUPPL             134     3 976
   016   HUANG NN              INFECTION SUPPL                  4   465 976
   017   MARKS MI              J CLIN PHARMACOL                15   246 975
   018   HUANG NN              CLINICAL EXPERIENCE WITH AMIK            976
   019   KHAN AJ               CURR THER RES                   19   479 976
   020   KLASTERSKY J          J MED MICROBIOL                  7   465 974
   021   LEVISON ME            ANTIMICROB AGENTS CHEMOTHER      5   667 974
   022   MCLAUGHLIN JE         LANCET                           1   261 971
   023   RIFF LJ               ARCH INTERN MED                130   887 972
   024   LEVINE BB             J INFECT DIS SUPPL             128   364 973
   025   TUANO SB              ANTIMICROB AGENTS CHEMOTHER      6   101 966
   026   BURTON JR             JAMA                           229   679 974
   027   THORNHILL TS          APPL MICROBIOL                  17   457 969
   028   STORE SD              J POSTGRAD MED                  21   121 975
   029   KIRBY WMM             J INFECT DIS SUPPL             128   341 973
   030   STANFORD HC           J INFECT DIS SUPPL             122     9 970
   031   HUANG NN              J PEDIATR                       78   338 971
   032   BROWN CH 3RD          N ENGL J MED                   291   265 974
   033   ERVIN ER              ANTIMICROB AGENTS CHEMOTHER      9    94 976
   034   PARRY MF              J PEDIATR                       90   144 977
   035   PARRY MF              J INFECT DIS SUPPL             134   194 976
   036   NEU HC                ANTIMICROB AGENTS CHEMOTHER      8   457 975
   037   HUANG NN              ANTIMICROB AGENTS CHEMOTHER      6   127 966
   038   PINES A               PRACTITIONER                   213   727 974
   039   BROGDEN RN            DRUGS                            9   251 975
   040   GROSSMAN ER           PEDIATRICS                      47   567 971
   041   FRIMPTER GW           JAMA                           184   111 963
   042   KABU SB               CLIN PHARMACOL THER              9   550 968
   043   BERGAN T              ACTA MED SCAND                 192   483 972
   044   LEWIN EB              J INFECT DIS SUPPL             128   618 973
   045   STORE SD              J POSTGRAD MED                  21   114 975
   046   KNIGHT D              LANCET                           2   717 975
   047   HUGHES WT             CANCER                          36  2004 975
   048   HUGHES WT             N ENGL J MED                   295   726 976

PN 78166
RN 00946 
AN 78072644
AU Holsclaw-D-S-Jr.  Keith-H-H.  Palmer-J.
TI Meconium screening for cystic fibrosis.
SO Pediatr-Ann. 1978 Jan. 7(1). P 29-30, 35, 38-40.
MJ CYSTIC-FIBROSIS: di.  MASS-SCREENING.  MECONIUM: an.
MN ALBUMINS: an.  CYSTIC-FIBROSIS: oc.  FALSE-NEGATIVE-REACTIONS.
   HUMAN.  INFANT-NEWBORN.  METHODS.  REAGENT-STRIPS.  SWEAT: an.
   SUPPORT-U-S-GOVT-NON-P-H-S.  UNITED-STATES.
AB In our hands, the BMC-Test Meconium has been a significant step
   towards the goal of developing an ideal newborn screening test for
   CF. It is easily performed, is highly specific, has reasonably high
   sensitivity, and--given its limitation of identifying only patients
   with CF who have intrauterine pancreatic insufficiency--is the best
   method of screening newborns for CF that has been devised to date.
   Many technical problems remain to be solved before the test can be
   endorsed without reservation. Because the test, as currently
   constituted, does not identify all potential subjects for further
   testing who might have CF, it should not be made mandatory. It is,
   however, better than other available screening methods for CF and can
   be praised for that benefit. The concept has indicated a valuable new
   direction for mass-screening possibilities and perhaps can, by future
   modification, be made sensitive enough to warrant universal usage.
RF 001   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   002   STEPHAN U             NEONATAL MASS SCREENING FOR C            976
   003   LANDSTEINER K         ZENTRALBL ALLG PATHOL           16   903 905
   004   KORNBLITH BA          AM J PATHOL                      5   249 929
   005   FARBER S              AM J DIS CHILD                  64   953 942
   006   FARBER S              J PEDIATR                       24   387 944
   007   RAPOPORT S            SCIENCE                        112   150 950
   008   BUCHANAN DJ           PEDIATRICS                       9   304 952
   009   GREEN MN              PEDIATRICS                      21   635 958
   010   WISER WC              PEDIATRICS                      33   115 964
   011   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   012   GREEN MN              PEDIATRICS                      41   989 968
   013   DAVIDSON AG           BR MED J                         4   362 971
   014   CAIN ARR              ARCH DIS CHILD                  47   131 972
   015   STEPHAN U             PADIATRISCHE PRAXIS             12   487 973
   016   SZIBOR R              HELV PAEDIATR ACTA              28   359 973
   017   SZIBOR R              DTSCH GESUNDHEITSW              28  2252 973
   018   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   019   BRUNS WT              AM J DIS CHILD                 131    71 977
   020   ANON                  PROC EWGCF 5TH ANNU MTG                  974
   021   STEPHAN U             PEDIATRICS                      55    35 975
   022   MCKUSICK VA           MENDELIAN INHERIT IN MAN             167 968
   023   ANON                  CF FND 1974 REP SURVI STUD PA            976
   024   SCRIVER CR            PEDIATRICS                      58   757 976
   025   HOLTZMAN NA           JAMA                           229   667 974
   026   FISHER DA             J PEDIATR                       89   692 976

PN 78167
RN 00947 
AN 78157263
AU Savoca-C-J.  Brasch-R-C.  Gooding-C-A.  Gamsu-G.
TI The right paratracheal stripe in children.
SO Pediatr-Radiol. 1978 Feb 28. 6(4). P 203-7.
MJ THORACIC-RADIOGRAPHY.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: ra.  HUMAN.
   INFANT.  LYMPHOSARCOMA: ra.  MALE.  NEOPLASM-RECURRENCE-LOCAL: ra.
   REFERENCE-VALUES.  PLEURAL-EFFUSION: ra.
   SALIVARY-GLAND-NEOPLASMS: ra.  SUBMANDIBULAR-GLAND: ra.
   SUPPORT-U-S-GOVT-P-H-S.
AB The width of the right paratracheal stripe (RPS) has been established
   in normal adults but not in normal children. The thymus and great
   vessels are relatively larger in children than in adults and could
   obscure or widen the RPS. We found that obscuration does occur and,
   therefore, the RPS is less often measurable in children than in
   adults. Widening by the thymus and great vessels, however, does not
   occur. The width of the RPS in normal children, 0.5 to 3.0 mm, is
   slightly less than in adults. From this study of normal children and
   our subsequent experience with pediatric patients, we conclude that
   in a child an RPS 4 mm or wider is reliable evidence of disease
   affecting the trachea, mediastinum, or pleura.
RF 001   SAVOCA CJ             RADIOLOGY                      122   295 977
CT   1   NEUFANG KFR           LYMPHOLOGY                      15   132 982

PN 78168
RN 00948 
AN 79054260
AU Moffat-R-E.  Sobonya-R-E.  Chang-C-H.
TI Childhood sarcoidosis with fatal cor pulmonale.
SO Pediatr-Radiol. 1978 Sep 26. 7(3). P 180-2.
MJ LUNG-DISEASES: di.  PULMONARY-HEART-DISEASE: di.  SARCOIDOSIS: di.
MN ADOLESCENCE.  CASE-REPORT.  CYSTIC-FIBROSIS: di.
   DIAGNOSIS-DIFFERENTIAL.  FEMALE.  HUMAN.  LUNG-DISEASES: ra.
   LUNG: ra.  PULMONARY-HEART-DISEASE: ra.  SARCOIDOSIS: ra.
AB A 14 year-old white girl who developed fatal cor pulmonale from
   severe pulmonary sarcoidosis had a previous clinical diagnosis of
   cystic fibrosis. Chest radiographs demonstrated marked pulmonary
   fibrosis without the changes of severe bronchiectasis that would be
   anticipated with cystic fibrosis.
RF 001   HAUSER H              OKLA STATE MED ASSOC            39   395 946
   002   KENDIG EL JR          CHEST                           70   351 976
   003   KIRKS DR              AM J ROENTG RAD THER NUCL MED  117   777 973
   004   KOERNER SK            N ENGL J MED                   293   268 975
   005   MCGOVERN JP           ADV PEDIATR                      8    97 956

PN 78169
RN 00949 
AN 79011613
AU Wilson-G-B.  Fudenberg-H-H.
TI Is cystic fibrosis protein a diagnostic marker for individuals who
   harbor the defective gene?  [letter].
SO Pediatr-Res. 1978 Jul. 12(7). P 801-4.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.  HETEROZYGOTE-DETECTION.
MN HUMAN.  SUPPORT-U-S-GOVT-P-H-S.
EX It has been almost 5 years since the publication of our original
   report describing a "cystic fibrosis factor" (now designated "cystic
   fibrosis protein" or CFP) detected in the serum of most homozygotes
   and heterozygotes for cystic fibrosis when analyzed using isoelectric
   focusing in thin layer polyacrylamide gels.  The recent report by
   Scholey et al. confirms that CFP is present in the majority of CF
   sera and that it can be detected by our methods.  Before discussing
   whether the CFP can be used as a diagnostic marker for cystic
   fibrosis, we would like to examine more closely some of the
   requirements of the method which seemed to have been critical for the
   detection of CFP by Scholey et al.  We would like to point out that
   Scholey and his coworkers adhered closely to most of our guidelines
   during their attempts to detect CFP.  The exact nature of CFP and the
   other ciliary dyskinesia factors is only partially known, and all
   aspects of their metabolism are not yet understood.  Therefore, it
   may be some time before we comprehend the incomplete concordance
   found between CFP and the pathogenesis of CF.
RF 001   ALTLAND K             HUMANGENETIK                    28   207 975
   002   AWDEH ZL              NATURE                         219    66 968
   003   DANES BS              CLIN GENET                      11    83 977
   004   SCHOLEY J             PEDIATR RES                     12   800 978
   005   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   006   SMITH QT              PEDIATR RES                     10   999 976
   007   THOMAS JM             PEDIATR RES                     11   138 977
   008   THOMAS JM             PEDIATR RES                     11  1148 977
   009   WARNER JO             LANCET                           1   990 976
   010   WILSON GB             PEDIATR RES                     11   986 977
   011   WILSON GB             PEDIATR RES                     10  1001 976
   014   WILSON GB             SCAND J IMMUNOL                  5   829 976
   015   WILSON GB             CLIN RES                        26   501 978
   016   WILSON GB             PEDIATR RES                     10    87 976
   017   WILSON GB             TEX REP BIOL MED                34    51 976
   018   WILSON GB             ADV POLYMINE RES                 2   281 978
   019   WILSON GB             PEDIATR RES                      9   635 975
   020   WILSON GB             CLIN CHIM ACTA                  49    79 973
   021   WILSON GB             IN: RADOLA BJ                        337 977
   022   WILSON GB             PEDIATR RES                     11   139 977
   023   ANON                  J PEDIATR                       88   711 976
CT   1   TULLY GW              PEDIATR RES                     13  1078 979
     2   WILSON GB             PEDIATR RES                     13  1079 979
     3   MANSON JC             LANCET                           1   330 980
     4   NEVIN GB              HUM GENET                       56   387 981
     5   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
     6   BULLOCK S             CLIN GENET                      21   336 982
     7   BROCK DJH             HUM GENET                       60    30 982
     8   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     9   WILSON GB             CLIN GENET                      26   331 984
    10   HODSON ME             POSTGRAD MED J                  60   225 984
    11   KLINGER KW            SEM RESPIR MED                   6   243 985
    12   KIRKPATRICK C         PEDIATR RES                     19  1341 985
    13   JAMIESON A            HUM GENET                       70   168 985
    14   KUZEMKO JA            J ROY SOC MED                   79     2 986

PN 78170
RN 00950 
AN 78157307
AU Impero-J-E.  Harrison-G-M.  Nelson-T-E.
TI Cystic fibrosis: isolation and physical properties of a salivary
   cystic fibrosis factor.
SO Pediatr-Res. 1978 Feb. 12(2). P 108-14.
MJ CYSTIC-FIBROSIS: me.  SALIVA: an.  SALIVARY-PROTEINS: ip.
MN ALPHA-AMYLASE: ip, pd.  ANIMAL.  CILIA: de.
   GLYCOGEN-DEBRANCHING-ENZYME: ai.  GLYCOGEN.  HEPARIN.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  IN-VITRO.  METHODS.  OYSTERS.  RABBITS.
   SALIVARY-PROTEINS: pd.  TEMPERATURE.  SUPPORT-U-S-GOVT-P-H-S.
AB A ciliostatic factor has been isolated from cystic fibrosis (CF)
   saliva by dialyzing it from purified alpha-amylase prepared by a
   glycogen-complex method. This method of isolating the CF factor is an
   improvement over the previously employed heparin procedure. The
   activity of the isolated factor is proportional with concentration
   using the oyster gill ciliostatic assay and in its inhibition of
   mammalian glycogen debranching enzyme. The ciliostatic action of the
   factor can be reversed by heparin under certain conditions. The type
   of inhibition of the debranching enzyme by the isolated CF factor
   indicates that its chemical structure is similar to that observed
   with hydroxyalkylamines and polyamine metabolites. Physical
   properties of the isolated factor indicate that it is of low
   molecular weight and is labile as a function of pH and temperature.
   At neutral pH the conditions under which it is maintained have a
   direct effect on the length of time that it is stable.
RF 001   ARAKI H               PEDIATR RES                      9   932 975
   002   ASANO T               AM J PHYSIOL                   207   415 964
   003   BERNFELD P            METHODS ENZYMOL                  1   149 955
   004   BESLEY GTN            J MED GENET                      6   278 969
   005   BISHOP SH             CF CLUB ABST                    14    25 973
   006   BOWMAN BH             IN: MANGOS JA                        277 976
   007   BOWMAN BH             SCIENCE                        164   325 969
   008   ANON                  GAP CONF REP CILIARY INHIBITO          2 973
   009   CONOVER JH            PEDIATR RES                      7   220 973
   010   DANES BS              CLIN GENET                       7   128 975
   011   DANES BS              J EXP MED                      136  1313 972
   012   DANES BS              CLIN GENET                       8    85 975
   013   DEARBORN DG           GAP CONF REP POLYAMINES               19 976
   014   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   015   DOGGETT RG            TEX REP BIOL MED                31   685 973
   016   DOGGETT RG            NATURE NEW BIOL                243   250 973
   018   DUBOIS M              ANAL CHEM                       28   350 956
   019   FISHER EH             BIOCHEM PREP                     8    27 961
   020   GILLARD BK            PEDIATR RES                     10   907 976
   021   GILLARD BK            BIOCHEMISTRY                    16  3978 977
   022   KAISER D              LANCET                           1  1003 970
   023   KIMES BW              BIOCHIM BIOPHYS ACTA           228   223 971
   024   LEVITZKI A            BIOCHIM BIOPHYS ACTA            81   101 964
   025   LOBECK CC             IN: STANBURY JB                     1605 972
   026   LOCKHART LH           TEX REP BIOL MED                31   631 973
   027   LOWRY OH              J BIOL CHEM                    193   265 951
   028   LOYTER A              BIOCHIM BIOPHYS ACTA            65   200 962
   029   MANGOS JA             SCIENCE                        158   135 967
   030   MANGOS JA             PEDIATR RES                      2   378 968
   031   MANGOS JA             PEDIATR RES                      1   436 967
   032   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   033   MCNEELY CM            CF CLUB ABST                    16     6 975
   034   MILLER GL             ANAL CHEM                       31   964 959
   035   NELSON TE             CF CLUB ABST                           7 974
   036   NELSON TE             FED PROC                        33  1311 974
   037   NELSON TE             BIOCHEMISTRY                     8  1419 969
   038   NELSON TE             FED PROC                        32   627 973
   039   SCHMOYER IR           BIOCHEM BIOPHYS RES COMMUN      46  1923 972
   040   SPOCK A               PEDIATR RES                      1   173 967
   041   TAYLOR A              PEDIATR RES                      8   861 974
   042   WATTS TE              ANAL BIOCHEM                    49   479 972
   043   WILSON GB             PEDIATR RES                      9   635 975
   044   WOOD RE               LANCET                           2  1452 973
CT   1   IMPERO JE             PEDIATR RES                     15   940 981
     2   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
     3   BOGART BI             J CHROMATOGR                   381    29 986

PN 78171
RN 00951 
AN 78248077
AU Platt-M-W.  Rao-G-J.  Nadler-H-L.
TI Reaction of 4-methylumbelliferylguanidinobenzoate with cultivated
   human skin fibroblasts derived from patients with cystic fibrosis.
SO Pediatr-Res. 1978 Aug. 12(8). P 874-7.
MJ BIOLOGICAL-ASSAY.  CYSTIC-FIBROSIS: en.  HYMECROMONE: du.
   PEPTIDE-HYDROLASES: me.  UMBELLIFERONES: du.
MN CELLS-CULTURED.  FIBROBLASTS: en.  GUANIDINES: du.  HUMAN.
   HYMECROMONE: aa.  SKIN: en.  SUPPORT-U-S-GOVT-P-H-S.
AB Protease activity in cultivated human skin fibroblasts has been
   quantitated using 4-methylumbelliferylguanidinobenzoate (MUGB), an
   active site titrant of trypsin-like proteases (7). The reaction of
   the proteases with MUGB was complete in 1 hr, inhibited both by
   benzamidine and (p-nitrophenyl)-p'-guanidinobenzoate, but not by p-
   hydroxymercuribenzoate. The extent of reaction was proportional to
   protein concentration and independent of MUGB concentration. This
   activity was present in the particulate fraction of the cell. The
   mean "titre" values (nanomoles of 4-methylumbelliferone released per
   mg protein) of the proteases in fibroblasts from eight controls (N),
   8 obligate heterozygotes (H), and 14 patients with cystic fibrosis
   (CF) were: N, 1.27 +/- 0.11; H, 0.82 +/- 0.12; CF, 0.66 +/- 0.10. The
   differences in the "titre" values for N:CF and N:H were significant
   (p less than 0.001) as were those for H:CF (p less than 0.01). The
   mean "titre" value obtained for cultivated control amniotic fluid
   cells was 1.29 +/- 0.17. These data indicate a reduction in the MUGB-
   reactive proteases in skin fibroblasts derived from patients with CF
   when compared either to control or to obligate heterozygotes. These
   data are consistent with our earlier suggestion (11, 15) that
   decreased proteolytic levels in the tissues and fluids of patients
   with CF may be a generalized phenomenon.
RF 001   BARRETT AJ            BIOCHEM J                      131   809 973
   002   BROWN CR              BIOCHEM J                      149   147 975
   003   CALLAHAN JW           PEDIATR RES                     11  1166 977
   004   CHASE T JR            BIOCHEM BIOPHYS RES COMMUN      29   508 967
   005   CHASE T JR            BIOCHEMISTRY                     8  2212 969
   006   HATCHER VB            BIOCHEM BIOPHYS RES COMMUN      76   602 977
   007   JAMESON GW            BIOCHEM J                      131   107 973
   008   KERR MA               BIOCHEMISTRY                    14  5088 975
   009   LOWRY OH              J BIOL CHEM                    193   265 951
   010   NADLER HL             NATURE                         213  1261 967
   011   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   012   RAO GJS               J PEDIATR                       80   573 972
   013   RAO GJS               PEDIATR RES                      8   684 974
   014   RAO GJS               PEDIATR RES                      9   739 975
CT   1   BROCK DJH             LANCET                           1  1245 979
     2   WALSH MM              LANCET                           1   622 979
     3   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     4   WALSHPLATT M          ENZYME                          24   224 979
     5   NADLER HL             LANCET                           2    96 980
     6   NADLER HL             PEDIATRICS                      66   690 980
     7   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
     8   TUMMLER B             CLIN CHIM ACTA                 125   219 982
     9   GREEN JR              EUR J PEDIATR                  139    35 982
    10   BROCK DJH             PRENAT DIAGN                     3     1 983
    11   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    12   CEDER O               ACTA PAEDIATR SCAND           1983     1 983
    13   BUYS CHCM             CLIN CHIM ACTA                 136   229 984

PN 78172
RN 00952 
AN 78201164
AU Knoke-J-D.  Stern-R-C.  Doershuk-C-F.  Boat-T-F.  Matthews-L-W.
TI Cystic fibrosis: the prognosis for five-year survival.
SO Pediatr-Res. 1978 May. 12(5). P 676-9.
MJ CYSTIC-FIBROSIS: mo.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  HUMAN.  INFANT.  PROBABILITY.
   PROGNOSIS.  SUPPORT-U-S-GOVT-P-H-S.
AB Statistical discriminant analysis is applied to 41 concomitant
   variables obtained during the first year of study of 226 patients
   with cystic fibrosis. A discriminant function based on six variables
   is developed which can be used as a predictive index. This index
   estimates the probability of 5-year survival for an individual
   patient and can also be used to classify patients into one of two
   groups: (1) will live for 5 years or (2) will die within 5 years.
   Speculation A classification rule for cystic fibrosis is presented
   which correctly assigns 90% of the 5-year survivors and 84% of those
   who expire. Such a classification scheme is useful for clinical and
   research purposes.
RF 001   AFIFI AA              AM J CARDIOL                    33   826 974
   002   AFIFI AA              N ENGL J MED                   285  1497 971
   003   CHANG PC              J AM STATIST ASSOC              69   336 974
   004   DIXON WJ              BMDP: BIOMEDICAL COMPUTER PRO            975
   005   DOERSHUK CF           J PEDIATR                       65   677 964
   006   LACHENBRUCH PA        DISCRIMINANT ANALYSIS                    975
   007   LACHENBRUCH PA        TECHNOMETRICS                   10     1 968
   008   LURIA MH              ANN INTERN MED                  85   561 976
   009   MATTHEWS LW           J PEDIATR                       65   558 964
   010   MCCABE GP JR          TECHNOMETRICS                   17   103 975
   011   MOORE DH              J AM STATIST ASSOC              68   399 973
   012   SHUBIN H              CARDIOVASC RES                   2   329 968
   013   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   014   STERN RC              J PEDIATR                       89   406 976
   015   TAUSSIG LM            J PEDIATR                       82   380 973
CT   1   KRAEMER R             HELV PAEDIATR ACTA              34   417 979
     2   TUMMLER B             MONATSSCHR KINDERHEILKD        130   157 982
     3   PARSONS HG            J PEDIATR GASTROENTEROL NUTR     2    44 983
     4   DAVIS PB              SEM RESPIR MED                   6   261 985

PN 78173
RN 00953 
AN 78248067
AU Wright-R-K.  Buehler-B-A.  Schott-S-N.  Rennert-O-M.
TI Spermine and spermidine, modulators of the cell surface enzyme
   adenylate cyclase.
SO Pediatr-Res. 1978 Aug. 12(8). P 830-3.
MJ ADENYL-CYCLASE: ai.  CYSTIC-FIBROSIS: en.  SPERMIDINE: pd.
   SPERMINE: pd.
MN ADULT.  CELL-MEMBRANE: de, en.  CELLS-CULTURED.  CHILD.
   CHILD-PRESCHOOL.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pa.
   FIBROBLASTS: de.  HUMAN.  IN-VITRO.  INFANT-NEWBORN.
   SUPPORT-U-S-GOVT-P-H-S.
AB Adenylate cyclase activity was measured in membrane preparations of
   cultured fibroblasts from controls and patients with cystic fibrosis.
   Enzyme activity increased as the transition from exponential growth
   to confluence occurred; sodium fluoride-stimulated activity more
   markedly displayed this relationship than basal cyclase activity. The
   in vitro addition of spermine (1 X 10(-6) to 2 X 10(-3) M) to
   membrane preparations caused inhibition of basal and sodium fluoride-
   stimulated enzyme activity, with 50% inhibition of basal activity
   occurring at 10(-6) M spermine. Spermidine (10(-4) M) caused 15--25%
   inhibition of adenylate cyclase activity. The increase in fibroblast
   adenylate cyclase activity during the transition from exponential
   growth was comparable in cells obtained from cystic fibrosis patients
   and control subjects. Basal and sodium-fluoride stimulated adenylate
   cyclase activity as well as inhibition of this enzyme activity by
   spermidine and spermine were undistinguishable between the different
   cell genotypes. A potential modulation of cellular proliferative
   activity through polyamine interaction with the adenylate cyclase
   system is postulated.
RF 001   ANDERSON WB           ADV CYCLIC NUCLEO RES            5   681 975
   002   AMATRUDA J            BIOCHIM BIOPHYS ACTA           373   266 974
   003   ARVANITAKIS S         TEX REP BIOL MED                34   175 976
   004   BUEHLER B             PEDIATR RES                     11   186 977
   005   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
   006   CHUN P                BIOCHEM BIOPHYS RES COMMUN      69  1095 976
   007   COHEN LF              PEDIATR RES                      9   334 975
   008   CUETRECASAS P         ADV CYCLIC NUCLEO RES            5    79 975
   009   DYKSTRA WG            SCIENCE                        149   428 965
   010   FRANKS DJ             FEBS LETTERS                    42   267 974
   011   HOLTTA E              BIOCHEM BIOPHYS RES COMMUN      54   350 973
   012   JOHNSON RA            J BIOL CHEM                    250  6599 975
   013   KOSSOROTOW A          BIOCHEM J                      144    21 974
   014   LOWRY OH              J BIOL CHEM                    193   265 951
   015   MANGOS JA             IN: MANGOS JA                        311 976
   016   ONEILL J              BIOCHIM BIOPHYS ACTA           404   243 975
   017   OTTEN J               J BIOL CHEM                    247  7082 972
   018   PROCTOR MS            J INVEST DERMATOL               65   409 975
   019   RAINA A               MED BIOL                        53   121 975
   020   RENNERT OM            TEX REP BIOL MED                34   187 976
   021   RICHARDS GM           ANAL BIOCHEM                    57   369 974
   022   ROSENTHAL S           BIOCHIM BIOPHYS ACTA           363   141 974
   023   RUSSELL DH            PROC NAT ACAD SCI USA           60  1420 968
   024   SALOMON Y             ANAL BIOCHEM                    58   541 974
   025   TASHIMA Y             BIOCHEM BIOPHYS RES COMMUN      66  1344 975
   026   WOLFF J               J BIOL CHEM                    250  6897 975
   027   WRIGHT RK             ARCH DERMATOL                  107    47 973
CT   1   ILLIANO G             BULL MOL BIOL MED                4   155 979
     2   CANELLAKIS ES         CURR TOP CELL REGUL             15   155 979
     3   TINTNER R             J NEUROCHEM                     33  1067 979
     4   ALLEN JC              EUR J BIOCHEM                  102   153 979
     5   GAHL WA               PEDIATR RES                     14   118 980
     6   KUROSHIMA A           JAP J PHYSIOL                   30   935 980
     7   KIMBERLY MM           ANAL CHEM                       53   789 981

PN 78174
RN 00954 
AN 79011612
AU Scholey-J.  Applegarth-D-A.  Davidson-A-G.  Wong-L-T.
TI Detection of cystic fibrosis protein by electrofocusing [letter].
SO Pediatr-Res. 1978 Jul. 12(7). P 800.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
MN HUMAN.  ISOELECTRIC-FOCUSING.
EX Wilson et al. reported a biophysical assay for cystic fibrosis that
   employed isoelectric focusing of serum proteins.  Their work appeared
   to establish the presence of a definitive marker for CF serum in the
   form of a protein band that was not present in normal serum.  We
   tried to repeat their work and found that the background color of the
   fresh electropherograms made it rather difficult to detect
   unequivocally the presence or absence of bands in the appropriate pH
   region in CF vs. control serum.  However, when the gels were
   photographed using Kodak Panatomic X film and a Wratten 25 A red
   filter, the color response and contrast of the film eliminated this
   interference to a great extent and it was much easier to detect the
   putative band.  We agree partially with the observations of Wilson
   and Fudenberg, but would like to stress that the technique is not a
   diagnostic test.
RF 001   SMITH QT              PEDIATR RES                     10   999 976
   002   THOMAS JM             PEDIATR RES                     11  1148 977
   003   WILSON GB             PEDIATR RES                     11   986 977
   004   WILSON GB             PEDIATR RES                     10  1001 976
   005   WILSON GB             PEDIATR RES                      9   635 975
   006   WILSON GB             PEDIATR RES                     11   139 977
CT   1   TULLY GW              PEDIATR RES                     13  1078 979
     2   WILSON GB             PEDIATR RES                     13  1079 979
     3   MANSON JC             LANCET                           1   330 980
     4   WILSON GB             LANCET                           2   313 980
     5   NEVIN GB              HUM GENET                       56   387 981
     6   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
     7   BULLOCK S             CLIN GENET                      21   336 982
     8   BROCK DJH             HUM GENET                       60    30 982
     9   BURY AF               CLIN CHIM ACTA                 118    45 982
    10   GRATAROLI R           PEDIATR RES                     18   130 984
    11   ANON                  LANCET                           2   249 985
    12   JAMIESON A            HUM GENET                       70   168 985
    13   QURESHI AR            J PEDIATR                      106   913 985
    14   HAYWARD C             J IMMUNOL METH                  91   117 986

PN 78175
RN 00955 
AN 78157324
AU Perlmutter-J.  Martinez-J-R.
TI The chronically reserpinized rat as a possible model for cystic
   fibrosis.  VII.  Alterations in the secretory response to
   cholecystokinin and to secretin from the pancreas in vivo.
SO Pediatr-Res. 1978 Mar. 12(3). P 188-94.
MJ CYSTIC-FIBROSIS: pp.  DISEASE-MODELS-ANIMAL.  PANCREATIC-JUICE: se.
   RESERPINE: pd.
MN AMYLASES: se.  ANIMAL.  CHOLECYSTOKININ: pd.  ELECTROLYTES: se.
   MALE.  ORGAN-WEIGHT: de.  PANCREATIC-JUICE: de.  PROTEINS: se.  RATS.
   SECRETIN: pd.  TIME-FACTORS.
AB The chronically reserpinized rat has been proposed as an animal
   model for cystic fibrosis on the basis of morphologic and secretory
   alterations in the submaxillary gland and of abnormalities in
   pulmonary secretions.  In this investigation, the volume and
   composition of pancreatic juice from reserpine treated rats (0.5
   mg/kg/day) have been compared to those of untreated controls after
   stimulation with purified cholecystokinin (0.1 microgram/kg body
   weight) and with crude and purified preparations of secretin (6
   microns/100 g body weight) infused iv for 30-min periods.  The
   results demonstrate that the treated animals secreted a
   significantly lower volume of pancreatic juice after stimulation
   with these secretagogues.  Flow rates were also significantly
   reduced after stimulation with cholecystokinin and crude secretin.
   Protein and amylase outputs in response to cholecystokinin were
   smaller than in control animals after unrestritced feedings, but
   greater after a 24-hr fast.  Total bicarbonate output was also
   reduced after stimulation with either crude or purified secretin and
   the normal excretion patterns for bicarbonate and chloride were
   either absent of reversed in the secretin-stimulated pancreatic
   juice of the treated animals.  Whole pancreas homogenates from the
   treated animals showed significant increases in Ca++ and protein
   content.  These results indicate that chronic administration of
   reserpine alters the secretion of water, protein, and bicarbonate
   from the rat pancreas and that it affects several of the exocrine
   glands involved in cystic fibrosis.  These findings lend support to
   the concept of an animal model for the human disease.  The chronic
   administration of reserpine to rats has been shown to induce
   alterations in salivary and pulmonary secretions which resemble
   those seen in patients with cystic fibrosis.  The concept of an
   animal model has been proposed on the basis of these observations.
   The pancreas is another exocrine gland prominently involved in
   cystic fibrosis and if it can be demonstrated that reserpine
   administration also induces alterations in pancreatic secretion, the
   concept of the animal model would be strengthened considerably.
RF 001   BOGART BI             PEDIATR RES                     11   131 977
   002   CASE RM               J PHYSIOL (LOND)               235    75 973
   003   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   004   EIMERL S              J BIOL CHEM                    249  3991 974
   005   HADORN B              IN: LAWSON D PROC 5TH INT CF          56 969
   006   IMMKEN L              CF CLUB ABST                    16     9 975
   007   LOWRY OH              J BIOL CHEM                    193   265 951
   008   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   009   MANGOS JA             AM J PHYSIOL                   221   496 971
   010   MANGOS JA             PROC SOC EXP BIOL MED          146   321 974
   011   MARTINEZ JR           PEDIATR RES                      9   463 975
   012   MARTINEZ JR           PEDIATR RES                      9   470 975
   013   SEWELL WA             J PHYSIOL (LOND)               252   379 975
   014   SHAW HM               AUST J BIOL SCI                 25   147 972
   015   SHAW HM               J EXP PHYSIOL                   58   229 973
   016   THOMPSON FE           PEDIATR RES                     10   632 976
   017   WILLIAMS JA           BIOCHEM BIOPHYS RES COMMUN      60   542 974
   018   WOOD DL               PEDIATR RES                     11   827 977
CT   1   SIMSON JAV            LAB INVEST                      39   157 978
     2   MARTINEZ JR           PEDIATR RES                     13  1156 979
     3   MAWHINNEY TP          PEDIATR RES                     13   760 979
     4   SETSER ME             LAB INVEST                      41   256 979
     5   DAVIS PB              PEDIATR RES                     14    83 980
     6   MAWHINNEY TP          PEDIATR RES                     14   872 980
     7   MORTON D              PEDIATR RES                     14    18 980
     8   MCCURDY RE            PEDIATR RES                     15  1308 981
     9   CUTLER LS             VIRCHOWS ARCH PATHOL ANAT HIS  392   185 981
    10   ROOMANS GM            ULTRASTRUCTURAL PATHOL           3   285 982
    11   SHIFFMAN ML           PEDIATR RES                     16   104 982
    12   MACLEOD RM            DEVELOP NEUROSCI                16   271 983
    13   MARTINEZ JR           PEDIATR RES                     17   523 983
    14   SHIFFMAN ML           PEDIATR RES                     17   486 983
    15   MODRZAKOWSKI MC       CAN J MICROBIOL                 29  1339 983
    16   LINGARD JM            AM J PHYSIOL                   245  G690 983
    17   LOGIN IS              BRAIN RES                      260    99 983
    18   CASTEELS R            J PHYSIOL (LOND)               340   403 983
    19   BOYD RL               PEDIATR RES                     18  1028 984
    20   CHUNG KS              PEDIATR RES                     18  1300 984
    21   SPICER SS             ENVIRON HEALTH PERSPECT         55   193 984
    22   MARTINEZ JR           PEDIATR RES                     19   711 985
    23   HAZLETT D             PEDIATR RES                     20  1236 986

PN 78176
RN 00956 
AN 78248075
AU Gillard-B-K.  Markman-H-C.  Feig-S-A.
TI Differences between cystic fibrosis and normal saliva alpha-amylase
   as a function of age and sex.
SO Pediatr-Res. 1978 Aug. 12(8). P 868-72.
MJ ALPHA-AMYLASE: me.  AMYLASES: me.  CYSTIC-FIBROSIS: en.  SALIVA: en.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  ALPHA-AMYLASE: an.  CHILD.
   COMPARATIVE-STUDY.  FEMALE.  HUMAN.  MALE.  MIDDLE-AGE.  PARENTS.
   SALIVA: an.  SALIVARY-PROTEINS: an.  SEX-FACTORS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Alpha-amylase activity and protein concentration of cystic fibrosis
   (CF), obligate heterozygote (H), and normal (N) saliva have been
   evaluated with respect to genotype, age, sex and clinical status.
   "Factors" present in CF saliva had no detectable effect on salivary
   amylase activity under reaction conditions optimized for both
   competitive and noncompetitive inhibition.  Tris
   [tris-(hydoxy-methyl)aminomethane] inhibited amylase activity with a
   Ki = 59 plus or minus 10 mM, but CF "factors" had no detectable
   effect on either substrate or Tris binding to alpha-amylase.
   Alpha-amylase concentrationand protein content of CF saliva had
   bimodal distributions.  Thirty-six percent of the CF patients were
   found to be amylase hypersecretors, with amylase concentration 3 or
   more SD above the N mean.  Amylase hypersecretion was marginally
   correlated with both genetic factors (with parent values, P = 0.075)
   and clinical status (with Scwachman scores, P = 0.068).  All the
   hypersecretors were in the 14-24 year age group.  Amylase
   concentration for this age was significant higher in CF samples
   (mean plus or minus SD), 82 plus or minus 37 starch units/ml (n = 
   12), than in N samples, 33 plus or minus 17 starch unites/ml (n =
   13), as measured by the Student t-test (P < 0.001).  Salivary
   protein content of 14- to 24-year-old CF males was elevated compared
   to all other groups [1.57 plus or minus 0.76 (n = 5) vs. 0.63 plus
   or minus  0.47 (n = 20); Student t-test, P < 0.005].  Mean specific
   activity of male saliva dropped sharply as age increased from 10-15
   years, from over 200 to less than 75 starch units/mg protein.  Mean
   normal female specific activity values were essentially constant [97
   plus or minus 50 (n = 18) starch units/mg protein] from 5-30 years
   of age.  CF male specific activity values decreased similarly to the
   N male values from preadolescence to adolescence, but the mean CF
   female values peaked later, at 17 years, with a maximum of 171 plus
   or minus 58 (n = 4).  This is significantly higher than all the
   other groups in the 16- to 20-year age range: 63 plus or minus 30 (n
   = 9), P < 0.005.  These data emphasize the need for age- and
   sex-matched controls in all studies of salivary composition.  We
   were unable to detect any effect of a salivary CF factor on the
   enzymatic activity of alpha-amylase.  Hypersecretion of salivary
   alpha-amylase was observed in 36% of CF patients.  This may reflect
   alterations in secretory function basic to CF, or be secondary to
   the disease process and result from decreased secretion from the
   mucous salivary glands or deterioration of pancreatic function.
RF 001   BISHOP SH             CF CLUB ABST                    14    25 973
   002   BLOMFIELD J           AUST PAEDIATR J                 10    75 974
   003   BLOMFIELD J           PEDIATR RES                     10   574 976
   004   BOWMAN BH             SCIENCE                        164   325 969
   005   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   006   DIXON M               BIOCHEM J                       55   170 953
   007   DIXON WJ              BMDP: BIOMEDICAL COMPUTER PRO            975
   008   DOGGETT RG            NATURE NEW BIOL                243   250 973
   009   DOGGETT RG            TEX REP BIOL MED                31   685 973
   010   FISHER EH             BIOCHEM PREP                     8    27 961
   011   GILLARD BK            PEDIATR RES                     10   907 976
   012   GILLARD BK            CLIN CHEM                       23  2279 977
   013   GILLARD BK            BIOCHEMISTRY                    16  3978 977
   014   ANON                  J PEDIATR                       88   711 976
   015   LEHNINGER AL          BIOCHEMISTRY                    14   197 975
   016   LOWRY OH              J BIOL CHEM                    193   265 951
   017   MANDEL ID             AM J DIS CHILD                 113   431 967
   018   MAYO JW               ARCH BIOCHEM BIOPHYS           175   507 976
   019   MCNEELY CM            CF CLUB ABST                    16     6 975
   020   MILLER GL             ANAL CHEM                       31   964 959
   021   NELSON TE             CF CLUB ABST                    15     7 974
   022   POULSEN JH            J PHYSIOL (LOND)               264   323 977
   023   ROBYT JF              IN: RADLEY JA                        431 968
   024   SHWACHMAN H           CF CLUB ABST                    16    19 975
   025   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   026   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   027   SMITH QT              PROC SOC EXP BIOL MED          153   241 976
   028   SPOCK A               PEDIATR RES                      1   173 967
   029   TOWNES PL             AM J HUM GENET                  28   378 976
   030   WOLF RO               J LAB CLIN MED                  87   164 976
   031   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   GILLARD BK            PEDIATR RES                     14  1168 980
     2   PARK RW               GASTROENTEROLOGY                81  1143 981
     3   GILLARD BK            CLIN CHEM                       29  1119 983

PN 78177
RN 00957 
AN 78157291
AU Bogart-B-I.  Conod-E-J.  Gaerlan-P-F.  Conover-J.
TI The biologic activities of cystic fibrosis serum.  II.
   Ultrastructural aspects of the effect of cystic fibrosis sera and
   calcium ionophore A23187 on rabbit tracheal explants.
SO Pediatr-Res. 1978 Jan. 12(1). P 15-24.
MJ A-23187: pd.  ANTIBIOTICS: pd.  CYSTIC-FIBROSIS: bl.  TRACHEA: de.
MN ANIMAL.  CALCIUM: me, ph.  CILIA: ul.  CYSTIC-FIBROSIS: pp.
   EPITHELIUM: ul.  MALE.  RABBITS.  TRACHEA: ul.
AB Ultrastructural and cytochemical observations indicate that both
   cystic fibrosis (CF) sera and calcium ionophore A23187 induce a
   swelling or an increase in the size and possibly the number of
   secondary lysosomes and an increase in mucus secretion in epithelium
   of the rabbit tracheal bioassay system. Extended incubation of the
   rabbit tracheal explants with either CF or control sera produces a
   cytotoxic effect on the tracheal epithelium, but only after the
   termination of the normal bioassay time period. Comparative
   ultrastructural study of the effect of both CF sera and calcium
   ionophore A23187 on the rabbit tracheal bioassay system indicates
   that increased membrane permeability to calcium may be important in
   the production of the ciliary dyskinesia response by CF serum
   factor(s) in the rabbit tracheal bioassay system.
RF 001   ADSHEAD PC            ANN NY ACAD SCI                253   192 975
   002   BARRETT LA            CANCER RES                      36  1003 976
   003   BAUR PS               TEX REP BIOL MED                34   155 976
   004   BOGART BI             J HISTOCHEM CYTOCHEM            16   572 968
   005   BOGART BI             J ULTRASTRUCT RES               52   139 975
   007   CHERRY JD             J PEDIATR                       79   937 971
   008   CHEUNG ATW            PEDIATR RES                     10   144 976
   009   COCHRANE DE           PROC NAT ACAD SCI USA           71   408 974
   010   CONOVER JH            PEDIATR RES                      7   220 973
   011   CONOVER JH            TEX REP BIOL MED                34    45 976
   012   DAEMS WT              IN: DINGLE JT                    1    64 969
   013   DETER RL              J CELL BIOL                     33   437 967
   014   DIRKSEN ER            CANCER RES                      28   906 968
   015   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   016   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   017   EIMERL S              J BIOL CHEM                    249  3991 974
   018   ERRICSSON JLE         IN: DINGLE JT                    2   345 969
   019   FARQUHAR MG           IN: DINGLE JT                    2   462 969
   020   FARRELL PM            PEDIATR RES                     10   127 976
   021   GALLIN JI             J CELL BIOL                     62   594 974
   022   GILLESPIE E           J CELL BIOL                     50   544 971
   023   GINN FL               AM J PATHOL                     53  1041 968
   024   JACQUES PJ            IN: DINGLE JT                    2   395 969
   025   KAGAYAMA M            J CELL BIOL                     62   519 974
   026   KIRSCHNA MW           J SUPRAMOL STRUCT                2   412 974
   027   KURIYAMA R            J BIOCHEM (TOKYO)               75   463 975
   028   LOBECK CC             IN: STANBURY JB                     1605 972
   029   LUFT JH               J BIOPHYS BIOCHEM CYTOL          9   409 961
   030   MIRA-MOSER F          EUR J CLIN INVEST                6   103 976
   031   MOTOKAWA T            J CELL BIOL                     66   377 975
   032   NEUTRA M              J CELL BIOL                     30   119 966
   033   PALADE GE             IN: HAYASHI T                         64 959
   034   PRESSMAN BC           FED PROC                        32  1698 973
   035   RAVAZZOLA M           LAB INVEST                      35   425 976
   036   REED PW               J BIOL CHEM                    247  6970 972
   037   SATIR P               SCIENCE                        190   586 975
   038   SELINGER Z            PROC NAT ACAD SCI USA           71   128 974
   039   SHELANSKI ML          PROC NAT ACAD SCI USA           70   765 973
   040   SOMLYO AP             J CELL BIOL                     66   425 975
   041   SPOCK A               PEDIATR RES                      1   173 967
   042   TRUMP BF              IN: TRUMP BF                           1 975
   043   TRUMP BF              IN: RICHTER GW                        84 971
   044   TRUMP BF              IN: KARBE F                          548 974
   045   WEISENBERG RC         SCIENCE                        177  1104 972
   046   WONG DT               ARCH BIOCHEM BIOPHYS           156   578 973
CT   1   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
     2   BOGART BI             BIOCHEM BIOPHYS RES COMMUN      88  1398 979
     3   KENNEDY JR            PEDIATR RES                     14  1173 980
     4   SANDERSON MJ          PEDIATR RES                     15   219 981
     5   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
     6   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
     7   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
     8   CEDER O               ULTRASTRUCTURAL PATHOL           4   305 983
     9   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    10   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    11   KATZ S                CELL CALC                        5   421 984
    12   NEAL JL               EVOLUTIONARY THEORY              7   153 985
    13   VONEULER AM           EXP MOL PATH                    43   142 985
    14   BOGART BI             J CHROMATOGR                   381    29 986
    15   ROOMANS GM            SCANN ELECTRON MICROSC        1986   165 986

PN 78178
RN 00958 
AN 78157289
AU Grinwald-P-M.  Segal-M-B.
TI Effect of saliva from cystic fibrosis patients and from normal
   subjects on red blood cell sodium transport.
SO Pediatr-Res. 1978 Jan. 12(1). P 1-3.
MJ CYSTIC-FIBROSIS: me.  ERYTHROCYTES: me.  SALIVA: ph.  SODIUM: me.
MN ADULT.  BIOLOGICAL-TRANSPORT.  CYSTIC-FIBROSIS: bl.  FEMALE.  HUMAN.
   MALE.  OUABAIN: pd.  SODIUM: bl.
AB Saliva, whether taken from patients with cystic fibrosis or from
   normal subjects, caused an increase in red blood cell Na+ efflux (in
   the presence or absence of ouabain) of 19-29% as compared with non-
   saliva controls. However, there was no significant difference between
   the effects of cystic fibrosis saliva and normal saliva.
RF 001   BALFE JW              SCIENCE                        162   689 968
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   003   DUFFY MJ              LANCET                           2   136 972
   004   HOFFMAN JF            ANN NY ACAD SCI                137   566 966
   005   KAISER D              LANCET                           1  1003 970
   006   LAPEY A               PEDIATR RES                      5   446 971
   007   MANGOS JA             PEDIATR RES                      1   436 967
   008   SACHS JR              J CLIN INVEST                   46    65 967
   009   TAUSSIG LM            LANCET                           1  1367 972
CT   1   SEALE TW              PEDIATR RES                     14  1398 980
     2   BERGHOUT AGRV         PEDIATR RES                     18  1017 984

PN 78179
RN 00959 
AN 79073912
AU Davidson-G-P.  Koheil-A.  Forstner-G-G.
TI Salivary amylase in cystic fibrosis: a marker of disordered
   autonomic function.
SO Pediatr-Res. 1978 Oct. 12(10). P 967-70.
MJ AMYLASES: bl.  CYSTIC-FIBROSIS: en.  SALIVA: en.
MN CHILD.  CYSTIC-FIBROSIS: me.  EATING.  FECES: an.  HUMAN.
   ISOENZYMES: bl.  LIPIDS: an.  PANCREAS: en.  PANCREATIC-DISEASES: en.
   SYNDROME.
AB Total serum amylase was determined in 83 patients with cystic
   fibrosis (CF) (14 of whom had no steatorrhea), 21 control patients,
   and 6 patients with Shwachman's syndrome. Patients with CF who had
   steatorrhea and therefore lacked pancreatic function had the same
   serum levels pre- and postprandially as the control subjects, whereas
   patients without steatorrhea and, therefore, with evidence of
   pancreatic function, had significantly higher levels. The patients
   with Shwachman's syndrome had significantly lower total serum amylase
   than the three other patient groups. Only the patients with
   Shwachman's syndrome demonstrated a significant postprandial rise in
   activity. Only the salivary isoenzyme was detected in patients with
   Shwachman's syndrome or CF and apparently absent pancreatic function,
   whereas CF patients without steatorrhea had both salivary and
   pancreatic isoenzymes. These results demonstrate that patients with
   CF have an increase in circulating salivary amylase isoenzyme whereas
   patients with Shwachman's syndrome do not. The increase probably
   reflects an autonomic hyperstimulation of salivary secretion which is
   primary to CF, and unrelated to the state of pancreatic activity.
RF 001   BARBERO GJ            PEDIATRICS                      29   788 962
   002   BARBERO GJ            CF CLUB ABST                           4 967
   003   BLOMFIELD J           AUST PAEDIATR J                 10    75 974
   004   BLOMFIELD J           PEDIATR RES                     10   574 976
   005   BONGIOVANNI AM        LAB INVEST                      10   956 961
   006   CARAWAY WT            AM J CLIN PATHOL                32    97 959
   007   GIBBS GE              PROC SOC EXP BIOL MED           77   251 951
   008   HAGLUND H             METHODS BIOCHEM ANAL            19     1 971
   009   JANOWITZ HD           AM J MED                        27   924 959
   010   MANDEL ID             AM J DIS CHILD                 113   431 967
   011   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   012   MARMAR J              GASTROENTEROLOGY                50   551 966
   013   NIKOLAJEK WP          EUR J PEDIATR                  122   289 976
   014   ODONNELL MD           CLIN CHEM                       23   560 977
   015   ROY CC                PEDIATR CLIN GASTROENTEROL               975
   016   RUBIN LS              PEDIATRICS                      38   865 966
   017   SHWACHMAN H           J PEDIATR                       65   645 964
   018   SHWACHMAN H           PEDIATRICS                      55    86 975
   019   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   020   SKUDE G               SCAND J GASTROENTEROL           11   525 976
   021   SUN DCH               GASTROENTEROLOGY                45   203 963
   022   TAUSSIG LM            PEDIATRICS                      54   229 974
   023   VESTERBERG O          ACTA CHEM SCAND                 20   820 966
   024   WOLF RO               J LAB CLIN MED                  87   164 976
   025   WORMSLEY KG           SCAND J GASTROENTEROL            4   623 969
CT   1   WOLF RO               PEDIATR RES                     13  1076 979
     2   QUINTON PM            NATURE                         279   551 979
     3   GILLARD BK            PEDIATR RES                     14  1168 980
     4   ROULET M              PEDIATR RES                     14  1360 980
     5   WOLF RO               PEDIATR RES                     14   968 980
     6   DAVIDSON GP           J CLIN PATHOL                   33   390 980
     7   PARK RW               GASTROENTEROLOGY                81  1143 981
     8   ROSCHER AA            J PHARMACOL EXP THER           216   419 981
     9   MITCHELL EA           AUST PAEDIATR J                 18   118 982
    10   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             2   249 984
    11   MORGENSTERN T         MONATSSCHR KINDERHEILKD        132   661 984
    12   MAILLIE AJ            SCAND J GASTROENTEROL           21   941 986
    13   LIU P                 J CAN ASSOC RADIOL              37   279 986

PN 78180
RN 00960 
AN 79073920
AU Katz-S.
TI Calcium and sodium transport processes in patients with cystic
   fibrosis.  I. A specific decrease in Mg2+-dependent, Ca2+-adenosine
   triphosphatase activity in erythrocyte membranes from cystic
   fibrosis patients.
SO Pediatr-Res. 1978 Nov. 12(11). P 1033-8.
MJ ADENOSINE-TRIPHOSPHATASE-CALCIUM: me.  CALCIUM: me.
   CYSTIC-FIBROSIS: en.  ERYTHROCYTE-MEMBRANE: en.  ERYTHROCYTES: en.
   MAGNESIUM: me.  SODIUM: me.
MN ADENOSINE-TRIPHOSPHATASE-SODIUM-POTASSIUM: me.  ADOLESCENCE.  ADULT.
   FEMALE.  HUMAN.  MALE.
AB Calcium-ATPase activity (Mg2+-dependent Ca2+-ATPase, ATP
   phosphohydrolase, EC 3.6.1.3) in erythrocyte membrane preparations
   from cystic fibrosis (CF) patients was greatly reduced compared to
   erythrocyte membranes from control subjects. The Km for calcium was
   found to be similar in the two groups; however, the Vmax, the maximal
   rate of activation of the Ca2+-ATPase, is reduced by 50% in the
   erythrocyte membrane preparations of the CF patients (P less than
   0.001). In contrast, the Mg2+-ATPase activity of erythrocyte
   membranes from CF patients was unchanged compared to the control
   subjects. No difference in the Na+,K+-ATPase activity in erythrocyte
   membranes from CF patients compared to control patients could be
   observed. This indicates that the Ca2+-ATPase activity noted in CF
   erythrocytes is not part of a generalized membrane or membrane-bound
   enzyme alteration. It remains to be determined whether this
   alteration in Ca2+-ATPase activity is directly related to a defect in
   calcium transport in these cells and is a generalized phenomenon in
   CF present in cell types more directly involved in secretion.
RF 001   BAKER PF              IN: BUTLER JAV                       179 972
   002   BETTELHEIM FA         BIOCHIM BIOPHYS ACTA           236   702 971
   003   BLOMFIELD J           ARCH DIS CHILD                  48   267 973
   004   BLOSTEIN R            J BIOL CHEM                    243  1957 968
   005   BLOSTEIN R            J BIOL CHEM                    245   270 970
   006   BOAT TF               PEDIATR RES                      8   531 974
   007   BOND GH               BIOCHIM BIOPHYS ACTA           323   592 973
   008   CALDWELL PG           IN: CUTHBERT AW                       10 973
   009   CHERNICK WS           J PEDIATR                       59   890 961
   010   COLE CH               PEDIATR RES                      6   616 972
   011   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   012   DOUGLAS WW            BR J PHARMACOL                  34   451 968
   013   FEIG SA               PEDIATR RES                      8   594 974
   014   FORSTNER JF           PEDIATR RES                     10   609 976
   015   GIBSON LE             PEDIATRICS                      48   695 971
   016   GLYNN IM              BIOCHEM J                       90   147 964
   017   HORTON CR             BIOCHEM BIOPHYS RES COMMUN      40   505 970
   018   KATZ S                CF CLUB ABST                    18     9 977
   019   KATZ S                BIOCHIM BIOPHYS ACTA           389   314 975
   020   KATZ AM               ADV CYCLIC NUCLEO RES            5   453 975
   021   LEE KS                J GEN PHYSIOL                   54   713 969
   022   LOWRY OH              J BIOL CHEM                    193   265 951
   023   MANDEL ID             CLIN PEDIATR                     8   161 969
   024   MCEVOY FA             CLIN CHIM ACTA                  54   195 974
   025   POST RL               METHODS ENZYMOL                 10   762 967
   026   RUSSELL JM            J GEN PHYSIOL                   63   144 974
   027   SCHATZMANN HJ         J PHYSIOL (LOND)               235   551 973
   028   WIESMANN UN           CF CLUB ABST                     9    12 968
   029   WINS P                BIOCHIM BIOPHYS ACTA           120   341 966
   030   ZIPKIN I              CF CLUB ABST                    11    57 970
CT   1   GOPINATH RM           AM J HEMATOL                     7   303 979
     2   ANSAH TA              CELL CALC                        1   195 980
     3   SCANLIN TF            CLIN CHEST MED                   1   424 980
     4   RAESS BU              J PHARMACOL METHODS              4   273 980
     5   DAVIS PB              PEDIATR RES                     14    83 980
     6   ANSAH TA              PROC WEST PHARMACOL SOC         23   389 980
     7   KATZ S                CLIN CHIM ACTA                 100   245 980
     8   FODER B               CLIN CHIM ACTA                 104   187 980
     9   KATZ S                CELL CALC                        2   545 981
    10   LARSEN FL             NATURE                         294   667 981
    11   SORSCHER EJ           LANCET                           1   368 982
    12   WARWICK WJ            AM J MED TECHNOLOGY             48   539 982
    13   REINILA M             ANAL BIOCHEM                   124    19 982
    14   APPLEGARTH DA         MED HYPOTHESES                  11   277 983
    15   FONDACARO JD          LIFE SCI                        32  1449 983
    16   HARRIS A              CLIN CHIM ACTA                 128    41 983
    17   MINER C               J PHYSIOL (LOND)               338  P 63 983
    18   NORDT FJ              ANN NY ACAD SCI                416   651 983
    19   SEYMOUR CA            BIOESSAYS                        1    38 984
    20   KATZ S                CELL CALC                        5   421 984
    21   BERGHOUT AGRV         PEDIATR RES                     18  1017 984
    22   DEARBORN DG           PEDIATR RES                     18   890 984
    23   VONRUECKER AA         PEDIATR RES                     18   594 984
    24   WALLER RL             LIFE SCI                        35   775 984
    25   PETTEGREW JW          J MAGNET RESON                  57   185 984
    26   CLOUGH DL             CLIN CHIM ACTA                 138   259 984
    27   WALLER RL             CELL CALC                        6   245 985
    28   SUTER S               PEDIATR RES                     19   346 985
    29   ALBAZZAZ FJ           J APPL PHYSIOL                  59  1191 985
    30   MUALLEM S             BIOCHIM BIOPHYS ACTA           819   143 985
    31   ALLEN BG              CELL CALC                        7   161 986
    32   BRIDGES MA            PEDIATR RES                     20   356 986
    33   DAVIS PB              PEDIATR RES                     20  1290 986
    34   RUPP GM               MED HYPOTHESES                  20   245 986
    35   MORRISSEY SM          DIGESTION                       34    28 986
    36   HUNSINGER RN          CLIN CHIM ACTA                 156   165 986
    37   SCHONI MH             CELL CALC                        8    53 987

PN 78181
RN 00961 
AN 78225004
AU Davis-P-B.  Braunstein-M.  Jay-C.
TI Decreased adenosine 3':5'-monophosphate response to isoproterenol in
   cystic fibrosis leukocytes.
SO Pediatr-Res. 1978 Jun. 12(6). P 703-7.
MJ ADENOSINE-CYCLIC-MONOPHOSPHATE: bl.  CYSTIC-FIBROSIS: bl.
   ISOPROTERENOL: pd.  LEUKOCYTES: me.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS.  CYSTIC-FIBROSIS: fg.  DIGOXIN.
   FEMALE.  GRANULOCYTES: me.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   LEUKOCYTES: de.  MALE.  MIDDLE-AGE.  PANCREATIC-EXTRACTS.
   PROSTAGLANDINS-E: pd.  RECEPTORS-ADRENERGIC-BETA: ph.
AB Leukocyte preparations from cystic fibrosis (CF) patients produced
   markedly less adenosine 3':5'-monophosphate (cAMP) in response to
   isoproterenol than normal cells.  Both stimulation ratio and net
   isoproterenol-stimulated accumulation of cAMP were significantly (P
   < 0.001) lower in mixed leukocyte preparations from 20 CF patients
   (29 trials) compared to 21 normal subjects (49 trials).  There was
   no significant correlation of results with clinical score, and no
   differences in the CF group attributable to medications or presence
   of pancreatic insufficiency.  CF heterozygotes had mean stimulation
   ratio and mean net isoproterenol-stimulated cAMP intermediate
   betweem normal and CF.  There were no statistically significant
   differences among normal subjects, CF patients, and CF heterozygotes
   in basal cAMP or prostaglandin E1-stimulated cAMP.  Purified
   mononuclear cells from five normal persons and seven CF homozygotes
   had the same basal and prostaglandin E1-stimulated cAMP, but
   isoproterenol-stimulated cAMP was markedly depressed (P < 0.01) in
   the CF cells.  Granulocytes from six normal persons and nine CF
   patients also had the same basal and prostaglandin E1-stimulated
   cAMP, but isoproterenol-stimulated cAMP was decreased (P < 0.05) in
   the CF samples.  These results clearly demonstrate a difference
   between normal and CF leukocytes in cAMP response to beta-adrenergic
   stimulation.  The diminised cAMP response to beta-adrenergic
   stimulation in CF is probably related to the presence of a CF gene,
   and may interact with other genetic abnormalities to produce the
   clinical syndrome of CF.
RF 001   ATKINSON JP           J CYCLIC NUCLEOTIDES RES         2   297 976
   002   BOLANDE RP            ARCH PATHOL                     95   172 973
   003   BOURNE HR             J PHARMACOL EXP THER           178     1 971
   004   BOYD EM               CAN MED ASSOC J                 82   821 960
   005   BOYUM A               SCAND J CLIN LAB INVEST SUPPL   97    77 968
   006   BRAUNSTEIN M          CF CLUB ABST                          28 975
   007   BROWN BL              ADV CYCLIC NUCLEO RES            2    25 972
   008   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
   009   BUSSE WW              J ALLERGY CLIN IMMUNOL          58   586 976
   010   CAMPBELL IM           PEDIATRICS                      57   480 976
   011   CHERNICK WS           MOD PROBL PEDIATR               10   125 967
   012   CHERNICK WS           J PEDIATR                       59   890 961
   013   CONOLLY ME            J CLIN INVEST                   58  1307 976
   015   DAVIS PB              FED PROC                        36   409 977
   016   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA        156 970
   017   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   018   ENGELHARD VH          PROC NAT ACAD SCI USA           73  4482 976
   019   FARBER S              AM J DIS CHILD                  64   953 942
   021   LEFKOWITZ RJ          N ENGL J MED                   295   323 976
   022   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   023   MARTINEZ JR           PEDIATR RES                      9   463 975
   024   MARTINEZ JR           PEDIATR RES                      9   470 975
   025   MCEVOY FA             LANCET                           2   236 975
   026   MICKEY J              J BIOL CHEM                    250  5727 975
   027   MURAD F               J CLIN ENDOCRINOL METAB         40   552 975
   028   PARKER DW             J CLIN INVEST                   52    48 973
   029   PATEL KR              CLIN ALLERGY                     4   311 974
   030   RUBIN LS              PEDIATRICS                      38   865 966
   031   SCHAAP T              IN: MANGOS JA                        291 976
   032   SIMOPOULOS AP         PEDIATR RES                      6   355 972
   033   SNIDER DE             J CLIN INVEST                   58   524 976
   034   STURGESS JM           BR J EXP PATHOL                 54   388 973
   035   TALLMAN JF            PROC NAT ACAD SCI USA           74   873 977
   036   TAUSSIG LM            J PEDIATR                       82   380 973
   037   THOMPSON FE           PEDIATR RES                     10   632 976
   038   WILLIAMS LT           J CLIN INVEST                   57   149 976
   039   WRIGHT R              PEDIATR RES                     10   373 976
   040   ZENSER TV             J BIOL CHEM                    251  7431 976
CT   1   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
     2   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
     3   LAKE CR               CLIN CHIM ACTA                  92   141 979
     4   DAVIS PB              IRCS MED SCI BIOCHEM             8   413 980
     5   AURBACH GD            ADV CYCLIC NUCLEO RES           12     1 980
     6   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     7   DAVIS PB              PEDIATR RES                     14    83 980
     8   DAVIS PB              PEDIATR RES                     14   863 980
     9   ROSCHER AA            PEDIATR RES                     14   261 980
    10   AITKEN DA             J MED GENET                     17   187 980
    11   DAVIS PB              J LAB CLIN MED                  96    75 980
    12   LEMANSKE RF           AM REV RESPIR DIS              122   213 980
    13   DAVIS PB              N ENGL J MED                   302  1453 980
    14   MARKOVAC J            BIOCHEM MED                     26   299 981
    15   JOHNSON DL            RES COMMUN CHEM PATH PHARM      32   377 981
    16   GALANT SP             J CLIN INVEST                   68   253 981
    17   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
    18   BYLUND DB             J PHARMACOL EXP THER           218   134 981
    19   FRASER CM             N ENGL J MED                   305  1165 981
    20   ROAN Y                PEDIATR RES                     16   591 982
    21   MOTULSKY HJ           N ENGL J MED                   307    18 982
    22   ZAMMARCHI E           RIV ITAL PEDIATR                 9   505 983
    23   DAVIS PB              J CHRON DIS                     36   269 983
    24   DAVIS PB              J CLIN INVEST                   71  1787 983
    25   CABRINI G             RIV ITAL PEDIATR                10   405 984
    26   STESSMAN J            J GERONTOL                      39   667 984
    27   SATO K                J CLIN INVEST                   73  1763 984
    28   EBSTEIN RP            ISR J MED SCI                   21   302 985
    29   MITCHELL EA           AUST PAEDIATR J                 21   127 985
    30   ERICKSON RP           AM J HUM GENET                  37   124 985
    31   KOPELMAN H            N ENGL J MED                   312   329 985
    32   DAVIS PB              HORM METAB RES                  18   217 986
    33   DAVIS PB              PEDIATR RES                     20  1290 986
    34   BOUCHER RC            J CLIN INVEST                   78  1245 986
    35   SCHONI MH             EUR J PEDIATR                  145    80 986
    36   SPAIDE RF             AM J OPHTHALMOL                103   204 987

PN 78182
RN 00962 
AN 78225040
AU Allue-X.  Sanjurjo-P.
TI Triglyceride levels after Intralipid infusion in children with
   cystic fibrosis.
SO Pediatrics. 1978 Jun. 61(6). P 924-5.
MJ CYSTIC-FIBROSIS: bl.  DIETARY-FATS: ad.  GLYCERIN: ad.
   PHOSPHATIDYLCHOLINES: ad.  TRIGLYCERIDES: bl.
MN CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: th.  DRUG-COMBINATIONS.
   FATTY-ACIDS-ESSENTIAL: bl.  FATTY-ACIDS-NONESTERIFIED: bl.  FEMALE.
   HUMAN.  MALE.  PARENTERAL-FEEDING.
EX Infusions of soybean oil emulsion (Intralipid) have been reported to
   correct essential fatty acid (EFA) deficiency in patients with cystic
   fibrosis of the pancreas.  This article reports the immediate effects
   of Intralipid infusion in patients with CF in an attempt to ascertain
   through biochemical data whether the use of Intralipid at the
   reported dose is free of untoward effects.  Six patients with CF were
   placed in a protocol that called for periodic infusions with soybean
   oil emulsion containing EFAs.  The first three patients received 2
   gm/kg of body weight of Intralipid over a four-hour period.  The
   other three patients received half that dose over the same period.
   The first three patients developed symptoms of paleness, nausea and
   mild discomfort two to three hours after the infusion.  Further
   information is needed to determine the best method of correction of
   EFA deficiency in children with CF.
RF 001   ELLIOTT RB            PEDIATRICS                      57   474 976
   002   TAUSSIG LM            J PEDIATR                       82   380 973
   003   SANJURJO P            LANCET                           1   752 977
   004   EGGSTEIN M            KLIN WOCHENSCHR                 44   267 966
   005   CALDWELL MD           J PEDIATR                       81   894 972
   006   SHENNAN AT            J PEDIATR                       91   134 977
   007   PRESS M               LANCET                           1   597 974
   008   TASHIRO T             J PEDIATR SURG                  10   203 975
   009   FRIEDMAN Z            PEDIATRICS                      58   650 976
   010   CHASE HP              PEDIATRICS                      57   441 976
CT   1   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
     2   MERRITT RJ            ADV NUTR RES                     5    77 983

PN 78183
RN 00963 
AN 78225020
AU Bureau-M-A.  McDougall-D-M.  Beaudry-P-H.  Belmonte-M-M.
TI Late effect of nocturnal mist tent therapy related to the severity
   of airway obstruction in children with cystic fibrosis.
SO Pediatrics. 1978 Jun. 61(6). P 842-6.
MJ AIRWAY-OBSTRUCTION: th.  CYSTIC-FIBROSIS: co.
   RESPIRATORY-THERAPY.
MN ADOLESCENCE.  AIRWAY-OBSTRUCTION: et.  CHILD.  CYSTIC-FIBROSIS: pp.
   FEMALE.  HUMAN.  MALE.  MAXIMAL-MIDEXPIRATORY-FLOW-RATE.
AB To evaluate the long-term effect of nocturnal mist tent therapy on
   the progression of airway obstruction in children with cystic
   fibrosis (CF) of varying severity, two matched groups each consisting
   of 24 children with CF were studied during 18 months on mist tent
   therapy and 18 months of therapy. The progression in airway
   obstruction was measured by change in serial measurements of maximal
   midexpiratory flow (MMEF), from which a regression equation of MMEF
   against time was obtained for each individual. Changes in MMEF value
   with or without therapy were compared in patients matched for
   severity of disease as indicated by initial MMEF values. For the
   group as a whole no differences were found in the progression of the
   airway obstruction whether the patients received mist tent therapy or
   not. This therapy failed to benefit any of the groups of children
   with CF who had early, moderate, or advanced airway obstruction as
   judged from their initial MMEF value. It is concluded that nocturnal
   mist tent therapy neither decreases airway obstruction nor prevents
   its progression in children with CF.
RF 001   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   002   CHANG N               AM REV RESPIR DIS              107   672 973
   003   TAUSSIG LM            J PEDIATR                       84   619 974
   004   JEHANNE M             ANN PEDIATR (PARIS)             21   595 974
   005   NORMAN AP             PRACTITIONER                   206   786 971
   006   MATTHEWS LW           J PEDIATR                       65   558 964
   007   MATTHEWS LW           PEDIATRICS                      39   176 967
   008   AVERY ME              PEDIATRICS                      39   160 967
   009   WOLFSDORF J           PEDIATRICS                      43   799 969
   010   ALDERSON PO           J PEDIATR                       84   479 974
   011   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   012   BEAUDRY PH            AM REV RESPIR DIS               95   248 967
   013   FOX WW                PEDIATRICS                      54   293 974
CT   1   LOURENCO RV           ARCH INTERN MED                142  2299 982

PN 78184
RN 00964 
AN 78157375
AU Mellis-C-M.  Levison-H.
TI Bronchial reactivity in cystic fibrosis.
SO Pediatrics. 1978 Mar. 61(3). P 446-50.
MJ ASTHMA: co.  BRONCHI: de.  CYSTIC-FIBROSIS: co.  HISTAMINE: pd.
MN ADOLESCENCE.  ADULT.  AEROSOLS.  AIRWAY-RESISTANCE.  BRONCHI: pp.
   CHILD.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pp.  FEMALE.
   FORCED-EXPIRATORY-VOLUME.  HISTAMINE: ad.  HUMAN.  MALE.
   MAXIMAL-MIDEXPIRATORY-FLOW-RATE.  SKIN-TESTS.  SPIROMETRY.
AB There is considerable dispute regarding the prevalence of asthma in
   patients with cystic fibrosis (CF). We studied 50 patients with CF
   and compared their responsiveness to inhaled histamine with that of
   asthmatic children. The incidence of positive responses to inhaled
   histamine was 24% in the patients with CF and more than 90% in the
   asthmatic patients. We found no correlation, in the patients with CF,
   between the histamine response and several indexes of atopy (clinical
   allergic disease and positive allergen skin tests). Positive
   responders to histamine were not evenly distributed over the disease
   spectrum of CF. Instead, positive responses occurred only in those
   patients whose prechallenge pulmonary function was abnormal. We
   conclude that the heightened bronchial reactivity in patients with CF
   reflects the severity of their underlying lung disease rather than
   the presence of coexistent asthma.
RF 001   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   002   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   003   WARNER JO             ARCH DIS CHILD                  51   507 976
   004   ABBOTT V              CAN MED ASSOC J                 64   419 951
   005   DERBES VJ             J ALLERGY                       28   287 957
   006   LANDAU LI             J PEDIATR                       82   863 973
   007   HEIMLICH EM           J ALLERGY CLIN IMMUNOL          37   103 966
   008   DAY G                 ARCH DIS CHILD                  48   355 973
   009   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   010   ITKIN IH              J ALLERGY CLIN IMMUNOL          40   245 967
   011   PARKER CD             ARCH INTERN MED                115   452 965
   012   DEKOCK MA             J APPL PHYSIOL                  21   185 966
   013   ANON                  LANCET                           2   691 975
   014   CHAI H                J ALLERGY CLIN IMMUNOL          56   323 975
   015   MERCER TT             ANN ALLERGY                     23   314 965
   016   DUBOIS AB             J CLIN INVEST                   35   322 956
   017   WENG TR               AM REV RESPIR DIS               99   879 969
   018   HALUSZKA J            RESPIRATION                     32   217 975
   019   ROTHSTEIN RJ          J ALLERGY CLIN IMMUNOL          53   100 974
   020   RUBINFELD AR          AM REV RESPIR DIS              115   381 977
   021   DOLOVICH MB           J APPL PHYSIOL                  40   468 976
   022   HOGG JC               N ENGL J MED                   278  1355 968
   023   EMPEY DW              AM REV RESPIR DIS              113   131 976
   024   GIMENO F              THORAX                          29    16 974
CT   1   MITCHELL I            J PEDIATR                       93   744 978
     2   LEUPOLD W             MONOGR PAEDIATR                 10   119 979
     3   ZAMBIE MF             ANN ALLERGY                     42   290 979
     4   LARSEN GL             AM REV RESPIR DIS              119   399 979
     5   NELSON LA             AM REV RESPIR DIS              120   863 979
     6   BURDON JGW            MED J AUST                       2    77 980
     7   SLY PD                AUST PAEDIATR J                 16   205 980
     8   VANASPEREN PP         AUST PAEDIATR J                 16    53 980
     9   TOBIN MJ              THORAX                          35   807 980
    10   TABACHNIK E           AM REV RESPIR DIS              122    97 980
    11   LARSEN GL             AM J DIS CHILD                 134  1143 980
    12   PULLAN CR             BR MED J                       280   364 980
    13   DOLOVICH J            THORAX                          36   641 981
    14   HOLZER FJ             ARCH DIS CHILD                  56   455 981
    15   FANTA CH              MED CLIN NORTH AM               65   473 981
    16   FREEDMAN PM           J ALLERGY CLIN IMMUNOL          67    59 981
    17   SMYTH JA              PEDIATRICS                      68   336 981
    18   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
    19   BECHTEL JJ            AM REV RESPIR DIS              124   759 981
    20   VANASPEREN P          AM J DIS CHILD                 135   815 981
    21   MYERS JR              JAMA                           246   225 981
    22   GEORGITIS JW          ANN ALLERGY                     48   175 982
    23   EIGEN H               PEDIATRICS                      70   698 982
    24   PULLAN CR             BR MED J                       284  1665 982
    25   NADEL JA              ADV INTERN MED                  28   207 983
    26   EASTON JG             ANN ALLERGY                     50   171 983
    27   NELSON HS             ANN ALLERGY                     51   488 983
    28   PRATTER MR            CHEST                           84    42 983
    29   LEE DA                BR MED J                       286  1256 983
    30   MOK JYQ               ARCH DIS CHILD                  59   299 984
    31   PEARLMAN DS           AM J DIS CHILD                 138   459 984
    32   HAIDER SA             BR MED J                       289   109 984
    33   RUBIN BK              PEDIATR INFECT DIS               4    88 985
    34   DAVIS PB              SEM RESPIR MED                   6   261 985
    35   WONNE R               CLIN ALLERGY                    15   455 985
    36   MAPP CE               ANN ALLERGY                     54   424 985
    37   MITCHELL I            ANN ALLERGY                     54   233 985
    38   KONIG P               ANN ALLERGY                     55    95 985
    39   RIVLIN J              EUR J RESPIR DIS                67   286 985
    40   CROPP GJA             CHEST                           87  S 55 985
    41   ENARSON DA            CHEST                           87   452 985
    42   HORDVIK NL            AM REV RESPIR DIS              131   889 985
    43   DARGA LL              PEDIATR PULMONOL                 2    82 986
    44   CHAY OM               AUST NZ J MED                   16   644 986
    45   MELILLO G             EUR J RESPIR DIS                69   282 986
    46   PIEDRA P              J PEDIATR                      108   817 986

PN 78185
RN 00965 
AN 79032974
AU Rimsza-M-E.  Hernried-L-S.  Kaplan-A-M.
TI Hemorrhagic retinopathy in a patient with cystic fibrosis.
SO Pediatrics. 1978 Sep. 62(3). P 336-8.
MJ CYSTIC-FIBROSIS: co.  RETINAL-HEMORRHAGE: et.
MN ACUTE-DISEASE.  ADULT.  ALTITUDE.  ANOXIA: co.  CASE-REPORT.  FEMALE.
   HUMAN.  RESPIRATORY-FUNCTION-TESTS.  RISK.  VISION-DISORDERS: et.
AB A 21-year-old woman with a history of chronic lung disease secondary
   to cystic fibrosis (CF) developed an acute hemorrhagic retinopathy
   during exposure to moderately high altitude. Although retinal
   hemorrhages are known to occur in patients with CF, we speculate that
   the retinopathy in this case was partially related to altitudinal
   change and that patients with chronic hypoxemia may be predisposed to
   high-altitude retinopathy at much lower altitudes.
RF 001   BRUCE GM              ARCH OPHTHALMOL                 63   391 960
   002   SPALTER HF            J PEDIATR OPHTHALMOL             8     6 971
   003   CHAZAN BI             J PEDIATR                       77    86 970
   004   WONG VG               AM J OPHTHALMOL                 59   763 965
   005   LIETMAN PA            JAMA                           189   924 964
   006   COCKE JG JR           J PEDIATR                       68    27 966
   007   STRAUSS RG            PEDIATRICS                      43   297 969
   008   HOUSTON CS            LANCET                           2   758 975
   009   SINGH I               N ENGL J MED                   280   175 969
   010   FRAYSER R             N ENGL J MED                   282  1183 970
   011   SHULTS WT             ARCH OPHTHALMOL                 93   404 975
   012   RENNIE D              ARCH OPHTHALMOL                 93   395 975
CT   1   BOLDER PM             ANESTHESIOLOGY                  61   595 984
     2   SPAIDE RF             AM J OPHTHALMOL                103   204 987

PN 78186
RN 00966 
AN 78094640
AU Gilmore-J-P.  Davis-M.  Gibbs-G-E.
TI Influence of cystic fibrotic and heterozygous serum on rat jejunum.
SO Proc-Soc-Exp-Biol-Med. 1978 Jan. 157(1). P 70-4.
MJ CYSTIC-FIBROSIS: bl.  SODIUM: me.
MN BIOLOGICAL-TRANSPORT.  CYSTIC-FIBROSIS: di, fg.  HETEROZYGOTE.
   HUMAN.  JEJUNUM: me.  MEMBRANE-POTENTIALS.  RATS.
EX The rat jejunum bioassay has been shown to be capable of identifying
   both the cystic fibrotic homozygote and heterozygote and therefore
   would appear to have great potential as a screening test for the
   latter.  It is suggested that the cystic fibrosis factor does not
   influence sodium reabsorption by inhibiting an active sodium
   reabsorption mechanism but rather by inhibiting passive sodium entry
   into the cell.
RF 001   WOOD RE               LANCET                           2  1452 973
   002   MANGOS JA             PEDIATR RES                      1   436 967
   003   ARAKI H               PEDIATR RES                      9   932 975
   004   ARAKI H               PROC INT CF CONG 7TH                  28 976
   005   USSING HH             ACTA PHYSIOL SCAND              61   484 964
   006   ARMITAGE P            STATISTICAL METHODS IN MEDICA            971
   007   KAISER D              PEDIATR RES                      5   167 971
CT   1   TUCKER RD             PEDIATR RES                     13  1371 979
     2   WILL PC               PEDIATR RES                     13  1129 979
     3   TUCKER RD             IEEE TRANS BIOMED ENG           26   607 979

PN 78187
RN 00967 
AN 78179933
AU Katz-S.
TI Calcium and sodium transport processes in patients with cystic
   fibrosis 2. Mg2+- dependent, Ca2+ ATPase activity in fibroblast
   membrane preparations from cystic fibrosis patients and controls.
SO Res-Commun-Chem-Pathol-Pharmacol. 1978 Mar. 19(3). P 491-503.
MJ ADENOSINE-TRIPHOSPHATASE: me.  CALCIUM: me.  CYSTIC-FIBROSIS: me.
   SODIUM: me.
MN ADOLESCENCE.  CELL-MEMBRANE: en.  CELLS-CULTURED.  CHILD.
   FIBROBLASTS: en, ul.  HUMAN.  MAGNESIUM: me, pd.
AB Mg2+-dependent Ca2+-ATPase activity was determined in membrane
   preparations of fibroblasts grown from skin biopsies of cystic
   fibrosis patients and age-matched controls. This enzyme was
   stimulated by increasing free calcium concentrations with an apparent
   Kdiss for calcium of approximately 45 micron. Although there was a
   great deal of variation in Ca2+-ATPase activity observed between
   individual strains, there was a significant decrease in the maximal
   activation of the Ca2+-ATPase in membrane preparations of fibroblasts
   obtained from cystic fibrosis patients compared to the controls (P
   less than 0.05). This observation indicates that decreased Ca2+-
   ATPase activity is a generalized phenomenon in cystic fibrosis found
   in more than one cell-type. This decrease in Ca2+-ATPase activity may
   have a number of implications that may explain some of the
   manifestations of the disease.
RF 001   BAKER PF              IN: BUTLER JAV                       179 972
   002   BARRANCO SC           J CELL PHYSIOL                  88    33 976
   003   BETTELHEIM FA         BIOCHIM BIOPHYS ACTA           236   702 971
   004   BLOMFIELD J           ARCH DIS CHILD                  48   267 973
   005   BLOSTEIN R            J BIOL CHEM                    243  1957 968
   006   BOAT TF               PEDIATR RES                      8   531 974
   007   BOND GH               BIOCHIM BIOPHYS ACTA           323   592 973
   008   CALDWELL PG           IN: CUTHBERT AW                       10 973
   009   CHERNICK WS           J PEDIATR                       59   890 961
   010   DANES BS              J EXP MED                      129   775 969
   011   DI SANTAGNESE PA      N ENGL J MED                   277  1344 967
   012   DOUGLAS WW            BR J PHARMACOL                  34   451 968
   013   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   014   FORSTNER JF           PEDIATR RES                     10   609 976
   015   GIBSON LE             PEDIATRICS                      48   695 971
   016   GLYNN IM              BIOCHEM J                       90   147 964
   017   KATZ S                CF CLUB ABST                    18     9 977
   018   KATZ S                BIOCHIM BIOPHYS ACTA           389   314 975
   019   KROOTH RS             MED CLIN NORTH AM               53   795 969
   020   LEWIS AE              BIOSTATISTICS                            966
   021   LOWRY OH              J BIOL CHEM                    193   265 951
   022   MANDEL ID             CLIN PEDIATR                     8   161 969
   023   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   024   POST RL               METHODS ENZYMOL                 10   762 967
   025   QUISSELL DO           NATURE                         247   115 974
   026   ROUFOGALIS BD         BIOCHIM BIOPHYS ACTA           318   360 973
   027   RUSSELL JM            J GEN PHYSIOL                   63   144 974
   028   SCHATZMANN HJ         J PHYSIOL (LOND)               235   551 973
   029   SHIGEKAWA M           J BIOL CHEM                    251  6984 976
CT   1   ANSAH TA              CELL CALC                        1   195 980
     2   ANSAH TA              PROC WEST PHARMACOL SOC         23   389 980
     3   THEOHARIDES TC        LIFE SCI                        27   703 980
     4   KATZ S                CLIN CHIM ACTA                 100   245 980
     5   FODER B               CLIN CHIM ACTA                 104   187 980
     6   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
     7   GNEGY ME              BIOCHEM MED                     26   294 981
     8   SORSCHER EJ           LANCET                           1   368 982
     9   HARRIS A              CLIN CHIM ACTA                 128    41 983
    10   KATZ S                CELL CALC                        5   421 984
    11   ALLEN BG              CELL CALC                        7   161 986
    12   BRIDGES MA            PEDIATR RES                     20   356 986
    13   MORRISSEY SM          DIGESTION                       34    28 986

PN 78188
RN 00968 
AN 79014649
AU Super-M.
TI Cystic fibrosis in Southern Africa.  Including the preparation of a
   register of carriers and potential carriers.
SO S-Afr-Med-J. 1978 Jul 1. 54(1). P 18-21.
MJ CYSTIC-FIBROSIS: oc.
MN CHILD.  CYSTIC-FIBROSIS: fg.  FEMALE.  HUMAN.  MALE.
   MEDICAL-RECORDS-PROBLEM-ORIENTED.  NAMIBIA.  ZIMBABWE.  SOUTH-AFRICA.
   WHITES.
AB Little has been published on cystic fibrosis (CF) in Whites in
   southern Africa, and no figures as to incidence exist. A register of
   CF patients, their parents (obligatory carriers), siblings, uncles,
   aunts and first cousins (potential carriers) has been compiled for
   southern Africa. The degree of co-operation shown by colleagues and
   by families whose addresses have been provided by them, and possible
   reasons for non-co-operation are discussed. From the numbers and
   birth dates of patients a rough estimate of the incidence in the
   Republic of South Africa, South West Africa and Rhodesia has been
   made. In all three regions, but especially in South Africa, incidence
   is likely to have been underestimated. Details available from the
   register include the number of CF patients alive and dead, those who
   presented with meconium ileus, the number of affected patients per
   family, consanguinity among the parents or grandparents, the
   frequency with which identical surnames were encountered, and the
   sibship sizes of all those on the register. Towns and districts with
   a population rich in the CF gene are mentioned. The number of
   potential carriers has been determined, so that they can be screened
   when a practicable detection test is devised. The register has
   answered a number of questions about CF in southern Africa. It has
   focused attention on the disease in the region and played a major
   catalytic role in the formation of the Southern African Cystic
   Fibrosis Association.
RF 001   GROVE SS              S AFR J LAB CLIN MED             5   113 959
   002   LEVIN SE              S AFR MED J                     41   482 967
   003   SUPER M               S AFR MED J                     49   818 975
   004   SUPER M               S AFR MED J                     50   238 976
   005   BARBERO GJ            IN: MANGOS JA                         83 976
   006   MACKENZIE DJM         S AFR MED J                     50  2083 975
   007   CARTER CO             ABC OF MEDICAL GENETICS                  969
   008   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   009   BOTHA MC              S AFR MED J SUPPL 1             46    22 972
   010   SUPER M               LANCET                           2  1288 977
   011   SUPER M               THESIS                                   978
   012   OLIVIER SP            PIONIERTREKKE NA GAZALAND             59 943
   013   MEYER ET              IN: GEDENKBOEK VAN DIE DORSLA          5 974
   014   EMERY AEH             ELEMENTS OF MEDICAL GENET            103 975
CT   1   SUPER M               MONOGR PAEDIATR                 10   106 979
     2   SUPER M               LANCET                           2  1200 983
     3   BOTHA MC              S AFR MED J                     64   609 983

PN 78189
RN 00969 
AN 79159331
AU Kollberg-H.  Mossberg-B.  Afzelius-B-A.  Philipson-K.  Camner-P.
TI Cystic fibrosis compared with the immotile-cilia syndrome.  A study
   of mucociliary clearance, ciliary ultrastructure, clinical picture
   and ventilatory function.
SO Scand-J-Respir-Dis. 1978. 59(6). P 297-306.
MJ BRONCHIAL-DISEASES: di.  CILIA.  CYSTIC-FIBROSIS: di.
   LUNG-DISEASES-OBSTRUCTIVE: et.
MN ADULT.  BRONCHI: pp.  BRONCHIAL-DISEASES: pa, pp.  CILIA: ph, ul.
   CLINICAL-TRIALS.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pa, pp.
   DOUBLE-BLIND-METHOD.  FEMALE.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: pa, pp.  MALE.  RESPIRATORY-FUNCTION-TESTS.
   RESPIRATORY-TRACT-INFECTIONS: pa, pp.  SPIROMETRY.  SYNDROME.
   TERBUTALINE: tu.
AB Patients with cystic fibrosis (CF) were investigated for mucociliary
   clearance (with and without stimulation by terbutaline), clinical
   picture, ventilatory function and ultrastructure of cilia. The
   results were compared with those of patients with congenitally
   immotile cilia (immotile-cilia syndrome). Mucociliary clearance could
   be demonstrated in all the seven CF patients who succeeded in
   inhaling the test aerosol. Ciliary ultrastructure from a deceased CF
   patient was normal. Patients with the immotile cilia syndrome had no
   substantial clearance and defective cilia. The CF patients coughed
   more during the clearance measurements than any other group studied
   earlier, and their coughing was effective. One patient succeeded in
   avoiding coughing in both measurements and had faster clearance when
   he got terbutaline than when he got the vehicle. Although younger,
   the CF patients tended to be more obstructed in their lungs and more
   handicapped than the patients suffering from the immotile-cilia
   syndrome. The latter patients had more discomfort from rhinitis,
   sinusitis and otitis than had the CF patients. An impairment of the
   mucociliary transport rate is hence unlikely to be a primary
   pathogenic factor for the respiratory tract disease in CF patients.
RF 001   AFZELIUS BA           SCIENCE                        193   317 976
   002   BERGLUND E            ACTA MED SCAND                 173   185 963
   003   CAMNER P              ENVIRON PHYSIOL                  1   137 971
   004   CAMNER P              SCAND J RESPIR DIS              54   272 973
   005   CAMNER P              AM REV RESPIR DIS              108   131 973
   006   CAMNER P              AM REV RESPIR DIS              112   807 975
   007   CAMNER P              ARCH ENVIRON HEALTH             31    79 976
   008   ELIASSON R            N ENGL J MED                   297     1 977
   009   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   010   GIBSON LE             PEDIATRICS                      23   545 959
   011   JARSTRAND C           AM REV RESPIR DIS              110   415 974
   012   KARTAGENER M          BEITR KLIN TUBERK               83   489 933
   013   KOLLBERG H            THESIS                                   974
   014   MOSSBERG B            SCAND J RESPIR DIS              57   281 976
   015   MOSSBERG B            SCAND J RESPIR DIS              57   119 976
   016   MOSSBERG B            SCAND J RESPIR DIS              59     1 978
   017   MOSSBERG B            SCAND J RESPIR DIS              59    55 978
   018   PEDERSEN H            NATURE                         262   494 976
   019   PHILIPSON K           J AEROLOL SCI                    4    51 977
   021   SANCHIS J             N ENGL J MED                   288   651 973
   022   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   023   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   024   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   025   THOMSON ML            N ENGL J MED                   289   749 973
   026   WOOD RE               AM REV RESPIR DIS              111   733 975
   027   YEATES DB             ARCH DIS CHILD                  51    28 976
CT   1   AFZELIUS B            BR MED J                         2   674 979
     2   PAVIA D               CLIN RESP PHYSIOL               16   335 980
     3   AFZELIUS BA           THORAX                          35   401 980
     4   CAMNER P              CLIN SCI                        59    79 980
     5   MOSSBERG B            EUR J RESPIR DIS                61     8 980
     6   MOSSBERG B            EUR J RESPIR DIS                61    51 980
     7   MOSSBERG B            EUR J RESPIR DIS                61    18 980
     8   MOSSBERG B            EUR J RESPIR DIS                61    47 980
     9   RUTLAND J             THORAX                          36   654 981
    10   TEGNER H              ACTA PAEDIATR SCAND             70   629 981
    11   AFZELIUS BA           AM REV RESPIR DIS              124   107 981
    12   CORKEY CWB            AM REV RESPIR DIS              124   544 981
    13   KONRADOVA V           EUR J RESPIR DIS                63   516 982
    14   MOSSBERG B            EUR J RESPIR DIS                63   111 982
    15   YARNAL JR             POSTGRAD MED                    71   195 982
    16   KOLLBERG H            ACTA PAEDIATR SCAND SUPPL 301 1982    15 982
    17   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    18   FERGUSON JA           AM PHARM                        23    48 983
    19   MOSSBERG B            EUR J RESPIR DIS                64   129 983
    20   NEWHOUSE MT           EUR J RESPIR DIS                64   151 983
    21   RUTLAND J             AM REV RESPIR DIS              128  1030 983
    22   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    23   KATZ S                CELL CALC                        5   421 984
    24   NEWHOUSE MT           SEM RESPIR MED                   5   341 984
    25   WOOD RE               SEM RESPIR MED                   5   336 984
    26   CAMNER P              ATEMWEGS LUNGENKRANKH           10   237 984
    27   CANET E               PRESSE MED                      13  1607 984
    28   BECKER B              RESPIRATION                     46   180 984
    29   ROSSMAN CM            AM REV RESPIR DIS              129   161 984
    30   HANDELSMAN DJ         N ENGL J MED                   310     3 984
    31   AFZELIUS BA           CRC CRIT REV BIOCHEM            19    63 985
    32   SATO T                EXP MOL PATH                    43    13 985
    33   KOHLER D              ATEMWEGS LUNGENKRANKH           12   358 986
    34   WILSON R              THORAX                          41   453 986
    35   SVARTENGREN M         EUR J RESPIR DIS                68   267 986
    36   KOHLER D              EUR J RESPIR DIS                69   319 986
    37   MOSSBERG B            EUR J RESPIR DIS                69   295 986
    38   WILSON R              J INFECT DIS                   153   376 986
    39   ZWAS ST               J NUCL MED                      28   161 987
    40   SYKES DA              THORAX                          42   256 987

PN 78190
RN 00970 
AN 78096506
AU Vaughan-W-J.  Lindgren-F-T.  Whalen-J-B.  Abraham-S.
TI Serum lipoprotein concentrations in cystic fibrosis.
SO Science. 1978 Feb 17. 199(4330). P 783-6.
MJ CYSTIC-FIBROSIS: bl.  LIPOPROTEINS: bl.
MN ADOLESCENCE.  ADULT.  CARRIER-STATE: bl.  CHILD.  CHILD-PRESCHOOL.
   ELECTROPHORESIS-AGAR-GEL.  ELECTROPHORESIS-POLYACRYLAMIDE-GEL.
   FEMALE.  HUMAN.  LIPOPROTEINS-HDL: bl.  LIPOPROTEINS-LDL: bl.
   LIPOPROTEINS-VLDL: bl.  MALE.  SUPPORT-U-S-GOVT-P-H-S.
   SUPPORT-U-S-GOVT-NON-P-H-S.
AB Two major classes of lipoproteins, low density and high density, are
   decreased in the serum of patients with cystic fibrosis; major
   apoproteins are also decreased. Since essential fatty acids and
   certain fat-soluble vitamins depend on lipoproteins for transport in
   the serum, knowledge of lipoprotein levels in cystic fibrosis
   patients could prove valuable in understanding (i) the basis for the
   abnormally low serum levels of these fatty acids and vitamins and
   (ii) the effects of therapies involving these molecules.
RF 001   DANKS DM              ANN HUM GENET                   28   323 965
   002A  DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002B  DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   003   WIESE HF              AM J CLIN NUTR                  18   155 966
   003   KUO PT                J CLIN INVEST                   44  1924 965
   004   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   004   ROSENLUND ML          NATURE                         251   719 974
   005   LOBECK CC             IN: STANBURY JB                     1605 972
   006   MCCORMICK EC          J LIPID RES                      1   221 960
   006   KRINSKY NI            ARCH BIOCHEM BIOPHYS            73   233 958
   006   KUTSKY RJ             HANDBOOK OF VITAMINS AND HORM         36 973
   006   SKIPSKI VP            IN: NELSON GJ                        471 972
   009   FERRO-LUZZI AMES G    J BIOL CHEM                    249   634 974
   009   VAUGHAN WJ            GERONTOLOGY                     23   110 977
   010   WEBER K               J BIOL CHEM                    244  4406 969
   011   MORRISETT JD          ANNU REV BIOCHEM                44   879 975
   012   LINDGREN FT           IN: NELSON GJ                        181 972
   014   HATCH FT              J LAB CLIN MED                  81   946 973
   017   DYERBERY J            SCAND J CLIN LAB INVEST         31   473 973
   017   SRINIVASAN SR         CIRCULATION                     54   309 976
   018   LOPEZ-S A             AM J CLIN NUTR                  20   808 967
   018   JOHNSON BC            J CHRON DIS                     18   147 965
   019   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   021   WILSON DE             J CLIN INVEST                   51  1051 972
   022   THOMPSON GR           CLIN SCI MOL MED                45   583 973
   024   SMITH FR              J LAB CLIN MED                  80   423 972
   025   HOLVEY DN             MERCK MANUAL OF DIAGNOSIS            739 972
   026   KESSLER JI            J BIOL CHEM                    245  5281 970
   026   GLICKMAN RM           J CLIN INVEST                   52  2910 973
   026   GLICKMAN RM           SCIENCE                        193  1254 976
   027   ELLIOTT RB            PEDIATRICS                      57   474 976
   027   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   027   ROSENLUND ML          PEDIATRICS                      59   428 977
CT   1   CHASE HP              J PEDIATR                       95   337 979
     2   YI PI                 BLOOD                           57  1055 981
     3   PARK RW               GASTROENTEROLOGY                81  1143 981
     4   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     5   KRAUSS RM             MED CLIN NORTH AM               66   403 982
     6   SCHONI M              PEDIATR RES                     18    66 984
     7   ABMAN SH              J PEDIATR GASTROENTEROL NUTR     5   393 986

PN 78191
RN 00971 
AN 78204217
AU Breslow-J-L.  Epstein-J.  Fontaine-J-H.  Forbes-G-B.
TI Enhanced dexamethasone resistance in cystic fibrosis cells:
   potential use for heterozygote detection and prenatal diagnosis.
SO Science. 1978 Jul 14. 201(4351). P 180-2.
MJ CYSTIC-FIBROSIS: pp.  DEXAMETHASONE: to.
MN AMNIOTIC-FLUID: cy.  CELL-SURVIVAL: de.  CYSTIC-FIBROSIS: di, fg.
   DRUG-RESISTANCE.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   PREGNANCY.  PRENATAL-DIAGNOSIS.  SUPPORT-U-S-GOVT-P-H-S.
AB Cultured skin fibroblasts from patients with cystic fibrosis (CF) are
   more resistant to dexamethasone toxicity than are normal cells. We
   now report that, when fibroblasts cultured from obligate CF
   heterozygotes are exposed to dexamethasone, they have an intermediate
   survival compared to normal and homozygous CF cells. When
   dexamethasone survival was tested on cells from four patients
   undergoing amniocentesis, cells from a woman at risk of producing a
   child with CF showed significant dexamethasone resistance, similar to
   that of fibroblasts derived from lnown CF homozygotes; the other
   amniotic cell specimens showed dexamethasone sensitivity similar to
   that of normal skin fibroblasts. These data suggest that the
   dexamethasone resistance previously observed in skin fibroblasts may
   also be useful in the prenatal diagnosis of CF.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   004   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   005   BRESLOW JL            CELL                            13   663 978
   006   BRESLOW JL            EXP CELL RES                   110   399 977
   008   FREUND JE             MODERN ELEMENTARY STATISTICS             967
CT   1   HOSLI P               LANCET                           2   543 979
     2   MAHONEY MJ            CLIN PERINATOL                   6   255 979
     3   KURNIT DM             ANNU REV GENET                  13   235 979
     4   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     5   SHWACHMAN H           J PEDIATR                       95   661 979
     6   HOSLI P               FEBS LETTERS                   104   271 979
     7   KURZ JB               SCIENCE                        206  1317 979
     8   SCANLIN TF            CLIN CHEST MED                   1   424 980
     9   DAVIS PB              PEDIATR RES                     14    83 980
    10   TARNOKY AL            J ROY SOC MED                   73    73 980
    11   BARDON A              CLIN CHIM ACTA                 101    17 980
    12   BRESLOW JL            SCIENCE                        207  1007 980
    13   DANIEL A              HUM GENET                       57    96 981
    14   KELLER GH             ARCH BIOCHEM BIOPHYS           211   321 981
    15   BRESLOW JL            N ENGL J MED                   304     1 981
    16   LITTLEFIELD JW        N ENGL J MED                   304    44 981
    17   SEALE TW              ANN CLIN LAB SCI                12   415 982
    18   KHALID BAK            CLIN ENDOCRINOL                 18   407 983
    19   KHALID BAK            MOL CELL ENDOCRINOL             30   303 983
    20   LANGHOFF E            PEDIATR RES                     18   488 984
    21   NELSON MM             S AFR MED J                     66   688 984
    22   GROSS NJ              AM REV RESPIR DIS              129   805 984
    23   BOUE A                PRESSE MED                      14   575 985
    24   POLANSKY J            INVEST OPHTHALMOL VIS SCI       26   805 985
    25   RAVIA Y               HUM GENET                       71   294 985
    26   BOUE A                HUM GENET                       74   288 986
    27   KUZEMKO JA            J ROY SOC MED                   79     2 986

PN 78192
RN 00972 
AN 78204186
AU Rosenblum-M-G.  Durie-B-G.  Beckerman-R-C.  Taussig-L-M.
   Russell-D-H.
TI Cystic fibrosis: decreased conjugation and excretion of
   [14C]spermidine.
SO Science. 1978 Jun 30. 200(4349). P 1496-7.
MJ CYSTIC-FIBROSIS: me.  SPERMIDINE: me.
MN HUMAN.  SPERMIDINE: bl, ur.  SUPPORT-U-S-GOVT-P-H-S.
AB Free and conjugated [14C]spermidine were measured in plasma samples
   from normal individuals and cystic fibrosis patients. Within 4
   minutes, the 14C-labeled material in the plasma from normal
   individuals was 70 percent conjugated compared to no detectable
   conjugation by cystic fibrosis patients. Further, the patients
   excreted only 11 to 13 percent of the [14C]spermidine in their urine
   within 72 hours whereas normal excretion was 60 to 76 percent. In
   both cases, the labeled material was in a conjugated form.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   003   BOWMAN BH             SCIENCE                        164   325 969
   003   TAUSSIG LM            IN: KELLEY VC                    4     1 976
   004   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   005   COHEN LF              BLOOD                           48   469 976
   007   RUSSELL DH            CLIN CHEM                       23    22 977
   008   ROSENBLUM MG          CANCER RES                      37    47 977
   009   ROSENBLUM MG          PROC AM ASSOC CANCER RES        17    15 976
   010   SEILER N              NEUROCHEM RES                    1   469 976
CT   1   ROSENBLUM MG          CANCER RES                      38  3161 978
     2   CAMPBELL RA           LANCET                           1   724 979
     3   RUSSELL DH            PEDIATR RES                     13  1137 979
     4   CANELLAKIS ES         CURR TOP CELL REGUL             15   155 979
     5   AIGNERHELD R          PROC NAT ACAD SCI USA           76  6652 979
     6   AIGNERHELD R          PHYSIOL CHEM PHYS               12   389 980
     7   MELVIN MAL            PHYSIOL CHEM PHYS               12   431 980
     8   BAYLIN SB             PEDIATR RES                     14   921 980
     9   SWENDSEID ME          LIFE SCI                        26   533 980
    10   THEOHARIDES TC        LIFE SCI                        27   703 980
    11   BARDON A              CLIN CHIM ACTA                 101    17 980
    12   SHIPE JR              CRC CRIT REV CLIN LAB SCI       16     1 981
    13   FAN MZ                PHYSIOL CHEM PHYS MED NMR       15    57 983
    14   FAN MZ                PHYSIOL CHEM PHYS MED NMR       15    69 983
    15   TAKAGI T              J CHROMATOGR                   272   279 983
    16   NORDLANDER JE         J ORGANIC CHEM                  49   133 984

PN 78193
RN 00973 
AN 78250613
AU Epstein-J.  Breslow-J-L.  Fitzsimmons-M-J.  Vayo-M-M.
TI Pleiotropic drug resistance in cystic fibrosis fibroblasts:
   increased resistance to cyclic AMP.
SO Somatic-Cell-Genet. 1978 Jul. 4(4). P 451-64.
MJ CYSTIC-FIBROSIS: pp.  DIBUTYRYL-CYCLIC-AMP: pd.
MN CELL-LINE.  CELL-SURVIVAL: de.  DRUG-RESISTANCE.  ISOPROTERENOL: pd.
   SUPPORT-U-S-GOVT-P-H-S.  3-5-CYCLIC-AMP-PHOSPHODIESTERASE: me.
AB In previous studies, cystic fibrosis (CF) fibroblasts were
   demonstrated to be resistant to the cytotoxic effects of ouabain,
   dexamethasone, and the sex hormones, dihydrotestosterone, 17beta-
   estradiol, and progesterone. We now show that CF fibroblasts also
   exhibit greatly increased resistance to the cytotoxic effects of
   exogenous dibutyryl cyclic AMP (cAMP), as well as to isoproterenol
   and theophylline, drugs which are known to increase endogenous levels
   of cAMP. CF cells were also shown to have normal amounts of (3H)cAMP
   binding to protein kinase as well as normal amounts of cAMP-
   stimulated protein kinase activity. Phosphodiesterase in CF cells was
   also found to be stimulated by cAMP to the same degree as in normal
   cells. These findings suggest that there is no detectable protein
   kinase deficiency in CF cells. cf cells thus appear to be unlike some
   cAMP-resistant mutants described by others which are defective in
   protein kinase activity and cAMP regulation of phosphodiesterase
   levels. The cross-resistance of CF fibroblasts to ouabain, steroid
   hormones, and cAMP may provide a unique opportunity to study the
   biochemical events involved in the metabolism of these drugs as well
   as the basic biochemical defect in a common human genetic disease.
RF 001   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   002   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   003   BRESLOW JL            CELL                            13   663 978
   004   BRESLOW JL            EXP CELL RES                   110   399 977
   005   LELIEVRE L            EXP CELL RES                   104   191 977
   006   LOWRY OH              J BIOL CHEM                    193   265 951
   007   INSEL PA              SCIENCE                        190   896 975
   008   GILMAN AG             PROC NAT ACAD SCI USA           67   305 970
   009   BEAVO JA              J BIOL CHEM                    245  5649 970
   010   MANGANIELLO VC        BIOCHIM BIOPHYS ACTA           362   509 974
   011   APPLEMAN MM           ADV CYCLIC NUCLEO RES            3    65 973
   012   KUO JF                PROC NAT ACAD SCI USA           64  1349 969
   013   ERLICHMAN J           J BIOL CHEM                    248  7607 973
   014   BEAVO JA              IN: DRUMMOND P                   5   241 975
   015   DANIEL V              PROC NAT ACAD SCI USA           70    76 973
   016   COFFINO P             J CELL PHYSIOL                  85   603 975
   017   BOURNE HR             J CELL PHYSIOL                  85   611 975
   018   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
   019   BOURNE HR             SCIENCE                        181   952 973
   020   D ARMIENTO M          PROC NAT ACAD SCI USA           69   459 972
   021   MAGANIELLO V          PROC NAT ACAD SCI USA           69   269 972
   022   THOMPSON EB           METABOLISM                      23   159 974
   023   MANKOVITZ R           CELL                             3   221 974
   024   LEVER JE              J CELL PHYSIOL                  88   343 976
   025   BAXTER JD             SCIENCE                        171   189 971
   026   SIBLEY CH             CELL                             2   221 974
   027   YAMAMOTO KR           IN: GREEP RO                    32     3 976
   028   BOURGEOIS S           CELL                            11   423 977
   029   BOURNE HR             SCIENCE                        187   750 975
   030$  GRANNER DK            NATURE                         259   572 974
   031   SCHAFFER LD           BIOCHIM BIOPHYS ACTA           192   304 969
   032   MILLER TB             J BIOL CHEM                    246  3672 971
   033   AXTON JH              J BIOL CHEM                    247  3579 972
   034   STELLWAGEN RH         BIOCHEM BIOPHYS RES COMMUN      47  1144 972
   035$  VAN RIJN H            J BIOL CHEM                     60   181 974
   036   LEMAIRE I             CELL                            11   149 977
   037   MOMMAERTS WFHM        PROC NAT ACAD SCI USA           45   791 959
   038   HUG G                 J CLIN INVEST                   48   704 969
   039   HUIJING F             AM J HUM GENET                  21   275 969
CT   1   KURZ JB               SCIENCE                        206  1317 979
     2   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     3   DAVIS PB              PEDIATR RES                     14    83 980
     4   DAVIS PB              PEDIATR RES                     14   863 980
     5   BRESLOW JL            SCIENCE                        207  1007 980
     6   GNEGY ME              BIOCHEM MED                     26   294 981
     7   MARKOVAC J            BIOCHEM MED                     26   299 981
     8   BRESLOW JL            N ENGL J MED                   304     1 981
     9   UNSICKER K            CELL TISSUE RES                223    73 982
    10   LANGHOFF E            PEDIATR RES                     18   488 984
    11   PINSKY L              ADV HUM GENET                   16   299 987

PN 78194
RN 00974 
AN 78204429
AU Carpentieri-U.  Gustavson-L-P.  Haggard-M-E.
TI Misdiagnosis of neglect in a child with bleeding disorder and cystic
   fibrosis.
SO South-Med-J. 1978 Jul. 71(7). P 854-5.
MJ CHILD-ABUSE.  CYSTIC-FIBROSIS: co.
   DISSEMINATED-INTRAVASCULAR-COAGULATION: et.  VITAMIN-K-DEFICIENCY: co.
MN CASE-REPORT.  CYSTIC-FIBROSIS: di.  DIAGNOSTIC-ERRORS.  HUMAN.
   INFANT.  MALE.
AB This report describes a child in whom a bleeding disorder secondary
   to vitamin K deficiency led to a mistaken diagnosis of child
   neglect, which was eventually corrected to that of cystic fibrosis.
RF 001   WALTERS TR            AM J DIS CHILD                 124   641 972
   002   TORSTENSON OL         PEDIATRICS                      45   857 970
   003   OPPENHEIMER EH        J PEDIATR                       88  1079 976
CT   1   OHARE AE              ARCH DIS CHILD                  59   860 984
     2   PAYNE NR              PEDIATRICS                      73   712 984
     3   LANE PA               J PEDIATR                      106   351 985

PN 78195
RN 00975 
AN 79077519
AU Lewis-R-W.
TI The biochemical basis of cystic fibrosis: an hypothesis based upon
   the polyelectrolytes of mucus.
SO Tex-Rep-Biol-Med. 1978. 36. P 33-8.
MJ CYSTIC-FIBROSIS: me.  ELECTROLYTES: me.  MUCUS: me.
MN CYSTIC-FIBROSIS: pp.  HUMAN.  MEMBRANE-PROTEINS: me.  MEMBRANES: me.
   MUCUS: se.  VISCOSITY.
AB The evidence shows that the pathology of cystic fibrosis (CF) is
   related to mucoid secretions. Consequently, the question of what
   governs the viscosity of mucus is examined in detail. It is generally
   agreed that the mucin gel consists of polyanionic glycoproteins and a
   hitherto unidentified poly cationic cross-linking protein. It is
   proposed that larger amounts of polycations increase viscosity and,
   in excess, cause mucus to become a polycation. As these compounds are
   known to inhibit the ductal reabsorption of sodium, the two principal
   aspects of the pathology of CF can be related to the same mechanism.
   The mucus globule membrane (MGM) has been proposed as the cross-
   linking protein.
RF 001   BARBERO GJ            PEDIATRICS                      22   945 958
   002   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   003   BOTELHO SY            J PEDIATR                       83   601 973
   004   CARLBORG L            ACTA ENDOCRINOL                 62   721 969
   005   COOK GMW              SURFACE CARBOHYDRATES OF THE          58 973
   006   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   007   DISCHE Z              FED PROC                        19   904 960
   008   DISCHE Z              PEDIATRICS                      24    74 959
   009   ELSTEIN M             J OBSTET GYNAECOL BR COMMONW    77   443 970
   010   FARBER S              J MICH MED SOC                  44   587 945
   011   GIBBONS RA            BIOCHEM J                       73   209 959
   012   GIBBONS RA            PROTIDES BIOL FLUIDS            16   299 968
   013   IACOBELLI S           FERTIL STERIL                   22   727 971
   014   JIRKA M               CLIN CHIM ACTA                   2   292 957
   015   JOHNSTON WH           ARCH DIS CHILD                  31   477 956
   016   KAISER D              PEDIATR RES                      5   167 971
   017   KIM SK                J ULTRASTRUCT RES               38   371 972
   018   KORNGUTH SE           EXP CELL RES                    24   484 961
   020   LEWIS RW              LIPIDS                           8   321 973
   021   MANDEL ID             AM J DIS CHILD                 110   646 965
   022   MANGOS JA             PEDIATR RES                      2   378 968
   023   MAMELAK M             J MEMBR BIOL                     1   144 969
   024   MASSON PL             IN: ELSTEIN M                         82 973
   025   NEUTRA M              J CELL BIOL                     30   119 966
   026   PALLAVICINI JC        ANN NY ACAD SCI                106   330 963
   027   POTTER JL             ANN NY ACAD SCI                106   692 963
   028   SCHUMACHER GFB        PROTIDES BIOL FLUIDS            16   525 968
   029   SHWACHMAN H           PEDIATRICS                       7   153 951
   030   ROELFS RE             AM J DIS CHILD                 113   419 967
   031   TANDLER B             J MORPHOL                      127   383 969
CT   1   PUCHELLE E            EUR J CLIN INVEST               15   389 985

PN 78196
RN 00976 
AN 78204754
AU Picot-R.  Das-I.  Reid-L.
TI Pus, deoxyribonucleic acid, and sputum viscosity.
SO Thorax. 1978 Apr. 33(2). P 235-42.
MJ DNA: an.  SPUTUM: an.
MN ADOLESCENCE.  ADULT.  AGED.  ASTHMA: me.  BRONCHIECTASIS: me.
   BRONCHITIS: me.  CHILD.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: me.
   FEMALE.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  MALE.  MIDDLE-AGE.
   SPUTUM: ph.  SUPPURATION.  VISCOSITY.
AB On 100 sputum specimens selected from patients suffering  from
   chronic bronchitis, bronchiectasis, asthma, and cystic fibrosis total
   deoxyribonucleic acid (DNA) content has been related to macroscopic
   type, to total dry weight yield, and to the apparent viscosity of the
   secretion at 1350 s-1: since DNA may be present, either as fibres or
   within cells, in one-third of the specimens the contribution of each
   form to the apparent viscosity was assessed. The effect on sputum
   viscosity of the addition of DNA in vitro has also been studied.
   Whereas between mucoid, mucopurulent, and purulent macroscopic types
   a significant difference in total DNA and dry weight yield has been
   found, viscosity was not significantly correlated with purulence.
   Similarly, the concentration of either cells or fibres correlated
   significantly with total DNA but not with viscosity. The in vitro
   addition of DNA to sputum caused a significant increase in its
   viscosity, and reasons for the differences between the iv vivo and in
   vitro effect are discussed. Certain constituents of purulent sputum
   tend to increase viscosity and others to reduce it, and the influence
   of these varies in the several diseases studied.
RF 001   ADLER K               AM REV RESPIR DIS              106    86 972
   002   BRUCE RA              BR MED J                         1   282 962
   003   BURGI H               MED THORAC                      21   156 964
   004   BURGI H               MED HYGIENE                     23  1169 965
   005   BURTON K              BIOCHEM J                       62   315 956
   006   CHARMAN J             BIORHEOLOGY                      9   185 972
   007   CONWAY BE             J POLYM SCI                     12   199 954
   008   CROFT DN              BIOCHEM J                       95   612 965
   009   DAVIS SS              BULL PHYSIOPATH RESPIR NANCY     9    47 973
   010   DAVIS SS              BIORHEOLOGY                      6    11 969
   011   FEATHER EA            BR J DIS CHEST                  64   192 970
   012   FEULGEN R             QUOTED IN: DRURY RAB                 158 967
   013   GUERRIN F             IN: POINSOT R                        249 969
   014   KEAL EE               POSTGRAD MED J                  47   171 971
   015   LEACH SA              NATURE                         199   486 963
   016   LIEBERMAN J           J LAB CLIN MED                  70   595 967
   017   LIEBERMAN J           PEDIATRICS                      31  1028 963
   018   LIEBERMAN J           LAB INVEST                      14   249 965
   019   LITT M                BIORHEOLOGY                     11   111 974
   020   LITT M                BIORHEOLOGY                     13    37 976
   021   LOPEZ-VIDRIERO MT     THORAX                          28   401 973
   022   LOPEZ-VIDRIERO MT     THESIS                                   976
   023$  LOPEZ-VIDRIERO MT     THORAX                               734 977
   024   MILLER DL             AM REV RESPIR DIS               88   473 963
   025   MOLINA C              J FRANC MED CHIR THORAC         23   734 969
   026   PALMER KNV            BR J DIS CHEST                  64   185 970
   027   PUCHELLE E            BULL PHYSIOPATH RESPIR NANCY     9   237 973
   028   ROSENBLUTH M          ARCH DIS CHILD                  49   606 974
   029   STURGESS J            RHEOL ACTA                      10    36 971
CT   1   SHIMURA S             BIORHEOLOGY                     17   363 980
     2   KING M                FED PROC                        39  3080 980
     3   MIRRAKHIMOV MM        TER ARKH                        52    22 980
     4   TAKISHIMA T           TOHOKU J EXP MED               131   103 980
     5   KING M                PEDIATR RES                     15   120 981
     6   MIRRAKHIMOV MM        TER ARKH                        53   110 981
     7   SNYDER CE             CARBOHYD RES                   105    87 982
     8   PUCHELLE E            EUR J CLIN INVEST               15   389 985

PN 78197
RN 00977 
AN 79077659
AU Hennequet-A.  Jehanne-M.  Betuel-H.  Gilly-R.  Schmid-M.  Hors-J.
TI Cystic fibrosis and HLA.
SO Tissue-Antigens. 1978 Sep. 12(3). P 159-62.
MJ CYSTIC-FIBROSIS: fg.  HLA-ANTIGENS.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  FEMALE.  GENE-FREQUENCY.
   HUMAN.  HLA-ANTIGENS: an.  INFANT.  MALE.  PEDIGREE.
AB In 94 children suffering from cystic fibrosis, no abnormal
   frequencies of HLA markers of the A and B locus were observed in
   comparison with the distribution of these antigens in control series.
   Furthermore, the HLA genotypes of seven pairs of diseased sibs are
   incompatible with the hypothesis of a closed linkage between CF--an
   autosomal recessive transmitted disease--and HLA.
RF 001   BRIMBLECOMBE FSW      LANCET                           2  1428 973
   002   CONOVER JH            LANCET                           1  1122 973
   003   DANES BS              J EXP MED                      129   775 969
   005   ANON                  TRANSPLANT REV                  22       975
   006   KAISER GI             HLA AND DISEASE                      252 976
   007   LAMM LU               ANN HUM GENET                   38   383 975
   008   LOWE CU               AM J DIS CHILD                  78   349 949
   009   MITTAL KK             TRANSPLANTATION                  6   913 968
   010   MORTON NE             AM J HUM GENET                   7   277 955
   011   POLYMENIDIS Z         LANCET                           2  1452 973
   012   RYDER LP              HUMANGENETIK                    25   251 974
CT   1   SCHWARZ HP            J PEDIATR                      104   799 984
     2   KNOPFLE G             KLIN PAEDIATR                  197    13 985

PN 78198
RN 00978 
AN 78229466
AU Hanawa-M.  Takebe-T.  Takahashi-S.  Koizumi-M.  Endo-K.
TI The significance of the sweat test in chronic pancreatitis.
SO Tohoku-J-Exp-Med. 1978 May. 125(1). P 59-69.
MJ PANCREATITIS: me.  SODIUM-CHLORIDE: an.  SWEAT: an.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  AGED.  CHILD.  CHRONIC-DISEASE.
   CYSTIC-FIBROSIS: me.  EATING.  FEMALE.  HUMAN.  MALE.  METHODS.
   MIDDLE-AGE.  PILOCARPINE: pd.  SEX-FACTORS.
AB In order to study the disposition which is thought to be latent in
   chronic pancreatitis, we investigated the sweat chloride
   concentration of 95 normal subjects, 43 cases of chronic
   pancreatitis, 12 cases of cholelithiasis, 15 cases of peptic ulcers,
   16 cases of hepatic diseases and 23 cases of diabetes mellitus with
   the sweat test, using the method of pilocarpine iontophoresis. We
   obtained the following results. (1) In normal subjects, the sweat
   chloride concentration was inclined to rise gradually with age from
   childhood to adulthood; the mean value of sweat chloride
   concentration was 30.0 mEq/liter in adults from 20 years old, and the
   upper limit was about 60 mEq/liter. (2) The mean value of sweat
   chloride concentration was 60.0 mEq/liter in chronic calcifying
   pancreatitis; this value was markedly higher than that of control
   subjects of the same age (p is less than 0.001). (3) The mean value
   of sweat chloride concentration in cholelithiasis, peptic ulcer and
   hepatic diseases did not differ significantly from control subjects.
   The mean value of sweat chloride concentration in diabetes mellitus
   was significantly higher than that of control subjects (p is less
   than 0.01), but was significantly lower than that in chronic
   pancreatitis (p is less than 0.01). (4) It was supposed that some
   cases of chronic pancreatitis have a congenital disposition toward
   abnormal secretion of sweat glands and epithelium in the pancreatic
   duct, resembling cystic fibrosis, and this disposition leads easily
   to pancreatic disorders when the individual is exposed to various
   external factors.
RF 001   CAREY MC              GUT                              9   700 968
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   GROSS JB              IN: DE REUCK AVS                     278 962
   004   KLATSKIN G            AM J MED                        12     3 952
   005   KOCH E                IN: HEINKEL K                        261 964
   006   NOVIS MH              LANCET                           1   748 975
   007   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   010   SARLES H              BIBL GASTROENT BASEL             7    75 965
   011   TAKEBE T              SAISHIN IGAKU                   27  1757 972
   012   VINK CLJ              IN: DE REUCK AVS                     310 962
CT   1   FIGARELLA C           EUR J CLIN INVEST               12   145 982
     2   QUINTON PM            ANNU REV MED                    34   429 983

PN 78199
RN 00979 
AN 80082663
AU Gogus-S.  Caglar-M.  Yilgor-E.  Altay-C.
TI Coexistence of sickle cell trait and cystic fibrosis.
SO Turk-J-Pediatr. 1978 Jan-Apr. 20(1-2). P 58-62.
MJ ANEMIA-SICKLE-CELL: co.  CYSTIC-FIBROSIS: co.  SICKLE-CELL-TRAIT: co.
MN CASE-REPORT.  CONSANGUINITY.  CYSTIC-FIBROSIS: pa.  FEMALE.  HUMAN.
   INFANT.  INFANT-NEWBORN.  MALE.  SICKLE-CELL-TRAIT: pa.
EX The aim of this paper is to report in detail the clinical and
   pathological observations in a case of cystic fibrosis showing widely
   disseminated intravascular sickling.  To the best of our knowledge no
   case of cystic fibrosis associated with sickle cell trait has been
   reported in the literature.  A six month old infant who was diagnosed
   to have cystic fibrosis and sickle cell trait was presented and the
   literature was reviewed for this coexistence.
RF 001   MYERSON RM            AM J MED                        26   543 959
   002   ALTAY C               HUM HERED                       28    56 978
   003   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   004   GURSON CT             HELV PAEDIATR ACTA              28   165 973
   005   OBER WB               N ENGL J MED                   263   947 960
   006   JONES SR              N ENGL J MED                   282   323 970
   007   MCCORMICK WF          AM J MED SCI                   241   329 961
   008   MULLICK FG            ARCH ENVIRON HEALTH             26   221 973

PN 78200
RN 00980 
AN 79161280
AU Foltinova-J.  Mikulikova-K.  Soltes-L.
TI Mucopolysaccharides in bronchial secretion of children.
SO Z-Mikrosk-Anat-Forsch. 1978. 92(2). P 409-15.
MJ ASTHMA: me.  BRONCHI: se.  BRONCHITIS: me.  CYSTIC-FIBROSIS: me.
   MUCOPOLYSACCHARIDES: an.  MUCUS: an.
MN CHILD.  HUMAN.  INFANT.  MUCUS: cy, se.
AB The diseases of respiratory system are nowadays one of the important
   medical, economical and social problems of modern civilization. A
   common symptom of these diseases regardless of their etiology,
   character, klinical manifestation and morphological findings is
   hypersecretion of bronchial sputum. Tracheobronchial mucus is
   produced by mucous bronchial glands and goblet cells. This mucus
   represents at physiological condition about 5 micrometer thick cover
   on mucous of nasopharynx, larynx, trachea, bronchi up to terminal
   bronchioles. Protective function of mucus cover resposes in
   mechanical and humoral barrier and also in removing the inhaled
   particles and their transport to the upper part of the respiratory
   system. In spite of the fact, that bronchial secretion has an
   important role in protective mechanism and in thermal and water
   exchange of respiratory tract, this secretion is not sufficiently
   scrutinized mainly of children yet.
RF 001   CHLAP Z               ACTA MED POL                    10   209 959
   002   GERTH B               Z ERKR ATMUNGSORGANE           132   223 970
   003   JONES R               HISTOCHEM J                      5    19 973
   004   KISZELI G             MIKROTECHNISCHE UND HISTOCHEM            964
   005   PEARSE AGE            HISTOCHEM THEORET AND APPLIED            974
   006   POGODIN BIV           VOPR CASNOJ PAT ANAT VORNA            81 973
   007   RAVETTO C             J HISTOCHEM CYTOCHEM            12    44 964
   008   LAMB D                HISTOCHEM J                      4    91 972
   009   SALVATO G             THORAX                          23   168 968
   010   SCOTT DE              HISTOCHEMIE                      5   221 965
   011   SPICER SS             J HISTOCHEM CYTOCHEM             8    18 960
   012   SPICER SS             J HISTOCHEM CYTOCHEM            13   211 965
   013   SPICER SS             TECH BULL REG MED TECHNOL       30    53 960
   014   SORVARI TE            J HISTOCHEM CYTOCHEM            17   291 969
CT   1   FOLTINOVA J           BIOLOGIA                        36   703 981

